{"id": 42937216, "time": "2025-01-13 00:10:43", "headline": "Bitcoin, Ethereum Lost Way But XRP Made Promising Headway \u2014 Here Are The Best Performers From Last Week", "summary": "The cryptocurrency market witnessed significant downsides last week, although some coins exhibited resilience with meaningful gains.\n\n\n\nWhat happened: BGB, the utility token for the centralized exchange Bitget, emerged as the best performer, rallying more than 11% over the week.", "symbols": ["BTCUSD", "DOGEUSD", "ETH", "ETHUSD", "SHIBUSD", "XDCUSD", "XRPUSD"], "source": "benzinga", "author": "Aniket Verma", "url": "https://www.benzinga.com/25/01/42937216/bitcoin-ethereum-lost-way-last-week-but-xrp", "tags": []}
{"id": 42937281, "time": "2025-01-13 00:30:39", "headline": "Reported Earlier, China Exports (YoY) For December 10.7% Vs. 7.3% Est.; 6.7% Prior", "summary": "", "symbols": ["FXI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/economics/macro-economic-events/25/01/42937281/reported-earlier-china-exports-yoy-for-december-10-7-vs-7-3-est-6-7-prior", "tags": []}
{"id": 42937284, "time": "2025-01-13 00:31:29", "headline": "Reported Earlier, China Imports (YoY) For December 1.0% Vs. -1.5% Est.; -3.9% Prior", "summary": "", "symbols": ["FXI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/economics/macro-economic-events/25/01/42937284/reported-earlier-china-imports-yoy-for-december-1-0-vs-1-5-est-3-9-prior", "tags": []}
{"id": 42937285, "time": "2025-01-13 00:31:53", "headline": "Reported Earlier, China Trade Balance (USD) For December 104.84B Vs. 100.00B Est.; 97.44B Prior", "summary": "", "symbols": ["FXI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/economics/macro-economic-events/25/01/42937285/reported-earlier-china-trade-balance-usd-for-december-104-84b-vs-100-00b-est-97-4", "tags": []}
{"id": 42937389, "time": "2025-01-13 01:04:53", "headline": "Tesla Hikes Model 3, Y Prices In Canada By C$1000 After Announcing Price Increase In China", "summary": "EV giant Tesla Inc has increased the price of all Model Y and Model 3 variants in Canada by C$1000.", "symbols": ["TSLA"], "source": "benzinga", "author": "Anan Ashraf", "url": "https://www.benzinga.com/tech/25/01/42937389/tesla-hikes-model-3-y-prices-in-canada-by-c1000-after-announcing-price-increase-in-china", "tags": []}
{"id": 42937450, "time": "2025-01-13 01:17:29", "headline": "W&T Offshore Announces Private Offering Of $350M To Replace 2026 Notes And Repay Term Loan", "summary": "", "symbols": ["WTI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42937450/w-t-offshore-announces-private-offering-of-350m-to-replace-2026-notes-and-repay-term-loan", "tags": ["offering"]}
{"id": 42937555, "time": "2025-01-13 01:21:55", "headline": "Jeff Bezos Says He Takes Elon Musk At 'Face Value' Despite His Close Ties To Trump, Dismisses Concerns About SpaceX Undercutting Blue Origin", "summary": "Amazon.com Inc. founder Jeff Bezos voiced confidence in the competitive landscape of the commercial space industry, despite President-elect Donald Trump&#39;s close ties with rival Elon Musk&#39;s SpaceX, as Blue Origin prepares for a pivotal rocket launch.", "symbols": [], "source": "benzinga", "author": "Kaustubh Bagalkote", "url": "https://www.benzinga.com/general/space/25/01/42937555/jeff-bezos-says-he-takes-elon-musk-at-face-value-despite-his-close-ties-to-trump-dismisses-concerns-about-spacex-undercutting-blue-origin", "tags": []}
{"id": 42937565, "time": "2025-01-13 01:29:48", "headline": "Lantheus Strengthens Radiopharmaceutical Leadership With $350M Acquisition Of Life Molecular Imaging", "summary": "", "symbols": ["LNTH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42937565/lantheus-strengthens-radiopharmaceutical-leadership-with-350m-acquisition-of-life-molecular-imaging", "tags": []}
{"id": 42937574, "time": "2025-01-13 01:32:07", "headline": "Sanofi's Sarclisa Gains First Approval In China, Expanding Access For Patients With Relapsed Or Refractory Multiple Myeloma", "summary": "", "symbols": ["SNY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42937574/sanofis-sarclisa-gains-first-approval-in-china-expanding-access-for-patients-with-relapsed-or-refrac", "tags": []}
{"id": 42937590, "time": "2025-01-13 01:37:03", "headline": "Roche's VENTANA ISH Test Secures FDA Clearance For Accurate B-Cell Lymphoma Diagnosis", "summary": "", "symbols": ["RHHBF", "RHHBY", "RHHVF"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42937590/roches-ventana-ish-test-secures-fda-clearance-for-accurate-b-cell-lymphoma-diagnosis", "tags": ["fda"]}
{"id": 42937626, "time": "2025-01-13 01:46:51", "headline": "Teva Partners With Formycon And Klinge To Commercialize Biosimilar To Eylea In Europe And Israel", "summary": "", "symbols": ["TEVA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42937626/teva-partners-with-formycon-and-klinge-to-commercialize-biosimilar-to-eylea-in-europe-and-israel", "tags": ["contract"]}
{"id": 42937753, "time": "2025-01-13 02:02:07", "headline": "argenx Preliminary 2024 Financial Results: $2.2B In Annual Product Sales, $737M In Q4 Revenue, And $3.4B In Cash Reserves", "summary": "", "symbols": ["ARGX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42937753/argenx-preliminary-2024-financial-results-2-2b-in-annual-product-sales-737m-in-q4-revenue-and-3-4b-i", "tags": ["earnings"]}
{"id": 42937761, "time": "2025-01-13 02:05:06", "headline": "Singapore Cracks Down On Polymarket: Regulator Issues Warning Against 'Illegal Gambling'", "summary": "Battling a legal soup in the U.S., controversial cryptocurrency-based betting platform Polymarket was refused access in another key financial market, Singapore, locals said on Sunday.", "symbols": ["POLUSD"], "source": "benzinga", "author": "Aniket Verma", "url": "https://www.benzinga.com/25/01/42937761/singapore-restricts-residents-from-using-prediction-platform-polymarket-over-gambling-law-violation", "tags": []}
{"id": 42937785, "time": "2025-01-13 02:08:59", "headline": "Reported Earlier, Praxis Announces 2025 Milestones: Advancing Relutrigine, Ulixacaltamide, And Rare Disease Programs With $470M In Cash Reserves", "summary": "", "symbols": ["PRAX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42937785/reported-earlier-praxis-announces-2025-milestones-advancing-relutrigine-ulixacaltamide-and-rare-dise", "tags": []}
{"id": 42937817, "time": "2025-01-13 02:14:42", "headline": "FDA Grants Priority Review to Daiichi Sankyo and AstraZeneca's Datopotamab Deruxtecan for Advanced Lung Cancer Treatment", "summary": "", "symbols": ["AZN", "DSKYF", "DSNKY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/government/25/01/42937817/fda-grants-priority-review-to-daiichi-sankyo-and-astrazenecas-datopotamab-deruxtecan-for-advanced-lu", "tags": ["fda"]}
{"id": 42937827, "time": "2025-01-13 02:15:45", "headline": "Reported Earlier, Merus And Biohaven Partner to Co-Develop Three Novel Bispecific Antibody Drug Conjugate (ADC) Programs", "summary": "", "symbols": ["BHVN", "MRUS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42937827/reported-earlier-merus-and-biohaven-partner-to-co-develop-three-novel-bispecific-antibody-drug-conju", "tags": []}
{"id": 42937828, "time": "2025-01-13 02:16:38", "headline": "GSK To Acquire Biopharma Firm IDRx for $1B And Earnout Of Up To $150M, Targets Precision Therapy for GIST Treatment", "summary": "", "symbols": ["GSK"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42937828/gsk-to-acquire-biopharma-firm-idrx-for-1b-and-earnout-of-up-to-150m-targets-precision-therapy-for-gi", "tags": ["merger"]}
{"id": 42937833, "time": "2025-01-13 02:19:04", "headline": "Elon Musk's SpaceX Delays Starship 7th Test Flight To Wednesday", "summary": "SpaceX said on Saturday that it is now targeting Wednesday for its upcoming 7th flight test, later than its previous timeline of Monday.", "symbols": [], "source": "benzinga", "author": "Anan Ashraf", "url": "https://www.benzinga.com/general/space/25/01/42937833/elon-musks-spacex-delays-starship-7th-test-flight-to-wednesday", "tags": []}
{"id": 42937843, "time": "2025-01-13 02:19:34", "headline": "Telix Pharma Reported Q4 Revenue Of $142M, Up 46% YoY, FY24 Revenue Of $517M, Up By 55% YoY", "summary": "", "symbols": ["TLX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42937843/telix-pharma-reported-q4-revenue-of-142m-up-46-yoy-fy24-revenue-of-517m-up-by-55-yoy", "tags": ["earnings"]}
{"id": 42937845, "time": "2025-01-13 02:20:56", "headline": "Natera Reports Preliminary 2024 Results: $1.7B In Annual Revenue (+56% YoY), $472M In Q4 Revenue (+52% YoY), And $86.3M In Positive Cash Flow For 2024", "summary": "", "symbols": ["NTRA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42937845/natera-reports-preliminary-2024-results-1-7b-in-annual-revenue-56-yoy-472m-in-q4-revenue-52-yoy-and", "tags": ["earnings"]}
{"id": 42937846, "time": "2025-01-13 02:21:24", "headline": "Medtronic Gains CE Mark Approval for BrainSense Adaptive DBS, Advancing Parkinson's Treatment in Europe and UK", "summary": "", "symbols": ["MDT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/government/25/01/42937846/medtronic-gains-ce-mark-approval-for-brainsense-adaptive-dbs-advancing-parkinsons-treatment-in-europ", "tags": []}
{"id": 42938082, "time": "2025-01-13 02:33:53", "headline": "Reported Earlier, Caribou Biosciences Advances CB-010, CB-011, And CB-012 Programs With Key Clinical Updates Expected In 2025; Cash Position $281M", "summary": "", "symbols": ["CRBU"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938082/reported-earlier-caribou-biosciences-advances-cb-010-cb-011-and-cb-012-programs-with-key-clinical-up", "tags": ["fda"]}
{"id": 42938083, "time": "2025-01-13 02:34:27", "headline": "Justin Trudeau Says Canada Is 'Ready To Respond With Tariffs As Necessary' Amid Potential Trump Trade War", "summary": "&#34;As we did last time, we are ready to respond with tariffs as necessary,&#34;\u00a0he said.\n\nTrudeau also mentioned Canada&#39;s increased spending on border security to address U.S. concerns about illegal migration and fentanyl.", "symbols": [], "source": "benzinga", "author": "Pooja Rajkumari", "url": "https://www.benzinga.com/news/25/01/42938083/justin-trudeau-says-canada-is-ready-to-respond-with-tariffs-as-necessary-amid-potential-trump-trade-war", "tags": []}
{"id": 42938104, "time": "2025-01-13 02:38:23", "headline": "Reported Earlier, Exact Sciences Reports Preliminary 2024 Results: Expects $2.76B In Annual Revenue (+10% YoY) And $713M In Q4 Revenue (+10% YoY)", "summary": "", "symbols": ["EXAS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938104/exact-sciences-reports-preliminary-2024-results-exepcts-2-76b-in-annual-revenue-10-yoy-and-713m-in-q", "tags": ["earnings"]}
{"id": 42938119, "time": "2025-01-13 02:44:18", "headline": "Lockheed Martin Donates $1M To Trump's Inaugural Committee As Speculation Grows Over Elon Musk-Led DOGE Crackdown On Traditional Defense Contracts", "summary": "Defense giant Lockheed Martin Corp. has donated $1 million to President-elect Donald Trump&#39;s inaugural committee.", "symbols": ["LMT", "PLTR"], "source": "benzinga", "author": "Kaustubh Bagalkote", "url": "https://www.benzinga.com/markets/equities/25/01/42938119/lockheed-martin-donates-1m-to-trumps-inaugural-committee-as-speculation-grows-over-elon-musk-led-doge-crackdown-on-traditional-defense-contracts", "tags": []}
{"id": 42938133, "time": "2025-01-13 02:46:29", "headline": "Reported Earlier, Telix To Acquire Imaginab's Drug Candidates And Cutting-Edge Antibody Engineering Platform For $45M", "summary": "", "symbols": ["TLX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42938133/reported-earlier-telix-to-acquire-imaginabs-drug-candidates-and-cutting-edge-antibody-engineering-pl", "tags": ["merger"]}
{"id": 42938138, "time": "2025-01-13 02:48:51", "headline": "Reported Earlier, Medical Properties Trust Supports Prospect's Chapter 11 Sale Plans For Connecticut Hospitals", "summary": "", "symbols": ["MPW"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938138/reported-earlier-medical-properties-trust-supports-prospects-chapter-11-sale-plans-for-connecticut-h", "tags": []}
{"id": 42938145, "time": "2025-01-13 02:51:12", "headline": "Reported Earlier, Cellectar Highlights Path Toward Accelerated Approval For Iopofosine I 131 and Expands Radioconjugate Development", "summary": "", "symbols": ["CLRB"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938145/reported-earlier-cellectar-highlights-path-toward-accelerated-approval-for-iopofosine-i-131-and-expa", "tags": []}
{"id": 42938259, "time": "2025-01-13 03:06:34", "headline": "CME Group Hits Record 7.8 Million Daily International Contracts in 2024, up 14% YoY Driven by Energy and Metals Growth", "summary": "", "symbols": ["CME"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938259/cme-group-hits-record-7-8-million-daily-international-contracts-in-2024-up-14-yoy-driven-by-energy-a", "tags": []}
{"id": 42938260, "time": "2025-01-13 03:09:35", "headline": "Castle Biosciences Reports Preliminary 2024 Results: Expects $320M-$330M In Annual Revenue (+50% YoY), 96,071 Total Tests Delivered (+36% YoY), And $293M In Cash And Investments", "summary": "", "symbols": ["CSTL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938260/castle-biosciences-reports-preliminary-2024-results-expects-320m-330m-in-annual-revenue-50-yoy-96-07", "tags": ["earnings"]}
{"id": 42938262, "time": "2025-01-13 03:10:45", "headline": "MaxCyte Expects Q4 Core Revenue Of $8.3M-$8.5M Vs $7.2M YoY And FY24 Core Revenue Of $32.2M-$32.4M Vs $29.8M YoY", "summary": "", "symbols": ["MXCT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938262/maxcyte-expects-q4-core-revenue-of-8-3m-8-5m-vs-7-2m-yoy-and-fy24-core-revenue-of-32-2m-32-4m-vs-29", "tags": ["earnings"]}
{"id": 42938299, "time": "2025-01-13 03:12:47", "headline": "Reported Earlier, Vertex Unveils Comprehensive Updates On CF, SCD, And Pipeline Progress Across Multiple Disease Areas For 2025", "summary": "", "symbols": ["VRTX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938299/reported-earlier-vertex-unveils-comprehensive-updates-on-cf-scd-and-pipeline-progress-across-multipl", "tags": []}
{"id": 42938301, "time": "2025-01-13 03:14:04", "headline": "Michael Saylor's MicroStrategy Will Struggle When Bitcoin's Volatility Falls, Says Arthur Hayes \u2014 I Would Not Trade MSTR At All", "summary": "Arthur Hayes, co-founder of cryptocurrency exchange\u00a0BitMEX and Chief Investment Officer at\u00a0Maelstrom\u00a0Fund, cast aspersions on MicroStrategy Inc.\u2019s (NASDAQ:MSTR) debt-powered Bitcoin (CRYPTO: ", "symbols": ["BTCUSD", "MSTR"], "source": "benzinga", "author": "Aniket Verma", "url": "https://www.benzinga.com/25/01/42938301/michael-saylors-microstrategy-will-struggle-when-bitcoins-volatility-falls-says-arthur-hayesi-would-not-trade-mstr-at-all", "tags": []}
{"id": 42938302, "time": "2025-01-13 03:14:19", "headline": "Illumina Launches Proteomics Pilot with 50,000 UK Biobank Samples, Partners with GSK, J&J, and Novartis", "summary": "", "symbols": ["GSK", "ILMN", "JNJ", "NVS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938302/illumina-launches-proteomics-pilot-with-50-000-uk-biobank-samples-partners-with-gsk-j-j-and-novartis", "tags": ["contract"]}
{"id": 42938312, "time": "2025-01-13 03:15:28", "headline": "Reported Earlier, Ascendis Pharma Projects \u20ac364M In 2024 Revenue, Reports \u20ac655M In Cash, Highlights SKYTROFA And YORVIPATH Growth, And Prepares For Transcon CNP NDA Filing In Early 2025", "summary": "", "symbols": ["ASND"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938312/reported-earlier-ascendis-pharma-projects-364m-in-2024-revenue-reports-655m-in-cash-highlights-skytr", "tags": ["earnings"]}
{"id": 42938328, "time": "2025-01-13 03:18:33", "headline": "Reported Earlier, Amicus Reported $528M In 2024 Revenue (+32% YoY), Projects 17-24% Growth In 2025, And Highlights First Full Year Of Pombiliti + Opfolda Sales", "summary": "", "symbols": ["FOLD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938328/reported-earlier-amicus-reported-528m-in-2024-revenue-32-yoy-projects-17-24-growth-in-2025-and-highl", "tags": ["earnings"]}
{"id": 42938329, "time": "2025-01-13 03:19:21", "headline": "US Reportedly Probes Barriers, Subsidies And Unfair Trade Practices By China In Global Shipbuilding As Trump Tariff Threat Looms", "summary": "The report indicates that China&#39;s share in\u00a0the $150 billion global shipbuilding\u00a0market has grown from 5% in 2000\u00a0to over 50% in 2023, largely due to government subsidies. ", "symbols": [], "source": "benzinga", "author": "Pooja Rajkumari", "url": "https://www.benzinga.com/news/global/25/01/42938329/us-reportedly-probes-barriers-subsidies-and-unfair-trade-practices-by-china-in-global-shipbuilding-as-trump-tariff-threat-looms", "tags": []}
{"id": 42938341, "time": "2025-01-13 03:21:10", "headline": "Reported Earlier, Exelixis Reports $2.165B In Preliminary 2024 Revenue, Projects $2.15B-2.25B In 2025, And Highlights Pipeline Progress", "summary": "", "symbols": ["EXEL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938341/reported-earlier-exelixis-reports-2-165b-in-preliminary-2024-revenue-projects-2-15b-2-25b-in-2025-an", "tags": ["earnings"]}
{"id": 42938407, "time": "2025-01-13 03:26:25", "headline": "Reported Earlier, Blueprint Medicines Sees AYVAKIT 2024 Revenue At $475M\u2013$480M (+130% YoY); Projects $4B SM Franchise Opportunity, Targets $2B AYVAKIT Revenue By 2030;", "summary": "", "symbols": ["BPMC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938407/reported-earlier-blueprint-medicines-sees-ayvakit-2024-revenue-at-475m-480m-130-yoy-projects-4b-sm-f", "tags": ["earnings"]}
{"id": 42938416, "time": "2025-01-13 03:32:02", "headline": "Reported Earlier, Alnylam Pharmaceuticals Preliminary Results: $1.6B In 2024 Net Product Revenue (+33% YoY); 2025 Revenue Guidance Of $2.05B\u2013$2.25B, And Highlights Key Pipeline Goals", "summary": "", "symbols": ["ALNY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938416/reported-earlier-alnylam-pharmaceuticals-preliminary-results-1-6b-in-2024-net-product-revenue-33-yoy", "tags": ["earnings", "guidance"]}
{"id": 42938417, "time": "2025-01-13 03:32:07", "headline": "Earnings Scheduled For January 13, 2025", "summary": " ", "symbols": ["AEHR", "CGO", "CMTL", "EDUC", "KBH", "TTAN"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/earnings/25/01/42938417/earnings-scheduled-for-january-13-2025", "tags": ["earnings"]}
{"id": 42938426, "time": "2025-01-13 03:32:28", "headline": "WD-40 Company, KB Home And 3 Stocks To Watch Heading Into Monday", "summary": "US stock futures down, stocks to watch: Comtech Telecommunications, WD-40, KB Home, Nordstrom, and ServiceTitan.", "symbols": ["CMTL", "JWN", "KBH", "TTAN", "WDFC"], "source": "benzinga", "author": "Avi Kapoor", "url": "https://www.benzinga.com/news/earnings/25/01/42938426/wd-40-company-kb-home-and-3-stocks-to-watch-heading-into-monday", "tags": []}
{"id": 42938441, "time": "2025-01-13 03:34:37", "headline": "Reported Earlies, Hologic Reports Preliminary Q1 FY25 Revenue Of $1.02B (+0.9% YoY), EPS Expected Near High-End Of Guidance", "summary": "", "symbols": ["HOLX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938441/reported-earlies-hologic-reports-preliminary-q1-fy25-revenue-of-1-02b-0-9-yoy-eps-expected-near-high", "tags": ["earnings", "guidance"]}
{"id": 42938480, "time": "2025-01-13 03:46:31", "headline": "Reported Earlier, Exagen Expects $55.3M-$55.8M In Annual Revenue (+33% YoY), And Narrowed EBITDA Loss Of $9.8M\u2013$10.8M In 2024; For Q4 Sees $13.3M-$13.8M In Revenue", "summary": "", "symbols": ["XGN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938480/reported-earlier-exagen-expects-55-3m-55-8m-in-annual-revenue-33-yoy-and-narrowed-ebitda-loss-of-9-8", "tags": ["earnings"]}
{"id": 42938506, "time": "2025-01-13 03:50:56", "headline": "Elon Musk Urges Mark Zuckerberg To Release Facebook Files, Calls It 'Good' After Meta Adopts X's Community Notes-Like Feature", "summary": "Tesla Inc. CEO Elon Musk endorsed calls for Meta Platforms Inc. to release its content moderation communications with government officials, responding &#34;That would be good&#34; to prominent tech investor Dave Lee&#39;s demand for transparency.", "symbols": ["META", "TSLA"], "source": "benzinga", "author": "Kaustubh Bagalkote", "url": "https://www.benzinga.com/general/social-media/25/01/42938506/elon-musk-urges-mark-zuckerberg-to-release-facebook-files-calls-it-good-after-meta-adopts-xs-community-notes-like-feature", "tags": ["management"]}
{"id": 42938508, "time": "2025-01-13 03:51:12", "headline": "Reported Sunday, 10x Genomics Reports $610.8M In 2024 Revenue (-1% YoY), $165M Q4 Revenue (-10% YoY), And $393M In Cash Reserves", "summary": "", "symbols": ["TXG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938508/reported-sunday-10x-genomics-reports-610-8m-in-2024-revenue-1-yoy-165m-q4-revenue-10-yoy-and-393m-in", "tags": ["earnings"]}
{"id": 42938576, "time": "2025-01-13 03:57:20", "headline": "Reported Sunday, Mereo BioPharma Reports Progress In Setrusumab Phase 3 Study For OI And Awaits EMA Decision On Alvelestat Orphan Designation", "summary": "", "symbols": ["MREO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938576/reported-sunday-mereo-biopharma-reports-progress-in-setrusumab-phase-3-study-for-oi-and-awaits-ema-d", "tags": ["fda"]}
{"id": 42938610, "time": "2025-01-13 04:04:24", "headline": "Ford Sold More Electric Mustangs Than Gas Mustangs In 2024", "summary": "Ford sold 51,745 Mustang Mach-E SUVs in the U.S. last year, trumping the sales numbers of its gas-powered counterpart Mustang.", "symbols": ["F"], "source": "benzinga", "author": "Anan Ashraf", "url": "https://www.benzinga.com/25/01/42938610/ford-sold-more-electric-mustangs-than-gas-mustangs-in-2024", "tags": []}
{"id": 42938620, "time": "2025-01-13 04:06:06", "headline": "Reported Sunday, Blue Owl Capital Expands Grand Slam Sponsorship, Partners With Jordan Thompson For Australian Open 2025", "summary": "", "symbols": ["OWL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938620/reported-sunday-blue-owl-capital-expands-grand-slam-sponsorship-partners-with-jordan-thompson-for-au", "tags": ["contract"]}
{"id": 42938643, "time": "2025-01-13 04:07:46", "headline": "Reported Saturday, Gilead And LEO Pharma Join Forces To Accelerate Oral STAT6 Development For Inflammation And Dermatology", "summary": "", "symbols": ["GILD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938643/reported-saturday-gilead-and-leo-pharma-join-forces-to-accelerate-oral-stat6-development-for-inflamm", "tags": []}
{"id": 42938649, "time": "2025-01-13 04:09:23", "headline": "Reported Saturday, CSX Secures Labor Agreement With BMWED, Covering 42% Of Unionized Workforce", "summary": "", "symbols": ["CSX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938649/reported-saturday-csx-secures-labor-agreement-with-bmwed-covering-42-of-unionized-workforce", "tags": ["contract"]}
{"id": 42938659, "time": "2025-01-13 04:15:16", "headline": "Reported Saturday, Sage Therapeutics Confirms Receipt Of Biogen's Nonbinding $7.22/Share Acquisition Proposal", "summary": "", "symbols": ["BIIB", "SAGE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938659/reported-saturday-sage-therapeutics-confirms-receipt-of-biogens-nonbinding-7-22share-acquisition-pro", "tags": []}
{"id": 42938683, "time": "2025-01-13 04:18:40", "headline": "Reported Friday, Lennar Moves Forward With Millrose Spin-Off; Record Date Set For January 21, Distribution On February 7", "summary": "", "symbols": ["LEN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42938683/reported-friday-lennar-moves-forward-with-millrose-spin-off-record-date-set-for-january-21-distribut", "tags": []}
{"id": 42938743, "time": "2025-01-13 04:22:32", "headline": "The US Court Of Appeals For The Federal Circuit Affirms The Validity Of The Novartis' Entresto (Sacubitril/Valsartan) Combination Patent", "summary": "", "symbols": ["NVS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42938743/the-us-court-of-appeals-for-the-federal-circuit-affirms-the-validity-of-the-novartis-entresto-sac", "tags": ["legal"]}
{"id": 42938948, "time": "2025-01-13 05:05:00", "headline": "MDxHealth Expects Q4 Revenue Of $24.7M And FY24 Revenue Of $90.0M, Both Up By 28% YoY, Expects FY25 Revenue Of $108M-$110M, Up By 20%-22% YoY And Eyes Adj EBITDA Profitability In First Half", "summary": "", "symbols": ["MDXH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42938948/mdxhealth-expects-q4-revenue-of-24-7m-and-fy24-revenue-of-90-0m-both-up-by-28-yoy-expects-fy25-reve", "tags": ["earnings"]}
{"id": 42938954, "time": "2025-01-13 05:05:15", "headline": "Michael Saylor's MicroStrategy Faces Risk If MSTR's 0% Convertible Bond Lenders Recall Non-Recourse Loans Due To Covenant Breach: Here's What It Means For Investors", "summary": "Bitcoin\u2018s (CRYPTO: BTC) levered play MicroStrategy Inc (NASDAQ:MSTR) could face the risk of redemption on its 0% convertible debt upon the occurrence of unforeseen events breaching the covenants governing these notes ", "symbols": ["BTCUSD", "MSTR"], "source": "benzinga", "author": "Rishabh Mishra", "url": "https://www.benzinga.com/general/market-summary/25/01/42938954/michael-saylors-microstrategy-faces-risk-if-mstrs-0-convertible-bond-lenders-recall-non-recourse-loans-due-to-covenant-breach-heres-what-it-means-for-investors", "tags": []}
{"id": 42939021, "time": "2025-01-13 05:06:43", "headline": "Personalis and UK Scientists Publish Study on Lung Cancer Detection Using ctDNA in Nature Medicine", "summary": "", "symbols": ["PSNL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939021/personalis-and-uk-scientists-publish-study-on-lung-cancer-detection-using-ctdna-in-nature-medicine", "tags": []}
{"id": 42939090, "time": "2025-01-13 05:20:10", "headline": "Jeff Bezos' Blue Origin Scraps New Glenn Liftoff Due To Vehicle Subsystem Issue, Next Launch Date Unclear", "summary": "Jeff Bezos\u2018\u00a0Blue Origin cancelled its attempt to launch its New Glenn launch vehicle on Monday after an issue was identified with a vehicle subsystem, the company said.", "symbols": [], "source": "benzinga", "author": "Anan Ashraf", "url": "https://www.benzinga.com/25/01/42939090/jeff-bezos-blue-origin-delays-new-glenn-launch-after-identifying-issue", "tags": []}
{"id": 42939201, "time": "2025-01-13 05:22:53", "headline": "Needham Reiterates Buy on Mereo BioPharma Group, Maintains $7 Price Target", "summary": "", "symbols": ["MREO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939201/needham-reiterates-buy-on-mereo-biopharma-group-maintains-7-price-target", "tags": ["analyst_other"]}
{"id": 42939205, "time": "2025-01-13 05:25:46", "headline": "Needham Maintains Buy on Silicon Laboratories, Raises Price Target to $140", "summary": "", "symbols": ["SLAB"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939205/needham-maintains-buy-on-silicon-laboratories-raises-price-target-to-140", "tags": ["analyst_other", "price_target_up"]}
{"id": 42939219, "time": "2025-01-13 05:27:06", "headline": "Dow Tumbles Around 700 Points Following Jobs Data, Investor Sentiment Dips Further: Greed Index Remains In 'Fear' Zone", "summary": " ", "symbols": ["CMTL", "DAL", "KBH", "TTAN", "WBA"], "source": "benzinga", "author": "Avi Kapoor", "url": "https://www.benzinga.com/25/01/42939219/dow-tumbles-around-700-points-following-jobs-data-investor-sentiment-dips-further-fear-greed-index-remains-in-fear-zone", "tags": []}
{"id": 42939229, "time": "2025-01-13 05:28:00", "headline": "Needham Maintains Buy on Silicon Motion Technology, Lowers Price Target to $70", "summary": "", "symbols": ["SIMO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939229/needham-maintains-buy-on-silicon-motion-technology-lowers-price-target-to-70", "tags": ["analyst_other", "price_target_down"]}
{"id": 42939240, "time": "2025-01-13 05:30:25", "headline": "Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $20", "summary": "", "symbols": ["ARQT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939240/needham-maintains-buy-on-arcutis-biotherapeutics-raises-price-target-to-20", "tags": ["analyst_other", "price_target_up"]}
{"id": 42939242, "time": "2025-01-13 05:32:17", "headline": "PermRock Royalty Trust Announces Sale Agreement of Underlying Oil and Gas Properties By Boaz Energy to T2S Permian Acquisition, Retaining Net Profits Interests", "summary": "", "symbols": ["PRT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939242/permrock-royalty-trust-announces-sale-agreement-of-underlying-oil-and-gas-properties-by-boaz-energy", "tags": ["contract"]}
{"id": 42939246, "time": "2025-01-13 05:32:42", "headline": "Needham Maintains Buy on ON Semiconductor, Lowers Price Target to $66", "summary": "", "symbols": ["ON"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939246/needham-maintains-buy-on-on-semiconductor-lowers-price-target-to-66", "tags": ["analyst_other", "price_target_down"]}
{"id": 42939247, "time": "2025-01-13 05:32:49", "headline": "India Consumer Price Index (YoY) For December 5.22% Vs. 5.30% Est.; 5.48% Prior", "summary": "", "symbols": ["INDA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/economics/macro-economic-events/25/01/42939247/india-consumer-price-index-yoy-for-december-5-22-vs-5-30-est-5-48-prior", "tags": []}
{"id": 42939256, "time": "2025-01-13 05:33:33", "headline": "Nutex Health Opens Starkey Ranch ER & Hospital in Florida, Offering 24/7 Concierge-Level Care", "summary": "", "symbols": ["NUTX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939256/nutex-health-opens-starkey-ranch-er-hospital-in-florida-offering-247-concierge-level-care", "tags": ["offering"]}
{"id": 42939258, "time": "2025-01-13 05:34:37", "headline": "Needham Maintains Buy on BioCryst Pharma, Raises Price Target to $15", "summary": "", "symbols": ["BCRX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939258/needham-maintains-buy-on-biocryst-pharma-raises-price-target-to-15", "tags": ["analyst_other", "price_target_up"]}
{"id": 42939296, "time": "2025-01-13 05:37:42", "headline": "Needham Upgrades Maplebear to Buy, Announces $56 Price Target", "summary": "", "symbols": ["CART"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939296/needham-upgrades-maplebear-to-buy-announces-56-price-target", "tags": ["analyst_up"]}
{"id": 42939302, "time": "2025-01-13 05:40:46", "headline": "Needham Reiterates Buy on RxSight, Announces $66 Price Target", "summary": "", "symbols": ["RXST"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939302/needham-reiterates-buy-on-rxsight-announces-66-price-target", "tags": ["analyst_other"]}
{"id": 42939308, "time": "2025-01-13 05:43:14", "headline": "Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $30", "summary": "", "symbols": ["PCRX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939308/needham-maintains-buy-on-pacira-biosciences-raises-price-target-to-30", "tags": ["analyst_other", "price_target_up"]}
{"id": 42939311, "time": "2025-01-13 05:45:02", "headline": "Wayfair Expands Google Cloud Partnership To Tap AI For Cost Cuts And Efficiency", "summary": "Wayfair strengthens its partnership with Google Cloud to enhance operations through Gemini on Vertex AI and Google Workspace. The collaboration optimizes product catalog management, automates categorization, and boosts employee efficiency. ", "symbols": ["W"], "source": "benzinga", "author": "Shivani Kumaresan", "url": "https://www.benzinga.com/25/01/42939311/wayfair-expands-google-cloud-partnership-to-tap-ai-for-cost-cuts-and-efficiency", "tags": ["contract"]}
{"id": 42939353, "time": "2025-01-13 05:45:28", "headline": "Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket", "summary": " ", "symbols": ["ARQT", "ATPC", "BDTX", "CPS", "CTM", "DRCT", "GCTK", "ITCI", "LAES", "LDTC", "MCY", "QBTS", "QMMM", "RGTI", "RIME", "SAGE", "STAI", "TG", "TRAW", "VMAR"], "source": "benzinga", "author": "Avi Kapoor", "url": "https://www.benzinga.com/25/01/42939353/why-sage-therapeutics-shares-are-trading-higher-by-over-34-here-are-20-stocks-moving-premarket", "tags": ["why_moving"]}
{"id": 42939374, "time": "2025-01-13 05:48:32", "headline": "US Treasury Yields Near Crucial 5% Mark Last Seen During 2008 Global Financial Crisis, But Analyst Dismisses Fears, Says 'Market Appears To Be Overreacting'", "summary": "As U.S. Treasury yields near the 5% mark which it last saw in 2023 and during the global financial crisis, analysts call it an overreaction.", "symbols": ["QQQ", "SPY"], "source": "benzinga", "author": "Rishabh Mishra", "url": "https://www.benzinga.com/25/01/42939374/as-bond-yields-near-the-crucial-5-mark-last-seen-briefly-in-2023-and-global-financial-crisis-this-analyst-says-market-appears-to-be-overreacting", "tags": []}
{"id": 42939407, "time": "2025-01-13 05:52:04", "headline": "Needham Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target", "summary": "", "symbols": ["BPMC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939407/needham-reiterates-buy-on-blueprint-medicines-maintains-135-price-target", "tags": ["analyst_other"]}
{"id": 42939690, "time": "2025-01-13 06:02:52", "headline": "European Wax Center Reveals Net New Center Openings; Expects FY24 System-wide Sales Near High End Of Prior Outlook Driven By Strong Q4 Wax Pass Sales And Continued Loyalty Of Core Guests", "summary": "", "symbols": ["EWCZ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939690/european-wax-center-reveals-net-new-center-openings-expects-fy24-system-wide-sales-near-high-end-of", "tags": ["guidance"]}
{"id": 42939697, "time": "2025-01-13 06:04:03", "headline": "Pediatrix Medical Has Appointed Executive Chair Mark Ordan To Return To His Former Position As CEO, Effective Immediately, Replacing James Swift Who Assumed The CEO Role In January 2023", "summary": "", "symbols": ["MD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939697/pediatrix-medical-has-appointed-executive-chair-mark-ordan-to-return-to-his-former-position-as-ceo-e", "tags": ["management"]}
{"id": 42939700, "time": "2025-01-13 06:04:34", "headline": "High Tide Expands into German Medical Cannabis Market with \u20ac4.8M Acquisition of Purecan Stake", "summary": "", "symbols": ["HITI", "TSXV:HITI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42939700/high-tide-expands-into-german-medical-cannabis-market-with-4-8m-acquisition-of-purecan-stake", "tags": []}
{"id": 42939704, "time": "2025-01-13 06:05:30", "headline": "NewGenIvf Launches Lifetime Egg Freezing Service in Asia, Offering One-Time Payment Option for Women", "summary": "", "symbols": ["NIVF"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939704/newgenivf-launches-lifetime-egg-freezing-service-in-asia-offering-one-time-payment-option-for-women", "tags": ["offering"]}
{"id": 42939706, "time": "2025-01-13 06:06:12", "headline": "European Wax Center Reiterates Its Previous FY24 Outlook For Total Revenue Of $216M -  $221M, Est $218.91M", "summary": "", "symbols": ["EWCZ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939706/european-wax-center-reiterates-its-previous-fy24-outlook-for-total-revenue-of-216m-221m-est-218-91m", "tags": ["analyst_other", "earnings", "guidance"]}
{"id": 42939716, "time": "2025-01-13 06:06:32", "headline": "Regeneron Partners with Truveta, Invests $119.5M to Launch Genome Project Linking DNA and Health Data", "summary": "", "symbols": ["REGN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939716/regeneron-partners-with-truveta-invests-119-5m-to-launch-genome-project-linking-dna-and-health-data", "tags": ["contract"]}
{"id": 42939760, "time": "2025-01-13 06:07:34", "headline": "Pediatrix Medical Expects To Hit The Upper End Of Its Projected Range For 2024 Adjusted Ebitda And Could Even Surpass It. The Company Previously Forecasted Adjusted EBITDA Of $205M-$215M For 2024 And Now Believes It Is On Track To Exceed Those Expectations", "summary": "", "symbols": ["MD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939760/pediatrix-medical-expects-to-hit-the-upper-end-of-its-projected-range-for-2024-adjusted-ebitda-and-c", "tags": []}
{"id": 42939765, "time": "2025-01-13 06:08:29", "headline": "Carvana Teams Up with Rush Soccer to Support Young Athletes and Families Nationwide", "summary": "", "symbols": ["CVNA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939765/carvana-teams-up-with-rush-soccer-to-support-young-athletes-and-families-nationwide", "tags": []}
{"id": 42939766, "time": "2025-01-13 06:11:25", "headline": "Quantum Computing Stocks Tumble After Mark Zuckerberg Backs Nvidia CEO Jensen Huang's 'Practical' Comments: QUBT Down 9%, RGTI Falls 16% And IONQ Loses 15%", "summary": "The declines followed Zuckerberg&#39;s appearance on Joe Rogan&#39;s podcast, where he expressed his view on the timeline for quantum computing adoption.", "symbols": ["IONQ", "QBTS", "QUBT", "RGTI"], "source": "benzinga", "author": "Pooja Rajkumari", "url": "https://www.benzinga.com/markets/equities/25/01/42939766/quantum-computing-stocks-tumble-after-mark-zuckerberg-backs-nvidia-ceo-jensen-huangs-practical-comments-qubt-down-9-rgti-falls-16-and-ionq-loses-15", "tags": ["management"]}
{"id": 42939786, "time": "2025-01-13 06:13:55", "headline": "Despite Elon Musk's Feud With Gavin Newsom, Tesla Rolls Out Support For California Amid Wildfires With Cybertrucks, Starlink And Megapack Chargers", "summary": "Tesla Inc CEO Elon Musk on Sunday pegged the delay in Cybertruck deliveries to expectant customers in the California area to the company&#39;s relief efforts in Los Angeles where multiple wildfires have claimed lives and belongings.", "symbols": ["TSLA"], "source": "benzinga", "author": "Anan Ashraf", "url": "https://www.benzinga.com/general/space/25/01/42939786/despite-elon-musks-feud-with-gavin-newsom-tesla-rolls-out-support-for-california-amid-wildfires-with-cybertrucks-starlink-and-megapack-chargers", "tags": ["management"]}
{"id": 42939799, "time": "2025-01-13 06:15:23", "headline": "Jefferies Downgrades Pinterest to Hold, Lowers Price Target to $32", "summary": "", "symbols": ["PINS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939799/jefferies-downgrades-pinterest-to-hold-lowers-price-target-to-32", "tags": ["analyst_down", "price_target_down"]}
{"id": 42939804, "time": "2025-01-13 06:16:56", "headline": "Jefferies Downgrades Constellation Brands to Hold, Lowers Price Target to $201", "summary": "", "symbols": ["STZ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939804/jefferies-downgrades-constellation-brands-to-hold-lowers-price-target-to-201", "tags": ["analyst_down", "price_target_down"]}
{"id": 42939863, "time": "2025-01-13 06:17:18", "headline": "BMO Capital Initiates Coverage On Axis Capital Holdings with Market Perform Rating, Announces Price Target of $93", "summary": "", "symbols": ["AXS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939863/bmo-capital-initiates-coverage-on-axis-capital-holdings-with-market-perform-rating-announces-price-t", "tags": ["analyst_init"]}
{"id": 42939865, "time": "2025-01-13 06:18:20", "headline": "Bank of America Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts", "summary": " ", "symbols": ["BAC"], "source": "benzinga", "author": "Avi Kapoor", "url": "https://www.benzinga.com/25/01/42939865/bank-of-america-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts", "tags": ["guidance"]}
{"id": 42939866, "time": "2025-01-13 06:18:29", "headline": "Jefferies Upgrades Etsy to Hold, Raises Price Target to $55", "summary": "", "symbols": ["ETSY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939866/jefferies-upgrades-etsy-to-hold-raises-price-target-to-55", "tags": ["analyst_up", "price_target_up"]}
{"id": 42939868, "time": "2025-01-13 06:18:37", "headline": "Asia And Europe Markets Fall, Dollar Hits New High - Global Markets Today While US Slept", "summary": "US markets ended lower due to strong job data reigniting inflation fears and Fed rate adjustment expectations. Oil prices surged on US sanctions on Russia, while dollar rose on strong jobs data.", "symbols": ["ADIV", "AGOV", "ASHR", "BBEU", "BOIL", "CQQQ", "DBC", "EEM", "EEMA", "EWU", "EZU", "FLAX", "FXA", "FXB", "FXC", "FXE", "FXI", "GLD", "GSG", "GXC", "IEMG", "IEUR", "IEV", "KDIV", "SPEM", "SPY", "UNG", "USDU", "USO", "UUP", "VGK", "VWO"], "source": "benzinga", "author": "Akanksha Bakshi", "url": "https://www.benzinga.com/25/01/42939868/asia-and-europe-markets-in-red-lower-crude-oil-gains-dollar-strengthens-global-markets-today-while-us-slept", "tags": []}
{"id": 42939884, "time": "2025-01-13 06:19:10", "headline": "Regeneron's Libtayo Extends Disease-Free Survival in High-Risk Skin Cancer Patients After Surgery", "summary": "", "symbols": ["REGN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939884/regenerons-libtayo-extends-disease-free-survival-in-high-risk-skin-cancer-patients-after-surgery", "tags": []}
{"id": 42939885, "time": "2025-01-13 06:19:13", "headline": "Needham Reiterates Hold on Amicus Therapeutics", "summary": "", "symbols": ["FOLD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939885/needham-reiterates-hold-on-amicus-therapeutics", "tags": ["analyst_other"]}
{"id": 42939887, "time": "2025-01-13 06:19:42", "headline": "BMO Capital Downgrades NextEra Energy Partners to Market Perform, Lowers Price Target to $18", "summary": "", "symbols": ["NEP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939887/bmo-capital-downgrades-nextera-energy-partners-to-market-perform-lowers-price-target-to-18", "tags": ["analyst_down", "price_target_down"]}
{"id": 42939907, "time": "2025-01-13 06:21:09", "headline": "JP Morgan Downgrades Constellation Brands to Neutral, Lowers Price Target to $203", "summary": "", "symbols": ["STZ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939907/jp-morgan-downgrades-constellation-brands-to-neutral-lowers-price-target-to-203", "tags": ["analyst_down", "price_target_down"]}
{"id": 42939925, "time": "2025-01-13 06:22:25", "headline": "BMO Capital Initiates Coverage On PG&E with Outperform Rating, Announces Price Target of $21", "summary": "", "symbols": ["PCG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42939925/bmo-capital-initiates-coverage-on-pg-e-with-outperform-rating-announces-price-target-of-21", "tags": ["analyst_init"]}
{"id": 42940004, "time": "2025-01-13 06:22:31", "headline": "JP Morgan Upgrades Nutrien to Neutral, Raises Price Target to $50", "summary": "", "symbols": ["NTR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940004/jp-morgan-upgrades-nutrien-to-neutral-raises-price-target-to-50", "tags": ["analyst_up", "price_target_up"]}
{"id": 42940128, "time": "2025-01-13 06:23:21", "headline": "Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $320 Price Target", "summary": "", "symbols": ["ALNY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940128/needham-reiterates-buy-on-alnylam-pharmaceuticals-maintains-320-price-target", "tags": ["analyst_other"]}
{"id": 42940140, "time": "2025-01-13 06:24:18", "headline": "Barclays Downgrades Terreno Realty to Equal-Weight, Lowers Price Target to $60", "summary": "", "symbols": ["TRNO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940140/barclays-downgrades-terreno-realty-to-equal-weight-lowers-price-target-to-60", "tags": ["analyst_down", "price_target_down"]}
{"id": 42940144, "time": "2025-01-13 06:26:08", "headline": "BMO Capital Upgrades Essex Property Trust to Outperform, Lowers Price Target to $310", "summary": "", "symbols": ["ESS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940144/bmo-capital-upgrades-essex-property-trust-to-outperform-lowers-price-target-to-310", "tags": ["analyst_up", "price_target_down"]}
{"id": 42940172, "time": "2025-01-13 06:28:37", "headline": "Barclays Upgrades Crown Castle to Overweight, Lowers Price Target to $104", "summary": "", "symbols": ["CCI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940172/barclays-upgrades-crown-castle-to-overweight-lowers-price-target-to-104", "tags": ["analyst_up", "price_target_down"]}
{"id": 42940174, "time": "2025-01-13 06:29:53", "headline": "Barclays Downgrades Definitive Healthcare to Underweight, Maintains Price Target to $4", "summary": "", "symbols": ["DH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940174/barclays-downgrades-definitive-healthcare-to-underweight-maintains-price-target-to-4", "tags": ["analyst_down", "analyst_other"]}
{"id": 42940208, "time": "2025-01-13 06:31:13", "headline": "KBR Secures Global EPCM Contract with BP for Conventional and New Energy Projects", "summary": "", "symbols": ["KBR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940208/kbr-secures-global-epcm-contract-with-bp-for-conventional-and-new-energy-projects", "tags": ["contract"]}
{"id": 42940214, "time": "2025-01-13 06:31:34", "headline": "Citigroup Reinstates Buy on Symbotic, Announces $37 Price Target", "summary": "", "symbols": ["SYM"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940214/citigroup-reinstates-buy-on-symbotic-announces-37-price-target", "tags": []}
{"id": 42940225, "time": "2025-01-13 06:33:19", "headline": "HC Wainwright & Co. Reiterates Buy on SoundHound AI, Maintains $26 Price Target", "summary": "", "symbols": ["SOUN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940225/hc-wainwright-co-reiterates-buy-on-soundhound-ai-maintains-26-price-target", "tags": ["analyst_other"]}
{"id": 42940226, "time": "2025-01-13 06:33:50", "headline": "Johnson & Johnson Has Agreed To Acquire Intra-cellular Therapies For $132.00 Per Share In Cash For A Total Equity Value Of Approximately $14.6B", "summary": "", "symbols": ["ITCI", "JNJ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/large-cap/25/01/42940226/johnson-johnson-has-agreed-to-acquire-intra-cellular-therapies-for-132-00-per-share-in-cash-for-a-", "tags": ["merger"]}
{"id": 42940227, "time": "2025-01-13 06:33:58", "headline": "Johnson & Johnson Agrees To Acquire Intra-cellular Therapies For $132.00 Per Share In Cash For Total Equity Value Of $14.6B", "summary": "", "symbols": ["ITCI", "JNJ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42940227/johnson-johnson-agrees-to-acquire-intra-cellular-therapies-for-132-00-per-share-in-cash-for-total-eq", "tags": ["merger"]}
{"id": 42940228, "time": "2025-01-13 06:34:10", "headline": "US Stock Futures Indicate Lower Opening On Monday After Last Week's Steep Fall: Analyst Says It's A 'Buying Opportunity,' But Market May Dip Further If This Happens", "summary": "U.S. stock futures declined on Monday following Friday&#39;s steep fall. Futures of all four major indices fell in premarket trade.", "symbols": ["ABTS", "AMD", "CMTL", "IONQ", "JWN", "KBH", "NVDA", "PLTR", "QBTS", "QQQ", "QUBT", "RGTI", "SPY", "WDFC"], "source": "benzinga", "author": "Rishabh Mishra", "url": "https://www.benzinga.com/25/01/42940228/us-stocks-to-open-lower-as-index-futures-decline-analysts-see-a-buying-opportunity", "tags": []}
{"id": 42940230, "time": "2025-01-13 06:34:29", "headline": "Lululemon Athletica Expects Q4 Revenue Of $3.56B-$3.58B (Prior $3.475B-$3.510B) Vs $3.517B Est, EPS Of $5.81-$5.85 (Prior $5.56-$5.64) Vs $5.66 Est", "summary": "", "symbols": ["LULU"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940230/lululemon-athletica-expects-q4-revenue-of-3-56b-3-58b-prior-3-475b-3-510b-vs-3-517b-est-eps-of-5-81", "tags": ["earnings"]}
{"id": 42940262, "time": "2025-01-13 06:35:47", "headline": "Johnson & Johnson Says Intra-Cellular Acquisition Includes CAPLYTA (Lumateperone), The First And Only US FDA-Approved Treatment For Bipolar I And II Depression As An Adjunctive And Monotherapy", "summary": "", "symbols": ["ITCI", "JNJ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42940262/johnson-johnson-says-intra-cellular-acquisition-includes-caplyta-lumateperone-the-first-and-only-us", "tags": ["fda"]}
{"id": 42940288, "time": "2025-01-13 06:37:24", "headline": "SpringWorks Therapeutics Reported Q4 OGSIVEO Revenue Of $61.5M, Cash Balance Of $461.9M", "summary": "", "symbols": ["SWTX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42940288/springworks-therapeutics-reported-q4-ogsiveo-revenue-of-61-5m-cash-balance-of-461-9m", "tags": ["earnings"]}
{"id": 42940289, "time": "2025-01-13 06:37:31", "headline": "Ocugen Reveals Two-Year Results From Phase 1/2 Trial Of OCU400, An Innovative Modifier Gene Therapy For Retinitis Pigmentosa", "summary": "", "symbols": ["OCGN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940289/ocugen-reveals-two-year-results-from-phase-12-trial-of-ocu400-an-innovative-modifier-gene-therapy-fo", "tags": ["fda"]}
{"id": 42940298, "time": "2025-01-13 06:38:10", "headline": "Needham Reiterates Buy on ServiceTitan, Maintains $125 Price Target", "summary": "", "symbols": ["TTAN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940298/needham-reiterates-buy-on-servicetitan-maintains-125-price-target", "tags": ["analyst_other"]}
{"id": 42940302, "time": "2025-01-13 06:38:58", "headline": "SuperCom Expands to Ohio, Secures Juvenile Probation EM Contract with Innovative PureOne Technology", "summary": "", "symbols": ["SPCB"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940302/supercom-expands-to-ohio-secures-juvenile-probation-em-contract-with-innovative-pureone-technology", "tags": ["contract"]}
{"id": 42940323, "time": "2025-01-13 06:41:08", "headline": "Clearwater Analytics to Acquire Enfusion for $1.5B in Cash and Stock Deal", "summary": "", "symbols": ["CWAN", "ENFN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42940323/clearwater-analytics-to-acquire-enfusion-for-1-5b-in-cash-and-stock-deal", "tags": ["merger", "contract"]}
{"id": 42940329, "time": "2025-01-13 06:42:09", "headline": "HC Wainwright & Co. Maintains Buy on NioCorp Developments, Lowers Price Target to $3.25", "summary": "", "symbols": ["NB"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940329/hc-wainwright-co-maintains-buy-on-niocorp-developments-lowers-price-target-to-3-25", "tags": ["analyst_other", "price_target_down"]}
{"id": 42940355, "time": "2025-01-13 06:43:11", "headline": "SMX Announces 28.5:1 Reverse Stock Split, Adjusted Trading to Begin January 15, 2025", "summary": "", "symbols": ["SMX", "SMXWW"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940355/smx-announces-28-5-1-reverse-stock-split-adjusted-trading-to-begin-january-15-2025", "tags": []}
{"id": 42940356, "time": "2025-01-13 06:43:47", "headline": "a.k.a. Brands Reports Preliminary 2024 Revenue Of $574.7M (+5.2% YoY), And Q4 $159M (+6.8% YoY); Expects Adjusted EBITDA Between $23M-$23.2M For 2024", "summary": "", "symbols": ["AKA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/small-business/25/01/42940356/a-k-a-brands-reports-preliminary-2024-revenue-of-574-7m-5-2-yoy-and-q4-159m-6-8-yoy-expects-adjust", "tags": ["earnings"]}
{"id": 42940363, "time": "2025-01-13 06:44:58", "headline": "Mosaic Sells Brazilian Phosphate Asset to Fosfatados Centro for $125M, Pending Regulatory Approval", "summary": "", "symbols": ["MOS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940363/mosaic-sells-brazilian-phosphate-asset-to-fosfatados-centro-for-125m-pending-regulatory-approval", "tags": []}
{"id": 42940384, "time": "2025-01-13 06:45:46", "headline": "HC Wainwright & Co. Reiterates Buy on Arcutis Biotherapeutics, Maintains $19 Price Target", "summary": "", "symbols": ["ARQT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940384/hc-wainwright-co-reiterates-buy-on-arcutis-biotherapeutics-maintains-19-price-target", "tags": ["analyst_other"]}
{"id": 42940385, "time": "2025-01-13 06:45:50", "headline": "B of A Securities Downgrades Atlas Energy Solutions to Neutral, Maintains Price Target to $22.5", "summary": "", "symbols": ["AESI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940385/b-of-a-securities-downgrades-atlas-energy-solutions-to-neutral-maintains-price-target-to-22-5", "tags": ["analyst_down", "analyst_other"]}
{"id": 42940389, "time": "2025-01-13 06:47:18", "headline": "Top 3 Real Estate Stocks That May Rocket Higher This Quarter", "summary": " ", "symbols": ["AAT", "ALX", "FOR"], "source": "benzinga", "author": "Avi Kapoor", "url": "https://www.benzinga.com/25/01/42940389/top-3-real-estate-stocks-that-may-rocket-higher-this-quarter", "tags": []}
{"id": 42940420, "time": "2025-01-13 06:48:13", "headline": "AirSculpt Technologies Expects 2024 Revenues Of Approximately $180M Compared To Previous Guidance Of $183M-$189M And Consensus Of $185.601M, With Adjusted EBITDA Of ~$20.5M Compared To Prior Guidance Of $23M-$28M", "summary": "", "symbols": ["AIRS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42940420/airsculpt-technologies-expects-2024-revenues-of-approximately-180m-compared-to-previous-guidance-of", "tags": ["guidance"]}
{"id": 42940421, "time": "2025-01-13 06:48:22", "headline": "a.k.a. Brands Announces New Leadership: Ciaran Long As CEO, Kevin Grant As CFO", "summary": "", "symbols": ["AKA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940421/a-k-a-brands-announces-new-leadership-ciaran-long-as-ceo-kevin-grant-as-cfo", "tags": ["management"]}
{"id": 42940422, "time": "2025-01-13 06:48:35", "headline": "US Foods Holding Reaffirms Previously Announced FY24 Guidance For Net Sales Of $37.7B - $38.0B  (Est $37.878B), Adjusted EPS Of $3.05 - $3.15 (Est $3.12)", "summary": "", "symbols": ["USFD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940422/us-foods-holding-reaffirms-previously-announced-fy24-guidance-for-net-sales-of-37-7b-38-0b-est-37-87", "tags": ["earnings", "guidance"]}
{"id": 42940429, "time": "2025-01-13 06:50:21", "headline": "Nuvalent Targets 2026 Approval With Accelerated NDA For Zidesamtinib In ROS1-Positive NSCLC", "summary": "", "symbols": ["NUVL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940429/nuvalent-targets-2026-approval-with-accelerated-nda-for-zidesamtinib-in-ros1-positive-nsclc", "tags": []}
{"id": 42940430, "time": "2025-01-13 06:50:22", "headline": "OneSpaWorld Expects Q4 Revenue Of $211M-$216M (Prior $210M-$215M) Vs $213.9M Est, FY24 Revenue Of $889M-$894M (Prior $888M-$893M) Vs $891.7M Est, FY25 Revenue Of $950M-$970M Vs $968.97M Est", "summary": "", "symbols": ["OSW"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940430/onespaworld-expects-q4-revenue-of-211m-216m-prior-210m-215m-vs-213-9m-est-fy24-revenue-of-889m-894m", "tags": ["earnings"]}
{"id": 42940434, "time": "2025-01-13 06:50:44", "headline": "Madrigal Pharmaceuticals Reports Preliminary Q4 And FY2024 Rezdiffra (Resmetirom) Net Sales Of $100M-$103M And $177M-$180M, Respectively, With Preliminary Cash Balance Of Approximately $931M, And As Of Year-end 2024, More Than 11,800 Patients On Rezdiffra", "summary": "", "symbols": ["MDGL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42940434/madrigal-pharmaceuticals-reports-preliminary-q4-and-fy2024-rezdiffra-resmetirom-net-sales-of-100m", "tags": []}
{"id": 42940435, "time": "2025-01-13 06:50:51", "headline": "Amer Sports Expects FY24 Revenue Growth To Be At High End Of Prior Guidance Range Of 16 \u2013 17% Despite Currency Headwinds In Q4", "summary": "", "symbols": ["AS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940435/amer-sports-expects-fy24-revenue-growth-to-be-at-high-end-of-prior-guidance-range-of-16-17-despite-c", "tags": ["earnings", "guidance"]}
{"id": 42940436, "time": "2025-01-13 06:51:15", "headline": "Evercore ISI Group Upgrades Caterpillar to In-Line, Announces $365 Price Target", "summary": "", "symbols": ["CAT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940436/evercore-isi-group-upgrades-caterpillar-to-in-line-announces-365-price-target", "tags": ["analyst_up"]}
{"id": 42940453, "time": "2025-01-13 06:52:26", "headline": "Wallbox Receives U.S. UL Certification For Quasar 2 Bidirectional Charger", "summary": "", "symbols": ["WBX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940453/wallbox-receives-u-s-ul-certification-for-quasar-2-bidirectional-charger", "tags": []}
{"id": 42940555, "time": "2025-01-13 06:52:46", "headline": "Bitcoin Slides To $91,000 Ahead Of Upcoming Key Inflation Data", "summary": "Bitcoin (CRYPTO: BTC) is entering a pivotal week, as concerns over a potentially overheating U.S. economy continue to drag down the apex cryptocurrency.", "symbols": ["BTCUSD", "COIN", "ETHUSD", "MSTR", "USDCUSD", "XRPUSD"], "source": "benzinga", "author": "Murtuza Merchant", "url": "https://www.benzinga.com/markets/cryptocurrency/25/01/42940555/bitcoin-slides-to-91000-ahead-of-upcoming-key-inflation-data", "tags": []}
{"id": 42940661, "time": "2025-01-13 06:53:31", "headline": "Pharvaris Unveils 2025 Strategic Priorities; Says Operating From Strong Financial Position With Estimated Cash Runway Into 3Q2026", "summary": "", "symbols": ["PHVS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940661/pharvaris-unveils-2025-strategic-priorities-says-operating-from-strong-financial-position-with-estim", "tags": []}
{"id": 42940666, "time": "2025-01-13 06:53:52", "headline": "Evercore ISI Group Upgrades Chewy to Outperform, Raises Price Target to $47", "summary": "", "symbols": ["CHWY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940666/evercore-isi-group-upgrades-chewy-to-outperform-raises-price-target-to-47", "tags": ["analyst_up", "price_target_up"]}
{"id": 42940662, "time": "2025-01-13 06:53:32", "headline": "Vision Marine Technologies Raises $5.8M In Brokered Private Placement", "summary": "", "symbols": ["VMAR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940662/vision-marine-technologies-raises-5-8m-in-brokered-private-placemen", "tags": ["offering"]}
{"id": 42940667, "time": "2025-01-13 06:54:03", "headline": "ANI Pharma Expects Q4 Purified Cortrophin Gel Revenues of $59.2M-$59.8M And $197.8M-$198.4M For FY24, Q4 ILUVIEN And YUTIQ Revenues Of $26.6M-$27.2M, FY25 Total Revenue Of $739M-$759M", "summary": "", "symbols": ["ANIP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940667/ani-pharma-expects-q4-purified-cortrophin-gel-revenues-of-59-2m-59-8m-and-197-8m-198-4m-for-fy24-q4", "tags": ["earnings"]}
{"id": 42940669, "time": "2025-01-13 06:54:27", "headline": "Inspire Medical Systems Reports Preliminary Q4 And FY2024 Revenues Of $239.5M-$239.7M And $802.6M-$802.8M Versus Consensus Of 233.29M And $796.09M, Respectively", "summary": "", "symbols": ["INSP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42940669/inspire-medical-systems-reports-preliminary-q4-and-fy2024-revenues-of-239-5m-239-7m-and-802-6m-802-", "tags": []}
{"id": 42940670, "time": "2025-01-13 06:54:55", "headline": "HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $81 Price Target", "summary": "", "symbols": ["CRNX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940670/hc-wainwright-co-reiterates-buy-on-crinetics-pharmaceuticals-maintains-81-price-target", "tags": ["analyst_other"]}
{"id": 42940675, "time": "2025-01-13 06:55:28", "headline": "Inspire Medical Systems Expects FY25 Sales Of $940M-$955M Versus Consensus Of $950.62M", "summary": "", "symbols": ["INSP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42940675/inspire-medical-systems-expects-fy25-sales-of-940m-955m-versus-consensus-of-950-62m", "tags": []}
{"id": 42940676, "time": "2025-01-13 06:56:13", "headline": "Brazil Potash And Mura Indigenous Council Partner For Autazes Potash Project Development", "summary": "", "symbols": ["GRO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940676/brazil-potash-and-mura-indigenous-council-partner-for-autazes-potash-project-development", "tags": []}
{"id": 42940720, "time": "2025-01-13 06:57:37", "headline": "J.Jill Reaffirms Its Q4 And Full Year 2024 Guidance; Continues To Expect Q4 Net Sales To Be Down 4% To 6%, FY24 To Be About Flat To Up 1%", "summary": "", "symbols": ["JILL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940720/j-jill-reaffirms-its-q4-and-full-year-2024-guidance-continues-to-expect-q4-net-sales-to-be-down-4-to", "tags": ["guidance"]}
{"id": 42940721, "time": "2025-01-13 06:57:51", "headline": "HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $6.5 Price Target", "summary": "", "symbols": ["NKTR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940721/hc-wainwright-co-reiterates-buy-on-nektar-therapeutics-maintains-6-5-price-target", "tags": ["analyst_other"]}
{"id": 42940722, "time": "2025-01-13 06:58:14", "headline": "Morgan Stanley Upgrades RH to Overweight, Raises Price Target to $530", "summary": "", "symbols": ["RH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940722/morgan-stanley-upgrades-rh-to-overweight-raises-price-target-to-530", "tags": ["analyst_up", "price_target_up"]}
{"id": 42940724, "time": "2025-01-13 07:00:03", "headline": "Citi Trends Reports Total Holiday Sales For Quarter-To-Date Period Ending January 4, 2025 Of $174.4M; Comparable Store Sales, Calculated On A Shifted 9-week To 9-week Basis, Increase 7.1%", "summary": "", "symbols": ["CTRN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940724/citi-trends-reports-total-holiday-sales-for-quarter-to-date-period-ending-january-4-2025-of-174-4m-c", "tags": []}
{"id": 42940803, "time": "2025-01-13 07:00:13", "headline": "A Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts", "summary": " ", "symbols": ["FOLD"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42940803/a-glimpse-into-the-expert-outlook-on-amicus-therapeutics-through-6-analysts", "tags": ["guidance"]}
{"id": 42940832, "time": "2025-01-13 07:00:19", "headline": "Jamie Dimon Says He's Not Against Blockchains But Trades Guns On Bitcoin Again\u2014It Has No Intrinsic Value: 'I Just Don't Feel Great About...'", "summary": "Jamie Dimon, the CEO of banking behemoth JPMorgan, reiterated his critical stance on Bitcoin (CRYPTO: BTC) while recognizing the importance of blockchain technology.", "symbols": ["BTC", "BTCUSD", "FBTC", "IBIT", "USDTUSD"], "source": "benzinga", "author": "Aniket Verma", "url": "https://www.benzinga.com/markets/cryptocurrency/25/01/42940832/jamie-dimon-says-hes-not-against-blockchains-but-trades-guns-on-bitcoin-again-it-has-no-intrinsic-value-i-just-dont-feel-great-about", "tags": ["management"]}
{"id": 42940839, "time": "2025-01-13 07:00:21", "headline": "Beyond The Numbers: 6 Analysts Discuss SoundHound AI Stock", "summary": " ", "symbols": ["SOUN"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42940839/beyond-the-numbers-6-analysts-discuss-soundhound-ai-stock", "tags": []}
{"id": 42940841, "time": "2025-01-13 07:00:29", "headline": "Beyond The Numbers: 6 Analysts Discuss Axis Capital Holdings Stock", "summary": " ", "symbols": ["AXS"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42940841/beyond-the-numbers-6-analysts-discuss-axis-capital-holdings-stock", "tags": []}
{"id": 42940843, "time": "2025-01-13 07:00:32", "headline": "HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target", "summary": "", "symbols": ["FDMT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940843/hc-wainwright-co-reiterates-buy-on-4d-molecular-therapeutics-maintains-36-price-target", "tags": ["analyst_other"]}
{"id": 42940844, "time": "2025-01-13 07:00:39", "headline": "Atlas Energy Solutions Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)", "summary": " ", "symbols": ["AESI"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42940844/atlas-energy-solutions-stock-a-deep-dive-into-analyst-perspectives-6-ratings", "tags": []}
{"id": 42940846, "time": "2025-01-13 07:00:47", "headline": "What 15 Analyst Ratings Have To Say About Alnylam Pharmaceuticals", "summary": " ", "symbols": ["ALNY"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42940846/what-15-analyst-ratings-have-to-say-about-alnylam-pharmaceuticals", "tags": []}
{"id": 42940853, "time": "2025-01-13 07:00:54", "headline": "Breaking Down Caterpillar: 9 Analysts Share Their Views", "summary": " ", "symbols": ["CAT"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42940853/breaking-down-caterpillar-9-analysts-share-their-views", "tags": []}
{"id": 42940858, "time": "2025-01-13 07:01:05", "headline": "Morgan Stanley Upgrades e.l.f. Beauty to Overweight, Raises Price Target to $153", "summary": "", "symbols": ["ELF"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940858/morgan-stanley-upgrades-e-l-f-beauty-to-overweight-raises-price-target-to-153", "tags": ["analyst_up", "price_target_up"]}
{"id": 42940870, "time": "2025-01-13 07:01:22", "headline": "Citi Trends Now Expects H2 Sales And EBITDA Results To Be At High End Of Previously Provided Outlook", "summary": "", "symbols": ["CTRN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940870/citi-trends-now-expects-h2-sales-and-ebitda-results-to-be-at-high-end-of-previously-provided-outlook", "tags": ["guidance"]}
{"id": 42940904, "time": "2025-01-13 07:02:30", "headline": "HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $30 Price Target", "summary": "", "symbols": ["TYRA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940904/hc-wainwright-co-reiterates-buy-on-tyra-biosciences-maintains-30-price-target", "tags": ["analyst_other"]}
{"id": 42940907, "time": "2025-01-13 07:02:44", "headline": "Papa John's International's Q4 Global System-Wide Sales Were ~$1.2B, Down 8% YoY, North America Comparable Sales Were Down 4% YoY", "summary": "", "symbols": ["PZZA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42940907/papa-johns-internationals-q4-global-system-wide-sales-were-1-2b-down-8-yoy-north-america-comparable", "tags": []}
{"id": 42940912, "time": "2025-01-13 07:02:54", "headline": "Citi Trends Expects Implied Q4 Comparable Store Sales To Be On High End Of Range Of Up Low To Mid-single Digits With Total Sales Down Low To Mid-single Digits", "summary": "", "symbols": ["CTRN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940912/citi-trends-expects-implied-q4-comparable-store-sales-to-be-on-high-end-of-range-of-up-low-to-mid-si", "tags": []}
{"id": 42940954, "time": "2025-01-13 07:04:24", "headline": "Standard BioTools Announced Preliminary Revenue For Q4 And FY 2024 Of Approximately $46.5M And $174M, Respectively, Compared To Consensus Of $43.03M And $171.20M", "summary": "", "symbols": ["LAB"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42940954/standard-biotools-announced-preliminary-revenue-for-q4-and-fy-2024-of-approximately-46-5m-and-174m-", "tags": ["earnings"]}
{"id": 42940964, "time": "2025-01-13 07:05:32", "headline": "Morgan Stanley Upgrades Ardagh Metal Packaging to Equal-Weight, Lowers Price Target to $3.1", "summary": "", "symbols": ["AMBP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940964/morgan-stanley-upgrades-ardagh-metal-packaging-to-equal-weight-lowers-price-target-to-3-1", "tags": ["analyst_up", "price_target_down"]}
{"id": 42940965, "time": "2025-01-13 07:05:33", "headline": "12 Industrials Stocks Moving In Monday's Pre-Market Session", "summary": " ", "symbols": ["ALTG", "BAER", "EHGO", "HOVR", "KULR", "MG", "NNBR", "PSIG", "RR", "SIDU", "SRFM", "XOS"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/movers/25/01/42940965/12-industrials-stocks-moving-in-mondays-pre-market-session", "tags": ["why_moving"]}
{"id": 42940967, "time": "2025-01-13 07:05:38", "headline": "12 Health Care Stocks Moving In Monday's Pre-Market Session", "summary": " ", "symbols": ["AIRS", "ALGS", "ATPC", "GCTK", "GDTC", "GTBP", "INDP", "ITCI", "NAYA", "NBY", "OCUL", "SAGE"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/movers/25/01/42940967/12-health-care-stocks-moving-in-mondays-pre-market-session", "tags": ["why_moving"]}
{"id": 42940968, "time": "2025-01-13 07:05:43", "headline": "12 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session", "summary": " ", "symbols": ["AGAE", "ARKR", "BODI", "CJET", "DMN", "LCUT", "LULU", "MKDW", "MSN", "OSW", "TCTM", "VMAR"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/movers/25/01/42940968/12-consumer-discretionary-stocks-moving-in-mondays-pre-market-session", "tags": ["why_moving"]}
{"id": 42940981, "time": "2025-01-13 07:05:49", "headline": "12 Financials Stocks Moving In Monday's Pre-Market Session", "summary": " ", "symbols": ["FAAS", "FBLA", "GHLD", "GRNQ", "HTBK", "MCVT", "MCY", "PSBD", "PX", "RNR", "VINP", "XHG"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/movers/25/01/42940981/12-financials-stocks-moving-in-mondays-pre-market-session", "tags": ["why_moving"]}
{"id": 42940991, "time": "2025-01-13 07:06:04", "headline": "TransMedics Addressed What We Believe Are Inaccurate And Misleading Claims Made In A Short-seller Report Issued By Scorpion Capital On January 10, 2025", "summary": "", "symbols": ["TMDX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42940991/transmedics-addressed-what-we-believe-are-inaccurate-and-misleading-claims-made-in-a-short-seller-r", "tags": []}
{"id": 42940994, "time": "2025-01-13 07:06:12", "headline": "CareDx Expects Q4 Revenue Of $85M-$86M Vs $82.16M Est, FY24 Revenue Of $332M-$333M Vs $329.4M Est, FY25 Revenue Of $370M Vs $366.7M Est", "summary": "", "symbols": ["CDNA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42940994/caredx-expects-q4-revenue-of-85m-86m-vs-82-16m-est-fy24-revenue-of-332m-333m-vs-329-4m-est-fy25-reve", "tags": ["earnings"]}
{"id": 42941003, "time": "2025-01-13 07:06:23", "headline": "Macy's Expects Q4 Adjusted EPS To Be In-line With Previously Issued Range Of $1.40 - $1.65 (Est $1.57) And Net Sales To Be At, To Slightly Below,  Low-end Of Prior Range Of $7.8B - $8.0B (Est $7.885B)", "summary": "", "symbols": ["M"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941003/macys-expects-q4-adjusted-eps-to-be-in-line-with-previously-issued-range-of-1-40-1-65-est-1-57-and-n", "tags": ["earnings"]}
{"id": 42941126, "time": "2025-01-13 07:07:52", "headline": "Morgan Stanley Upgrades Crown Holdings to Overweight, Lowers Price Target to $105", "summary": "", "symbols": ["CCK"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941126/morgan-stanley-upgrades-crown-holdings-to-overweight-lowers-price-target-to-105", "tags": ["analyst_up", "price_target_down"]}
{"id": 42941131, "time": "2025-01-13 07:08:30", "headline": "Guardant Health Announced Preliminary Q4 Sales Of Approximately $200M, An Increase Of 29% Compared To Consensus Of $186.73M", "summary": "", "symbols": ["GH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42941131/guardant-health-announced-preliminary-q4-sales-of-approximately-200m-an-increase-of-29-compared-to-", "tags": []}
{"id": 42941136, "time": "2025-01-13 07:08:48", "headline": "HC Wainwright & Co. Reiterates Buy on Rallybio, Maintains $5 Price Target", "summary": "", "symbols": ["RLYB"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941136/hc-wainwright-co-reiterates-buy-on-rallybio-maintains-5-price-target", "tags": ["analyst_other"]}
{"id": 42941138, "time": "2025-01-13 07:09:05", "headline": "ADMA Reports 2024 Preliminary Revenue Of $ $417M-425M ($422.39M Est.) With With Over $100M Cash, Projects FY 2025 Revenue Over $485M And FY 2026 Above $600M", "summary": "", "symbols": ["ADMA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941138/adma-reports-2024-preliminary-revenue-of-417m-425m-422-39m-est-with-with-over-100m-cash-projects-fy", "tags": ["earnings"]}
{"id": 42941140, "time": "2025-01-13 07:09:29", "headline": "iRobot Expects To Report Q4 Revenue Of Approximately $171M, Est $187.839M", "summary": "", "symbols": ["IRBT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941140/irobot-expects-to-report-q4-revenue-of-approximately-171m-est-187-839m", "tags": ["earnings"]}
{"id": 42941141, "time": "2025-01-13 07:09:37", "headline": "EDAP Reported Preliminary Worldwide Q4 Sales of 11 Focal One Systems, US Q4 Focal One System Sales", "summary": "", "symbols": ["EDAP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941141/edap-reported-preliminary-worldwide-q4-sales-of-11-focal-one-systems-us-q4-focal-one-system-sales", "tags": []}
{"id": 42941142, "time": "2025-01-13 07:09:58", "headline": "Guardant Health Announced Preliminary FY2024 Sales Of Approximately $737M, An Increase Of 31% Compared To Consensus Of $723.9M", "summary": "", "symbols": ["GH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42941142/guardant-health-announced-preliminary-fy2024-sales-of-approximately-737m-an-increase-of-31-compared", "tags": []}
{"id": 42941143, "time": "2025-01-13 07:10:17", "headline": "MSTR Stock Down Over 4% In Monday Pre-Market After Michael Saylor's 10th Consecutive Week Of Bitcoin Tracker Update, Hinting At Impending BTC Purchase", "summary": "Hayes further stated he would not trade MicroStrategy&#39;s stock, suggesting there are more effective methods to invest in Bitcoin, either long or short.", "symbols": ["BTCUSD", "MSTR"], "source": "benzinga", "author": "Pooja Rajkumari", "url": "https://www.benzinga.com/markets/equities/25/01/42941143/mstr-stock-down-over-4-in-pre-market-after-michael-saylors-10th-consecutive-week-of-bitcoin-tracker-update-hinting-at-impending-btc-purchase", "tags": []}
{"id": 42941154, "time": "2025-01-13 07:11:11", "headline": "HC Wainwright & Co. Maintains Buy on Barinthus Biotherapeutics, Lowers Price Target to $3", "summary": "", "symbols": ["BRNS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941154/hc-wainwright-co-maintains-buy-on-barinthus-biotherapeutics-lowers-price-target-to-3", "tags": ["analyst_other", "price_target_down"]}
{"id": 42941155, "time": "2025-01-13 07:11:22", "headline": "For 2025, iRobot Currently Expects To Return To YoY Top-line Growth As It Introduces New And Revitalized Products", "summary": "", "symbols": ["IRBT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941155/for-2025-irobot-currently-expects-to-return-to-yoy-top-line-growth-as-it-introduces-new-and-revitali", "tags": []}
{"id": 42941159, "time": "2025-01-13 07:11:36", "headline": "Bicycle Therapeutics Announced Updated Topline Phase 1 Combination Data For Zelenectide Pevedotin Plus Pembrolizumab In Previously Untreated (First-line) Cisplatin-ineligible Patients With Metastatic Urothelial Cancer", "summary": "", "symbols": ["BCYC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42941159/bicycle-therapeutics-announced-updated-topline-phase-1-combination-data-for-zelenectide-pevedotin", "tags": ["fda"]}
{"id": 42941160, "time": "2025-01-13 07:11:45", "headline": "Fractyl Health Reports Initial Results Showing Sustained Weight Maintenance After GLP-1 Discontinuation And Revita Treatment In First REVEAL-1 Cohort Patient", "summary": "", "symbols": ["GUTS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941160/fractyl-health-reports-initial-results-showing-sustained-weight-maintenance-after-glp-1-discontinuat", "tags": []}
{"id": 42941208, "time": "2025-01-13 07:12:43", "headline": "Comtech Telecom Q1 2025 Adj. EPS $(1.27) Misses $(0.16) Estimate, Sales $115.800M Miss $125.525M Estimate", "summary": "", "symbols": ["CMTL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42941208/comtech-telecom-q1-2025-adj-eps-1-27-misses-0-16-estimate-sales-115-800m-miss-125-525m-estimate", "tags": ["earnings"]}
{"id": 42941222, "time": "2025-01-13 07:14:09", "headline": "Morgan Stanley Upgrades Wix.com to Overweight, Raises Price Target to $276", "summary": "", "symbols": ["WIX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941222/morgan-stanley-upgrades-wix-com-to-overweight-raises-price-target-to-276", "tags": ["analyst_up", "price_target_up"]}
{"id": 42941223, "time": "2025-01-13 07:14:19", "headline": "China's Coal Consumption At New Highs, As Real Estate Crisis Fails To Slow Energy Demands", "summary": "Coal consumption reached all-time high in 2024 due to demand from India and Indonesia, offsetting reductions in advanced economies. China plays pivotal role, with imports and domestic use remaining high despite efforts to diversify energy sources. Global coal demand expected to plateau but remain at record levels.", "symbols": ["COAL", "CSCO", "CXSE", "FEDM", "FEIG", "FEUS", "GXC", "HEAT", "KBA", "SPY"], "source": "benzinga", "author": "Stjepan Kalinic", "url": "https://www.benzinga.com/news/guidance/25/01/42941223/chinas-coal-consumption-at-new-highs-as-real-estate-crisis-fails-to-slow-energy-demands", "tags": []}
{"id": 42941232, "time": "2025-01-13 07:14:56", "headline": "HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $3", "summary": "", "symbols": ["INO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941232/hc-wainwright-co-maintains-neutral-on-inovio-pharmaceuticals-lowers-price-target-to-3", "tags": ["analyst_other", "price_target_down"]}
{"id": 42941236, "time": "2025-01-13 07:15:10", "headline": "Novocure Reports Preliminary Net Revenues For FY2024 Of $605.2M, Up 19% YoY Compared To Consensus Of $594.9M", "summary": "", "symbols": ["NVCR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42941236/novocure-reports-preliminary-net-revenues-for-fy2024-of-605-2m-up-19-yoy-compared-to-consensus-of-5", "tags": []}
{"id": 42941238, "time": "2025-01-13 07:15:33", "headline": "Abercrombie & Fitch Increases Q4 Net Sales Growth Outlook To 7% - 8% From Prior Range Of 5% - 7%; FY24 Net Sales Of Around 15% Vs. Prior Range Of 14% - 15%", "summary": "", "symbols": ["ANF"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941238/abercrombie-fitch-increases-q4-net-sales-growth-outlook-to-7-8-from-prior-range-of-5-7-fy24-net-sale", "tags": ["guidance"]}
{"id": 42941243, "time": "2025-01-13 07:15:45", "headline": "Potbelly Corp Reported Q4 Same Store Sales Growth Of 0.2%-0.3%, Adj EBITDA Of $8.0M-$8.4M", "summary": "", "symbols": ["PBPB"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42941243/potbelly-corp-reported-q4-same-store-sales-growth-of-0-2-0-3-adj-ebitda-of-8-0m-8-4m", "tags": []}
{"id": 42941248, "time": "2025-01-13 07:16:36", "headline": "Novocure Reports Preliminary Net Revenues For Q4 Of $161.3M, Up 21% YoY Compared To Consensus Of $153.052M", "summary": "", "symbols": ["NVCR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42941248/novocure-reports-preliminary-net-revenues-for-q4-of-161-3m-up-21-yoy-compared-to-consensus-of-153-0", "tags": []}
{"id": 42941331, "time": "2025-01-13 07:17:59", "headline": "HC Wainwright & Co. Reiterates Buy on Y-mAbs Therapeutics, Maintains $22 Price Target", "summary": "", "symbols": ["YMAB"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941331/hc-wainwright-co-reiterates-buy-on-y-mabs-therapeutics-maintains-22-price-target", "tags": ["analyst_other"]}
{"id": 42941332, "time": "2025-01-13 07:18:01", "headline": "Noodles & Co Reported Q4 System-Wide Comparable Sales Growth Of 0.8% YoY, Flat YoY Average Unit Volumes", "summary": "", "symbols": ["NDLS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42941332/noodles-co-reported-q4-system-wide-comparable-sales-growth-of-0-8-yoy-flat-yoy-average-unit-volumes", "tags": []}
{"id": 42941333, "time": "2025-01-13 07:18:18", "headline": "Nurix Therapeutics Outlined Key Objectives And Anticipated Milestones For 2025, Which Will Be The Subject Of Nurix's Corporate Update At The Annual J.P. Morgan Healthcare Conference", "summary": "", "symbols": ["NRIX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42941333/nurix-therapeutics-outlined-key-objectives-and-anticipated-milestones-for-2025-which-will-be-the-", "tags": []}
{"id": 42941334, "time": "2025-01-13 07:18:24", "headline": "Option Care Health Board Approves New $500M Stock Repurchase Program", "summary": "", "symbols": ["OPCH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941334/option-care-health-board-approves-new-500m-stock-repurchase-program", "tags": ["buyback"]}
{"id": 42941351, "time": "2025-01-13 07:19:52", "headline": "Atea Pharmaceuticals Reports Its Cash, Cash Equivalents And Marketable Securities Balance Of $454.7M At December 31, 2024 And A Cash Runway Anticipated Into 2028", "summary": "", "symbols": ["AVIR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42941351/atea-pharmaceuticals-reports-its-cash-cash-equivalents-and-marketable-securities-balance-of-454-7", "tags": []}
{"id": 42941352, "time": "2025-01-13 07:20:05", "headline": "Red Robin Gourmet Burgers Reported Q4 Revenue Of $285.2M, Down By $23.8M YoY", "summary": "", "symbols": ["RRGB"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42941352/red-robin-gourmet-burgers-reported-q4-revenue-of-285-2m-down-by-23-8m-yoy", "tags": ["earnings"]}
{"id": 42941360, "time": "2025-01-13 07:21:06", "headline": "Edible Garden Signs Non-binding LoI To Purchase Outstanding Share Capital Of Narayan D.O.O. And Its Subsidiaries; Co. To Issue Its Shares To Narayan Shareholders", "summary": "", "symbols": ["EDBL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42941360/edible-garden-signs-non-binding-loi-to-purchase-outstanding-share-capital-of-narayan-d-o-o-and-its-s", "tags": []}
{"id": 42941373, "time": "2025-01-13 07:22:30", "headline": "Akero Therapeutics Said It Has Completed Enrollment In The Double-blind Portion Of The Phase 3 SYNCHRONY Real-world Study Of Efruxifermin (EFX) For Metabolic Dysfunction-Associated Steatohepatits Or Steatotic Liver Disease, Results Expected In 1H Of 2026", "summary": "", "symbols": ["AKRO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42941373/akero-therapeutics-said-it-has-completed-enrollment-in-the-double-blind-portion-of-the-phase-3-sy", "tags": ["fda"]}
{"id": 42941417, "time": "2025-01-13 07:22:48", "headline": "Option Care Health Expects Q4 Net Revenue Of $1.34B - $1.35B, Est $1.27B; Adjusted EPS Of $0.42 - $0.45 (Est $0.33)", "summary": "", "symbols": ["OPCH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941417/option-care-health-expects-q4-net-revenue-of-1-34b-1-35b-est-1-27b-adjusted-eps-of-0-42-0-45-est-0-3", "tags": ["earnings"]}
{"id": 42941610, "time": "2025-01-13 07:23:15", "headline": "Teledyne FLIR Defense Bags $74M Deal to Boost US Coast Guard Surveillance Systems", "summary": "", "symbols": ["TDY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/government/25/01/42941610/teledyne-flir-defense-bags-74m-deal-to-boost-us-coast-guard-surveillance-systems", "tags": ["contract"]}
{"id": 42941616, "time": "2025-01-13 07:23:22", "headline": "Wells Fargo Upgrades American Well to Overweight, Maintains Price Target to $15", "summary": "", "symbols": ["AMWL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941616/wells-fargo-upgrades-american-well-to-overweight-maintains-price-target-to-15", "tags": ["analyst_up", "analyst_other"]}
{"id": 42941683, "time": "2025-01-13 07:24:30", "headline": "Option Care Health Expects FY24 Net Revenue Of $4.99B - $5.00B (Est $4.922B), Adjusted EPS Of $1.55 - $1.59 (Est $1.21)", "summary": "", "symbols": ["OPCH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941683/option-care-health-expects-fy24-net-revenue-of-4-99b-5-00b-est-4-922b-adjusted-eps-of-1-55-1-59-est", "tags": ["earnings"]}
{"id": 42941778, "time": "2025-01-13 07:26:08", "headline": "Option Care Health Expects Preliminary FY25 Net Revenue Of $5.2B - $5.4B (Est $5.233B), Adjusted EPS Of $1.59 - $1.69 (Est $1.24)", "summary": "", "symbols": ["OPCH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941778/option-care-health-expects-preliminary-fy25-net-revenue-of-5-2b-5-4b-est-5-233b-adjusted-eps-of-1-59", "tags": ["earnings"]}
{"id": 42941850, "time": "2025-01-13 07:28:25", "headline": "Needham Maintains Buy on Shutterstock, Lowers Price Target to $45", "summary": "", "symbols": ["SSTK"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941850/needham-maintains-buy-on-shutterstock-lowers-price-target-to-45", "tags": ["analyst_other", "price_target_down"]}
{"id": 42941851, "time": "2025-01-13 07:28:59", "headline": "Greenwich LifeSciences Announced The Activation Of Clinical Sites In France And Has Partnered With Unicancer For FLAMINGO-01 study Of GLSI-100, An Immunotherapy To Prevent Breast Cancer Recurrences", "summary": "", "symbols": ["GLSI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42941851/greenwich-lifesciences-announced-the-activation-of-clinical-sites-in-france-and-has-partnered-wit", "tags": ["fda"]}
{"id": 42941852, "time": "2025-01-13 07:29:05", "headline": "Moderna  Updates 2025 Expected Revenue Range To $1.5B - $2.5B, Est $2.951B", "summary": "", "symbols": ["MRNA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941852/moderna-updates-2025-expected-revenue-range-to-1-5b-2-5b-est-2-951b", "tags": ["earnings"]}
{"id": 42941853, "time": "2025-01-13 07:29:15", "headline": "Morgan Stanley Upgrades SEMrush Hldgs to Overweight, Raises Price Target to $20", "summary": "", "symbols": ["SEMR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941853/morgan-stanley-upgrades-semrush-hldgs-to-overweight-raises-price-target-to-20", "tags": ["analyst_up", "price_target_up"]}
{"id": 42941895, "time": "2025-01-13 07:30:34", "headline": "Moderna Expects To Reduce 2025 Cash Cost Expenses By $1B With Plan For Additional 2026 Cost Reductions Of $0.5B", "summary": "", "symbols": ["MRNA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941895/moderna-expects-to-reduce-2025-cash-cost-expenses-by-1b-with-plan-for-additional-2026-cost-reduction", "tags": []}
{"id": 42941923, "time": "2025-01-13 07:30:57", "headline": "Needham Reiterates Buy on TeraWulf, Maintains $9.5 Price Target", "summary": "", "symbols": ["WULF"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941923/needham-reiterates-buy-on-terawulf-maintains-9-5-price-target", "tags": ["analyst_other"]}
{"id": 42941927, "time": "2025-01-13 07:31:10", "headline": "Vera Therapeutics Announced An Exclusive License Agreement With Stanford University For Fusion Protein Targeting BAFF And APRIL, Known As VT-109, With Therapeutic Potential Across The Spectrum Of B Cell-mediated Diseases For Undisclosed Upfront And Milestone Payments", "summary": "", "symbols": ["VERA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42941927/vera-therapeutics-announced-an-exclusive-license-agreement-with-stanford-university-for-fusion-pr", "tags": ["contract"]}
{"id": 42941928, "time": "2025-01-13 07:31:23", "headline": "FY 2024 Preliminary Results: Denny's Opens 14 New Restaurants, Projects Adjusted EBITDA At Low End Of $81M-$84M Range", "summary": "", "symbols": ["DENN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941928/fy-2024-preliminary-results-dennys-opens-14-new-restaurants-projects-adjusted-ebitda-at-low-end-of-8", "tags": []}
{"id": 42941929, "time": "2025-01-13 07:31:24", "headline": "Moderna Expects Milestones Across 10 Prioritized Programs, Including Up To Three Potential 2025 Approvals And Six Registrational Data Readouts", "summary": "", "symbols": ["MRNA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941929/moderna-expects-milestones-across-10-prioritized-programs-including-up-to-three-potential-2025-appro", "tags": []}
{"id": 42941937, "time": "2025-01-13 07:31:38", "headline": "D. Boral Capital Initiates Coverage On Checkpoint Therapeutics with Buy Rating, Announces Price Target of $9", "summary": "", "symbols": ["CKPT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941937/d-boral-capital-initiates-coverage-on-checkpoint-therapeutics-with-buy-rating-announces-price-target", "tags": ["analyst_init"]}
{"id": 42941948, "time": "2025-01-13 07:32:38", "headline": "Urban Outfitters Total Company Net Sales For Two Months Ended December 31, 2024, Increase 10%", "summary": "", "symbols": ["URBN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941948/urban-outfitters-total-company-net-sales-for-two-months-ended-december-31-2024-increase-10", "tags": []}
{"id": 42941958, "time": "2025-01-13 07:32:47", "headline": "Littelfuse Taps Director Dr. Greg Henderson As CEO, Effective February 10 After David Heinzmann Announces Retirement", "summary": "", "symbols": ["LFUS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941958/littelfuse-taps-director-dr-greg-henderson-as-ceo-effective-february-10-after-david-heinzmann-announ", "tags": ["management"]}
{"id": 42941961, "time": "2025-01-13 07:33:11", "headline": "Piper Sandler Upgrades Douglas Emmett to Overweight, Maintains Price Target to $20", "summary": "", "symbols": ["DEI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941961/piper-sandler-upgrades-douglas-emmett-to-overweight-maintains-price-target-to-20", "tags": ["analyst_up", "analyst_other"]}
{"id": 42941962, "time": "2025-01-13 07:33:32", "headline": "Axsome Therapeutics Announced Preliminary Net Product Revenue Of Approximately $118.3M And $385.2M For Q4 And FY2024, Respectively", "summary": "", "symbols": ["AXSM"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42941962/axsome-therapeutics-announced-preliminary-net-product-revenue-of-approximately-118-3m-and-385-2m-", "tags": ["earnings"]}
{"id": 42941963, "time": "2025-01-13 07:33:44", "headline": "D. Boral Capital Initiates Coverage On Cormedix with Buy Rating, Announces Price Target of $15", "summary": "", "symbols": ["CRMD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941963/d-boral-capital-initiates-coverage-on-cormedix-with-buy-rating-announces-price-target-of-15", "tags": ["analyst_init"]}
{"id": 42941966, "time": "2025-01-13 07:33:59", "headline": "Needham Maintains Buy on Bitdeer Technologies, Raises Price Target to $22", "summary": "", "symbols": ["BTDR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941966/needham-maintains-buy-on-bitdeer-technologies-raises-price-target-to-22", "tags": ["analyst_other", "price_target_up"]}
{"id": 42941982, "time": "2025-01-13 07:35:12", "headline": "DexCom Expects Q4 Total Revenue Of At Least $1.113B, Up 8% YoY (Est $1.097B); Expects Gross Margin To Be Adversely Impacted By Non-cash Charge", "summary": "", "symbols": ["DXCM"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941982/dexcom-expects-q4-total-revenue-of-at-least-1-113b-up-8-yoy-est-1-097b-expects-gross-margin-to-be-ad", "tags": ["earnings"]}
{"id": 42941985, "time": "2025-01-13 07:35:25", "headline": "22nd Century Prepares To Scale VLN Cigarettes As FDA Nears Reduced Nicotine Mandate", "summary": "", "symbols": ["XXII"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941985/22nd-century-prepares-to-scale-vln-cigarettes-as-fda-nears-reduced-nicotine-mandate", "tags": ["fda"]}
{"id": 42941995, "time": "2025-01-13 07:35:44", "headline": "Cytokinetics Outlined Its Aspirational Vision 2030, Five-year Strategic Objectives", "summary": "", "symbols": ["CYTK"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42941995/cytokinetics-outlined-its-aspirational-vision-2030-five-year-strategic-objectives", "tags": []}
{"id": 42941999, "time": "2025-01-13 07:36:26", "headline": "Needham Reiterates Buy on Hut 8, Maintains $38 Price Target", "summary": "", "symbols": ["HUT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42941999/needham-reiterates-buy-on-hut-8-maintains-38-price-target", "tags": ["analyst_other"]}
{"id": 42942000, "time": "2025-01-13 07:36:27", "headline": "DexCom Currently Anticipates FY25 Total Revenue Of $4.60B, Representing Expected Growth Of 14% Over 2024; Est $4.608B", "summary": "", "symbols": ["DXCM"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942000/dexcom-currently-anticipates-fy25-total-revenue-of-4-60b-representing-expected-growth-of-14-over-202", "tags": ["earnings"]}
{"id": 42942003, "time": "2025-01-13 07:36:56", "headline": "D. Boral Capital Maintains Buy on US Energy, Maintains $2 Price Target", "summary": "", "symbols": ["USEG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942003/d-boral-capital-maintains-buy-on-us-energy-maintains-2-price-target", "tags": ["analyst_other"]}
{"id": 42942005, "time": "2025-01-13 07:37:16", "headline": "Corvus Pharmaceuticals Releases Data From Phase 1 Placebo-Controlled Trial Of Soquelitinib In Atopic Dermatitis Cohort 2", "summary": "", "symbols": ["CRVS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942005/corvus-pharmaceuticals-releases-data-from-phase-1-placebo-controlled-trial-of-soquelitinib-in-atopic", "tags": ["fda"]}
{"id": 42942064, "time": "2025-01-13 07:38:59", "headline": "Needham Reiterates Buy on Constellation Brands, Lowers Price Target to $240", "summary": "", "symbols": ["STZ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942064/needham-reiterates-buy-on-constellation-brands-lowers-price-target-to-240", "tags": ["analyst_other", "price_target_down"]}
{"id": 42942065, "time": "2025-01-13 07:39:20", "headline": "Rosenblatt Maintains Buy on Bitdeer Technologies, Maintains $22 Price Target", "summary": "", "symbols": ["BTDR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942065/rosenblatt-maintains-buy-on-bitdeer-technologies-maintains-22-price-target", "tags": ["analyst_other"]}
{"id": 42942073, "time": "2025-01-13 07:40:17", "headline": "Kiniksa Pharmaceuticals Reports Preliminary Q4 And FY2024 Arcalyst Net Product Revenue Of $121.9M And $416.4M, Respectively", "summary": "", "symbols": ["KNSA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42942073/kiniksa-pharmaceuticals-reports-preliminary-q4-and-fy2024-arcalyst-net-product-revenue-of-121-9m-", "tags": ["earnings"]}
{"id": 42942074, "time": "2025-01-13 07:40:24", "headline": "Kiniksa Pharma Reports Q4 ARCALYST Revenue Of $121.9M, Cash Balance Of $243.6M", "summary": "", "symbols": ["KNSA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42942074/kiniksa-pharma-reports-q4-arcalyst-revenue-of-121-9m-cash-balance-of-243-6m", "tags": ["earnings"]}
{"id": 42942075, "time": "2025-01-13 07:40:35", "headline": "Five Below Net Sales For Holiday Period Increase By 8.7% To $1.19B, Comparable Sales Decrease By 3.2%", "summary": "", "symbols": ["FIVE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942075/five-below-net-sales-for-holiday-period-increase-by-8-7-to-1-19b-comparable-sales-decrease-by-3-2", "tags": []}
{"id": 42942083, "time": "2025-01-13 07:40:45", "headline": "Rosenblatt Maintains Buy on TeraWulf, Maintains $10 Price Target", "summary": "", "symbols": ["WULF"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942083/rosenblatt-maintains-buy-on-terawulf-maintains-10-price-target", "tags": ["analyst_other"]}
{"id": 42942102, "time": "2025-01-13 07:41:10", "headline": "B of A Securities Upgrades American Electric Power to Buy, Raises Price Target to $104", "summary": "", "symbols": ["AEP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942102/b-of-a-securities-upgrades-american-electric-power-to-buy-raises-price-target-to-104", "tags": ["analyst_up", "price_target_up"]}
{"id": 42942115, "time": "2025-01-13 07:42:05", "headline": "Context Therapeutics Taps Andy Pasternak as Chairman As Richard Berman Departs Effective January 12", "summary": "", "symbols": ["CNTX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942115/context-therapeutics-taps-andy-pasternak-as-chairman-as-richard-berman-departs-effective-january-12", "tags": []}
{"id": 42942124, "time": "2025-01-13 07:42:25", "headline": "Five Below Now Expects To Deliver Q4 Sales In The Upper Half Of Guidance Range, Reiterates EPS Outlook", "summary": "", "symbols": ["FIVE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942124/five-below-now-expects-to-deliver-q4-sales-in-the-upper-half-of-guidance-range-reiterates-eps-outloo", "tags": ["analyst_other", "earnings", "guidance"]}
{"id": 42942125, "time": "2025-01-13 07:42:26", "headline": "X4 Pharmaceuticals Secures Licensing Deal With Norgine To Bring Mavorixafor To Europe, Australia, And New Zealand; Total Deal Value Could Exceed \u20ac254M", "summary": "", "symbols": ["XFOR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942125/x4-pharmaceuticals-secures-licensing-deal-with-norgine-to-bring-mavorixafor-to-europe-australia-and", "tags": ["contract"]}
{"id": 42942128, "time": "2025-01-13 07:42:37", "headline": "Telsey Advisory Group Maintains Market Perform on Nordstrom, Maintains $24 Price Target", "summary": "", "symbols": ["JWN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942128/telsey-advisory-group-maintains-market-perform-on-nordstrom-maintains-24-price-target", "tags": ["analyst_other"]}
{"id": 42942129, "time": "2025-01-13 07:42:37", "headline": "HC Wainwright & Co. Reiterates Buy on Dyne Therapeutics, Maintains $55 Price Target", "summary": "", "symbols": ["DYN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942129/hc-wainwright-co-reiterates-buy-on-dyne-therapeutics-maintains-55-price-target", "tags": ["analyst_other"]}
{"id": 42942165, "time": "2025-01-13 07:43:19", "headline": "B of A Securities Upgrades Ovintiv to Buy, Lowers Price Target to $54", "summary": "", "symbols": ["OVV"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942165/b-of-a-securities-upgrades-ovintiv-to-buy-lowers-price-target-to-54", "tags": ["analyst_up", "price_target_down"]}
{"id": 42942169, "time": "2025-01-13 07:44:03", "headline": "Beam Therapeutics Expects Cash Runway To Support Operating Plans Into 2027, Now Inclusive Of Commercial Readiness Activities For BEAM-101", "summary": "", "symbols": ["BEAM"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942169/beam-therapeutics-expects-cash-runway-to-support-operating-plans-into-2027-now-inclusive-of-commerci", "tags": []}
{"id": 42942176, "time": "2025-01-13 07:45:01", "headline": "B of A Securities Downgrades Magnolia Oil & Gas to Neutral, Lowers Price Target to $28", "summary": "", "symbols": ["MGY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942176/b-of-a-securities-downgrades-magnolia-oil-gas-to-neutral-lowers-price-target-to-28", "tags": ["analyst_down", "price_target_down"]}
{"id": 42942182, "time": "2025-01-13 07:45:34", "headline": "CRISPR Therapeutics Highlights Strategic Priorities And Anticipated 2025 Milestones", "summary": "", "symbols": ["CRSP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942182/crispr-therapeutics-highlights-strategic-priorities-and-anticipated-2025-milestones", "tags": []}
{"id": 42942186, "time": "2025-01-13 07:45:56", "headline": "Market-Moving News for January 13th", "summary": "", "symbols": ["LULU", "MRNA", "XHG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/trading-ideas/movers/25/01/42942186/market-moving-news-for-january-13th", "tags": []}
{"id": 42942187, "time": "2025-01-13 07:46:03", "headline": "HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target", "summary": "", "symbols": ["CGON"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942187/hc-wainwright-co-reiterates-buy-on-cg-oncology-maintains-75-price-target", "tags": ["analyst_other"]}
{"id": 42942193, "time": "2025-01-13 07:46:44", "headline": "Arbutus Biopharma Held $123M In Cash Balance, Eying Placebo-Controlled Phase 2b Clinical Trial", "summary": "", "symbols": ["ABUS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942193/arbutus-biopharma-held-123m-in-cash-balance-eying-placebo-controlled-phase-2b-clinical-trial", "tags": ["fda"]}
{"id": 42942232, "time": "2025-01-13 07:47:50", "headline": "Boeing Stock Wiped Out 47% Of Investor Wealth Over The Last 5 Years Amid Multiple Issues \u2014 Now, This Expert Suggests A Breakup Could Benefit The Airplane Maker", "summary": "The Edge founder Jim Osman is reportedly campaigning for a full breakup of planemaker Boeing Co. ", "symbols": ["BA"], "source": "benzinga", "author": "Anan Ashraf", "url": "https://www.benzinga.com/markets/equities/25/01/42942232/boeing-stock-wiped-out-47-of-investor-wealth-over-the-last-5-years-amid-multiple-issues-now-this-expert-suggests-a-breakup-could-benefit-the-airplane-maker", "tags": []}
{"id": 42942233, "time": "2025-01-13 07:47:59", "headline": "Bausch + Lomb Affiliate Acquires Whitecap Biosciences, LLC; No Terms Disclosed", "summary": "", "symbols": ["BLCO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42942233/bausch-lomb-affiliate-acquires-whitecap-biosciences-llc-no-terms-disclosed", "tags": ["merger"]}
{"id": 42942249, "time": "2025-01-13 07:48:49", "headline": "B of A Securities Downgrades EOG Resources to Neutral, Lowers Price Target to $144", "summary": "", "symbols": ["EOG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942249/b-of-a-securities-downgrades-eog-resources-to-neutral-lowers-price-target-to-144", "tags": ["analyst_down", "price_target_down"]}
{"id": 42942264, "time": "2025-01-13 07:50:16", "headline": "D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target", "summary": "", "symbols": ["CTSO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942264/d-boral-capital-maintains-buy-on-cytosorbents-maintains-10-price-target", "tags": ["analyst_other"]}
{"id": 42942267, "time": "2025-01-13 07:50:20", "headline": "Aquestive Therapeutics Outlines 2025 Goals, Including Anaphylm Launch and AQST-108 Phase 2a Trial", "summary": "", "symbols": ["AQST"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942267/aquestive-therapeutics-outlines-2025-goals-including-anaphylm-launch-and-aqst-108-phase-2a-trial", "tags": ["fda"]}
{"id": 42942269, "time": "2025-01-13 07:50:23", "headline": "Oshkosh Secures $29.9M Contract Modification To Integrate Next-generation Autonomous Technology Into ROGUE-Fires With Deliveries Beginning In 2025", "summary": "", "symbols": ["OSK"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942269/oshkosh-secures-29-9m-contract-modification-to-integrate-next-generation-autonomous-technology-into", "tags": ["contract"]}
{"id": 42942281, "time": "2025-01-13 07:50:53", "headline": "B of A Securities Downgrades Chord Energy to Neutral, Lowers Price Target to $138", "summary": "", "symbols": ["CHRD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942281/b-of-a-securities-downgrades-chord-energy-to-neutral-lowers-price-target-to-138", "tags": ["analyst_down", "price_target_down"]}
{"id": 42942290, "time": "2025-01-13 07:52:01", "headline": "First Watch Restaurant Reports Q4 25 New Restaurant Openings", "summary": "", "symbols": ["FWRG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942290/first-watch-restaurant-reports-q4-25-new-restaurant-openings", "tags": []}
{"id": 42942291, "time": "2025-01-13 07:52:11", "headline": "EXCLUSIVE: Bitcoin Tumbling, But Bull Market Top Isn't In Yet, Experts Say", "summary": "Cryptocurrency experts are largely united in their belief that Bitcoin\u2018s (CRYPTO: BTC) long-term bull run remains intact, even as the apex crypto struggl", "symbols": ["BTCUSD"], "source": "benzinga", "author": "Murtuza Merchant", "url": "https://www.benzinga.com/markets/cryptocurrency/25/01/42942291/exclusive-bitcoin-tumbling-but-bull-market-top-isnt-in-yet-experts-say", "tags": []}
{"id": 42942292, "time": "2025-01-13 07:52:26", "headline": "Shake Shack Says Preliminary Unaudited Results Show That In Q4, It Grew Same-shack Sales By 4.3%, Total Revenue By 14.8%", "summary": "", "symbols": ["SHAK"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942292/shake-shack-says-preliminary-unaudited-results-show-that-in-q4-it-grew-same-shack-sales-by-4-3-total", "tags": ["earnings"]}
{"id": 42942297, "time": "2025-01-13 07:52:46", "headline": "B of A Securities Upgrades Gulfport Energy to Buy, Raises Price Target to $227", "summary": "", "symbols": ["GPOR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942297/b-of-a-securities-upgrades-gulfport-energy-to-buy-raises-price-target-to-227", "tags": ["analyst_up", "price_target_up"]}
{"id": 42942316, "time": "2025-01-13 07:52:47", "headline": "HC Wainwright & Co. Reiterates Buy on GH Research, Maintains $40 Price Target", "summary": "", "symbols": ["GHRS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942316/hc-wainwright-co-reiterates-buy-on-gh-research-maintains-40-price-target", "tags": ["analyst_other"]}
{"id": 42942523, "time": "2025-01-13 07:53:21", "headline": "Shake Shack Expects To Grow FY25 Total Revenue By 16% - 18%, Continue To Expand Restaurant Margins To Approximately 22% And Grow Adjusted EBITDA By 14% - 20%", "summary": "", "symbols": ["SHAK"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942523/shake-shack-expects-to-grow-fy25-total-revenue-by-16-18-continue-to-expand-restaurant-margins-to-app", "tags": ["earnings"]}
{"id": 42942530, "time": "2025-01-13 07:53:52", "headline": "Phio Pharmaceuticals Reports 100% Tumor Clearance in Two Patients Using PH-762 in Phase 1b Cancer Study", "summary": "", "symbols": ["PHIO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942530/phio-pharmaceuticals-reports-100-tumor-clearance-in-two-patients-using-ph-762-in-phase-1b-cancer-stu", "tags": []}
{"id": 42942533, "time": "2025-01-13 07:54:35", "headline": "B of A Securities Upgrades Range Resources to Buy, Raises Price Target to $45", "summary": "", "symbols": ["RRC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942533/b-of-a-securities-upgrades-range-resources-to-buy-raises-price-target-to-45", "tags": ["analyst_up", "price_target_up"]}
{"id": 42942535, "time": "2025-01-13 07:55:03", "headline": "Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending", "summary": "", "symbols": ["SLRX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/25/01/42942535/trading-halt-halted-at-7-55-00-a-m-et-trading-halt-halt-news-pending", "tags": ["halt"]}
{"id": 42942537, "time": "2025-01-13 07:55:30", "headline": "Cartesian Therapeutics Expects Cash Resources  To Support Planned Operations, Including Completion Of Planned Phase 3 Trial For Descartes-08 For Myasthenia Gravis, Into Mid-2027", "summary": "", "symbols": ["RNAC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942537/cartesian-therapeutics-expects-cash-resources-to-support-planned-operations-including-completion-of", "tags": ["fda"]}
{"id": 42942538, "time": "2025-01-13 07:56:05", "headline": "HC Wainwright & Co. Maintains Buy on Inozyme Pharma, Raises Price Target to $16", "summary": "", "symbols": ["INZY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942538/hc-wainwright-co-maintains-buy-on-inozyme-pharma-raises-price-target-to-16", "tags": ["analyst_other", "price_target_up"]}
{"id": 42941939, "time": "2025-01-13 07:31:58", "headline": "Nvidia Down 3%, AMD Falls 2% After White House Imposes New AI Chip Export Restrictions", "summary": "The White House on Monday declared new limitations on the export of artificial intelligence chips. This move is set to impact major tech companies, including\u00a0Nvidia\u00a0(NASDAQ: NVDA) and\u00a0Advanced Micro Devices\u00a0(NASDAQ: AMD).", "symbols": ["AMD", "NVDA"], "source": "benzinga", "author": "Navdeep Yadav", "url": "https://www.benzinga.com/markets/25/01/42941939/nvidia-down-3-amd-falls-2-after-white-house-imposes-new-ai-chip-export-restrictions", "tags": []}
{"id": 42942545, "time": "2025-01-13 07:56:45", "headline": "Verve Therapeutics Says Well-capitalized With Cash Runway Extending Into Mid-2027", "summary": "", "symbols": ["VERV"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942545/verve-therapeutics-says-well-capitalized-with-cash-runway-extending-into-mid-2027", "tags": []}
{"id": 42942546, "time": "2025-01-13 07:56:45", "headline": "B of A Securities Maintains Underperform on Walgreens Boots Alliance, Raises Price Target to $8.5", "summary": "", "symbols": ["WBA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942546/b-of-a-securities-maintains-underperform-on-walgreens-boots-alliance-raises-price-target-to-8-5", "tags": ["analyst_other", "price_target_up"]}
{"id": 42942569, "time": "2025-01-13 07:58:27", "headline": "Schr\u00f6dinger Unveils Its Strategic Priorities For 2025; Expands Research Collaboration With Otsuka; Expects To Receive Upfront Payment Of $150M From Novartis In Q1 Of 2025", "summary": "", "symbols": ["SDGR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942569/schr-dinger-unveils-its-strategic-priorities-for-2025-expands-research-collaboration-with-otsuka-exp", "tags": []}
{"id": 42942571, "time": "2025-01-13 07:58:44", "headline": "Silexion Therapeutics To Present SIL-204 Data In KRAS-Driven Pancreatic Cancer At The 2025 ASCO Gastrointestinal Cancers Symposium", "summary": "", "symbols": ["SLXN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42942571/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-g", "tags": []}
{"id": 42942581, "time": "2025-01-13 07:59:35", "headline": "Morgan Stanley Maintains Overweight on Tesla, Raises Price Target to $430", "summary": "", "symbols": ["TSLA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942581/morgan-stanley-maintains-overweight-on-tesla-raises-price-target-to-430", "tags": ["analyst_other", "price_target_up"]}
{"id": 42942582, "time": "2025-01-13 07:59:39", "headline": "Agios Reveals Anticipated Key 2025 Milestones And Value-driving Catalysts Through 2026", "summary": "", "symbols": ["AGIO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942582/agios-reveals-anticipated-key-2025-milestones-and-value-driving-catalysts-through-2026", "tags": []}
{"id": 42942696, "time": "2025-01-13 08:00:18", "headline": "A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 6 Analysts", "summary": " ", "symbols": ["FDMT"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42942696/a-glimpse-into-the-expert-outlook-on-4d-molecular-therapeutics-through-6-analysts", "tags": ["guidance"]}
{"id": 42942777, "time": "2025-01-13 08:00:30", "headline": "VivoPower's Caret Digital Secures CAD$140 Million Definitive Binding Investment Commitment From Global Alternative Investment Group, GEM Global Yield LLC SCS; DOGE Coin Mining Is Consistent With Caret Digital's Power-To-X Strategy That Seeks To Activate The Highest And Best Use Cases For Renewable Power Capacity", "summary": "", "symbols": ["VVPR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942777/vivopowers-caret-digital-secures-cad-140-million-definitive-binding-investment-commitment-from-globa", "tags": []}
{"id": 42942780, "time": "2025-01-13 08:00:32", "headline": "Expert Outlook: CytoSorbents Through The Eyes Of 7 Analysts", "summary": " ", "symbols": ["CTSO"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42942780/expert-outlook-cytosorbents-through-the-eyes-of-7-analysts", "tags": ["guidance"]}
{"id": 42942785, "time": "2025-01-13 08:00:39", "headline": "Zumiez Comparable Sales For Nine-week Period Ended January 4, 2025, Increase 5.6%", "summary": "", "symbols": ["ZUMZ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942785/zumiez-comparable-sales-for-nine-week-period-ended-january-4-2025-increase-5-6", "tags": []}
{"id": 42942790, "time": "2025-01-13 08:00:47", "headline": "Breaking Down TeraWulf: 9 Analysts Share Their Views", "summary": " ", "symbols": ["WULF"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42942790/breaking-down-terawulf-9-analysts-share-their-views", "tags": []}
{"id": 42942799, "time": "2025-01-13 08:01:05", "headline": "Demystifying Arcutis Biotherapeutics: Insights From 5 Analyst Reviews", "summary": " ", "symbols": ["ARQT"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42942799/demystifying-arcutis-biotherapeutics-insights-from-5-analyst-reviews", "tags": []}
{"id": 42942818, "time": "2025-01-13 08:01:16", "headline": "9 Analysts Have This To Say About Nordstrom", "summary": " ", "symbols": ["JWN"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42942818/9-analysts-have-this-to-say-about-nordstrom", "tags": []}
{"id": 42942838, "time": "2025-01-13 08:01:42", "headline": "Morgan Stanley Maintains Overweight on Constellation Brands, Lowers Price Target to $220", "summary": "", "symbols": ["STZ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942838/morgan-stanley-maintains-overweight-on-constellation-brands-lowers-price-target-to-220", "tags": ["analyst_other", "price_target_down"]}
{"id": 42942846, "time": "2025-01-13 08:01:56", "headline": "Bionano Preliminary Revenue For Q4 2024 Expected Between $7.9M-$8.1M Despite 25% Decrease; Optical Genome Mapping Systems Increase By 14% To 371 Units; Nanochannel Array Flowcells Sales Rise 1% To 8,058 Units", "summary": "", "symbols": ["BNGO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42942846/bionano-preliminary-revenue-for-q4-2024-expected-between-7-9m-8-1m-despite-25-decrease-optical-ge", "tags": ["earnings"]}
{"id": 42942851, "time": "2025-01-13 08:02:10", "headline": "Sono-Tek Q3 2025 GAAP EPS $0.02, Inline, Sales $5.191M Beat $5.109M Estimate", "summary": "", "symbols": ["SOTK"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42942851/sono-tek-q3-2025-gaap-eps-0-02-inline-sales-5-191m-beat-5-109m-estimate", "tags": ["earnings"]}
{"id": 42942853, "time": "2025-01-13 08:02:16", "headline": "Deep Dive Into Range Resources Stock: Analyst Perspectives (11 Ratings)", "summary": " ", "symbols": ["RRC"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42942853/deep-dive-into-range-resources-stock-analyst-perspectives-11-ratings", "tags": []}
{"id": 42942879, "time": "2025-01-13 08:02:49", "headline": "Indaptus Therapeutics Announces $2.25M Private Placement Of An Aggregate Of 2,109,383 Of Its Shares Of Common Stock And Accompanying Warrants To Purchase Up To An Aggregate Of 2,109,383 Of Its Shares Of Common Stock At Purchase Price Of $1.065", "summary": "", "symbols": ["INDP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942879/indaptus-therapeutics-announces-2-25m-private-placement-of-an-aggregate-of-2-109-383-of-its-shares-o", "tags": ["offering"]}
{"id": 42942923, "time": "2025-01-13 08:03:29", "headline": "Zumiez Cuts Q4 Net Sales Outlook From $284M - $288M To $275M - $277M (Est $285.499M); EPS Outlook From $0.83 - $0.93 To $0.72 - $0.77  (Est $0.89)", "summary": "", "symbols": ["ZUMZ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942923/zumiez-cuts-q4-net-sales-outlook-from-284m-288m-to-275m-277m-est-285-499m-eps-outlook-from-0-83-0-93", "tags": ["earnings", "guidance"]}
{"id": 42942935, "time": "2025-01-13 08:03:47", "headline": "Cabaletta Bio Outlines 2025 Milestones, Plans Meeting With FDA On Rese-cel Trial Designs, Favorable Safety With 90% Patients Showing No Significant Side Effects, First Enrollments In RESET-PV And RESET-Myositis Trials, IND Cleared For RESET-MS With Fast Track Status", "summary": "", "symbols": ["CABA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42942935/cabaletta-bio-outlines-2025-milestones-plans-meeting-with-fda-on-rese-cel-trial-designs-favorable", "tags": ["fda"]}
{"id": 42942952, "time": "2025-01-13 08:04:27", "headline": "Chefs' Warehouse Announces FY25 Outlook, Sees Net Sales $3.94B-$4.04B, Gross Profit $951M-$976M, Adjusted EBITDA $233M-$246M", "summary": "", "symbols": ["CHEF"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42942952/chefs-warehouse-announces-fy25-outlook-sees-net-sales-3-94b-4-04b-gross-profit-951m-976m-adjusted-eb", "tags": ["guidance"]}
{"id": 42942960, "time": "2025-01-13 08:05:03", "headline": "ORIC Pharmaceuticals Announces Clinical Supply Agreement To Evaluate ORIC-114 In Combination With Amivantamab For The First-Line Treatment Of NSCLC With EGFR Exon 20 Insertion Mutations", "summary": "", "symbols": ["ORIC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42942960/oric-pharmaceuticals-announces-clinical-supply-agreement-to-evaluate-oric-114-in-combination-with", "tags": ["fda", "contract"]}
{"id": 42942978, "time": "2025-01-13 08:05:08", "headline": "Sono-Tek Earnings Review: Q3 Summary", "summary": " ", "symbols": ["SOTK"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/earnings/25/01/42942978/sono-tek-earnings-review-q3-summary", "tags": ["earnings"]}
{"id": 42943003, "time": "2025-01-13 08:05:41", "headline": "Morgan Stanley Downgrades LiveRamp Holdings to Equal-Weight, Maintains Price Target to $35", "summary": "", "symbols": ["RAMP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943003/morgan-stanley-downgrades-liveramp-holdings-to-equal-weight-maintains-price-target-to-35", "tags": ["analyst_down", "analyst_other"]}
{"id": 42943006, "time": "2025-01-13 08:05:46", "headline": "Ekso Bionics Expects Q4 2024 Revenue Of $5M-$5.1M, Surpassing Q4 2023 Revenue Of $4.8M", "summary": "", "symbols": ["EKSO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943006/ekso-bionics-expects-q4-2024-revenue-of-5m-5-1m-surpassing-q4-2023-revenue-of-4-8m", "tags": ["earnings"]}
{"id": 42943022, "time": "2025-01-13 08:06:42", "headline": "Day One Biopharmaceuticals Announces $57.2M Preliminary 2024 OJEMDA Revenue, Cleared Phase 1a/b DAY301 Dose Cohort, $531.7M In Cash, To Present At J.P. Morgan Healthcare Conference Today At 6:45 p.m. Eastern Time", "summary": "", "symbols": ["DAWN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42943022/day-one-biopharmaceuticals-announces-57-2m-preliminary-2024-ojemda-revenue-cleared-phase-1ab-day3", "tags": ["earnings"]}
{"id": 42943048, "time": "2025-01-13 08:07:13", "headline": "Gilat Satellite Networks Gets Orders Exceeding $3M From Service Providers For Gateway Solid State Power Amplifiers To Support LEO Constellations", "summary": "", "symbols": ["GILT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943048/gilat-satellite-networks-gets-orders-exceeding-3m-from-service-providers-for-gateway-solid-state-pow", "tags": []}
{"id": 42943052, "time": "2025-01-13 08:07:51", "headline": "Morgan Stanley Upgrades Amplitude to Equal-Weight, Raises Price Target to $11", "summary": "", "symbols": ["AMPL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943052/morgan-stanley-upgrades-amplitude-to-equal-weight-raises-price-target-to-11", "tags": ["analyst_up", "price_target_up"]}
{"id": 42943078, "time": "2025-01-13 08:07:57", "headline": "Adaptimmune Reports Breakthrough Therapy Designation From FDA For Letetresgene Autoleucel In Treating MRCLS After Anthracycline Chemotherapy With 43% Response Rate; Synovial Sarcoma Shows 41% Response In Phase II Trial; Updates To Be Provided At J.P. Morgan Healthcare Conference", "summary": "", "symbols": ["ADAP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42943078/adaptimmune-reports-breakthrough-therapy-designation-from-fda-for-letetresgene-autoleucel-in-trea", "tags": ["fda"]}
{"id": 42943112, "time": "2025-01-13 08:07:58", "headline": "D. Boral Capital Maintains Buy on CARISMA Therapeutics, Maintains $12 Price Target", "summary": "", "symbols": ["CARM"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943112/d-boral-capital-maintains-buy-on-carisma-therapeutics-maintains-12-price-target", "tags": ["analyst_other"]}
{"id": 42943124, "time": "2025-01-13 08:08:30", "headline": "Sonos Announces Patrick Spence To Step Down As CEO; Tom Conrad Appointed Interim CEO", "summary": "", "symbols": ["SONO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943124/sonos-announces-patrick-spence-to-step-down-as-ceo-tom-conrad-appointed-interim-ceo", "tags": ["management"]}
{"id": 42943134, "time": "2025-01-13 08:09:08", "headline": "American Eagle Outfitters Raises Q4 Operating Profit Outlook From $125M-$130M To $135M", "summary": "", "symbols": ["AEO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943134/american-eagle-outfitters-raises-q4-operating-profit-outlook-from-125m-130m-to-135m", "tags": ["guidance"]}
{"id": 42943135, "time": "2025-01-13 08:09:23", "headline": "D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target", "summary": "", "symbols": ["AVXL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943135/d-boral-capital-maintains-buy-on-anavex-life-sciences-maintains-46-price-target", "tags": ["analyst_other"]}
{"id": 42943139, "time": "2025-01-13 08:09:45", "headline": "Neuronetics Announces Q4 Revenue Of $22.1M And FY24 Revenue Of $74.5M; Projects 12%-19% Revenue Growth And $22M In Synergies For 2025; Aims For Cash Flow Breakeven In Q3 2025", "summary": "", "symbols": ["STIM"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943139/neuronetics-announces-q4-revenue-of-22-1m-and-fy24-revenue-of-74-5m-projects-12-19-revenue-growth-an", "tags": ["earnings"]}
{"id": 42943143, "time": "2025-01-13 08:10:36", "headline": "Leading And Lagging Sectors For January 13, 2025", "summary": " ", "symbols": ["XLB", "XLC", "XLE", "XLF", "XLI", "XLK", "XLP", "XLRE", "XLV", "XLY"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/sector-etfs/25/01/42943143/leading-and-lagging-sectors-for-january-13-2025", "tags": []}
{"id": 42943161, "time": "2025-01-13 08:10:59", "headline": "Truist Securities Initiates Coverage On California Resources with Buy Rating, Announces Price Target of $75", "summary": "", "symbols": ["CRC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943161/truist-securities-initiates-coverage-on-california-resources-with-buy-rating-announces-price-target", "tags": ["analyst_init"]}
{"id": 42943168, "time": "2025-01-13 08:11:03", "headline": "KORU Medical Systems Announces Preliminary Q4 Net Revenues Of $8.9M, 23% Growth; Sees FY24 Revenues At $33.7M, Up 18%; Cash Balance At $9.6M, Q4 Cash Flow Of $0.8M, Yearly Cash Burn Improved by 67%", "summary": "", "symbols": ["KRMD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943168/koru-medical-systems-announces-preliminary-q4-net-revenues-of-8-9m-23-growth-sees-fy24-revenues-at-3", "tags": []}
{"id": 42943185, "time": "2025-01-13 08:11:37", "headline": "Barrick Urges Shareholders To Reject TRC Capital's 'Mini-Tender' Offer For Common Shares", "summary": "", "symbols": ["GOLD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943185/barrick-urges-shareholders-to-reject-trc-capitals-mini-tender-offer-for-common-shares", "tags": []}
{"id": 42943187, "time": "2025-01-13 08:11:41", "headline": "Delcath Systems Announces Q4 2024 Revenue At $15.1M, Full Year At $37.2M; HEPZATO Kit At $13.7M In Q4, $32.3M Annually; Gross Margins Between 80%-85%; $53.2M Cash And No Debt As Of Year-End 2024", "summary": "", "symbols": ["DCTH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943187/delcath-systems-announces-q4-2024-revenue-at-15-1m-full-year-at-37-2m-hepzato-kit-at-13-7m-in-q4-32", "tags": ["earnings"]}
{"id": 42943319, "time": "2025-01-13 08:13:10", "headline": "Tempus AI Announces FY24 Preliminary Q4 Revenue At $200M, 35% YoY Growth; FY24 Revenue $693M , 30% YoY Growth", "summary": "", "symbols": ["TEM"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943319/tempus-ai-announces-fy24-preliminary-q4-revenue-at-200m-35-yoy-growth-fy24-revenue-693m-30-yoy-growt", "tags": ["earnings"]}
{"id": 42943324, "time": "2025-01-13 08:14:08", "headline": "Rigel Reports Q4 2024 Revenue Of $57.6M With TAVALISSE $31M, REZLIDHIA $7.4M, GAVRETO $8.1M; R289 Receives FDA Orphan Drug Status For MDS; 2025 Revenue Projected At $200M-$210M", "summary": "", "symbols": ["RIGL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42943324/rigel-reports-q4-2024-revenue-of-57-6m-with-tavalisse-31m-rezlidhia-7-4m-gavreto-8-1m-r289-receiv", "tags": ["earnings", "fda"]}
{"id": 42943325, "time": "2025-01-13 08:14:08", "headline": "HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $16 Price Target", "summary": "", "symbols": ["SLDB"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943325/hc-wainwright-co-reiterates-buy-on-solid-biosciences-maintains-16-price-target", "tags": ["analyst_other"]}
{"id": 42943338, "time": "2025-01-13 08:15:11", "headline": "BXP Secures 20-Year Lease Renewal and Expansion with KnitWell Group at 7 Times Square", "summary": "", "symbols": ["BXP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943338/bxp-secures-20-year-lease-renewal-and-expansion-with-knitwell-group-at-7-times-square", "tags": []}
{"id": 42943339, "time": "2025-01-13 08:15:12", "headline": "IonQ Announced $21.1M Project With US Air Force Research Lab To Develop Quantum Network Infrastructure, Install At Innovare Center NY; Effort Extends IonQ's Networking Expertise Via Qubitekk Acquisition", "summary": "", "symbols": ["IONQ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42943339/ionq-announced-21-1m-project-with-us-air-force-research-lab-to-develop-quantum-network-infrastructur", "tags": []}
{"id": 42943341, "time": "2025-01-13 08:15:20", "headline": "A Look Into Royal Caribbean Gr Inc's Price Over Earnings", "summary": " ", "symbols": ["RCL"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42943341/a-look-into-royal-caribbean-gr-incs-price-over-earnings", "tags": ["earnings"]}
{"id": 42943358, "time": "2025-01-13 08:15:47", "headline": "ArsenalBio Says Bristol Myers Squibb Exercised Its Exclusive License Option For AB-4000 Series", "summary": "", "symbols": ["BMY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943358/arsenalbio-says-bristol-myers-squibb-exercised-its-exclusive-license-option-for-ab-4000-series", "tags": []}
{"id": 42943363, "time": "2025-01-13 08:16:09", "headline": "HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $12 Price Target", "summary": "", "symbols": ["ACXP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943363/hc-wainwright-co-reiterates-buy-on-acurx-pharmaceuticals-maintains-12-price-target", "tags": ["analyst_other"]}
{"id": 42943364, "time": "2025-01-13 08:16:10", "headline": "Harmony Biosciences Reports $714M 2024 Revenue For WAKIX; 2025 Forecast $820M-$860M With Potential $1B+; Key Catalysts In Each Quarter; FDA Review For Pitolisant sNDA, Orexin Data, Fragile X Topline, And Narcolepsy Trial; Six Phase 3 Programs Expected By Year-End 2025", "summary": "", "symbols": ["HRMY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42943364/harmony-biosciences-reports-714m-2024-revenue-for-wakix-2025-forecast-820m-860m-with-potential-1b", "tags": ["earnings", "guidance", "fda"]}
{"id": 42943378, "time": "2025-01-13 08:16:49", "headline": "Korro Announces Initiation Of Dosing In REWRITE Study For KRRO-110 Using OPERATM Platform; Interim Results Expected H2 2025; Plans To Advance Additional Pipeline Program", "summary": "", "symbols": ["KRRO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42943378/korro-announces-initiation-of-dosing-in-rewrite-study-for-krro-110-using-operatm-platform-interim", "tags": []}
{"id": 42943383, "time": "2025-01-13 08:17:18", "headline": "Comstock Announces Strategic Expansion Plans, Including Renewable Fuels and Metals Projects in Nevada and Oklahoma, Explores Spin-Off of Fuels Business and Reverse Stock Split", "summary": "", "symbols": ["LODE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943383/comstock-announces-strategic-expansion-plans-including-renewable-fuels-and-metals-projects-in-nevada", "tags": []}
{"id": 42943393, "time": "2025-01-13 08:18:05", "headline": "Zevia Expects Q4 2024 Net Sales Of $39.5M, Adjusted EBITDA Loss Of $3.9M-$4.2M Due To Holiday Campaign Investment", "summary": "", "symbols": ["ZVIA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943393/zevia-expects-q4-2024-net-sales-of-39-5m-adjusted-ebitda-loss-of-3-9m-4-2m-due-to-holiday-campaign-i", "tags": []}
{"id": 42943397, "time": "2025-01-13 08:18:10", "headline": "NV5 To Acquire Group Delta; Terms Not Disclosed", "summary": "", "symbols": ["NVEE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42943397/nv5-to-acquire-group-delta-terms-not-disclosed", "tags": ["merger"]}
{"id": 42943403, "time": "2025-01-13 08:19:01", "headline": "Moody's Announced Acquisition Of CAPE Analytics To Enhance Property Risk Insights; Terms Not Disclosed", "summary": "", "symbols": ["MCO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42943403/moodys-announced-acquisition-of-cape-analytics-to-enhance-property-risk-insights-terms-not-disclosed", "tags": []}
{"id": 42943409, "time": "2025-01-13 08:19:31", "headline": "Truist Securities Maintains Buy on Northern Oil & Gas, Raises Price Target to $55", "summary": "", "symbols": ["NOG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943409/truist-securities-maintains-buy-on-northern-oil-gas-raises-price-target-to-55", "tags": ["analyst_other", "price_target_up"]}
{"id": 42943410, "time": "2025-01-13 08:19:35", "headline": "Aditxt Announces Plans To Take Subsidiary Pearsanta Public In 2025 Via IPO; Focus On Early Cancer Detection And Growth Expansion", "summary": "", "symbols": ["ADTX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943410/aditxt-announces-plans-to-take-subsidiary-pearsanta-public-in-2025-via-ipo-focus-on-early-cancer-det", "tags": []}
{"id": 42943416, "time": "2025-01-13 08:20:06", "headline": "Needham Reiterates Buy on Hologic, Maintains $90 Price Target", "summary": "", "symbols": ["HOLX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943416/needham-reiterates-buy-on-hologic-maintains-90-price-target", "tags": ["analyst_other"]}
{"id": 42943418, "time": "2025-01-13 08:20:59", "headline": "Astria Therapeutics Announces ALPHA-ORBIT Phase 3 Trial Design For Navenibart In HAE; Features 3- And 6-Month Dosing, Primary Analysis At 6 Months; Expected Q1 2025 Initiation And Early 2027 Results; Strong Financial Position Supports Until Top-Line Outcomes", "summary": "", "symbols": ["ATXS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42943418/astria-therapeutics-announces-alpha-orbit-phase-3-trial-design-for-navenibart-in-hae-features-3-a", "tags": ["fda"]}
{"id": 42943430, "time": "2025-01-13 08:21:06", "headline": "BioAffinity Technologies Announced CyPath Lung Beta Launch in Texas With 600+ Tests Sold in 2024", "summary": "", "symbols": ["BIAF"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42943430/bioaffinity-technologies-announced-cypath-lung-beta-launch-in-texas-with-600-tests-sold-in-2024", "tags": []}
{"id": 42943433, "time": "2025-01-13 08:21:09", "headline": "Truist Securities Maintains Buy on Chord Energy, Raises Price Target to $186", "summary": "", "symbols": ["CHRD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943433/truist-securities-maintains-buy-on-chord-energy-raises-price-target-to-186", "tags": ["analyst_other", "price_target_up"]}
{"id": 42943443, "time": "2025-01-13 08:21:41", "headline": "Travere Therapeutics Expects Q4 Net Product Sales To Be $74M;", "summary": "", "symbols": ["TVTX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943443/travere-therapeutics-expects-q4-net-product-sales-to-be-74m", "tags": []}
{"id": 42943444, "time": "2025-01-13 08:21:44", "headline": "Destination XL Reports Holiday Sales Of $94.7M Vs $102.4m YoY, Expects FY24 Sales Of $467.0M-$470.0M (Prior $470M) Vs $469M Est", "summary": "", "symbols": ["DXLG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943444/destination-xl-reports-holiday-sales-of-94-7m-vs-102-4m-yoy-expects-fy24-sales-of-467-0m-470-0m-prio", "tags": []}
{"id": 42943450, "time": "2025-01-13 08:22:09", "headline": "CPI Aero Announces $33.4M Deal With Raytheon Technologies For Next Gen Jammer Mid-Band Lot 4 Production; 34 Pods Delivery Starting H2 2025", "summary": "", "symbols": ["CVU", "RTX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943450/cpi-aero-announces-33-4m-deal-with-raytheon-technologies-for-next-gen-jammer-mid-band-lot-4-producti", "tags": ["contract"]}
{"id": 42943451, "time": "2025-01-13 08:22:15", "headline": "Stephens & Co. Reiterates Overweight on Papa John's International, Maintains $62 Price Target", "summary": "", "symbols": ["PZZA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943451/stephens-co-reiterates-overweight-on-papa-johns-international-maintains-62-price-target", "tags": ["analyst_other"]}
{"id": 42943462, "time": "2025-01-13 08:22:45", "headline": "JP Morgan Upgrades LegalZoom.com to Overweight, Raises Price Target to $9", "summary": "", "symbols": ["LZ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943462/jp-morgan-upgrades-legalzoom-com-to-overweight-raises-price-target-to-9", "tags": ["analyst_up", "price_target_up"]}
{"id": 42943545, "time": "2025-01-13 08:23:08", "headline": "ARS Pharma Announces Preliminary Q4 2024 Results With Neffy Revenue At $6.5M; 14.5K Units Delivered. Cash Reserves At $314M To Fund Operations For 3 Years; 2025 Strategy Includes Expanding Neffy Access, Increasing Awareness, And Seeking FDA Approval For Neffy 1mg For Children", "summary": "", "symbols": ["SPRY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42943545/ars-pharma-announces-preliminary-q4-2024-results-with-neffy-revenue-at-6-5m-14-5k-units-delivered", "tags": ["earnings", "fda"]}
{"id": 42943693, "time": "2025-01-13 08:23:20", "headline": "Spyre Therapeutics Anticipates Cash Runway Into H2 2028; Expects Phase 1 Results For SPY002 In Q2 2025", "summary": "", "symbols": ["SYRE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943693/spyre-therapeutics-anticipates-cash-runway-into-h2-2028-expects-phase-1-results-for-spy002-in-q2-202", "tags": ["fda"]}
{"id": 42943756, "time": "2025-01-13 08:24:06", "headline": "Establishment Labs Announces Peter Caldini To Become Interim CEO Effective March 1, 2025; Anticipates 2024 Revenue Between $166M-$166.5M, Q4 Revenue Between $44.5M-$45M; $3.2M From U.S. Motiva Sales", "summary": "", "symbols": ["ESTA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943756/establishment-labs-announces-peter-caldini-to-become-interim-ceo-effective-march-1-2025-anticipates", "tags": ["earnings", "management"]}
{"id": 42943758, "time": "2025-01-13 08:24:39", "headline": "EyePoint Expects Cash Runway Into 2027 Beyond Topline DURAVYU Phase 3 Wet AMD Data Expected In 2026", "summary": "", "symbols": ["EYPT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943758/eyepoint-expects-cash-runway-into-2027-beyond-topline-duravyu-phase-3-wet-amd-data-expected-in-2026", "tags": ["fda"]}
{"id": 42943764, "time": "2025-01-13 08:25:36", "headline": "Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times", "summary": "", "symbols": ["SLRX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/25/01/42943764/trading-halt-halt-status-updated-at-8-25-00-am-et-quotation-resumption-news-and-resumption-times", "tags": []}
{"id": 42943765, "time": "2025-01-13 08:25:45", "headline": "Salarius And Decoy Announces Merger, Decoy To Hold 86% Post-Conversion; Lead Asset To File IND With FDA; Advancements In Broad-Acting Antiviral And Peptide Drug Conjugate; Data Expected From MDACC Trial", "summary": "", "symbols": ["SLRX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42943765/salarius-and-decoy-announces-merger-decoy-to-hold-86-post-conversion-lead-asset-to-file-ind-with-fda", "tags": ["fda", "merger"]}
{"id": 42943766, "time": "2025-01-13 08:25:51", "headline": "Nu Skin Enterprises Expects Q4 Preliminary Revenue At High End Of Company's Guidance Range", "summary": "", "symbols": ["NUS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943766/nu-skin-enterprises-expects-q4-preliminary-revenue-at-high-end-of-companys-guidance-range", "tags": ["earnings", "guidance"]}
{"id": 42943769, "time": "2025-01-13 08:25:56", "headline": "Autolus Reports FDA Approval and NCCN Inclusion of AUCATZYL, Sets Milestones for Pipeline Growth", "summary": "", "symbols": ["AUTL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/government/25/01/42943769/autolus-reports-fda-approval-and-nccn-inclusion-of-aucatzyl-sets-milestones-for-pipeline-growth", "tags": ["fda"]}
{"id": 42943780, "time": "2025-01-13 08:26:36", "headline": "Akebia Announced Near 100% U.S. Dialysis Coverage For Vafseo, Vafseo Shipments Commence, Phase 3 Trial For Late-Stage Non-Dialysis CKD Patients Planned for Mid-2025", "summary": "", "symbols": ["AKBA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42943780/akebia-announced-near-100-u-s-dialysis-coverage-for-vafseo-vafseo-shipments-commence-phase-3-tria", "tags": ["fda"]}
{"id": 42943791, "time": "2025-01-13 08:27:05", "headline": "D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target", "summary": "", "symbols": ["HUMA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943791/d-boral-capital-maintains-buy-on-humacyte-maintains-25-price-target", "tags": ["analyst_other"]}
{"id": 42943801, "time": "2025-01-13 08:27:27", "headline": "LifeVantage Announces 2025 Vision At Global Kickoff, Emphasizes MindBody GLP-1 System Expansion, Philippines, Taiwan, Hong Kong, Singapore To Transition To Evolve Plan On March 1, Thailand By Fiscal Year End", "summary": "", "symbols": ["LFVN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42943801/lifevantage-announces-2025-vision-at-global-kickoff-emphasizes-mindbody-glp-1-system-expansion-ph", "tags": []}
{"id": 42943806, "time": "2025-01-13 08:28:08", "headline": "Revvity Partners with Element Biosciences to Develop Neonatal Sequencing Diagnostic Solution", "summary": "", "symbols": ["RVTY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943806/revvity-partners-with-element-biosciences-to-develop-neonatal-sequencing-diagnostic-solution", "tags": ["contract"]}
{"id": 42943807, "time": "2025-01-13 08:28:12", "headline": "Ashford Trust Announces 66% Q4 2024 Occupancy With $190 Daily Rate, RevPAR Up 3% From Q4 2023", "summary": "", "symbols": ["AHT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943807/ashford-trust-announces-66-q4-2024-occupancy-with-190-daily-rate-revpar-up-3-from-q4-2023", "tags": []}
{"id": 42943842, "time": "2025-01-13 08:28:39", "headline": "Sapiens Reports Availability Of SaaS Solutions In Microsoft Azure Marketplace", "summary": "", "symbols": ["SPNS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943842/sapiens-reports-availability-of-saas-solutions-in-microsoft-azure-marketplace", "tags": []}
{"id": 42943846, "time": "2025-01-13 08:29:05", "headline": "BARK Announces Preliminary Q3 2025 Results, Sees Revenue Up 1.1% To $126.4M; Net Loss Widened To $11.5M; Adjusted EBITDA Improved By $4.9M Year-Over-Year", "summary": "", "symbols": ["BARK"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943846/bark-announces-preliminary-q3-2025-results-sees-revenue-up-1-1-to-126-4m-net-loss-widened-to-11-5m-a", "tags": ["earnings"]}
{"id": 42943848, "time": "2025-01-13 08:29:49", "headline": "Semler Scientific Announces Acquisition Of 237 Bitcoins For $23.3M; Total Holdings Reach 2,321 Bitcoins Valued At $191.9M. ATM Offering Raised $121.8M, Expanding Total Offering To $150.0M. BTC Yield At 72.6% Since October 2024 And 99.3% Since July 2024, Evaluated As KPI", "summary": "", "symbols": ["SMLR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/markets/cryptocurrency/25/01/42943848/semler-scientific-announces-acquisition-of-237-bitcoins-for-23-3m-total-holdings-reach-2-3", "tags": ["offering"]}
{"id": 42943850, "time": "2025-01-13 08:30:01", "headline": "EXCLUSIVE: Artelo Biosciences Tells Benzinga Co. Announces Successful Completion Of The Safety Review Of The First Cohort Of Eight Healthy Volunteers In A Phase I Study Of ART26.12", "summary": "", "symbols": ["ARTL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943850/exclusive-artelo-biosciences-tells-benzinga-co-announces-successful-completion-of-the-safety-review", "tags": ["fda"]}
{"id": 42943894, "time": "2025-01-13 08:30:09", "headline": "EXCLUSIVE: Artelo Biosciences Tells Benzinga 'The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects', 'Initial safety and pharmacokinetic data expected during the first half 2025'", "summary": "", "symbols": ["ARTL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943894/exclusive-artelo-biosciences-tells-benzinga-the-first-selective-fatty-acid-binding-protein-5-inhibit", "tags": []}
{"id": 42943914, "time": "2025-01-13 08:30:26", "headline": "EXCLUSIVE: Artelo Biosciences Concludes First Cohort Of Healthy Volunteers Of FABP Inhibitor Program", "summary": "Artelo Biosciences advances its pipeline with ART26.12 for neuropathic pain and ART27.13 for cancer-related anorexia, targeting 2025 milestones.", "symbols": ["ARTL"], "source": "benzinga", "author": "Vandana Singh", "url": "https://www.benzinga.com/general/biotech/25/01/42943914/exclusive-artelo-biosciences-concludes-first-cohort-of-healthy-volunteers-of-fabp-inhibitor-program", "tags": []}
{"id": 42943919, "time": "2025-01-13 08:30:46", "headline": "Protara Therapeutics Announces 6-Month Data From ADVANCED-2 Trial; Expects New Data Mid-2025, Begins Dosing In THRIVE-3 Trial In H1 2025, Awaits Results For STARBORN-1 Trial By End Of H1 2025.", "summary": "", "symbols": ["TARA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42943919/protara-therapeutics-announces-6-month-data-from-advanced-2-trial-expects-new-data-mid-2025-begins-d", "tags": ["fda"]}
{"id": 42944045, "time": "2025-01-13 08:31:10", "headline": "Kratos Receives New Hypersonic System Program Award With Total Potential Value Of ~$100M", "summary": "", "symbols": ["KTOS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944045/kratos-receives-new-hypersonic-system-program-award-with-total-potential-value-of-100m", "tags": []}
{"id": 42944063, "time": "2025-01-13 08:31:45", "headline": "Purple Innovation Expects FY24 Revenue Of $486M-$488M (Prior $490M-$510M) Vs $489.56M Est", "summary": "", "symbols": ["PRPL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944063/purple-innovation-expects-fy24-revenue-of-486m-488m-prior-490m-510m-vs-489-56m-est", "tags": ["earnings"]}
{"id": 42944075, "time": "2025-01-13 08:31:59", "headline": "Jupiter Neurosciences Announces Strategic Focus On NLRP3 Inflammasome Targeting In Clinical Trials For Neurodegenerative Diseases With JOTROL Platform", "summary": "", "symbols": ["JUNS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42944075/jupiter-neurosciences-announces-strategic-focus-on-nlrp3-inflammasome-targeting-in-clinical-trial", "tags": ["fda"]}
{"id": 42944090, "time": "2025-01-13 08:32:40", "headline": "89bio Announces Completion Of Enrollment In Phase 3 ENTRUST Trial For Severe Hypertriglyceridemia; Topline Data Expected In H2 2025. Phase 3 ENLIGHTEN Program For MASH Continues Enrollment. Cash And Equivalents Total $440M As Of Dec 31, 2024", "summary": "", "symbols": ["ETNB"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42944090/89bio-announces-completion-of-enrollment-in-phase-3-entrust-trial-for-severe-hypertriglyceridemia", "tags": ["fda"]}
{"id": 42944145, "time": "2025-01-13 08:33:25", "headline": "JP Morgan Maintains Overweight on Boot Barn Holdings, Raises Price Target to $200", "summary": "", "symbols": ["BOOT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944145/jp-morgan-maintains-overweight-on-boot-barn-holdings-raises-price-target-to-200", "tags": ["analyst_other", "price_target_up"]}
{"id": 42944156, "time": "2025-01-13 08:33:46", "headline": "Perspective Therapeutics Announced Clinical Updates Expected In 12-18 Months, Has $227.8M In Funds, Expansion Of Manufacturing Capabilities", "summary": "", "symbols": ["CATX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42944156/perspective-therapeutics-announced-clinical-updates-expected-in-12-18-months-has-227-8m-in-funds-", "tags": ["fda"]}
{"id": 42944165, "time": "2025-01-13 08:34:32", "headline": "MultiPlan Consolidates Cloud Infrastructure On Oracle To Enhance Growth And Accelerate Product Launches, And Support Clients And Patients Efficiently", "summary": "", "symbols": ["MPLN", "ORCL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944165/multiplan-consolidates-cloud-infrastructure-on-oracle-to-enhance-growth-and-accelerate-product-launc", "tags": []}
{"id": 42944170, "time": "2025-01-13 08:35:03", "headline": "Elevation Oncology Advances EO-3021 Trials to Target Advanced Gastric and GEJ Cancers with Improved Care", "summary": "", "symbols": ["ELEV"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944170/elevation-oncology-advances-eo-3021-trials-to-target-advanced-gastric-and-gej-cancers-with-improved", "tags": []}
{"id": 42944172, "time": "2025-01-13 08:35:23", "headline": "Health Catalyst Announces Acquisition Of Upfront Healthcare Services, Expanding Patient Engagement Capabilities; Terms Not Disclosed", "summary": "", "symbols": ["HCAT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42944172/health-catalyst-announces-acquisition-of-upfront-healthcare-services-expanding-patient-engagement-ca", "tags": []}
{"id": 42944192, "time": "2025-01-13 08:36:33", "headline": "Anavex Reports Long-Term Benefits of Blarcamesine in Slowing Early Alzheimer's Disease Progression", "summary": "", "symbols": ["AVXL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944192/anavex-reports-long-term-benefits-of-blarcamesine-in-slowing-early-alzheimers-disease-progression", "tags": []}
{"id": 42944200, "time": "2025-01-13 08:37:16", "headline": "AngioDynamics Announces 35.5% Clot Reduction With AlphaVac F1885 System in Trial, Meeting Primary Endpoints In Pulmonary Embolism Treatment Published In The Journal Of The Society For Cardiovascular Angiography & Interventions Titled \"Novel Mechanical Aspiration Thrombectomy In Patients With Acute Pulmonary Embolism: Results From The Prospective APEX-AV Trial\"", "summary": "", "symbols": ["ANGO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42944200/angiodynamics-announces-35-5-clot-reduction-with-alphavac-f1885-system-in-trial-meeting-primary-e", "tags": ["fda"]}
{"id": 42944205, "time": "2025-01-13 08:37:58", "headline": "Anterix Expands Partnership with LCRA, Providing Additional 900 MHz Licenses for Texas Growth", "summary": "", "symbols": ["ATEX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944205/anterix-expands-partnership-with-lcra-providing-additional-900-mhz-licenses-for-texas-growth", "tags": ["contract"]}
{"id": 42944206, "time": "2025-01-13 08:38:02", "headline": "Immunovant Announces $450M Private Placement Of 22.5M Shares Of Common Stock At A Purchase Price Of $20.00 Per Share To Three Institutional Accredited Investors In A Private Investment In Public Equity", "summary": "", "symbols": ["IMVT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944206/immunovant-announces-450m-private-placement-of-22-5m-shares-of-common-stock-at-a-purchase-price-of-2", "tags": ["offering"]}
{"id": 42944266, "time": "2025-01-13 08:38:52", "headline": "Needham Reiterates Buy on RxSight, Maintains $66 Price Target", "summary": "", "symbols": ["RXST"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944266/needham-reiterates-buy-on-rxsight-maintains-66-price-target", "tags": ["analyst_other"]}
{"id": 42944267, "time": "2025-01-13 08:38:52", "headline": "How To Earn $500 A Month From Fastenal Stock Ahead Of Q4 Earnings", "summary": "Fastenal offers an annual dividend yield of 2.18%. So, how can investors exploit its dividend yield to pocket a regular $500 monthly?", "symbols": ["FAST"], "source": "benzinga", "author": "Avi Kapoor", "url": "https://www.benzinga.com/news/earnings/25/01/42944267/how-to-earn-500-a-month-from-fastenal-stock-ahead-of-q4-earnings", "tags": ["earnings", "dividend"]}
{"id": 42944268, "time": "2025-01-13 08:38:53", "headline": "Why Intel, Airbnb, Joby Aviation Are Among JPMorgan's Short Ideas", "summary": "JPMorgan analysts flag big names like Intel, Airbnb, Joby Aviation as short ideas with unique headwinds and downside risks, urging caution for investors.", "symbols": ["ABNB", "INTC", "JOBY"], "source": "benzinga", "author": "Surbhi Jain", "url": "https://www.benzinga.com/25/01/42944268/why-intel-airbnb-joby-aviation-are-among-jpmorgans-short-ideas", "tags": []}
{"id": 42944276, "time": "2025-01-13 08:39:11", "headline": "Apyx Medical Announces Q4 2024 Revenue Between $14.1M-$14.3M, A 3%-4% Decrease YOY; Advanced Energy Revenue Flat At $12.0M-$12.2M; OEM Revenue Down 17% To $2.1M; FY24 Revenue Between $48.0M-$48.2M, An 8% Decrease YOY; Advanced Energy Down 11% To $38.5M-$38.7M; OEM Up 6% To $9.5M.", "summary": "", "symbols": ["APYX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944276/apyx-medical-announces-q4-2024-revenue-between-14-1m-14-3m-a-3-4-decrease-yoy-advanced-energy-revenu", "tags": ["earnings"]}
{"id": 42944283, "time": "2025-01-13 08:39:19", "headline": "Cybin Highlights 2024 Progress, Launches Phase 3 Study for CYB003 to Treat Major Depressive Disorder", "summary": "", "symbols": ["CYBN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944283/cybin-highlights-2024-progress-launches-phase-3-study-for-cyb003-to-treat-major-depressive-disorder", "tags": ["fda"]}
{"id": 42944304, "time": "2025-01-13 08:40:22", "headline": "Verastem Secures $150M Credit Facility and $7.5M Equity Investment to Advance Cancer Treatments", "summary": "", "symbols": ["VSTM"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944304/verastem-secures-150m-credit-facility-and-7-5m-equity-investment-to-advance-cancer-treatments", "tags": []}
{"id": 42944306, "time": "2025-01-13 08:40:29", "headline": "CVRx Announces Q4 Revenue Growth Of 35% To $15.2M-$15.3M, Full-Year Revenue Growth Of 30% To $51.1M-$51.2M; Projects Fiscal 2025 Revenue Growth Of 23%-27% To $63M-$65M", "summary": "", "symbols": ["CVRX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944306/cvrx-announces-q4-revenue-growth-of-35-to-15-2m-15-3m-full-year-revenue-growth-of-30-to-51-1m-51-2m", "tags": ["earnings"]}
{"id": 42944318, "time": "2025-01-13 08:41:41", "headline": "Denali Therapeutics Announces Key 2025 Milestones, FDA Breakthrough Therapy For Tividenofusp Alfa In Hunter Syndrome, BLA Submission In Early 2025, Commercial Launch Late 2025 Or Early 2026; Accelerated Approval Pathway For DNL126 In Sanfilippo Syndrome Type A; Expands TransportVehicle Programs", "summary": "", "symbols": ["DNLI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42944318/denali-therapeutics-announces-key-2025-milestones-fda-breakthrough-therapy-for-tividenofusp-alfa-", "tags": ["fda"]}
{"id": 42944321, "time": "2025-01-13 08:41:57", "headline": "OSI Systems Wins $81M Order For Mobile Cargo, Vehicle Inspection Systems", "summary": "", "symbols": ["OSIS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944321/osi-systems-wins-81m-order-for-mobile-cargo-vehicle-inspection-systems", "tags": []}
{"id": 42944323, "time": "2025-01-13 08:42:01", "headline": "Volato to Receive Second Gulfstream G280 in January 2025, Expanding Super-Midsize Jet Fleet", "summary": "", "symbols": ["SOAR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944323/volato-to-receive-second-gulfstream-g280-in-january-2025-expanding-super-midsize-jet-fleet", "tags": []}
{"id": 42944327, "time": "2025-01-13 08:42:11", "headline": "Barclays Maintains Equal-Weight on TD Synnex, Raises Price Target to $148", "summary": "", "symbols": ["SNX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944327/barclays-maintains-equal-weight-on-td-synnex-raises-price-target-to-148", "tags": ["analyst_other", "price_target_up"]}
{"id": 42944341, "time": "2025-01-13 08:42:46", "headline": "AtriCure Announces Q4 2024 Preliminary Revenue Of $124.3M, Up 17%, And FY Revenue Of $465.3M, U.S. Revenue Up 14% To $101.6M, International Revenue Increased 28% To $22.7M; Forecasted 2024 Adjusted EBITDA Is $26M-$29M And Adjusted Loss Per Share Is $0.74-$0.80", "summary": "", "symbols": ["ATRC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42944341/atricure-announces-q4-2024-preliminary-revenue-of-124-3m-up-17-and-fy-revenue-of-465-3m-u-s-reven", "tags": ["earnings"]}
{"id": 42944344, "time": "2025-01-13 08:43:02", "headline": "SciSparc Merger Partner AutoMax Receives First Shipment Of Vehicles Manufactured By Anhui Jianghuai Automobile Group", "summary": "", "symbols": ["SPRC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944344/scisparc-merger-partner-automax-receives-first-shipment-of-vehicles-manufactured-by-anhui-jianghuai", "tags": ["merger"]}
{"id": 42944413, "time": "2025-01-13 08:43:40", "headline": "Srivaru Holding To Implement 50-For-1 Reverse Share Split On January 15, 2025", "summary": "", "symbols": ["SVMH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944413/srivaru-holding-to-implement-50-for-1-reverse-share-split-on-january-15-2025", "tags": []}
{"id": 42944415, "time": "2025-01-13 08:43:53", "headline": "Postal Realty Trust Snapped 63 Properties Leased to the USPS for ~$30.7M", "summary": "", "symbols": ["PSTL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944415/postal-realty-trust-snapped-63-properties-leased-to-the-usps-for-30-7m", "tags": []}
{"id": 42944443, "time": "2025-01-13 08:45:16", "headline": "Peering Into Tradeweb Markets's Recent Short Interest", "summary": " ", "symbols": ["TW"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42944443/peering-into-tradeweb-marketss-recent-short-interest", "tags": []}
{"id": 42944444, "time": "2025-01-13 08:45:21", "headline": "(EQT) - Analyzing EQT's Short Interest", "summary": " ", "symbols": ["EQT"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42944444/eqt-analyzing-eqts-short-interest", "tags": []}
{"id": 42944445, "time": "2025-01-13 08:45:26", "headline": "Looking Into AAON's Recent Short Interest", "summary": " ", "symbols": ["AAON"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42944445/looking-into-aaons-recent-short-interest", "tags": []}
{"id": 42944474, "time": "2025-01-13 08:46:00", "headline": "Donald Trump Jr. Joins Kalshi Prediction Market As Strategic Advisor", "summary": "Donald Trump Jr. joins Kalshi prediction market as strategic advisor, revealing the importance &amp; regulatory battles of this growing industry.", "symbols": [], "source": "benzinga", "author": "Murtuza Merchant", "url": "https://www.benzinga.com/markets/cryptocurrency/25/01/42944474/donald-trump-jr-joins-kalshi-prediction-market-as-strategic-advisor", "tags": []}
{"id": 42944475, "time": "2025-01-13 08:46:05", "headline": "VEON And Cohen Circle Announced LOI For Business Combination Aiming To List Kyivstar On Nasdaq", "summary": "", "symbols": ["CCIRU", "VEON"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944475/veon-and-cohen-circle-announced-loi-for-business-combination-aiming-to-list-kyivstar-on-nasdaq", "tags": []}
{"id": 42944479, "time": "2025-01-13 08:46:07", "headline": "Barclays Maintains Overweight on Cousins Props, Raises Price Target to $36", "summary": "", "symbols": ["CUZ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944479/barclays-maintains-overweight-on-cousins-props-raises-price-target-to-36", "tags": ["analyst_other", "price_target_up"]}
{"id": 42944497, "time": "2025-01-13 08:46:36", "headline": "Tesla, Robinhood And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session", "summary": " ", "symbols": ["HOOD", "IONQ", "LAES", "MCY", "QBTS", "RGTI", "RZLV", "TG", "TSLA"], "source": "benzinga", "author": "Avi Kapoor", "url": "https://www.benzinga.com/trading-ideas/movers/25/01/42944497/tesla-robinhood-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session", "tags": ["why_moving"]}
{"id": 42944506, "time": "2025-01-13 08:46:54", "headline": "Annexon Announces 2025 Outlook, ANX005 Targets Guillain-Barr\u00e9 Syndrome BLA In H1 2025, ANX007 Completes Phase 3 Enrollment For Geographic Atrophy In H2 2025, ANX1502 Seeks Clinical Data In Q1 2025; Cash Runway Extends To H2 2026", "summary": "", "symbols": ["ANNX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42944506/annexon-announces-2025-outlook-anx005-targets-guillain-barr-syndrome-bla-in-h1-2025-anx007-comple", "tags": ["guidance", "fda"]}
{"id": 42944526, "time": "2025-01-13 08:47:43", "headline": "Barclays Maintains Equal-Weight on CubeSmart, Lowers Price Target to $50", "summary": "", "symbols": ["CUBE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944526/barclays-maintains-equal-weight-on-cubesmart-lowers-price-target-to-50", "tags": ["analyst_other", "price_target_down"]}
{"id": 42944528, "time": "2025-01-13 08:47:43", "headline": "Cogent Biosciences Announces 2025 Milestones, SUMMIT Results In NonAdvSM In July, PEAK Phase 3 In 2nd-Line GIST By Year-End, APEX In AdvSM in H2; Presenting at J.P. Morgan Healthcare Conference Tomorrow At 10:30 AM ET", "summary": "", "symbols": ["COGT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42944528/cogent-biosciences-announces-2025-milestones-summit-results-in-nonadvsm-in-july-peak-phase-3-in-2", "tags": ["fda"]}
{"id": 42944529, "time": "2025-01-13 08:47:50", "headline": "Planet Fitness Ended 2024 With Total Membership Of ~19.7M, System-Wide Same Club Increased 5%", "summary": "", "symbols": ["PLNT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944529/planet-fitness-ended-2024-with-total-membership-of-19-7m-system-wide-same-club-increased-5", "tags": []}
{"id": 42944554, "time": "2025-01-13 08:48:36", "headline": "Immuneering Announces 50% ORR In Phase 2a With IMM-1-104 Plus mFFX In Pancreatic Cancer, Surpassing 32% Benchmark", "summary": "", "symbols": ["IMRX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42944554/immuneering-announces-50-orr-in-phase-2a-with-imm-1-104-plus-mffx-in-pancreatic-cancer-surpassing", "tags": []}
{"id": 42944561, "time": "2025-01-13 08:48:54", "headline": "Barclays Maintains Overweight on Extra Space Storage, Lowers Price Target to $184", "summary": "", "symbols": ["EXR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944561/barclays-maintains-overweight-on-extra-space-storage-lowers-price-target-to-184", "tags": ["analyst_other", "price_target_down"]}
{"id": 42944579, "time": "2025-01-13 08:49:23", "headline": "Edgewise Therapeutics Announces 2025 Priorities, Progress In Muscular Dystrophy And Cardiac Therapies; Seeks Completion Of GRAND CANYON Recruitment For Becker Trials In Q1; Targets Phase 2 FDA Feedback On CANYON In H1; Plans Phase 3 For Duchenne", "summary": "", "symbols": ["EWTX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42944579/edgewise-therapeutics-announces-2025-priorities-progress-in-muscular-dystrophy-and-cardiac-therap", "tags": ["fda"]}
{"id": 42944596, "time": "2025-01-13 08:50:33", "headline": "Treace Medical Concepts Announces Preliminary Q4 Revenue Of $68.4M-$68.8M, Up 10% YoY; FY24 Revenue Of $209M-$209.4M, Up 12%; Added 280 Surgeons, Now 3,135 Active; Plans Innovative Product Launches In 2025", "summary": "", "symbols": ["TMCI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944596/treace-medical-concepts-announces-preliminary-q4-revenue-of-68-4m-68-8m-up-10-yoy-fy24-revenue-of-20", "tags": ["earnings"]}
{"id": 42944603, "time": "2025-01-13 08:50:58", "headline": "Barclays Maintains Equal-Weight on Kilroy Realty, Lowers Price Target to $43", "summary": "", "symbols": ["KRC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944603/barclays-maintains-equal-weight-on-kilroy-realty-lowers-price-target-to-43", "tags": ["analyst_other", "price_target_down"]}
{"id": 42944606, "time": "2025-01-13 08:51:26", "headline": "Werewolf Therapeutics Outlines 2025 Milestones, Sees Phase 1/1b Results For WTX-124 Monotherapy And Combo With Pembrolizumab Expected In H1 And Q4 2025; Phase 1/2 Trial For WTX-330 To Begin In Q1 2025; Cash Runway Through Q2 2026", "summary": "", "symbols": ["HOWL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42944606/werewolf-therapeutics-outlines-2025-milestones-sees-phase-11b-results-for-wtx-124-monotherapy-and", "tags": ["fda"]}
{"id": 42944621, "time": "2025-01-13 08:52:23", "headline": "Barclays Maintains Equal-Weight on National Storage, Lowers Price Target to $42", "summary": "", "symbols": ["NSA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944621/barclays-maintains-equal-weight-on-national-storage-lowers-price-target-to-42", "tags": ["analyst_other", "price_target_down"]}
{"id": 42944625, "time": "2025-01-13 08:52:41", "headline": "Apollo Announced Acquisition Of Argo Infrastructure Partners; Terms Not Disclosed", "summary": "", "symbols": ["APO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42944625/apollo-announced-acquisition-of-argo-infrastructure-partners-terms-not-disclosed", "tags": []}
{"id": 42944804, "time": "2025-01-13 08:53:32", "headline": "N2OFF, Inc. Announces Germany Regulatory Approval Of Its 111 MWp Solar PV Project", "summary": "", "symbols": ["NITO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944804/n2off-inc-announces-germany-regulatory-approval-of-its-111-mwp-solar-pv-project", "tags": []}
{"id": 42944816, "time": "2025-01-13 08:53:34", "headline": "Alector Highlights Strategic Focus For 2025, Phase 3 INFRONT-3 Data On Latozinemab For FTD-GRN By Q4 2025; 75% Enrollment For AL101 Trial In Early Alzheimer's Achieved; $457.2M Cash Expected To Fund Operations Through 2026", "summary": "", "symbols": ["ALEC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42944816/alector-highlights-strategic-focus-for-2025-phase-3-infront-3-data-on-latozinemab-for-ftd-grn-by-", "tags": ["fda"]}
{"id": 42944898, "time": "2025-01-13 08:54:03", "headline": "Bentley Systems Welcomes James Lee As Chief Operating Officer", "summary": "", "symbols": ["BSY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944898/bentley-systems-welcomes-james-lee-as-chief-operating-officer", "tags": []}
{"id": 42944904, "time": "2025-01-13 08:54:53", "headline": "Candel Therapeutics Announces 2025 Milestones, CAN-2409 Updates For PDAC, NSCLC In Q1 2025, BLA Submission For Prostate Cancer In Q4 2026; Phase 3 Data To Be Presented; CAN-3110 Trial Results For rHGG By Q4 2025; $103M Cash To Fund Operations Into Q1 2027", "summary": "", "symbols": ["CADL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42944904/candel-therapeutics-announces-2025-milestones-can-2409-updates-for-pdac-nsclc-in-q1-2025-bla-subm", "tags": ["fda"]}
{"id": 42944909, "time": "2025-01-13 08:55:04", "headline": "Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times", "summary": "", "symbols": ["TSDD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/25/01/42944909/trading-halt-halt-status-updated-at-8-55-00-am-et-quotation-resumption-news-and-resumption-times", "tags": []}
{"id": 42944921, "time": "2025-01-13 08:55:38", "headline": "Ginkgo Bioworks Partners With Universal Cells To Advance Next-Generation iPSC-Derived Cell Therapies For Solid Tumors", "summary": "", "symbols": ["DNA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42944921/ginkgo-bioworks-partners-with-universal-cells-to-advance-next-generation-ipsc-derived-cell-therap", "tags": ["contract"]}
{"id": 42944933, "time": "2025-01-13 08:55:54", "headline": "Barclays Maintains Overweight on Public Storage, Lowers Price Target to $361", "summary": "", "symbols": ["PSA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944933/barclays-maintains-overweight-on-public-storage-lowers-price-target-to-361", "tags": ["analyst_other", "price_target_down"]}
{"id": 42944934, "time": "2025-01-13 08:55:55", "headline": "Wall Street Slashes Interest Rate Cut Bets After Jobs Data: Are Hikes Back On The Table?", "summary": "Wall Street analysts are rethinking their interest rate forecasts after December&#39;s strong jobs report shattered previous expectations.", "symbols": ["SPY", "TLT"], "source": "benzinga", "author": "Piero Cingari", "url": "https://www.benzinga.com/economics/macro-economic-events/25/01/42944934/wall-street-slashes-interest-rate-cut-bets-after-jobs-data-are-hikes-back-on-the-table", "tags": []}
{"id": 42944947, "time": "2025-01-13 08:57:12", "headline": "Ardelyx Announces 2024 U.S. Sales Of $319M, Projects IBSRELA To Surpass $1B, XPHOZAH At $750M; Ends Year With $250M In Cash And Investments", "summary": "", "symbols": ["ARDX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42944947/ardelyx-announces-2024-u-s-sales-of-319m-projects-ibsrela-to-surpass-1b-xphozah-at-750m-ends-year", "tags": []}
{"id": 42944948, "time": "2025-01-13 08:57:30", "headline": "Barclays Maintains Underweight on Rexford Industrial Realty, Lowers Price Target to $41", "summary": "", "symbols": ["REXR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944948/barclays-maintains-underweight-on-rexford-industrial-realty-lowers-price-target-to-41", "tags": ["analyst_other", "price_target_down"]}
{"id": 42944949, "time": "2025-01-13 08:57:47", "headline": "NRx Pharmaceuticals Has Filed An Application With NASDAQ To Uplist To The NASDAQ Global Market From The NASDAQ Capital Market", "summary": "", "symbols": ["NRXP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944949/nrx-pharmaceuticals-has-filed-an-application-with-nasdaq-to-uplist-to-the-nasdaq-global-market-from", "tags": []}
{"id": 42944960, "time": "2025-01-13 08:58:21", "headline": "SaverOne Signs New Distribution Agreement With uniSmart Vertriebs GmbH; Terms Not Disclosed", "summary": "", "symbols": ["SVRE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944960/saverone-signs-new-distribution-agreement-with-unismart-vertriebs-gmbh-terms-not-disclosed", "tags": ["contract"]}
{"id": 42944986, "time": "2025-01-13 08:58:53", "headline": "High Roller Technologies Announces 30% QoQ Revenue Growth, 54% Rise In First-Time Depositors, Completes IPO Raising $10M For Expansion, Increased Active Players By 37%, Reports Enhanced Market Exposure Post-IPO", "summary": "", "symbols": ["ROLR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944986/high-roller-technologies-announces-30-qoq-revenue-growth-54-rise-in-first-time-depositors-completes", "tags": ["earnings"]}
{"id": 42945006, "time": "2025-01-13 08:59:48", "headline": "Top 2 Industrials Stocks That May Fall Off A Cliff In January", "summary": " ", "symbols": ["ALK", "BA"], "source": "benzinga", "author": "Avi Kapoor", "url": "https://www.benzinga.com/25/01/42945006/top-2-industrials-stocks-that-may-fall-off-a-cliff-in-january", "tags": []}
{"id": 42945069, "time": "2025-01-13 09:00:08", "headline": "SEALSQ In Cooperation With WISeKey Expands Post-Quantum Footprint In Saudi Arabia", "summary": "", "symbols": ["LAES", "WKEY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945069/sealsq-in-cooperation-with-wisekey-expands-post-quantum-footprint-in-saudi-arabia", "tags": []}
{"id": 42945114, "time": "2025-01-13 09:00:13", "headline": "$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today", "summary": " ", "symbols": ["NET"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42945114/1000-invested-in-this-stock-5-years-ago-would-be-worth-this-much-today", "tags": []}
{"id": 42945131, "time": "2025-01-13 09:00:15", "headline": "Deep Dive Into US Energy Stock: Analyst Perspectives (4 Ratings)", "summary": " ", "symbols": ["USEG"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42945131/deep-dive-into-us-energy-stock-analyst-perspectives-4-ratings", "tags": []}
{"id": 42945178, "time": "2025-01-13 09:00:22", "headline": "8 Analysts Have This To Say About Crown Castle", "summary": " ", "symbols": ["CCI"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42945178/8-analysts-have-this-to-say-about-crown-castle", "tags": []}
{"id": 42945190, "time": "2025-01-13 09:00:25", "headline": "Barclays Maintains Overweight on American Tower, Lowers Price Target to $215", "summary": "", "symbols": ["AMT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945190/barclays-maintains-overweight-on-american-tower-lowers-price-target-to-215", "tags": ["analyst_other", "price_target_down"]}
{"id": 42945204, "time": "2025-01-13 09:00:29", "headline": "6 Analysts Assess Pacira BioSciences: What You Need To Know", "summary": " ", "symbols": ["PCRX"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42945204/6-analysts-assess-pacira-biosciences-what-you-need-to-know", "tags": []}
{"id": 42945210, "time": "2025-01-13 09:00:36", "headline": "The Analyst Verdict: CubeSmart In The Eyes Of 6 Experts", "summary": " ", "symbols": ["CUBE"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42945210/the-analyst-verdict-cubesmart-in-the-eyes-of-6-experts", "tags": []}
{"id": 42945213, "time": "2025-01-13 09:00:43", "headline": "Breaking Down American Tower: 6 Analysts Share Their Views", "summary": " ", "symbols": ["AMT"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42945213/breaking-down-american-tower-6-analysts-share-their-views", "tags": []}
{"id": 42945216, "time": "2025-01-13 09:00:51", "headline": "9 Analysts Have This To Say About Ovintiv", "summary": " ", "symbols": ["OVV"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42945216/9-analysts-have-this-to-say-about-ovintiv", "tags": []}
{"id": 42945220, "time": "2025-01-13 09:00:57", "headline": "Nature's Miracle Holding Enters Into $29.7M Securities Purchase Agreement", "summary": "", "symbols": ["NMHI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945220/natures-miracle-holding-enters-into-29-7m-securities-purchase-agreement", "tags": ["contract"]}
{"id": 42945237, "time": "2025-01-13 09:01:04", "headline": "Mirum Pharmaceuticals Projects $336M Sales Exceed 2024 Guidance; 2025 Sales Forecast $420M-$435M; VISTAS Study Enrollment For Volixibat In Primary Sclerosing Cholangitis Completing H2 2025, Topline Data Expected 2026", "summary": "", "symbols": ["MIRM"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42945237/mirum-pharmaceuticals-projects-336m-sales-exceed-2024-guidance-2025-sales-forecast-420m-435m-vist", "tags": ["guidance"]}
{"id": 42945266, "time": "2025-01-13 09:01:45", "headline": "Why Is Department Store Chain Macy's Stock Sliding Today?", "summary": "Macy&#39;s updates its fiscal Q4 guidance, revealing strong growth in its First 50 stores and luxury segments, while non-First 50 locations underperformed. The company sees net sales near the lower end of $7.8 billion to $8.0 billion.", "symbols": ["M"], "source": "benzinga", "author": "Shivani Kumaresan", "url": "https://www.benzinga.com/25/01/42945266/why-department-store-chain-macys-stocks-are-sliding-on-monday-premarket", "tags": ["guidance", "why_moving"]}
{"id": 42945290, "time": "2025-01-13 09:02:48", "headline": "Karyopharm Therapeutics Announces Phase 3 SENTRY Trial Data For Selinexor In JAKi-Na\u00efve Myelofibrosis Expected In H2 2025; Enrollment By H1 2025; Lori Macomber Appointed Chief Financial Officer; Preliminary 2024 Revenue At $145M And XPOVIO Sales Reached $113M", "summary": "", "symbols": ["KPTI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42945290/karyopharm-therapeutics-announces-phase-3-sentry-trial-data-for-selinexor-in-jaki-na-ve-myelofibr", "tags": ["earnings", "fda"]}
{"id": 42945303, "time": "2025-01-13 09:03:26", "headline": "Crown Laboratories Extension Of Tender Offer To Acquire Revance Therapeutics, Inc. At A Price Of $3.10 Per Share In Cash", "summary": "", "symbols": ["RVNC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42945303/crown-laboratories-extension-of-tender-offer-to-acquire-revance-therapeutics-inc-at-a-price-of-3-10", "tags": ["merger"]}
{"id": 42945347, "time": "2025-01-13 09:03:39", "headline": "Barclays Maintains Overweight on SBA Comms, Lowers Price Target to $254", "summary": "", "symbols": ["SBAC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945347/barclays-maintains-overweight-on-sba-comms-lowers-price-target-to-254", "tags": ["analyst_other", "price_target_down"]}
{"id": 42945348, "time": "2025-01-13 09:03:41", "headline": "Illumina, NVIDIA To Collaborate To 'Decode Biology And Propel Precision Health;' Illumina Shares Spike Higher", "summary": "", "symbols": ["ILMN", "NVDA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945348/illumina-nvidia-to-collaborate-to-decode-biology-and-propel-precision-health-illumina-shares-spike-h", "tags": []}
{"id": 42945351, "time": "2025-01-13 09:03:49", "headline": "Truist Securities Maintains Hold on Antero Resources, Raises Price Target to $38", "summary": "", "symbols": ["AR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945351/truist-securities-maintains-hold-on-antero-resources-raises-price-target-to-38", "tags": ["analyst_other", "price_target_up"]}
{"id": 42945396, "time": "2025-01-13 09:05:13", "headline": "GeneDx Preliminary FY24 Revenue To Exceed $299M With Q4 Revenue At Least $92M; FY Adjusted Gross Margin Projected At 64% And Q4 At 68%", "summary": "", "symbols": ["WGS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945396/genedx-preliminary-fy24-revenue-to-exceed-299m-with-q4-revenue-at-least-92m-fy-adjusted-gross-margin", "tags": ["earnings"]}
{"id": 42945412, "time": "2025-01-13 09:05:30", "headline": "Truist Securities Maintains Buy on Astrana Health, Lowers Price Target to $50", "summary": "", "symbols": ["ASTH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945412/truist-securities-maintains-buy-on-astrana-health-lowers-price-target-to-50", "tags": ["analyst_other", "price_target_down"]}
{"id": 42945414, "time": "2025-01-13 09:05:42", "headline": "Barclays Maintains Equal-Weight on HF Sinclair, Lowers Price Target to $37", "summary": "", "symbols": ["DINO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945414/barclays-maintains-equal-weight-on-hf-sinclair-lowers-price-target-to-37", "tags": ["analyst_other", "price_target_down"]}
{"id": 42945425, "time": "2025-01-13 09:06:18", "headline": "T-Mobile to Acquire Vistar Media, Will Pay $600M In Cash", "summary": "", "symbols": ["TMUS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42945425/t-mobile-to-acquire-vistar-media-will-pay-600m-in-cash", "tags": ["merger"]}
{"id": 42945430, "time": "2025-01-13 09:06:35", "headline": "SeaStar Medical Announces FDA Approval For IDE Application To Study SCD-ADULT With $3.6M NIH Grant; Study Targets Inflammation In Acute Heart Failure Patients With Worsening Renal Function; 20 Patients To Be Enrolled; Breakthrough Device Designation Granted September 2023", "summary": "", "symbols": ["ICU"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42945430/seastar-medical-announces-fda-approval-for-ide-application-to-study-scd-adult-with-3-6m-nih-grant", "tags": ["fda"]}
{"id": 42945434, "time": "2025-01-13 09:07:12", "headline": "Clover Health Reports 27% Growth In Its Medicare Advantage Membership", "summary": "", "symbols": ["CLOV"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/health-care/25/01/42945434/clover-health-reports-27-growth-in-its-medicare-advantage-membership", "tags": []}
{"id": 42945450, "time": "2025-01-13 09:07:20", "headline": "Lead Real Estate Co Announces Sale Of Two Luxury Condominium Buildings In Prime Locations In Tokyo; No Financial Terms Disclosed", "summary": "", "symbols": ["LRE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945450/lead-real-estate-co-announces-sale-of-two-luxury-condominium-buildings-in-prime-locations-in-tokyo-n", "tags": []}
{"id": 42945451, "time": "2025-01-13 09:07:34", "headline": "Truist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $180", "summary": "", "symbols": ["AXSM"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945451/truist-securities-maintains-buy-on-axsome-therapeutics-raises-price-target-to-180", "tags": ["analyst_other", "price_target_up"]}
{"id": 42945453, "time": "2025-01-13 09:07:59", "headline": "Palladyne AI Corp. Awarded Contract From Air Force Research Laboratory To Migrate Its Pilot Autonomous Drone Software To AI Computing Chipsets", "summary": "", "symbols": ["PDYN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945453/palladyne-ai-corp-awarded-contract-from-air-force-research-laboratory-to-migrate-its-pilot-autonomou", "tags": ["contract"]}
{"id": 42945454, "time": "2025-01-13 09:08:04", "headline": "Barclays Maintains Overweight on Excelerate Energy, Raises Price Target to $31", "summary": "", "symbols": ["EE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945454/barclays-maintains-overweight-on-excelerate-energy-raises-price-target-to-31", "tags": ["analyst_other", "price_target_up"]}
{"id": 42945456, "time": "2025-01-13 09:08:09", "headline": "SI-BONE Sees Prelim Q4 Worldwide Revenue $48.8M-$49.0M", "summary": "", "symbols": ["SIBN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945456/si-bone-sees-prelim-q4-worldwide-revenue-48-8m-49-0m", "tags": ["earnings"]}
{"id": 42945457, "time": "2025-01-13 09:08:20", "headline": "SI-BONE Sees Prelim. FY24 Worldwide Revenue $167.0M-$161.1M", "summary": "", "symbols": ["SIBN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945457/si-bone-sees-prelim-fy24-worldwide-revenue-167-0m-161-1m", "tags": ["earnings"]}
{"id": 42945458, "time": "2025-01-13 09:08:24", "headline": "ReWalk Unveils 2025 Priorities, To Focus On Exoskeletons, AlterG Growth, FDA Clearance For ReWalk 7, Targeting H2 2026 Profitability With $5M Capital Raised, Investor Event Set For February 20 In NYC", "summary": "", "symbols": ["LFWD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42945458/rewalk-unveils-2025-priorities-to-focus-on-exoskeletons-alterg-growth-fda-clearance-for-rewalk-7-", "tags": ["fda"]}
{"id": 42945527, "time": "2025-01-13 09:08:57", "headline": "Truist Securities Maintains Buy on BKV, Raises Price Target to $30", "summary": "", "symbols": ["BKV"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945527/truist-securities-maintains-buy-on-bkv-raises-price-target-to-30", "tags": ["analyst_other", "price_target_up"]}
{"id": 42945531, "time": "2025-01-13 09:09:39", "headline": "Barclays Maintains Equal-Weight on Expedia Group, Raises Price Target to $166", "summary": "", "symbols": ["EXPE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945531/barclays-maintains-equal-weight-on-expedia-group-raises-price-target-to-166", "tags": ["analyst_other", "price_target_up"]}
{"id": 42945532, "time": "2025-01-13 09:09:41", "headline": "iRhythm Technologies Anticipates 2024 Revenue Above $587.5M; Expect Revenue For FY25 Of ~$675M-$685M", "summary": "", "symbols": ["IRTC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945532/irhythm-technologies-anticipates-2024-revenue-above-587-5m-expect-revenue-for-fy25-of-675m-685m", "tags": ["earnings"]}
{"id": 42945535, "time": "2025-01-13 09:10:17", "headline": "Keybanc Maintains Overweight on BKV, Raises Price Target to $27", "summary": "", "symbols": ["BKV"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945535/keybanc-maintains-overweight-on-bkv-raises-price-target-to-27", "tags": ["analyst_other", "price_target_up"]}
{"id": 42945536, "time": "2025-01-13 09:10:25", "headline": "VSee Health Awarded Multi-Year, $6M First Year, Government Contract To Deliver Rapid Configurable Telehealth", "summary": "", "symbols": ["VSEE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945536/vsee-health-awarded-multi-year-6m-first-year-government-contract-to-deliver-rapid-configurable-teleh", "tags": ["contract"]}
{"id": 42945537, "time": "2025-01-13 09:10:33", "headline": "QuidelOrtho Sees Prelim Q4 Revenue $702M-$707M Vs $698.041M Est.", "summary": "", "symbols": ["QDEL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945537/quidelortho-sees-prelim-q4-revenue-702m-707m-vs-698-041m-est", "tags": ["earnings"]}
{"id": 42945538, "time": "2025-01-13 09:10:40", "headline": "Truist Securities Maintains Hold on Chevron, Raises Price Target to $164", "summary": "", "symbols": ["CVX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945538/truist-securities-maintains-hold-on-chevron-raises-price-target-to-164", "tags": ["analyst_other", "price_target_up"]}
{"id": 42945541, "time": "2025-01-13 09:11:08", "headline": "Dynavax Prelim. 2024 HEPLISAV-B Net Product Revenue Grew 26% YoY To $268M", "summary": "", "symbols": ["DVAX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945541/dynavax-prelim-2024-heplisav-b-net-product-revenue-grew-26-yoy-to-268m", "tags": ["earnings"]}
{"id": 42945546, "time": "2025-01-13 09:11:36", "headline": "Caleres Sees FY24 Net Sales Down 3%-3.5%; GAAP EPS Of $3.10-$3.20; Adjusted EPS $3.20-$3.30", "summary": "", "symbols": ["CAL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945546/caleres-sees-fy24-net-sales-down-3-3-5-gaap-eps-of-3-10-3-20-adjusted-eps-3-20-3-30", "tags": ["earnings"]}
{"id": 42945547, "time": "2025-01-13 09:11:39", "headline": "Barclays Maintains Equal-Weight on Cboe Global Markets, Lowers Price Target to $212", "summary": "", "symbols": ["CBOE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945547/barclays-maintains-equal-weight-on-cboe-global-markets-lowers-price-target-to-212", "tags": ["analyst_other", "price_target_down"]}
{"id": 42945551, "time": "2025-01-13 09:11:49", "headline": "IQVIA Collaborates With NVIDIA To Combine IQVIA Connected Intelligence With NVIDIA AI Foundry To Help Transform Life Science Processes From R&D Through Commercialization", "summary": "", "symbols": ["IQV", "NVDA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945551/iqvia-collaborates-with-nvidia-to-combine-iqvia-connected-intelligence-with-nvidia-ai-foundry-to-hel", "tags": []}
{"id": 42945552, "time": "2025-01-13 09:11:54", "headline": "Wall Street's Most Accurate Analysts Give Their Take On 3 Utilities Stocks Delivering High-Dividend Yields", "summary": " ", "symbols": ["CWEN", "POR", "SR"], "source": "benzinga", "author": "Avi Kapoor", "url": "https://www.benzinga.com/25/01/42945552/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-delivering-high-dividend-yields-2", "tags": ["dividend"]}
{"id": 42945555, "time": "2025-01-13 09:12:20", "headline": "Kinder Morgan Acquires Natural Gas System In Williston Basin For $640M, Gains 270 MMcf/d Processing Plant And 350 MMcf/d Capacity Gas Header", "summary": "", "symbols": ["KMI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42945555/kinder-morgan-acquires-natural-gas-system-in-williston-basin-for-640m-gains-270-mmcfd-processing-pla", "tags": ["merger"]}
{"id": 42945565, "time": "2025-01-13 09:12:41", "headline": "Keybanc Maintains Overweight on Constellation Energy, Raises Price Target to $337", "summary": "", "symbols": ["CEG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945565/keybanc-maintains-overweight-on-constellation-energy-raises-price-target-to-337", "tags": ["analyst_other", "price_target_up"]}
{"id": 42945566, "time": "2025-01-13 09:12:45", "headline": "China Liberal Education Holdings Regains Compliance With Nasdaq's Minimum Bid Price Deficiency", "summary": "", "symbols": ["CLEU"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945566/china-liberal-education-holdings-regains-compliance-with-nasdaqs-minimum-bid-price-deficiency", "tags": []}
{"id": 42945568, "time": "2025-01-13 09:12:58", "headline": "Simcere Zaiming And AbbVie Partner To Develop Novel Trispecific Antibody Candidate In Multiple Myeloma", "summary": "", "symbols": ["ABBV"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42945568/simcere-zaiming-and-abbvie-partner-to-develop-novel-trispecific-antibody-candidate-in-multiple-my", "tags": []}
{"id": 42945569, "time": "2025-01-13 09:13:20", "headline": "Spirit Announces Sale Of Fiber MaterialsTo Tex Tech Industries For $165M In Cash", "summary": "", "symbols": ["SPR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945569/spirit-announces-sale-of-fiber-materialsto-tex-tech-industries-for-165m-in-cash", "tags": []}
{"id": 42945616, "time": "2025-01-13 09:13:42", "headline": "Barclays Maintains Overweight on Intercontinental Exchange, Lowers Price Target to $179", "summary": "", "symbols": ["ICE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945616/barclays-maintains-overweight-on-intercontinental-exchange-lowers-price-target-to-179", "tags": ["analyst_other", "price_target_down"]}
{"id": 42945702, "time": "2025-01-13 09:14:00", "headline": "Silicom Announces Design Win With US-Based Cyber Security Firm For Advanced Edge System; Expects $2M/Year Revenue By H2 2025", "summary": "", "symbols": ["SILC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945702/silicom-announces-design-win-with-us-based-cyber-security-firm-for-advanced-edge-system-expects-2mye", "tags": ["earnings"]}
{"id": 42945704, "time": "2025-01-13 09:14:27", "headline": "RTX's Raytheon Wins $333M Contract For SM-6 Block IA Production", "summary": "", "symbols": ["RTX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945704/rtxs-raytheon-wins-333m-contract-for-sm-6-block-ia-production", "tags": ["contract"]}
{"id": 42945705, "time": "2025-01-13 09:14:32", "headline": "Duke Energy Appoints Harry Sideris As President And Chief Executive Officer, Effective April 1; Succeeds Lynn Good, Who Retires As Chair And CEO", "summary": "", "symbols": ["DUK"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945705/duke-energy-appoints-harry-sideris-as-president-and-chief-executive-officer-effective-april-1-succee", "tags": ["management"]}
{"id": 42945715, "time": "2025-01-13 09:15:12", "headline": "$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today", "summary": " ", "symbols": ["INTU"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42945715/1000-invested-in-this-stock-20-years-ago-would-be-worth-this-much-today", "tags": []}
{"id": 42945744, "time": "2025-01-13 09:15:43", "headline": "NeurAxis CEO Brian Carrico Issues Letter To Shareholders", "summary": "", "symbols": ["NRXS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945744/neuraxis-ceo-brian-carrico-issues-letter-to-shareholders", "tags": ["management"]}
{"id": 42945767, "time": "2025-01-13 09:17:07", "headline": "BioLife Solutions Reports $22.7M Q4 Revenue Up 31%; Cell Processing Platform Up 37%, Evo And Thaw Platform Down 8%; Full Year Revenue At $82.3M, Up 8%; Cell Processing Up 12%, Evo And Thaw Down 14%", "summary": "", "symbols": ["BLFS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42945767/biolife-solutions-reports-22-7m-q4-revenue-up-31-cell-processing-platform-up-37-evo-and-thaw-plat", "tags": ["earnings"]}
{"id": 42945768, "time": "2025-01-13 09:17:40", "headline": "NAYA Biosciences Prices 13,615,171 Unit Offering At $0.70/Unit", "summary": "", "symbols": ["NAYA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945768/naya-biosciences-prices-13-615-171-unit-offering-at-0-70unit", "tags": ["offering"]}
{"id": 42945769, "time": "2025-01-13 09:17:43", "headline": "Barclays Maintains Equal-Weight on MarketAxess Holdings, Lowers Price Target to $256", "summary": "", "symbols": ["MKTX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945769/barclays-maintains-equal-weight-on-marketaxess-holdings-lowers-price-target-to-256", "tags": ["analyst_other", "price_target_down"]}
{"id": 42945770, "time": "2025-01-13 09:18:01", "headline": "BioLife Solutions Divests Freezer Units; Reports $100.7M Total Revenue For 2024, Exceeding Guidance By 1-3%; $73.5M From Cell Processing, $18.4M From SciSafe, And $8.7M From Biostorage Services Including Evo And Thaw", "summary": "", "symbols": ["BLFS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42945770/biolife-solutions-divests-freezer-units-reports-100-7m-total-revenue-for-2024-exceeding-guidance-by", "tags": ["earnings", "guidance"]}
{"id": 42945825, "time": "2025-01-13 09:19:12", "headline": "Ichor Holdings Sees Prelim. Q4 Revenue $233M Vs $227.11M Est.; EPS Below Prior Guidance Ranges", "summary": "", "symbols": ["ICHR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945825/ichor-holdings-sees-prelim-q4-revenue-233m-vs-227-11m-est-eps-below-prior-guidance-ranges", "tags": ["earnings", "guidance"]}
{"id": 42945827, "time": "2025-01-13 09:19:22", "headline": "Ichor Holdings Sees Q1 Revenue $235M-$250M Vs $229.273M Est.", "summary": "", "symbols": ["ICHR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945827/ichor-holdings-sees-q1-revenue-235m-250m-vs-229-273m-est", "tags": ["earnings"]}
{"id": 42945836, "time": "2025-01-13 09:19:33", "headline": "Nevro Announces Q4 2024 Revenue Decline To $105M-$106M; U.S. Revenue Falls To $91M-$92M; FY24 Revenue At $408M-$409M; Exceeds Guidance Due To SCS Device Replacement Surge; Cash Reserves Increase To $292.5M By Year-End", "summary": "", "symbols": ["NVRO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945836/nevro-announces-q4-2024-revenue-decline-to-105m-106m-u-s-revenue-falls-to-91m-92m-fy24-revenue-at-40", "tags": ["earnings", "guidance"]}
{"id": 42945841, "time": "2025-01-13 09:20:24", "headline": "This Caterpillar Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday", "summary": " ", "symbols": ["AEP", "CART", "CAT", "ETSY", "RH"], "source": "benzinga", "author": "Avi Kapoor", "url": "https://www.benzinga.com/25/01/42945841/this-caterpillar-analyst-is-no-longer-bearish-here-are-top-5-upgrades-for-monday", "tags": ["analyst_up"]}
{"id": 42945867, "time": "2025-01-13 09:21:02", "headline": "Eli Lilly To Acquire Scorpion Therapeutics' Nutant-selective PI3K\u03b1 Inhibitor Program; Scorpion Shareholders Could Receive Up To $2.5M In Cash", "summary": "", "symbols": ["LLY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42945867/eli-lilly-to-acquire-scorpion-therapeutics-nutant-selective-pi3k-inhibitor-program-scorpion-sharehol", "tags": ["merger"]}
{"id": 42945870, "time": "2025-01-13 09:21:18", "headline": "XTI Aerospace Announces Acquisition Of 30% Stake In ReadyMonitor; Option To Acquire Remaining 70% Within 12 Months; Expected To Close Q1 2025; No Financial Terms Disclosed", "summary": "", "symbols": ["XTIA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42945870/xti-aerospace-announces-acquisition-of-30-stake-in-readymonitor-option-to-acquire-remaining-70-withi", "tags": ["merger"]}
{"id": 42945880, "time": "2025-01-13 09:21:50", "headline": "Barclays Maintains Overweight on Nasdaq, Lowers Price Target to $96", "summary": "", "symbols": ["NDAQ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945880/barclays-maintains-overweight-on-nasdaq-lowers-price-target-to-96", "tags": ["analyst_other", "price_target_down"]}
{"id": 42945884, "time": "2025-01-13 09:22:09", "headline": "Cosmos Health And Virax Biolabs Announce Exclusive Distribution Agreement For Avian Influenza Virus PCR Kits In Greece And Cyprus, With Additional Rights In Select European And GCC Countries", "summary": "", "symbols": ["COSM", "VRAX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945884/cosmos-health-and-virax-biolabs-announce-exclusive-distribution-agreement-for-avian-influenza-virus", "tags": ["contract"]}
{"id": 42945886, "time": "2025-01-13 09:22:25", "headline": "Cerus Announces Preliminary 2024 Revenues Of $180.3M, Up 15% From 2023; 2025 Revenue Projected At $194M-$200M, Indicating 8%-11% Growth; IFC Revenue Grows 42% In 2024; 2025 IFC Revenue Predicted Between $12M-$15M; Anticipates LED Illuminator Launch In Europe", "summary": "", "symbols": ["CERS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42945886/cerus-announces-preliminary-2024-revenues-of-180-3m-up-15-from-2023-2025-revenue-projected-at-194", "tags": ["earnings"]}
{"id": 42945889, "time": "2025-01-13 09:23:01", "headline": "Cantor Fitzgerald Initiates Coverage On Onto Innovation with Overweight Rating, Announces Price Target of $250", "summary": "", "symbols": ["ONTO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945889/cantor-fitzgerald-initiates-coverage-on-onto-innovation-with-overweight-rating-announces-price-targe", "tags": ["analyst_init"]}
{"id": 42945891, "time": "2025-01-13 09:23:04", "headline": "Barclays Maintains Overweight on Tradeweb Markets, Raises Price Target to $154", "summary": "", "symbols": ["TW"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945891/barclays-maintains-overweight-on-tradeweb-markets-raises-price-target-to-154", "tags": ["analyst_other", "price_target_up"]}
{"id": 42945893, "time": "2025-01-13 09:23:24", "headline": "QT Imaging Holdings Announces Financial Strengthening, Clears Short-Term Liabilities, And Amends Convertible Notes Maturing March 2026; Forecasts Revenue Growth To $18M In 2025 And $27M In 2026", "summary": "", "symbols": ["QTI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42945893/qt-imaging-holdings-announces-financial-strengthening-clears-short-term-liabilities-and-amends-conve", "tags": ["earnings"]}
{"id": 42946149, "time": "2025-01-13 09:24:20", "headline": "FlexShopper Announces Preliminary Results Of Rights Offering Expired Jan 10; 5.5M Rights Exercised For 21% Of Stock, $9.4M Raised; $2.5M Subordinated Debt Converted; Units Sold At $1.70; Additional 21M Rights Available Over Next 90 Days", "summary": "", "symbols": ["FPAY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946149/flexshopper-announces-preliminary-results-of-rights-offering-expired-jan-10-5-5m-rights-exercised-fo", "tags": ["offering"]}
{"id": 42946150, "time": "2025-01-13 09:24:30", "headline": "Barclays Maintains Overweight on Interactive Brokers Gr, Raises Price Target to $224", "summary": "", "symbols": ["IBKR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946150/barclays-maintains-overweight-on-interactive-brokers-gr-raises-price-target-to-224", "tags": ["analyst_other", "price_target_up"]}
{"id": 42946151, "time": "2025-01-13 09:24:40", "headline": "Cantor Fitzgerald Initiates Coverage On Nova with Overweight Rating, Announces Price Target of $275", "summary": "", "symbols": ["NVMI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946151/cantor-fitzgerald-initiates-coverage-on-nova-with-overweight-rating-announces-price-target-of-275", "tags": ["analyst_init"]}
{"id": 42946152, "time": "2025-01-13 09:24:54", "headline": "Alphatec Holdings Sees Prelim. Q4 Revenue $175.5M-$177.0M Vs $170.317M Est.", "summary": "", "symbols": ["ATEC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946152/alphatec-holdings-sees-prelim-q4-revenue-175-5m-177-0m-vs-170-317m-est", "tags": ["earnings"]}
{"id": 42946158, "time": "2025-01-13 09:25:18", "headline": "Alphatec Holdings Sees Prelim. FY24 Revenue $610.3M-$611.8M Vs $605.109M Est.", "summary": "", "symbols": ["ATEC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946158/alphatec-holdings-sees-prelim-fy24-revenue-610-3m-611-8m-vs-605-109m-est", "tags": ["earnings"]}
{"id": 42946159, "time": "2025-01-13 09:25:28", "headline": "Discount Stores Chain Five Below Holiday Period Sales Surge 8.7%; Stock Rises", "summary": "Five Below reported an 8.7% rise in net sales to $1.19 billion for the holiday period from November 3 to January 4, compared to $1.10 billion last year. ", "symbols": ["FIVE"], "source": "benzinga", "author": "Shivani Kumaresan", "url": "https://www.benzinga.com/25/01/42946159/discount-stores-chain-five-below-boosts-holiday-sales-by-87-stock-rises", "tags": []}
{"id": 42946169, "time": "2025-01-13 09:25:46", "headline": "ReShape And Vyome Announced All-Stock Merger; ReShape To Be Renamed Vyome Holdings, Listed As \"HIND\" On Nasdaq; ReShape Sells Major Assets To Biorad Medisys; No Financial Terms Disclosed", "summary": "", "symbols": ["RSLS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42946169/reshape-and-vyome-announced-all-stock-merger-reshape-to-be-renamed-vyome-holdings-listed-as-hind-on", "tags": ["merger"]}
{"id": 42946174, "time": "2025-01-13 09:26:01", "headline": "Truist Securities Maintains Buy on Civitas Resources, Lowers Price Target to $80", "summary": "", "symbols": ["CIVI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946174/truist-securities-maintains-buy-on-civitas-resources-lowers-price-target-to-80", "tags": ["analyst_other", "price_target_down"]}
{"id": 42946175, "time": "2025-01-13 09:26:03", "headline": "Alphatec Holdings Sees FY25 Revenue $732M Vs $729.465M Est.", "summary": "", "symbols": ["ATEC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946175/alphatec-holdings-sees-fy25-revenue-732m-vs-729-465m-est", "tags": ["earnings"]}
{"id": 42946180, "time": "2025-01-13 09:26:33", "headline": "Barclays Maintains Overweight on LPL Finl Hldgs, Raises Price Target to $379", "summary": "", "symbols": ["LPLA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946180/barclays-maintains-overweight-on-lpl-finl-hldgs-raises-price-target-to-379", "tags": ["analyst_other", "price_target_up"]}
{"id": 42946194, "time": "2025-01-13 09:26:52", "headline": "Cantor Fitzgerald Initiates Coverage On Camtek with Neutral Rating, Announces Price Target of $100", "summary": "", "symbols": ["CAMT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946194/cantor-fitzgerald-initiates-coverage-on-camtek-with-neutral-rating-announces-price-target-of-100", "tags": ["analyst_init"]}
{"id": 42946196, "time": "2025-01-13 09:26:59", "headline": "OneMedNet Regains Compliance With NASDAQ Listing Requirements", "summary": "", "symbols": ["ONMD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946196/onemednet-regains-compliance-with-nasdaq-listing-requirements", "tags": []}
{"id": 42946200, "time": "2025-01-13 09:27:18", "headline": "Barclays Maintains Overweight on Robinhood Markets, Raises Price Target to $54", "summary": "", "symbols": ["HOOD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946200/barclays-maintains-overweight-on-robinhood-markets-raises-price-target-to-54", "tags": ["analyst_other", "price_target_up"]}
{"id": 42946201, "time": "2025-01-13 09:27:21", "headline": "Truist Securities Maintains Hold on Comstock Resources, Raises Price Target to $19", "summary": "", "symbols": ["CRK"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946201/truist-securities-maintains-hold-on-comstock-resources-raises-price-target-to-19", "tags": ["analyst_other", "price_target_up"]}
{"id": 42946197, "time": "2025-01-13 09:27:23", "headline": "Robots To The Rescue? Nvidia Researcher Suggests AI Could Battle Wildfires In Future", "summary": "A senior research\u00a0manager at Nvidia, has pointed out the advantages of AI in firefighting.", "symbols": ["NVDA"], "source": "benzinga", "author": "Pooja Rajkumari", "url": "https://www.benzinga.com/tech/25/01/42946197/nvidias-ai-robots-may-revolutionize-firefighting-amid-california-wildfires", "tags": []}
{"id": 42946216, "time": "2025-01-13 09:28:12", "headline": "This PG&E Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday", "summary": " ", "symbols": ["AXS", "CKPT", "CRC", "ONTO", "PCG"], "source": "benzinga", "author": "Avi Kapoor", "url": "https://www.benzinga.com/25/01/42946216/this-pg-here-are-top-5-initiations-for-monday-2", "tags": ["analyst_init"]}
{"id": 42946218, "time": "2025-01-13 09:28:35", "headline": "Eco Wave Power Engages MOQ For Wave Energy Project Design In Porto, Portugal; Part Of 20 MW Concession With APDL, Featuring Underwater Energy Museum; Targeted 2026 Launch", "summary": "", "symbols": ["WAVE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946218/eco-wave-power-engages-moq-for-wave-energy-project-design-in-porto-portugal-part-of-20-mw-concession", "tags": []}
{"id": 42946219, "time": "2025-01-13 09:28:38", "headline": "MicroStrategy Acquires 2,530 Bitcoin For $243M, Reaching 450,000 BTC In Total Holdings", "summary": "MicroStrategy Incorporated (NASDAQ:MSTR) has expanded its Bitcoin (CRYPTO: BTC) holdings by purchasing an additional 2,530 bitcoins for approximately $243 million, ", "symbols": ["BTCUSD", "MSTR"], "source": "benzinga", "author": "Murtuza Merchant", "url": "https://www.benzinga.com/markets/cryptocurrency/25/01/42946219/microstrategy-acquires-2530-bitcoin-for-243m-reaching-450000-btc-in-total-holdings", "tags": ["merger"]}
{"id": 42946225, "time": "2025-01-13 09:28:43", "headline": "Barclays Maintains Overweight on BlackRock, Lowers Price Target to $1160", "summary": "", "symbols": ["BLK"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946225/barclays-maintains-overweight-on-blackrock-lowers-price-target-to-1160", "tags": ["analyst_other", "price_target_down"]}
{"id": 42946229, "time": "2025-01-13 09:28:51", "headline": "Emergent BioSolutions Receives $16.7M Contract Option To Continue Development Collaboration With BARDA On Ebanga Treatment For Ebola", "summary": "", "symbols": ["EBS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946229/emergent-biosolutions-receives-16-7m-contract-option-to-continue-development-collaboration-with-bard", "tags": ["contract"]}
{"id": 42946250, "time": "2025-01-13 09:29:00", "headline": "Bitcoin Drops To $91,000 Amid Inflation Data Concerns; Dow Sheds 700 Points After Jobs Report, Sentiment Worsens; Greed Index Stays In 'Fear' Zone; Quantum Computing Stocks Fall As Zuckerberg Supports Nvidia's Jensen \u2013 Top Headlines While the U.S. Slept", "summary": " ", "symbols": ["BTCUSD", "ETHUSD", "SPY"], "source": "benzinga", "author": "Akanksha Bakshi", "url": "https://www.benzinga.com/25/01/42946250/bitcoin-drops-to-91000-amid-inflation-data-concerns-dow-sheds-700-points-after-jobs-report-sentiment-worsens-greed-index-stays-in-fear-zone-quantum-computing-stocks-fall-as-zuckerberg-supports-nvidias-jensen-top-headlines-while-the-us-slept", "tags": []}
{"id": 42946254, "time": "2025-01-13 09:29:08", "headline": "Greenwave Technology Solutions Announces $4M Offering Priced at Market; 7,544,323 Common Shares At $0.5302/Share", "summary": "", "symbols": ["GWAV"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946254/greenwave-technology-solutions-announces-4m-offering-priced-at-market-7-544-323-common-shares-at-0-5", "tags": ["offering"]}
{"id": 42946260, "time": "2025-01-13 09:29:37", "headline": "Truist Securities Maintains Buy on ConocoPhillips, Raises Price Target to $139", "summary": "", "symbols": ["COP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946260/truist-securities-maintains-buy-on-conocophillips-raises-price-target-to-139", "tags": ["analyst_other", "price_target_up"]}
{"id": 42946263, "time": "2025-01-13 09:29:45", "headline": "Scilex Announces ZTlido Shows 51.9% Decrease In Opioid Use Compared To 45.5% With 5% Lidocaine Patch; 21.3% Achieve 20% Opioid Reduction Vs. 13.4% With Lidocaine; Non-Significant Opioid Use Change With ZTlido Vs. Significant Increase With 5% Patch", "summary": "", "symbols": ["SCLX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42946263/scilex-announces-ztlido-shows-51-9-decrease-in-opioid-use-compared-to-45-5-with-5-lidocaine-patch", "tags": []}
{"id": 42946264, "time": "2025-01-13 09:29:53", "headline": "Cantor Fitzgerald Reiterates Overweight on Exagen, Maintains $8 Price Target", "summary": "", "symbols": ["XGN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946264/cantor-fitzgerald-reiterates-overweight-on-exagen-maintains-8-price-target", "tags": ["analyst_other"]}
{"id": 42946266, "time": "2025-01-13 09:29:56", "headline": "Blue Hat Prices $4.3M Registered Direct Offering Of 77,989,800 Shares At $0.055/Share", "summary": "", "symbols": ["BHAT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946266/blue-hat-prices-4-3m-registered-direct-offering-of-77-989-800-shares-at-0-055share", "tags": ["offering"]}
{"id": 42946319, "time": "2025-01-13 09:30:12", "headline": "If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today", "summary": " ", "symbols": ["EQT"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42946319/if-you-invested-100-in-this-stock-5-years-ago-you-would-have-this-much-today", "tags": []}
{"id": 42946379, "time": "2025-01-13 09:30:27", "headline": "Ming Shing Unit Lead Benefit Buys 500 Bitcoins At $94,375 Each, $47M Total, For Short-Term Investment To Boost Assets", "summary": "", "symbols": ["MSW"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/markets/cryptocurrency/25/01/42946379/ming-shing-unit-lead-benefit-buys-500-bitcoins-at-94-375-each-47m-total-for-short-term-inv", "tags": []}
{"id": 42946397, "time": "2025-01-13 09:31:34", "headline": "Wave Life Sciences Announces 2025 Plans, Phase 1 INLIGHT Trial For Obesity Target WVE-007; RNA Editing Advancements With WVE-006; Regulatory Feedback And 48-Week Data For WVE-N531 In DMD Expected Q1 2025; Phase 2/3 Study For HD Treatment WVE-003 In Planning; Capital Runway To 2027", "summary": "", "symbols": ["WVE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946397/wave-life-sciences-announces-2025-plans-phase-1-inlight-trial-for-obesity-target-wve-007-rna-editing", "tags": ["fda"]}
{"id": 42946400, "time": "2025-01-13 09:31:41", "headline": "Cantor Fitzgerald Reiterates Overweight on IDEAYA Biosciencesto Overweight", "summary": "", "symbols": ["IDYA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946400/cantor-fitzgerald-reiterates-overweight-on-ideaya-biosciencesto-overweight", "tags": ["analyst_other"]}
{"id": 42946401, "time": "2025-01-13 09:32:08", "headline": "Bitcoin Down 8% In A Week: What Does Technical Analysis Say?", "summary": "Bitcoin (CRYPTO: BTC) has dipped below $91,000, a move that aligns with historical post-halving patterns, according to prominent technical analysts.", "symbols": ["BTCUSD"], "source": "benzinga", "author": "Khyathi Dalal", "url": "https://www.benzinga.com/markets/cryptocurrency/25/01/42946401/bitcoin-down-8-in-a-week-what-does-technical-analysis-say", "tags": []}
{"id": 42946417, "time": "2025-01-13 09:32:36", "headline": "Barclays Maintains Equal-Weight on Blackstone, Lowers Price Target to $192", "summary": "", "symbols": ["BX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946417/barclays-maintains-equal-weight-on-blackstone-lowers-price-target-to-192", "tags": ["analyst_other", "price_target_down"]}
{"id": 42946445, "time": "2025-01-13 09:33:43", "headline": "Freight Technologies Renews Logistics Services Contract With Kimberly-Clark de M\u00e9xico For Additional Two Years", "summary": "", "symbols": ["FRGT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946445/freight-technologies-renews-logistics-services-contract-with-kimberly-clark-de-m-xico-for-additional", "tags": ["contract"]}
{"id": 42946454, "time": "2025-01-13 09:33:49", "headline": "Moderna Expects Lower Annual Sales, Expands Cost-Cutting Initiatives", "summary": "Moderna targets ten product approvals by 2027 while cutting R&amp;D costs by $1.1 billion. FY2024 revenue reached $3 billion-$3.1 billion, with $9.5B in cash reserves.", "symbols": ["MRNA"], "source": "benzinga", "author": "Vandana Singh", "url": "https://www.benzinga.com/25/01/42946454/moderna-expects-lower-annual-sales-expands-cost-cutting-initiatives", "tags": ["earnings"]}
{"id": 42946455, "time": "2025-01-13 09:33:54", "headline": "Top 10 Trending Stocks On WallStreetBets As Of January 13, 2025 (Via Swaggy Stocks)", "summary": "", "symbols": ["AAPL", "AMD", "BTCUSD", "DJT", "GAP", "MRNA", "MSTR", "NVDA", "QQQ", "TSLA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/trading-ideas/25/01/42946455/top-10-trending-stocks-on-wallstreetbets-as-of-january-13-2025-via-swaggy-stocks", "tags": []}
{"id": 42946475, "time": "2025-01-13 09:34:06", "headline": "Truist Securities Maintains Buy on Coterra Energy, Raises Price Target to $37", "summary": "", "symbols": ["CTRA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946475/truist-securities-maintains-buy-on-coterra-energy-raises-price-target-to-37", "tags": ["analyst_other", "price_target_up"]}
{"id": 42946486, "time": "2025-01-13 09:34:31", "headline": "Addentax Acquires 2.5% Equity Stake In Well InfoTech For $750,000", "summary": "", "symbols": ["ATXG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42946486/addentax-acquires-2-5-equity-stake-in-well-infotech-for-750-000", "tags": ["merger"]}
{"id": 42946509, "time": "2025-01-13 09:35:12", "headline": "Truist Securities Maintains Buy on Crescent Energy, Raises Price Target to $21", "summary": "", "symbols": ["CRGY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946509/truist-securities-maintains-buy-on-crescent-energy-raises-price-target-to-21", "tags": ["analyst_other", "price_target_up"]}
{"id": 42946595, "time": "2025-01-13 09:35:53", "headline": "Carrier To Hire 1,000 Service Technicians", "summary": "", "symbols": ["CARR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946595/carrier-to-hire-1-000-service-technicians", "tags": []}
{"id": 42946606, "time": "2025-01-13 09:36:06", "headline": "This Pinterest Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday", "summary": " ", "symbols": ["EOG", "NEP", "PINS", "RAMP", "STZ"], "source": "benzinga", "author": "Avi Kapoor", "url": "https://www.benzinga.com/25/01/42946606/this-pinterest-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-monday", "tags": ["analyst_down"]}
{"id": 42946614, "time": "2025-01-13 09:36:17", "headline": "Truist Securities Maintains Hold on Devon Energy, Lowers Price Target to $42", "summary": "", "symbols": ["DVN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946614/truist-securities-maintains-hold-on-devon-energy-lowers-price-target-to-42", "tags": ["analyst_other", "price_target_down"]}
{"id": 42946646, "time": "2025-01-13 09:36:41", "headline": "Editas Medicine Announces In Vivo Preclinical Proof Of Concept In HSC And Liver Cells, 2025 Milestones, And Strategic Priorities Through 2027 With Operational Runway Into Q2 2027", "summary": "", "symbols": ["EDIT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42946646/editas-medicine-announces-in-vivo-preclinical-proof-of-concept-in-hsc-and-liver-cells-2025-milest", "tags": []}
{"id": 42946657, "time": "2025-01-13 09:36:59", "headline": "eBay To Acquire Caramel; Terms Not Disclosed", "summary": "", "symbols": ["EBAY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42946657/ebay-to-acquire-caramel-terms-not-disclosed", "tags": ["merger"]}
{"id": 42946662, "time": "2025-01-13 09:37:09", "headline": "Wedbush Reiterates Neutral on UMH Properties, Maintains $20 Price Target", "summary": "", "symbols": ["UMH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946662/wedbush-reiterates-neutral-on-umh-properties-maintains-20-price-target", "tags": ["analyst_other"]}
{"id": 42946679, "time": "2025-01-13 09:37:26", "headline": "Truist Securities Maintains Buy on Diamondback Energy, Raises Price Target to $236", "summary": "", "symbols": ["FANG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946679/truist-securities-maintains-buy-on-diamondback-energy-raises-price-target-to-236", "tags": ["analyst_other", "price_target_up"]}
{"id": 42946705, "time": "2025-01-13 09:38:11", "headline": "Truist Securities Maintains Hold on EOG Resources, Raises Price Target to $137", "summary": "", "symbols": ["EOG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946705/truist-securities-maintains-hold-on-eog-resources-raises-price-target-to-137", "tags": ["analyst_other", "price_target_up"]}
{"id": 42946734, "time": "2025-01-13 09:38:41", "headline": "Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?", "summary": "Sage Therapeutics reviews Biogen&#39;s $7.22 per share acquisition proposal amid ongoing restructuring and focus on Zurzuvae for postpartum depression.", "symbols": ["BIIB", "SAGE"], "source": "benzinga", "author": "Vandana Singh", "url": "https://www.benzinga.com/25/01/42946734/why-is-depression-focused-sage-therapeutics-stock-surging-higher-on-monday", "tags": ["why_moving"]}
{"id": 42946735, "time": "2025-01-13 09:38:45", "headline": "AbCellera Expands AbbVie Collaboration To Include Discovery Of T-Cell Engagers In Oncology", "summary": "", "symbols": ["ABBV", "ABCL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42946735/abcellera-expands-abbvie-collaboration-to-include-discovery-of-t-cell-engagers-in-oncology", "tags": []}
{"id": 42946741, "time": "2025-01-13 09:38:52", "headline": "HealthEquity Sees HSA Assets ~$31B", "summary": "", "symbols": ["HQY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946741/healthequity-sees-hsa-assets-31b", "tags": []}
{"id": 42946784, "time": "2025-01-13 09:39:22", "headline": "Wedbush Reiterates Neutral on Ultragenyx Pharmaceutical, Maintains $48 Price Target", "summary": "", "symbols": ["RARE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946784/wedbush-reiterates-neutral-on-ultragenyx-pharmaceutical-maintains-48-price-target", "tags": ["analyst_other"]}
{"id": 42946796, "time": "2025-01-13 09:39:50", "headline": "Tenaya Therapeutics Announces Progress In Gene Therapies TN-201 And TN-401 For Cardiomyopathies; Dosing Started In Cohort 2 Of MyPEAK-1 Phase 1b/2 Trial; Cohort 1 Data Expected H1 2025; Initial Data From RIDGE-1 Trial Of TN-401 Expected In H2 2025", "summary": "", "symbols": ["TNYA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42946796/tenaya-therapeutics-announces-progress-in-gene-therapies-tn-201-and-tn-401-for-cardiomyopathies-d", "tags": ["fda"]}
{"id": 42946854, "time": "2025-01-13 09:40:40", "headline": "Truist Securities Maintains Hold on EQT, Raises Price Target to $56", "summary": "", "symbols": ["EQT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946854/truist-securities-maintains-hold-on-eqt-raises-price-target-to-56", "tags": ["analyst_other", "price_target_up"]}
{"id": 42946908, "time": "2025-01-13 09:41:47", "headline": "Walmart Announces Brand Refresh Embracing Evolution And Legacy To Enhance Customer Experience; Focus On Health, Wealth, And Sustainability", "summary": "", "symbols": ["WMT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946908/walmart-announces-brand-refresh-embracing-evolution-and-legacy-to-enhance-customer-experience-focus", "tags": []}
{"id": 42946910, "time": "2025-01-13 09:41:48", "headline": "Wedbush Reiterates Outperform on Blueprint Medicines, Lowers Price Target to $124", "summary": "", "symbols": ["BPMC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946910/wedbush-reiterates-outperform-on-blueprint-medicines-lowers-price-target-to-124", "tags": ["analyst_other", "price_target_down"]}
{"id": 42946934, "time": "2025-01-13 09:42:19", "headline": "Truist Securities Maintains Buy on Evolent Health, Lowers Price Target to $20", "summary": "", "symbols": ["EVH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946934/truist-securities-maintains-buy-on-evolent-health-lowers-price-target-to-20", "tags": ["analyst_other", "price_target_down"]}
{"id": 42946958, "time": "2025-01-13 09:42:54", "headline": "AtlasClear Holdings Plans Financial Services Firm; Hanire Invests $5M At $15/Share With 19.99% Limit, Remainder Convertible Note", "summary": "", "symbols": ["ATCH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42946958/atlasclear-holdings-plans-financial-services-firm-hanire-invests-5m-at-15share-with-19-99-limit-rema", "tags": []}
{"id": 42946987, "time": "2025-01-13 09:43:37", "headline": "Dogecoin Plummets 17% In A Week: What Is Going On?", "summary": "Dogecoin (CRYPTO: DOGE) opens the week down 6% after dropping 17% over the past seven days, with traders voicing only muted optimism for its future.", "symbols": ["DOGEUSD", "PEPEUSD", "SHIBUSD", "SOLUSD"], "source": "benzinga", "author": "Khyathi Dalal", "url": "https://www.benzinga.com/markets/cryptocurrency/25/01/42946987/dogecoin-plummets-17-in-a-week-what-is-going-on", "tags": []}
{"id": 42947031, "time": "2025-01-13 09:44:02", "headline": "Truist Securities Maintains Buy on Expand Energy, Raises Price Target to $133", "summary": "", "symbols": ["EXE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42947031/truist-securities-maintains-buy-on-expand-energy-raises-price-target-to-133", "tags": ["analyst_other", "price_target_up"]}
{"id": 42944447, "time": "2025-01-13 08:45:30", "headline": "Reported Jan 10, 2025: Broadcom Issues $3B Senior Notes, $1.1B At 4.8% Due 2028, $800M At 5.05% Due 2030, $1.1B At 5.2% Due 2032; To Use Proceeds For General Corporate Purposes And Debt Repayment", "summary": "", "symbols": ["AVGO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42944447/broadcom-issues-3b-senior-notes-1-1b-at-4-8-due-2028-800m-at-5-05-due-2030-1-1b-at-5-2-due-2032-to-u", "tags": []}
{"id": 42947072, "time": "2025-01-13 09:45:05", "headline": "Truist Securities Maintains Hold on Exxon Mobil, Raises Price Target to $119", "summary": "", "symbols": ["XOM"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42947072/truist-securities-maintains-hold-on-exxon-mobil-raises-price-target-to-119", "tags": ["analyst_other", "price_target_up"]}
{"id": 42947079, "time": "2025-01-13 09:45:12", "headline": "$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today", "summary": " ", "symbols": ["HLNE"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42947079/100-invested-in-this-stock-5-years-ago-would-be-worth-this-much-today", "tags": []}
{"id": 42947095, "time": "2025-01-13 09:45:26", "headline": "What the Options Market Tells Us About Oracle", "summary": " ", "symbols": ["ORCL"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42947095/what-the-options-market-tells-us-about-oracle", "tags": []}
{"id": 42947097, "time": "2025-01-13 09:45:32", "headline": "MicroStrategy Unusual Options Activity", "summary": " ", "symbols": ["MSTR"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42947097/microstrategy-unusual-options-activity", "tags": []}
{"id": 42947100, "time": "2025-01-13 09:45:37", "headline": "Amazon.com Unusual Options Activity", "summary": " ", "symbols": ["AMZN"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42947100/amazon-com-unusual-options-activity", "tags": []}
{"id": 42947122, "time": "2025-01-13 09:46:10", "headline": "Truist Securities Maintains Buy on Gulfport Energy, Raises Price Target to $246", "summary": "", "symbols": ["GPOR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42947122/truist-securities-maintains-buy-on-gulfport-energy-raises-price-target-to-246", "tags": ["analyst_other", "price_target_up"]}
{"id": 42947179, "time": "2025-01-13 09:47:13", "headline": "Truist Securities Maintains Hold on HighPeak Energy, Raises Price Target to $15", "summary": "", "symbols": ["HPK"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42947179/truist-securities-maintains-hold-on-highpeak-energy-raises-price-target-to-15", "tags": ["analyst_other", "price_target_up"]}
{"id": 42947203, "time": "2025-01-13 09:47:38", "headline": "U.S. National Security Adviser Sullivan Says We Have Seen China Developing Ability To Conduct Destructive Cyberattacks In The Future, Trump Team Will Have To Work On That Issue", "summary": "", "symbols": ["FXI", "SPY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42947203/u-s-national-security-adviser-sullivan-says-we-have-seen-china-developing-ability-to-conduct-destruc", "tags": []}
{"id": 42947205, "time": "2025-01-13 09:47:41", "headline": "Cleveland-Cliffs Partners With Nucor In Potential Bid For U.S. Steel", "summary": "", "symbols": ["CLF", "NUE", "X"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42947205/cleveland-cliffs-partners-with-nucor-in-potential-bid-for-u-s-steel", "tags": ["contract"]}
{"id": 42947236, "time": "2025-01-13 09:48:13", "headline": "Truist Securities Maintains Buy on Kimbell Royalty Partners, Raises Price Target to $22", "summary": "", "symbols": ["KRP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42947236/truist-securities-maintains-buy-on-kimbell-royalty-partners-raises-price-target-to-22", "tags": ["analyst_other", "price_target_up"]}
{"id": 42947245, "time": "2025-01-13 09:48:33", "headline": "'Walmart GoLocal And IBM Collaboration Makes Last-Mile Delivery Easier For Retailers' - IBM", "summary": "", "symbols": ["IBM", "WMT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42947245/walmart-golocal-and-ibm-collaboration-makes-last-mile-delivery-easier-for-retailers-ibm", "tags": []}
{"id": 42947287, "time": "2025-01-13 09:49:17", "headline": "Truist Securities Maintains Buy on Mach Natural Resources, Raises Price Target to $24", "summary": "", "symbols": ["MNR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42947287/truist-securities-maintains-buy-on-mach-natural-resources-raises-price-target-to-24", "tags": ["analyst_other", "price_target_up"]}
{"id": 42947291, "time": "2025-01-13 09:49:21", "headline": "The Offer Would Be In The High $30s/Share; Cleveland-Cliffs Would Purchase All Of U.S. Steel For All Cash And Then Sell Off The Big River Steel Subsidiary To Nucor", "summary": "", "symbols": ["CLF", "NUE", "X"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42947291/the-offer-would-be-in-the-high-30sshare-cleveland-cliffs-would-purchase-all-of-u-s-steel-for-all-cas", "tags": []}
{"id": 42947328, "time": "2025-01-13 09:50:38", "headline": "Benchmark Reiterates Hold on EOG Resourcesto Hold", "summary": "", "symbols": ["EOG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42947328/benchmark-reiterates-hold-on-eog-resourcesto-hold", "tags": ["analyst_other"]}
{"id": 42947329, "time": "2025-01-13 09:50:39", "headline": "Truist Securities Maintains Buy on Magnolia Oil & Gas, Raises Price Target to $34", "summary": "", "symbols": ["MGY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42947329/truist-securities-maintains-buy-on-magnolia-oil-gas-raises-price-target-to-34", "tags": ["analyst_other", "price_target_up"]}
{"id": 42947348, "time": "2025-01-13 09:51:21", "headline": "Tesla To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Monday", "summary": " ", "symbols": ["BOOT", "CEG", "CHWY", "COP", "ETSY", "GPOR", "HOOD", "RH", "SNX", "TSLA"], "source": "benzinga", "author": "Avi Kapoor", "url": "https://www.benzinga.com/25/01/42947348/tesla-to-rally-around-9-here-are-10-top-analyst-forecasts-for-monday", "tags": []}
{"id": 42947353, "time": "2025-01-13 09:51:25", "headline": "Truist Securities Maintains Buy on Matador Resources, Raises Price Target to $80", "summary": "", "symbols": ["MTDR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42947353/truist-securities-maintains-buy-on-matador-resources-raises-price-target-to-80", "tags": ["analyst_other", "price_target_up"]}
{"id": 42947521, "time": "2025-01-13 09:53:41", "headline": "Why Is Lululemon Athletica Stock Gaining On Monday?", "summary": "lululemon athletica raises its fourth-quarter revenue projections to between $3.56 billion and $3.58 billion, reflecting an 11-12% increase year-over-year. The company also upgraded its earnings per share forecast to $5.81-$5.85.", "symbols": ["LULU"], "source": "benzinga", "author": "Shivani Kumaresan", "url": "https://www.benzinga.com/news/guidance/25/01/42947521/why-is-lululemon-athletica-stock-gaining-on-monday", "tags": ["analyst_up", "earnings", "guidance", "why_moving"]}
{"id": 42947553, "time": "2025-01-13 09:53:43", "headline": "Truist Securities Maintains Buy on Murphy Oil, Raises Price Target to $42", "summary": "", "symbols": ["MUR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42947553/truist-securities-maintains-buy-on-murphy-oil-raises-price-target-to-42", "tags": ["analyst_other", "price_target_up"]}
{"id": 42947562, "time": "2025-01-13 09:53:44", "headline": "Taiwan Semiconductor Begins 4nm Chip Production in Arizona, Eyes $11.4 Billion Q4 Profit", "summary": "Taiwan Semiconductor has begun production of advanced 4-nm chips for US customers in Arizona, with a $6.6 billion grant and plans to add a third fab by 2030.", "symbols": ["AAPL", "NVDA", "SEMI", "SHOC", "TSM"], "source": "benzinga", "author": "Anusuya Lahiri", "url": "https://www.benzinga.com/government/regulations/25/01/42947562/taiwan-semiconductor-begins-4nm-chip-production-in-arizona-eyes-11-4-billion-q4-profit", "tags": []}
{"id": 42947722, "time": "2025-01-13 09:54:11", "headline": "Benchmark Downgrades NeoGenomics to Hold", "summary": "", "symbols": ["NEO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42947722/benchmark-downgrades-neogenomics-to-hold", "tags": ["analyst_down"]}
{"id": 42947746, "time": "2025-01-13 09:54:35", "headline": "Barclays Maintains Equal-Weight on Kinetik Holdings, Raises Price Target to $61", "summary": "", "symbols": ["KNTK"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42947746/barclays-maintains-equal-weight-on-kinetik-holdings-raises-price-target-to-61", "tags": ["analyst_other", "price_target_up"]}
{"id": 42947768, "time": "2025-01-13 09:55:14", "headline": "Truist Securities Maintains Hold on Occidental Petroleum, Raises Price Target to $58", "summary": "", "symbols": ["OXY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42947768/truist-securities-maintains-hold-on-occidental-petroleum-raises-price-target-to-58", "tags": ["analyst_other", "price_target_up"]}
{"id": 42947786, "time": "2025-01-13 09:56:03", "headline": "Truist Securities Maintains Buy on Ovintiv, Raises Price Target to $60", "summary": "", "symbols": ["OVV"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42947786/truist-securities-maintains-buy-on-ovintiv-raises-price-target-to-60", "tags": ["analyst_other", "price_target_up"]}
{"id": 42947803, "time": "2025-01-13 09:56:31", "headline": "Barclays Maintains Equal-Weight on Kodiak Gas Services, Raises Price Target to $44", "summary": "", "symbols": ["KGS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42947803/barclays-maintains-equal-weight-on-kodiak-gas-services-raises-price-target-to-44", "tags": ["analyst_other", "price_target_up"]}
{"id": 42947813, "time": "2025-01-13 09:56:49", "headline": "Benchmark Reiterates Buy on Imax, Maintains $30 Price Target", "summary": "", "symbols": ["IMAX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42947813/benchmark-reiterates-buy-on-imax-maintains-30-price-target", "tags": ["analyst_other"]}
{"id": 42947887, "time": "2025-01-13 09:58:31", "headline": "Barclays Maintains Overweight on MPLX, Raises Price Target to $52", "summary": "", "symbols": ["MPLX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42947887/barclays-maintains-overweight-on-mplx-raises-price-target-to-52", "tags": ["analyst_other", "price_target_up"]}
{"id": 42947914, "time": "2025-01-13 09:59:21", "headline": "Benchmark Reiterates Buy on Exact Sciences, Maintains $65 Price Target", "summary": "", "symbols": ["EXAS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42947914/benchmark-reiterates-buy-on-exact-sciences-maintains-65-price-target", "tags": ["analyst_other"]}
{"id": 42947956, "time": "2025-01-13 10:00:06", "headline": "Preview: Uni-Fuels Holdings Limited Set To IPO Tomorrow", "summary": " ", "symbols": ["UFG"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/ipos/25/01/42947956/preview-uni-fuels-holdings-limited-set-to-ipo-tomorrow", "tags": []}
{"id": 42947974, "time": "2025-01-13 10:00:11", "headline": "Here's How Much $100 Invested In Synopsys 10 Years Ago Would Be Worth Today", "summary": " ", "symbols": ["SNPS"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42947974/heres-how-much-100-invested-in-synopsys-10-years-ago-would-be-worth-today", "tags": []}
{"id": 42947970, "time": "2025-01-13 10:00:11", "headline": "Ethereum Decreases More Than 6% Within 24 hours", "summary": "Ethereum&#39;s (CRYPTO: ETH) price has decreased 6.92% over the past 24 hours to $3,041.15, continuing its downward trend over the past week of -17.0%, moving from $3,683.38 to its current price. ", "symbols": ["ETHUSD"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/cryptocurrency/25/01/42947970/ethereum-decreases-more-than-6-within-24-hours", "tags": []}
{"id": 42947982, "time": "2025-01-13 10:00:14", "headline": "Analyzing NVIDIA In Comparison To Competitors In Semiconductors &amp; Semiconductor Equipment Industry", "summary": " ", "symbols": ["NVDA"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42947982/analyzing-nvidia-in-comparison-to-competitors-in-semiconductors-amp-semiconductor-equipment-industr", "tags": []}
{"id": 42948011, "time": "2025-01-13 10:00:22", "headline": "Competitor Analysis: Evaluating Microsoft And Competitors In Software Industry", "summary": " ", "symbols": ["MSFT"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42948011/competitor-analysis-evaluating-microsoft-and-competitors-in-software-industry", "tags": []}
{"id": 42948017, "time": "2025-01-13 10:00:25", "headline": "This Is What Whales Are Betting On Rocket Lab USA", "summary": " ", "symbols": ["RKLB"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42948017/this-is-what-whales-are-betting-on-rocket-lab-usa", "tags": []}
{"id": 42948026, "time": "2025-01-13 10:00:31", "headline": "Vertiv Hldgs's Options Frenzy: What You Need to Know", "summary": " ", "symbols": ["VRT"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42948026/vertiv-hldgss-options-frenzy-what-you-need-to-know", "tags": []}
{"id": 42948027, "time": "2025-01-13 10:00:31", "headline": "Understanding Apple's Position In Technology Hardware, Storage &amp; Peripherals Industry Compared To Competitors", "summary": " ", "symbols": ["AAPL"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42948027/understanding-apples-position-in-technology-hardware-storage-amp-peripherals-industry-compared-to-c", "tags": []}
{"id": 42948033, "time": "2025-01-13 10:00:36", "headline": "Looking At Costco Wholesale's Recent Unusual Options Activity", "summary": " ", "symbols": ["COST"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42948033/looking-at-costco-wholesales-recent-unusual-options-activity", "tags": []}
{"id": 42948035, "time": "2025-01-13 10:00:39", "headline": "Comparing Meta Platforms With Industry Competitors In Interactive Media &amp; Services Industry", "summary": " ", "symbols": ["META"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42948035/comparing-meta-platforms-with-industry-competitors-in-interactive-media-amp-services-industry", "tags": []}
{"id": 42948038, "time": "2025-01-13 10:00:48", "headline": "Industry Comparison: Evaluating Amazon.com Against Competitors In Broadline Retail Industry", "summary": " ", "symbols": ["AMZN"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42948038/industry-comparison-evaluating-amazon-com-against-competitors-in-broadline-retail-industry", "tags": []}
{"id": 42948042, "time": "2025-01-13 10:00:51", "headline": "Barclays Maintains Overweight on P10, Raises Price Target to $16", "summary": "", "symbols": ["PX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42948042/barclays-maintains-overweight-on-p10-raises-price-target-to-16", "tags": ["analyst_other", "price_target_up"]}
{"id": 42948148, "time": "2025-01-13 10:03:02", "headline": "What's Going On With Kratos Defense & Security Solutions Stock Monday?", "summary": "Kratos Defense &amp; Security Solutions Inc (NASDAQ:KTOS) shares are trading higher. The company on Monday announced it received a new hypersonic system program award with a total value of up to $100 million.", "symbols": ["KTOS"], "source": "benzinga", "author": "Adam Eckert", "url": "https://www.benzinga.com/news/contracts/25/01/42948148/whats-going-on-with-kratos-defense-security-solutions-stock-monday", "tags": ["why_moving"]}
{"id": 42948150, "time": "2025-01-13 10:03:04", "headline": "Barclays Maintains Equal-Weight on Phillips 66, Lowers Price Target to $115", "summary": "", "symbols": ["PSX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42948150/barclays-maintains-equal-weight-on-phillips-66-lowers-price-target-to-115", "tags": ["analyst_other", "price_target_down"]}
{"id": 42948170, "time": "2025-01-13 10:03:27", "headline": "Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal", "summary": "Johnson &amp; Johnson&#39;s $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline.", "symbols": ["ABBV", "BMY", "ITCI", "JNJ"], "source": "benzinga", "author": "Vandana Singh", "url": "https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal", "tags": ["fda", "contract"]}
{"id": 42948251, "time": "2025-01-13 10:04:41", "headline": "Needham Reiterates Buy on Axsome Therapeutics, Maintains $133 Price Target", "summary": "", "symbols": ["AXSM"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42948251/needham-reiterates-buy-on-axsome-therapeutics-maintains-133-price-target", "tags": ["analyst_other"]}
{"id": 42948313, "time": "2025-01-13 10:05:37", "headline": "Why Novavax (NVAX) Stock Is Falling", "summary": "Novavax shares are trading lower by 9.8% during Monday&#39;s session. Shares of vaccine stocks are trading lower after Moderna issued 2025 revenue\u00a0guidance\u00a0below analyst estimates.", "symbols": ["NVAX"], "source": "benzinga", "author": "Henry Khederian", "url": "https://www.benzinga.com/news/25/01/42948313/why-novavax-nvax-stock-is-falling", "tags": ["earnings", "guidance", "why_moving"]}
{"id": 42948339, "time": "2025-01-13 10:06:00", "headline": "Barclays Maintains Overweight on Targa Resources, Raises Price Target to $204", "summary": "", "symbols": ["TRGP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42948339/barclays-maintains-overweight-on-targa-resources-raises-price-target-to-204", "tags": ["analyst_other", "price_target_up"]}
{"id": 42948362, "time": "2025-01-13 10:06:27", "headline": "Truist Securities Maintains Buy on Permian Resources, Raises Price Target to $23", "summary": "", "symbols": ["PR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42948362/truist-securities-maintains-buy-on-permian-resources-raises-price-target-to-23", "tags": ["analyst_other", "price_target_up"]}
{"id": 42948363, "time": "2025-01-13 10:06:30", "headline": "Needham Reiterates Buy on Paragon 28, Maintains $13 Price Target", "summary": "", "symbols": ["FNA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42948363/needham-reiterates-buy-on-paragon-28-maintains-13-price-target", "tags": ["analyst_other"]}
{"id": 42948376, "time": "2025-01-13 10:06:46", "headline": "Barclays Maintains Overweight on Carlyle Group, Raises Price Target to $60", "summary": "", "symbols": ["CG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42948376/barclays-maintains-overweight-on-carlyle-group-raises-price-target-to-60", "tags": ["analyst_other", "price_target_up"]}
{"id": 42948424, "time": "2025-01-13 10:07:14", "headline": "Truist Securities Maintains Hold on Range Resources, Raises Price Target to $35", "summary": "", "symbols": ["RRC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42948424/truist-securities-maintains-hold-on-range-resources-raises-price-target-to-35", "tags": ["analyst_other", "price_target_up"]}
{"id": 42948462, "time": "2025-01-13 10:08:03", "headline": "Truist Securities Maintains Buy on Riley Exploration Permian, Raises Price Target to $47", "summary": "", "symbols": ["REPX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42948462/truist-securities-maintains-buy-on-riley-exploration-permian-raises-price-target-to-47", "tags": ["analyst_other", "price_target_up"]}
{"id": 42948514, "time": "2025-01-13 10:09:05", "headline": "Truist Securities Maintains Hold on SM Energy, Raises Price Target to $45", "summary": "", "symbols": ["SM"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42948514/truist-securities-maintains-hold-on-sm-energy-raises-price-target-to-45", "tags": ["analyst_other", "price_target_up"]}
{"id": 42948604, "time": "2025-01-13 10:10:27", "headline": "Truist Securities Maintains Buy on Sitio Royalties, Raises Price Target to $30", "summary": "", "symbols": ["STR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42948604/truist-securities-maintains-buy-on-sitio-royalties-raises-price-target-to-30", "tags": ["analyst_other", "price_target_up"]}
{"id": 42948649, "time": "2025-01-13 10:10:55", "headline": "Oil Could Hit $90, Goldman Sachs Says: 'Trump May Not Ease Sanctions' On Russia", "summary": "Brent crude could reach $90 per barrel as Goldman Sachs warns of potential oil price risks due to U.S. sanctions on Russian energy sector.", "symbols": ["USO"], "source": "benzinga", "author": "Piero Cingari", "url": "https://www.benzinga.com/25/01/42948649/goldman-sachs-warns-of-90-oil-risk-trump-may-not-ease-sanctions-once-he-takes-office", "tags": []}
{"id": 42948664, "time": "2025-01-13 10:11:19", "headline": "Truist Securities Maintains Hold on Veeva Systems, Lowers Price Target to $210", "summary": "", "symbols": ["VEEV"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42948664/truist-securities-maintains-hold-on-veeva-systems-lowers-price-target-to-210", "tags": ["analyst_other", "price_target_down"]}
{"id": 42948684, "time": "2025-01-13 10:11:40", "headline": "Wells Fargo Maintains Overweight on Constellation Energy, Raises Price Target to $375", "summary": "", "symbols": ["CEG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42948684/wells-fargo-maintains-overweight-on-constellation-energy-raises-price-target-to-375", "tags": ["analyst_other", "price_target_up"]}
{"id": 42948695, "time": "2025-01-13 10:11:48", "headline": "USA CB Employment Trends Index For Dec. 109.70 Vs 109.45 Prior", "summary": "", "symbols": ["SPY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/economics/macro-economic-events/25/01/42948695/usa-cb-employment-trends-index-for-dec-109-70-vs-109-45-prior", "tags": []}
{"id": 42948706, "time": "2025-01-13 10:12:07", "headline": "Truist Securities Maintains Buy on Viper Energy, Raises Price Target to $71", "summary": "", "symbols": ["VNOM"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42948706/truist-securities-maintains-buy-on-viper-energy-raises-price-target-to-71", "tags": ["analyst_other", "price_target_up"]}
{"id": 42948772, "time": "2025-01-13 10:12:58", "headline": "Wells Fargo Maintains Equal-Weight on Halozyme Therapeutics, Lowers Price Target to $57", "summary": "", "symbols": ["HALO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42948772/wells-fargo-maintains-equal-weight-on-halozyme-therapeutics-lowers-price-target-to-57", "tags": ["analyst_other", "price_target_down"]}
{"id": 42948779, "time": "2025-01-13 10:12:59", "headline": "Truist Securities Maintains Buy on Vital Energy, Raises Price Target to $49", "summary": "", "symbols": ["VTLE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42948779/truist-securities-maintains-buy-on-vital-energy-raises-price-target-to-49", "tags": ["analyst_other", "price_target_up"]}
{"id": 42948807, "time": "2025-01-13 10:13:43", "headline": "Wells Fargo Maintains Equal-Weight on Doximity, Raises Price Target to $43", "summary": "", "symbols": ["DOCS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42948807/wells-fargo-maintains-equal-weight-on-doximity-raises-price-target-to-43", "tags": ["analyst_other", "price_target_up"]}
{"id": 42948922, "time": "2025-01-13 10:15:02", "headline": "Wells Fargo Maintains Equal-Weight on Omnicell, Lowers Price Target to $40", "summary": "", "symbols": ["OMCL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42948922/wells-fargo-maintains-equal-weight-on-omnicell-lowers-price-target-to-40", "tags": ["analyst_other", "price_target_down"]}
{"id": 42948928, "time": "2025-01-13 10:15:11", "headline": "Here's How Much $100 Invested In Wingstop 5 Years Ago Would Be Worth Today", "summary": " ", "symbols": ["WING"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42948928/heres-how-much-100-invested-in-wingstop-5-years-ago-would-be-worth-today", "tags": []}
{"id": 42948930, "time": "2025-01-13 10:15:11", "headline": "Piper Sandler Upgrades Nutrien to Overweight, Raises Price Target to $58", "summary": "", "symbols": ["NTR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42948930/piper-sandler-upgrades-nutrien-to-overweight-raises-price-target-to-58", "tags": ["analyst_up", "price_target_up"]}
{"id": 42948932, "time": "2025-01-13 10:15:16", "headline": "How Is The Market Feeling About Pure Storage?", "summary": " ", "symbols": ["PSTG"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42948932/how-is-the-market-feeling-about-pure-storage", "tags": []}
{"id": 42948943, "time": "2025-01-13 10:15:21", "headline": "How Is The Market Feeling About Dell Technologies?", "summary": " ", "symbols": ["DELL"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42948943/how-is-the-market-feeling-about-dell-technologies", "tags": []}
{"id": 42948950, "time": "2025-01-13 10:15:27", "headline": "Looking Into Camping World Holdings's Recent Short Interest", "summary": " ", "symbols": ["CWH"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42948950/looking-into-camping-world-holdingss-recent-short-interest", "tags": []}
{"id": 42948979, "time": "2025-01-13 10:15:54", "headline": "Wells Fargo Maintains Overweight on Inozyme Pharma, Lowers Price Target to $11", "summary": "", "symbols": ["INZY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42948979/wells-fargo-maintains-overweight-on-inozyme-pharma-lowers-price-target-to-11", "tags": ["analyst_other", "price_target_down"]}
{"id": 42949041, "time": "2025-01-13 10:17:03", "headline": "Piper Sandler Upgrades Mosaic to Neutral, Raises Price Target to $30", "summary": "", "symbols": ["MOS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949041/piper-sandler-upgrades-mosaic-to-neutral-raises-price-target-to-30", "tags": ["analyst_up", "price_target_up"]}
{"id": 42949049, "time": "2025-01-13 10:17:20", "headline": "Wells Fargo Maintains Underweight on KB Home, Lowers Price Target to $65", "summary": "", "symbols": ["KBH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949049/wells-fargo-maintains-underweight-on-kb-home-lowers-price-target-to-65", "tags": ["analyst_other", "price_target_down"]}
{"id": 42949090, "time": "2025-01-13 10:18:27", "headline": "Piper Sandler Upgrades LSB Industries to Overweight, Raises Price Target to $11", "summary": "", "symbols": ["LXU"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949090/piper-sandler-upgrades-lsb-industries-to-overweight-raises-price-target-to-11", "tags": ["analyst_up", "price_target_up"]}
{"id": 42949111, "time": "2025-01-13 10:18:51", "headline": "Wells Fargo Maintains Equal-Weight on Smith Douglas Homes, Lowers Price Target to $24", "summary": "", "symbols": ["SDHC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949111/wells-fargo-maintains-equal-weight-on-smith-douglas-homes-lowers-price-target-to-24", "tags": ["analyst_other", "price_target_down"]}
{"id": 42949192, "time": "2025-01-13 10:19:26", "headline": "Piper Sandler Upgrades CF Industries Holdings to Overweight, Raises Price Target to $105", "summary": "", "symbols": ["CF"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949192/piper-sandler-upgrades-cf-industries-holdings-to-overweight-raises-price-target-to-105", "tags": ["analyst_up", "price_target_up"]}
{"id": 42949217, "time": "2025-01-13 10:20:19", "headline": "Wells Fargo Maintains Overweight on Canadian National Railway, Lowers Price Target to $123", "summary": "", "symbols": ["CNI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949217/wells-fargo-maintains-overweight-on-canadian-national-railway-lowers-price-target-to-123", "tags": ["analyst_other", "price_target_down"]}
{"id": 42949261, "time": "2025-01-13 10:20:52", "headline": "Eli Lilly Scoops Up Scorpion Therapeutics' Early-Stage Cancer Program For $2.5 Billion", "summary": "Eli Lilly plans to acquire Scorpion&#39;s PI3K\u03b1 program for $2.5 billion, reinvesting Mounjaro and Zepbound profits to expand its precision medicines pipeline.", "symbols": ["LLY"], "source": "benzinga", "author": "Vandana Singh", "url": "https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion", "tags": ["merger"]}
{"id": 42949270, "time": "2025-01-13 10:21:05", "headline": "Wells Fargo Maintains Overweight on AppLovin, Raises Price Target to $366", "summary": "", "symbols": ["APP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949270/wells-fargo-maintains-overweight-on-applovin-raises-price-target-to-366", "tags": ["analyst_other", "price_target_up"]}
{"id": 42949284, "time": "2025-01-13 10:21:14", "headline": "Piper Sandler Assumes Atlantic Union Bankshares at Overweight, Announces Price Target of $51", "summary": "", "symbols": ["AUB"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949284/piper-sandler-assumes-atlantic-union-bankshares-at-overweight-announces-price-target-of-51", "tags": []}
{"id": 42949308, "time": "2025-01-13 10:21:39", "headline": "U.S. Issues Counter-Terrorism Related Sanctions; Sanctions The Terrorgram Collective", "summary": "", "symbols": ["SPY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949308/u-s-issues-counter-terrorism-related-sanctions-sanctions-the-terrorgram-collective", "tags": []}
{"id": 42949313, "time": "2025-01-13 10:22:04", "headline": "Wells Fargo Maintains Overweight on Trade Desk, Raises Price Target to $142", "summary": "", "symbols": ["TTD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949313/wells-fargo-maintains-overweight-on-trade-desk-raises-price-target-to-142", "tags": ["analyst_other", "price_target_up"]}
{"id": 42949341, "time": "2025-01-13 10:23:37", "headline": "Piper Sandler Maintains Overweight on Exelixis, Raises Price Target to $37", "summary": "", "symbols": ["EXEL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949341/piper-sandler-maintains-overweight-on-exelixis-raises-price-target-to-37", "tags": ["analyst_other", "price_target_up"]}
{"id": 42949570, "time": "2025-01-13 10:25:15", "headline": "Piper Sandler Maintains Overweight on Inozyme Pharma, Lowers Price Target to $30", "summary": "", "symbols": ["INZY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949570/piper-sandler-maintains-overweight-on-inozyme-pharma-lowers-price-target-to-30", "tags": ["analyst_other", "price_target_down"]}
{"id": 42949623, "time": "2025-01-13 10:26:34", "headline": "Piper Sandler Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $140", "summary": "", "symbols": ["RARE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949623/piper-sandler-maintains-overweight-on-ultragenyx-pharmaceutical-raises-price-target-to-140", "tags": ["analyst_other", "price_target_up"]}
{"id": 42949641, "time": "2025-01-13 10:27:14", "headline": "Salarius Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now up 298.1%", "summary": "", "symbols": ["SLRX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/trading-ideas/25/01/42949641/salarius-pharmaceuticals-shares-halted-on-circuit-breaker-to-the-upside-stock-now-up-298-1", "tags": ["halt"]}
{"id": 42949660, "time": "2025-01-13 10:27:59", "headline": "Wells Fargo Maintains Equal-Weight on Alphabet, Raises Price Target to $190", "summary": "", "symbols": ["GOOG", "GOOGL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949660/wells-fargo-maintains-equal-weight-on-alphabet-raises-price-target-to-190", "tags": ["analyst_other", "price_target_up"]}
{"id": 42949667, "time": "2025-01-13 10:28:20", "headline": "Piper Sandler Maintains Overweight on Constellation Brands, Lowers Price Target to $245", "summary": "", "symbols": ["STZ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949667/piper-sandler-maintains-overweight-on-constellation-brands-lowers-price-target-to-245", "tags": ["analyst_other", "price_target_down"]}
{"id": 42949679, "time": "2025-01-13 10:28:36", "headline": "US Stocks Mixed; Nasdaq Down Over 1%", "summary": " ", "symbols": ["CMTL", "KAPA", "LODE", "PHIO", "SLRX", "SVMH", "WDFC"], "source": "benzinga", "author": "Avi Kapoor", "url": "https://www.benzinga.com/25/01/42949679/us-stocks-mixed-nasdaq-down-over-1", "tags": []}
{"id": 42949740, "time": "2025-01-13 10:30:03", "headline": "Wells Fargo Maintains Overweight on Meta Platforms, Raises Price Target to $685", "summary": "", "symbols": ["META"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949740/wells-fargo-maintains-overweight-on-meta-platforms-raises-price-target-to-685", "tags": ["analyst_other", "price_target_up"]}
{"id": 42949757, "time": "2025-01-13 10:30:16", "headline": "Price Over Earnings Overview: Nokia", "summary": " ", "symbols": ["NOK"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42949757/price-over-earnings-overview-nokia", "tags": ["earnings"]}
{"id": 42949833, "time": "2025-01-13 10:31:17", "headline": "e.l.f. Beauty Sees Fresh Glow: Analyst Highlights Market Share Gains", "summary": "Elf Beauty&#39;s stock price doesn&#39;t reflect its growth potential, according to Morgan Stanley. Analyst upgraded rating to Overweight with $153 PT.", "symbols": ["ELF"], "source": "benzinga", "author": "Priya Nigam", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42949833/e-l-f-beauty-sees-fresh-glow-analyst-highlights-market-share-gains", "tags": ["analyst_up"]}
{"id": 42949838, "time": "2025-01-13 10:31:28", "headline": "Comtech Telecommunications Shares Halted On Circuit Breaker To The Downside, Stock Now Down -46.7%", "summary": "", "symbols": ["CMTL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/trading-ideas/25/01/42949838/comtech-telecommunications-shares-halted-on-circuit-breaker-to-the-downside-stock-now-down-46-7", "tags": ["halt"]}
{"id": 42949859, "time": "2025-01-13 10:31:44", "headline": "Wells Fargo Maintains Overweight on Pinterest, Lowers Price Target to $39", "summary": "", "symbols": ["PINS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949859/wells-fargo-maintains-overweight-on-pinterest-lowers-price-target-to-39", "tags": ["analyst_other", "price_target_down"]}
{"id": 42949860, "time": "2025-01-13 10:31:45", "headline": "Salarius Pharmaceuticals Shares Resume Trade", "summary": "", "symbols": ["SLRX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/trading-ideas/25/01/42949860/salarius-pharmaceuticals-shares-resume-trade", "tags": []}
{"id": 42949866, "time": "2025-01-13 10:31:54", "headline": "Evercore ISI Group Maintains Outperform on BioCryst Pharma, Raises Price Target to $12", "summary": "", "symbols": ["BCRX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949866/evercore-isi-group-maintains-outperform-on-biocryst-pharma-raises-price-target-to-12", "tags": ["analyst_other", "price_target_up"]}
{"id": 42949881, "time": "2025-01-13 10:32:12", "headline": "Needham Reiterates Buy on Bicycle Therapeutics, Maintains $32 Price Target", "summary": "", "symbols": ["BCYC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949881/needham-reiterates-buy-on-bicycle-therapeutics-maintains-32-price-target", "tags": ["analyst_other"]}
{"id": 42949922, "time": "2025-01-13 10:32:53", "headline": "Evercore ISI Group Maintains Outperform on CBRE Group, Lowers Price Target to $141", "summary": "", "symbols": ["CBRE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949922/evercore-isi-group-maintains-outperform-on-cbre-group-lowers-price-target-to-141", "tags": ["analyst_other", "price_target_down"]}
{"id": 42949926, "time": "2025-01-13 10:32:58", "headline": "Wells Fargo Maintains Overweight on Snap, Raises Price Target to $15", "summary": "", "symbols": ["SNAP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949926/wells-fargo-maintains-overweight-on-snap-raises-price-target-to-15", "tags": ["analyst_other", "price_target_up"]}
{"id": 42949969, "time": "2025-01-13 10:33:58", "headline": "Needham Reiterates Buy on AtriCure, Maintains $40 Price Target", "summary": "", "symbols": ["ATRC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949969/needham-reiterates-buy-on-atricure-maintains-40-price-target", "tags": ["analyst_other"]}
{"id": 42949975, "time": "2025-01-13 10:34:06", "headline": "ASP Isotopes To Host Investor Event In South Africa; Highlights Quantum Enrichment's 678 Enrichment Factor, Exceeding Previous Expectations; Explores Advanced Nuclear Fuels Venture; Silicon-28, Ytterbium-176 Production Set For Q1 2025; Carbon-14 Shipments Arrive Early 2025", "summary": "", "symbols": ["ASPI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42949975/asp-isotopes-to-host-investor-event-in-south-africa-highlights-quantum-enrichments-678-enrichment-fa", "tags": []}
{"id": 42950016, "time": "2025-01-13 10:34:38", "headline": "Wells Fargo Maintains Underweight on Arrow Electronics, Lowers Price Target to $100", "summary": "", "symbols": ["ARW"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950016/wells-fargo-maintains-underweight-on-arrow-electronics-lowers-price-target-to-100", "tags": ["analyst_other", "price_target_down"]}
{"id": 42950019, "time": "2025-01-13 10:34:40", "headline": "Evercore ISI Group Maintains In-Line on Nordstrom, Raises Price Target to $24", "summary": "", "symbols": ["JWN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950019/evercore-isi-group-maintains-in-line-on-nordstrom-raises-price-target-to-24", "tags": ["analyst_other", "price_target_up"]}
{"id": 42950025, "time": "2025-01-13 10:34:49", "headline": "GSK To Buy US-Based Stomach Cancer Drug Developer For Over $1 Billion", "summary": "GSK&#39;s $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages.", "symbols": ["GSK", "MKGAF", "MKKGY"], "source": "benzinga", "author": "Vandana Singh", "url": "https://www.benzinga.com/25/01/42950025/gsk-to-buy-us-based-stomach-cancer-drug-developer-for-over-1-billion", "tags": ["fda"]}
{"id": 42950065, "time": "2025-01-13 10:35:22", "headline": "Comtech Telecommunications Shares Resume Trade", "summary": "", "symbols": ["CMTL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/trading-ideas/25/01/42950065/comtech-telecommunications-shares-resume-trade", "tags": []}
{"id": 42950089, "time": "2025-01-13 10:36:03", "headline": "Evercore ISI Group Maintains In-Line on Paramount Group, Raises Price Target to $6", "summary": "", "symbols": ["PGRE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950089/evercore-isi-group-maintains-in-line-on-paramount-group-raises-price-target-to-6", "tags": ["analyst_other", "price_target_up"]}
{"id": 42950099, "time": "2025-01-13 10:36:17", "headline": "Wells Fargo Maintains Overweight on ASML Holding, Raises Price Target to $860", "summary": "", "symbols": ["ASML"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950099/wells-fargo-maintains-overweight-on-asml-holding-raises-price-target-to-860", "tags": ["analyst_other", "price_target_up"]}
{"id": 42950110, "time": "2025-01-13 10:37:04", "headline": "Evercore ISI Group Maintains Outperform on Constellation Brands, Lowers Price Target to $250", "summary": "", "symbols": ["STZ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950110/evercore-isi-group-maintains-outperform-on-constellation-brands-lowers-price-target-to-250", "tags": ["analyst_other", "price_target_down"]}
{"id": 42950111, "time": "2025-01-13 10:37:07", "headline": "Benzinga Market Summary: Nasdaq Slides As Chip Stocks Fall On US Export Restrictions, Cleveland-Cliffs And Nucor Partner For Potential US Steel Bid, Lululemon Raises Guidance", "summary": "", "symbols": ["CLF", "LULU", "NUE", "NVDA", "QQQ", "SM", "X"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/economics/macro-economic-events/25/01/42950111/benzinga-market-summary-nasdaq-slides-as-chip-stocks-fall-on-us-export-restrictio", "tags": ["guidance"]}
{"id": 42950117, "time": "2025-01-13 10:37:17", "headline": "Wells Fargo Maintains Equal-Weight on Advanced Energy Indus, Raises Price Target to $115", "summary": "", "symbols": ["AEIS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950117/wells-fargo-maintains-equal-weight-on-advanced-energy-indus-raises-price-target-to-115", "tags": ["analyst_other", "price_target_up"]}
{"id": 42950139, "time": "2025-01-13 10:38:15", "headline": "Needham Maintains Buy on Geron, Raises Price Target to $7", "summary": "", "symbols": ["GERN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950139/needham-maintains-buy-on-geron-raises-price-target-to-7", "tags": ["analyst_other", "price_target_up"]}
{"id": 42950142, "time": "2025-01-13 10:38:23", "headline": "Wells Fargo Maintains Overweight on Applied Mat, Lowers Price Target to $200", "summary": "", "symbols": ["AMAT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950142/wells-fargo-maintains-overweight-on-applied-mat-lowers-price-target-to-200", "tags": ["analyst_other", "price_target_down"]}
{"id": 42950152, "time": "2025-01-13 10:38:54", "headline": "Reported Earlier, Comtech Appoints Kenneth H. Traub As President And Chief Executive Officer, Effective Immediately", "summary": "", "symbols": ["CMTL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950152/reported-earlier-comtech-appoints-kenneth-h-traub-as-president-and-chief-executive-officer-effective", "tags": ["management"]}
{"id": 42950162, "time": "2025-01-13 10:39:07", "headline": "Evercore ISI Group Maintains In-Line on Walgreens Boots Alliance, Raises Price Target to $12", "summary": "", "symbols": ["WBA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950162/evercore-isi-group-maintains-in-line-on-walgreens-boots-alliance-raises-price-target-to-12", "tags": ["analyst_other", "price_target_up"]}
{"id": 42950202, "time": "2025-01-13 10:39:51", "headline": "Bitcoin's 2024 Revolution: ETPs Double Crypto Market Cap, Big Winners Emerge", "summary": "Bitcoin (CRYPTO: BTC) broke new ground in 2024 with the launch of its spot exchange-traded products (ETPs). According to JPMorgan analyst Kenneth B. Worthington, the impact was game-changing.", "symbols": ["BLK", "BTCUSD", "COIN", "SOLUSD", "VIRT", "XRPUSD"], "source": "benzinga", "author": "Surbhi Jain", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42950202/bitcoins-2024-revolution-etps-double-crypto-market-cap-big-winners-emerge", "tags": []}
{"id": 42950233, "time": "2025-01-13 10:40:30", "headline": "Wells Fargo Maintains Overweight on KLA, Lowers Price Target to $795", "summary": "", "symbols": ["KLAC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950233/wells-fargo-maintains-overweight-on-kla-lowers-price-target-to-795", "tags": ["analyst_other", "price_target_down"]}
{"id": 42950250, "time": "2025-01-13 10:40:59", "headline": "Needham Downgrades Intra-Cellular Therapies to Hold, Maintains Price Target to $100", "summary": "", "symbols": ["ITCI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950250/needham-downgrades-intra-cellular-therapies-to-hold-maintains-price-target-to-100", "tags": ["analyst_down", "analyst_other"]}
{"id": 42950256, "time": "2025-01-13 10:41:15", "headline": "Stifel Maintains Buy on Alphabet, Raises Price Target to $225", "summary": "", "symbols": ["GOOG", "GOOGL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950256/stifel-maintains-buy-on-alphabet-raises-price-target-to-225", "tags": ["analyst_other", "price_target_up"]}
{"id": 42950270, "time": "2025-01-13 10:42:01", "headline": "Stifel Maintains Buy on Arhaus, Raises Price Target to $14", "summary": "", "symbols": ["ARHS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950270/stifel-maintains-buy-on-arhaus-raises-price-target-to-14", "tags": ["analyst_other", "price_target_up"]}
{"id": 42950275, "time": "2025-01-13 10:42:11", "headline": "Wells Fargo Maintains Equal-Weight on Lam Research, Lowers Price Target to $82", "summary": "", "symbols": ["LRCX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950275/wells-fargo-maintains-equal-weight-on-lam-research-lowers-price-target-to-82", "tags": ["analyst_other", "price_target_down"]}
{"id": 42950281, "time": "2025-01-13 10:42:30", "headline": "'Lilly Sees New Weight-Loss Pill Approval in Early 2026, CEO Says' - Bloomberg News", "summary": "", "symbols": ["LLY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42950281/lilly-sees-new-weight-loss-pill-approval-in-early-2026-ceo-says-bloomberg-news", "tags": ["management"]}
{"id": 42950289, "time": "2025-01-13 10:43:04", "headline": "Stifel Maintains Hold on RxSight, Lowers Price Target to $35", "summary": "", "symbols": ["RXST"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950289/stifel-maintains-hold-on-rxsight-lowers-price-target-to-35", "tags": ["analyst_other", "price_target_down"]}
{"id": 42950300, "time": "2025-01-13 10:43:45", "headline": "Wells Fargo Maintains Overweight on ARM Holdings, Raises Price Target to $162", "summary": "", "symbols": ["ARM"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950300/wells-fargo-maintains-overweight-on-arm-holdings-raises-price-target-to-162", "tags": ["analyst_other", "price_target_up"]}
{"id": 42950344, "time": "2025-01-13 10:44:43", "headline": "'Microsoft Says Jay Parikh To Lead New Core AI \u2013 Platform And Tools Org' - Microsoft Blog", "summary": "", "symbols": ["MSFT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950344/microsoft-says-jay-parikh-to-lead-new-core-ai-platform-and-tools-org-microsoft-blog", "tags": []}
{"id": 42950373, "time": "2025-01-13 10:45:12", "headline": "$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today", "summary": " ", "symbols": ["UFPI"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42950373/1000-invested-in-this-stock-10-years-ago-would-be-worth-this-much-today", "tags": []}
{"id": 42950375, "time": "2025-01-13 10:45:13", "headline": "Price Over Earnings Overview: Ultra Clean Hldgs", "summary": " ", "symbols": ["UCTT"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42950375/price-over-earnings-overview-ultra-clean-hldgs", "tags": ["earnings"]}
{"id": 42950414, "time": "2025-01-13 10:45:56", "headline": "Tesla Stock Sold By Europe's Largest Pension Fund In Q3: 'We Had A Problem' With Musk Pay", "summary": "Europe&#39;s largest pension fund sold its Tesla stake in the third quarter, missing out on future gains. A look at the reasons why it sold.", "symbols": ["TSLA"], "source": "benzinga", "author": "Chris Katje", "url": "https://www.benzinga.com/news/global/25/01/42950414/tesla-stock-sold-by-europes-largest-pension-fund-in-q3-we-had-a-problem-with-musk-pay", "tags": []}
{"id": 42950427, "time": "2025-01-13 10:46:21", "headline": "HC Wainwright & Co. Reiterates Buy on Astria Therapeutics, Maintains $16 Price Target", "summary": "", "symbols": ["ATXS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950427/hc-wainwright-co-reiterates-buy-on-astria-therapeutics-maintains-16-price-target", "tags": ["analyst_other"]}
{"id": 42950433, "time": "2025-01-13 10:46:31", "headline": "Wells Fargo Maintains Overweight on Allegro Microsystems, Raises Price Target to $27", "summary": "", "symbols": ["ALGM"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950433/wells-fargo-maintains-overweight-on-allegro-microsystems-raises-price-target-to-27", "tags": ["analyst_other", "price_target_up"]}
{"id": 42950470, "time": "2025-01-13 10:47:40", "headline": "Wells Fargo Maintains Equal-Weight on MaxLinear, Raises Price Target to $19", "summary": "", "symbols": ["MXL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950470/wells-fargo-maintains-equal-weight-on-maxlinear-raises-price-target-to-19", "tags": ["analyst_other", "price_target_up"]}
{"id": 42950501, "time": "2025-01-13 10:48:48", "headline": "Wells Fargo Maintains Overweight on ON Semiconductor, Lowers Price Target to $80", "summary": "", "symbols": ["ON"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950501/wells-fargo-maintains-overweight-on-on-semiconductor-lowers-price-target-to-80", "tags": ["analyst_other", "price_target_down"]}
{"id": 42950522, "time": "2025-01-13 10:49:22", "headline": "Needham Maintains Buy on Alphatec Holdings, Raises Price Target to $16", "summary": "", "symbols": ["ATEC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950522/needham-maintains-buy-on-alphatec-holdings-raises-price-target-to-16", "tags": ["analyst_other", "price_target_up"]}
{"id": 42950547, "time": "2025-01-13 10:49:32", "headline": "Teamsters Says Over 430 Sysco Drivers, Warehouse Workers, Mechanics Represented By Teamsters Local 988 Preparing To Strike For Fair Contract", "summary": "", "symbols": ["SYY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950547/teamsters-says-over-430-sysco-drivers-warehouse-workers-mechanics-represented-by-teamsters-local-988", "tags": ["contract"]}
{"id": 42950577, "time": "2025-01-13 10:50:40", "headline": "Wells Fargo Maintains Equal-Weight on Synopsys, Lowers Price Target to $540", "summary": "", "symbols": ["SNPS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950577/wells-fargo-maintains-equal-weight-on-synopsys-lowers-price-target-to-540", "tags": ["analyst_other", "price_target_down"]}
{"id": 42950613, "time": "2025-01-13 10:51:50", "headline": "Needham Reiterates Buy on SI-BONE, Maintains $19 Price Target", "summary": "", "symbols": ["SIBN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950613/needham-reiterates-buy-on-si-bone-maintains-19-price-target", "tags": ["analyst_other"]}
{"id": 42950618, "time": "2025-01-13 10:52:12", "headline": "Wells Fargo Maintains Equal-Weight on Texas Instruments, Lowers Price Target to $208", "summary": "", "symbols": ["TXN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950618/wells-fargo-maintains-equal-weight-on-texas-instruments-lowers-price-target-to-208", "tags": ["analyst_other", "price_target_down"]}
{"id": 42950647, "time": "2025-01-13 10:53:34", "headline": "Wells Fargo Maintains Overweight on Advanced Micro Devices, Lowers Price Target to $165", "summary": "", "symbols": ["AMD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950647/wells-fargo-maintains-overweight-on-advanced-micro-devices-lowers-price-target-to-165", "tags": ["analyst_other", "price_target_down"]}
{"id": 42950783, "time": "2025-01-13 10:54:47", "headline": "Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target", "summary": "", "symbols": ["AUTL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950783/needham-reiterates-buy-on-autolus-therapeutics-maintains-10-price-target", "tags": ["analyst_other"]}
{"id": 42950820, "time": "2025-01-13 10:56:06", "headline": "Wells Fargo Maintains Overweight on Marvell Tech, Raises Price Target to $140", "summary": "", "symbols": ["MRVL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950820/wells-fargo-maintains-overweight-on-marvell-tech-raises-price-target-to-140", "tags": ["analyst_other", "price_target_up"]}
{"id": 42950881, "time": "2025-01-13 10:56:58", "headline": "American Eagle Boosts Q4 Operating Profit Outlook After Strong Holiday Sales Growth: Details", "summary": "American Eagle shares gained after announcing a low single-digit comparable sales increase for fourth quarter-to-date, surpassing expectations.  ", "symbols": ["AEO"], "source": "benzinga", "author": "Shivani Kumaresan", "url": "https://www.benzinga.com/25/01/42950881/american-eagle-boosts-q4-outlook-after-strong-holiday-sales-growth", "tags": ["guidance"]}
{"id": 42950902, "time": "2025-01-13 10:57:29", "headline": "Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday", "summary": " ", "symbols": ["AGL", "BIIB", "BPMC", "CF", "CRML", "DJT", "HUM", "ITCI", "LAB", "LXU", "NUS", "RADX", "SAGE", "SIBN", "X"], "source": "benzinga", "author": "Avi Kapoor", "url": "https://www.benzinga.com/25/01/42950902/intra-cellular-therapies-standard-biotools-si-bone-and-other-big-stocks-moving-higher-on-monday", "tags": ["why_moving"]}
{"id": 42950914, "time": "2025-01-13 10:57:58", "headline": "Needham Reiterates Buy on Harmony Biosciences, Maintains $52 Price Target", "summary": "", "symbols": ["HRMY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42950914/needham-reiterates-buy-on-harmony-biosciences-maintains-52-price-target", "tags": ["analyst_other"]}
{"id": 42951018, "time": "2025-01-13 11:00:13", "headline": "If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today", "summary": " ", "symbols": ["IBKR"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42951018/if-you-invested-1000-in-this-stock-15-years-ago-you-would-have-this-much-today", "tags": []}
{"id": 42951019, "time": "2025-01-13 11:00:14", "headline": "(NU) - Analyzing Nu Holdings's Short Interest", "summary": " ", "symbols": ["NU"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42951019/nu-analyzing-nu-holdingss-short-interest", "tags": []}
{"id": 42951022, "time": "2025-01-13 11:00:18", "headline": "HC Wainwright & Co. Reiterates Buy on Bicycle Therapeutics, Maintains $33 Price Target", "summary": "", "symbols": ["BCYC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951022/hc-wainwright-co-reiterates-buy-on-bicycle-therapeutics-maintains-33-price-target", "tags": ["analyst_other"]}
{"id": 42951023, "time": "2025-01-13 11:00:19", "headline": "Looking Into Novavax's Recent Short Interest", "summary": " ", "symbols": ["NVAX"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42951023/looking-into-novavaxs-recent-short-interest", "tags": []}
{"id": 42951040, "time": "2025-01-13 11:00:24", "headline": "Looking Into IES Hldgs's Recent Short Interest", "summary": " ", "symbols": ["IESC"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42951040/looking-into-ies-hldgss-recent-short-interest", "tags": []}
{"id": 42951118, "time": "2025-01-13 11:00:43", "headline": "What's Going On With Rigetti Computing (RGTI) Stock?", "summary": "Shares of Rigetti Computing are down 18% Monday morning. Nvidia CEO Jensen Huang&#39;s recent comments raised doubts about the near-term viability of quantum computing.", "symbols": ["RGTI"], "source": "benzinga", "author": "Henry Khederian", "url": "https://www.benzinga.com/news/25/01/42951118/whats-going-on-with-rigetti-computing-rgti-stock-3", "tags": ["why_moving", "management"]}
{"id": 42951199, "time": "2025-01-13 11:01:37", "headline": "NY Fed 1-Year Consumer Inflation Expectations For December 3.0% Vs 3.0% Prior (Unchanged)", "summary": "", "symbols": ["SPY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/economics/macro-economic-events/25/01/42951199/ny-fed-1-year-consumer-inflation-expectations-for-december-3-0-vs-3-0-prior-uncha", "tags": []}
{"id": 42947823, "time": "2025-01-13 11:02:10", "headline": "Sonos Announces CEO Transition: The Details (CORRECTED)", "summary": "Sonos on Monday announced that Patrick Spence will step down from his role as CEO and as a member of Sonos&#39; board. Tom Conrad has been appointed as interim CEO while the board conducts a search for its next CEO. ", "symbols": ["SONO"], "source": "benzinga", "author": "Adam Eckert", "url": "https://www.benzinga.com/news/management/25/01/42947823/sonos-shares-jump-after-company-announces-ceo-transition-the-details", "tags": ["management"]}
{"id": 42951228, "time": "2025-01-13 11:02:50", "headline": "What's Going On With IonQ Stock Today?", "summary": "IonQ Inc (NYSE:IONQ) shares are trading lower Monday alongside several other quantum computing stocks as the quantum sector continues to face selling pressure on the back of cautious commentary from Nvidia Corp (NASDAQ:NVDA) CEO Jensen Huang.", "symbols": ["IONQ", "META", "NVDA"], "source": "benzinga", "author": "Adam Eckert", "url": "https://www.benzinga.com/news/contracts/25/01/42951228/whats-going-on-with-ionq-stock-today-3", "tags": ["why_moving", "management"]}
{"id": 42951330, "time": "2025-01-13 11:05:58", "headline": "Oppenheimer Maintains Outperform on Cboe Global Markets, Lowers Price Target to $218", "summary": "", "symbols": ["CBOE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951330/oppenheimer-maintains-outperform-on-cboe-global-markets-lowers-price-target-to-218", "tags": ["analyst_other", "price_target_down"]}
{"id": 42951338, "time": "2025-01-13 11:06:26", "headline": "'10 EU Nations Say It's Time to Sanction Russian Natural Gas, LNG' - Bloomberg News", "summary": "", "symbols": ["SPY", "UNG", "VGK"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/economics/macro-economic-events/25/01/42951338/10-eu-nations-say-its-time-to-sanction-russian-natural-gas-lng-bloomberg-news", "tags": []}
{"id": 42951339, "time": "2025-01-13 11:06:28", "headline": "Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target", "summary": "", "symbols": ["DAWN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951339/needham-reiterates-buy-on-day-one-biopharmaceutical-maintains-33-price-target", "tags": ["analyst_other"]}
{"id": 42951363, "time": "2025-01-13 11:06:58", "headline": "Why BioNTech (BNTX) Shares Are Volatile Today", "summary": "Shares of BioNTech fell 4% on Monday. Vaccine stocks are volatile after Moderna&#39;s updated revenue guidance for 2025, which fell below analyst expectations.", "symbols": ["BNTX"], "source": "benzinga", "author": "Henry Khederian", "url": "https://www.benzinga.com/news/25/01/42951363/why-biontech-bntx-shares-are-volatile-today", "tags": ["earnings", "guidance"]}
{"id": 42951364, "time": "2025-01-13 11:07:07", "headline": "Oppenheimer Maintains Outperform on Clean Harbors, Raises Price Target to $256", "summary": "", "symbols": ["CLH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951364/oppenheimer-maintains-outperform-on-clean-harbors-raises-price-target-to-256", "tags": ["analyst_other", "price_target_up"]}
{"id": 42951366, "time": "2025-01-13 11:07:12", "headline": "Leerink Partners Maintains Outperform on Merck & Co, Lowers Price Target to $119", "summary": "", "symbols": ["MRK"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951366/leerink-partners-maintains-outperform-on-merck-co-lowers-price-target-to-119", "tags": ["analyst_other", "price_target_down"]}
{"id": 42951413, "time": "2025-01-13 11:08:47", "headline": "Oppenheimer Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $40", "summary": "", "symbols": ["NTLA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951413/oppenheimer-maintains-outperform-on-intellia-therapeutics-lowers-price-target-to-40", "tags": ["analyst_other", "price_target_down"]}
{"id": 42951415, "time": "2025-01-13 11:08:50", "headline": "Bruker Expects Q4 2024 Revenue Between $970M-$980M; Projects 2025 Constant Exchange Rate Revenue Growth In Upper Mid-Single Digits", "summary": "", "symbols": ["BRKR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951415/bruker-expects-q4-2024-revenue-between-970m-980m-projects-2025-constant-exchange-rate-revenue-growth", "tags": ["earnings"]}
{"id": 42951417, "time": "2025-01-13 11:08:52", "headline": "Needham Reiterates Buy on Immuneering, Maintains $15 Price Target", "summary": "", "symbols": ["IMRX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951417/needham-reiterates-buy-on-immuneering-maintains-15-price-target", "tags": ["analyst_other"]}
{"id": 42951441, "time": "2025-01-13 11:09:46", "headline": "Oppenheimer Maintains Outperform on Nasdaq, Raises Price Target to $89", "summary": "", "symbols": ["NDAQ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951441/oppenheimer-maintains-outperform-on-nasdaq-raises-price-target-to-89", "tags": ["analyst_other", "price_target_up"]}
{"id": 42951469, "time": "2025-01-13 11:11:22", "headline": "Oppenheimer Maintains Outperform on Snowflake, Raises Price Target to $200", "summary": "", "symbols": ["SNOW"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951469/oppenheimer-maintains-outperform-on-snowflake-raises-price-target-to-200", "tags": ["analyst_other", "price_target_up"]}
{"id": 42951471, "time": "2025-01-13 11:11:28", "headline": "HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $21 Price Target", "summary": "", "symbols": ["ORIC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951471/hc-wainwright-co-reiterates-buy-on-oric-pharmaceuticals-maintains-21-price-target", "tags": ["analyst_other"]}
{"id": 42951473, "time": "2025-01-13 11:11:42", "headline": "Real Estate Stock To Watch After Los Angeles Wildfires", "summary": "Amid LA wildfires, analyst picks Douglas Emmett Inc as a long-term beneficiary of rebuilding efforts. Office space demand expected to increase.", "symbols": ["DEI"], "source": "benzinga", "author": "Hayden Buckfire", "url": "https://www.benzinga.com/real-estate/reit/25/01/42951473/real-estate-stock-to-watch-after-los-angeles-wildfires", "tags": []}
{"id": 42951487, "time": "2025-01-13 11:11:47", "headline": "Apple's iPhone Market Share Declines in China, Huawei and Xiaomi Gain Momentum in 2024: Counterpoint", "summary": "Apple&#39;s iPhones lost ground in China as domestic players gained traction in 2024. Counterpoint predicts market recovery in 2024 after decline.", "symbols": ["AAPL", "SSNLF", "XIACF", "XIACY"], "source": "benzinga", "author": "Anusuya Lahiri", "url": "https://www.benzinga.com/markets/emerging-markets/25/01/42951487/apples-iphone-market-share-declines-in-china-huawei-and-xiaomi-gain-momentum-in-2024-counterpoint", "tags": []}
{"id": 42951493, "time": "2025-01-13 11:11:55", "headline": "'U.S. Steel Stock Jumps On Report Of Possible Bid From Cleveland-cliffs And Nucor; Company Will Be Holding A Press Conference At 1 p.m. ET' - Axios", "summary": "", "symbols": ["CLF", "NUE", "X"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42951493/u-s-steel-stock-jumps-on-report-of-possible-bid-from-cleveland-cliffs-and-nucor-company-will-be-hold", "tags": []}
{"id": 42951520, "time": "2025-01-13 11:12:32", "headline": "Leerink Partners Maintains Outperform on 4D Molecular Therapeutics, Lowers Price Target to $27", "summary": "", "symbols": ["FDMT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951520/leerink-partners-maintains-outperform-on-4d-molecular-therapeutics-lowers-price-target-to-27", "tags": ["analyst_other", "price_target_down"]}
{"id": 42951533, "time": "2025-01-13 11:12:57", "headline": "Why Lantheus Holdings (LNTH) Stock Is Down 4%", "summary": "Lantheus shares are trading lower by 5.4% during Monday&#39;s session. The company announced a\u00a0$350 million\u00a0acquisition.", "symbols": ["LNTH"], "source": "benzinga", "author": "Henry Khederian", "url": "https://www.benzinga.com/news/25/01/42951533/why-lantheus-holdings-lnth-stock-is-down-5", "tags": ["why_moving"]}
{"id": 42951534, "time": "2025-01-13 11:12:57", "headline": "Morgan Stanley Maintains Overweight on 10x Genomics, Lowers Price Target to $28", "summary": "", "symbols": ["TXG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951534/morgan-stanley-maintains-overweight-on-10x-genomics-lowers-price-target-to-28", "tags": ["analyst_other", "price_target_down"]}
{"id": 42951555, "time": "2025-01-13 11:13:27", "headline": "Alcami Announces Bill Humphries To Retire; Board Chair And Former Chief Executive Officer Patrick Walsh Will Serve As Interim CEO", "summary": "", "symbols": ["ANIP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951555/alcami-announces-bill-humphries-to-retire-board-chair-and-former-chief-executive-officer-patrick-wal", "tags": ["management"]}
{"id": 42951760, "time": "2025-01-13 11:14:54", "headline": "RH Is Poised For 'Positive Inflection' In 2025 Earnings: Analyst", "summary": "Morgan Stanley upgrades RH to Overweight with $530 price target, citing positive inflection and long-term fundamentals.", "symbols": ["RH"], "source": "benzinga", "author": "Priya Nigam", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42951760/rh-is-poised-for-positive-inflection-in-2025-earnings-analyst", "tags": ["analyst_up", "earnings"]}
{"id": 42951761, "time": "2025-01-13 11:14:59", "headline": "HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $63 Price Target", "summary": "", "symbols": ["ARCT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951761/hc-wainwright-co-reiterates-buy-on-arcturus-therapeutics-maintains-63-price-target", "tags": ["analyst_other"]}
{"id": 42951785, "time": "2025-01-13 11:15:24", "headline": "Decoding Home Depot's Options Activity: What's the Big Picture?", "summary": " ", "symbols": ["HD"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42951785/decoding-home-depots-options-activity-whats-the-big-picture", "tags": []}
{"id": 42951794, "time": "2025-01-13 11:15:33", "headline": "A Closer Look at Pfizer's Options Market Dynamics", "summary": " ", "symbols": ["PFE"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42951794/a-closer-look-at-pfizers-options-market-dynamics", "tags": []}
{"id": 42951808, "time": "2025-01-13 11:15:49", "headline": "Morgan Stanley Maintains Underweight on 4D Molecular Therapeutics, Lowers Price Target to $6", "summary": "", "symbols": ["FDMT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951808/morgan-stanley-maintains-underweight-on-4d-molecular-therapeutics-lowers-price-target-to-6", "tags": ["analyst_other", "price_target_down"]}
{"id": 42951856, "time": "2025-01-13 11:16:36", "headline": "iRobot Shares Plunge As Preliminary Q4 Results Misses Mark\u2014But CEO Bets Big On 2025 Comeback", "summary": "iRobot shares drop after revealing preliminary Q4 results, with projected revenue of $171 million and expected GAAP operating loss of $59 million. ", "symbols": ["IRBT"], "source": "benzinga", "author": "Shivani Kumaresan", "url": "https://www.benzinga.com/25/01/42951856/why-consumer-robot-maker-irobot-stocks-are-plunging-monday", "tags": ["earnings", "management"]}
{"id": 42951877, "time": "2025-01-13 11:16:57", "headline": "Biohaven Highlights Phase 1 Data For BHV-1400 In IgA Nephropathy With 70% Reduction In Target Antibody. Advances Include BHV-1600 For PPCM And BHV-1300 For Graves' Disease. Multiple Trials Set For 2025", "summary": "", "symbols": ["BHVN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42951877/biohaven-highlights-phase-1-data-for-bhv-1400-in-iga-nephropathy-with-70-reduction-in-target-anti", "tags": ["fda"]}
{"id": 42951885, "time": "2025-01-13 11:17:03", "headline": "Morgan Stanley Maintains Underweight on Airbnb, Raises Price Target to $125", "summary": "", "symbols": ["ABNB"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951885/morgan-stanley-maintains-underweight-on-airbnb-raises-price-target-to-125", "tags": ["analyst_other", "price_target_up"]}
{"id": 42951886, "time": "2025-01-13 11:17:04", "headline": "Leerink Partners Maintains Outperform on ARS Pharmaceuticals, Raises Price Target to $27", "summary": "", "symbols": ["SPRY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951886/leerink-partners-maintains-outperform-on-ars-pharmaceuticals-raises-price-target-to-27", "tags": ["analyst_other", "price_target_up"]}
{"id": 42951945, "time": "2025-01-13 11:18:13", "headline": "Morgan Stanley Maintains Overweight on Alphabet, Raises Price Target to $215", "summary": "", "symbols": ["GOOG", "GOOGL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951945/morgan-stanley-maintains-overweight-on-alphabet-raises-price-target-to-215", "tags": ["analyst_other", "price_target_up"]}
{"id": 42951949, "time": "2025-01-13 11:18:26", "headline": "Needham Reiterates Buy on Cartesian Therapeutics, Maintains $41 Price Target", "summary": "", "symbols": ["RNAC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951949/needham-reiterates-buy-on-cartesian-therapeutics-maintains-41-price-target", "tags": ["analyst_other"]}
{"id": 42951978, "time": "2025-01-13 11:19:18", "headline": "Morgan Stanley Maintains Overweight on Amazon.com, Raises Price Target to $280", "summary": "", "symbols": ["AMZN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951978/morgan-stanley-maintains-overweight-on-amazon-com-raises-price-target-to-280", "tags": ["analyst_other", "price_target_up"]}
{"id": 42951981, "time": "2025-01-13 11:19:37", "headline": "'Mali Has Begun Seizing Barrick Gold By Helicopter, Sources Say' - Reuters News", "summary": "", "symbols": ["GOLD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951981/mali-has-begun-seizing-barrick-gold-by-helicopter-sources-say-reuters-news", "tags": []}
{"id": 42951982, "time": "2025-01-13 11:19:40", "headline": "Leerink Partners Maintains Outperform on Vir Biotechnology, Raises Price Target to $20", "summary": "", "symbols": ["VIR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42951982/leerink-partners-maintains-outperform-on-vir-biotechnology-raises-price-target-to-20", "tags": ["analyst_other", "price_target_up"]}
{"id": 42951999, "time": "2025-01-13 11:20:42", "headline": "LegalZoom Gets Double Upgrade On 'Incrementally Positive' Business Formations Data", "summary": "LegalZoom.com Inc (LZ) could benefit from positive trend in business formations, as per JPMorgan analyst. Upgraded rating to Overweight, PT $9.", "symbols": ["LZ"], "source": "benzinga", "author": "Priya Nigam", "url": "https://www.benzinga.com/25/01/42951999/legalzoomcom-gets-double-upgrade-on-incrementally-positive-business-formations-data", "tags": ["analyst_up"]}
{"id": 42952006, "time": "2025-01-13 11:20:50", "headline": "Stephens & Co. Reiterates Overweight on One Group Hospitality, Maintains $6 Price Target", "summary": "", "symbols": ["STKS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952006/stephens-co-reiterates-overweight-on-one-group-hospitality-maintains-6-price-target", "tags": ["analyst_other"]}
{"id": 42952050, "time": "2025-01-13 11:22:27", "headline": "Greenland Prime Minister Says We Would Like To Work With The U.S. On Defense And Mining", "summary": "", "symbols": ["EDEN", "SPY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/economics/macro-economic-events/25/01/42952050/greenland-prime-minister-says-we-would-like-to-work-with-the-u-s-on-defense-and-m", "tags": []}
{"id": 42952051, "time": "2025-01-13 11:22:28", "headline": "Morgan Stanley Maintains Overweight on Ball, Lowers Price Target to $75", "summary": "", "symbols": ["BALL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952051/morgan-stanley-maintains-overweight-on-ball-lowers-price-target-to-75", "tags": ["analyst_other", "price_target_down"]}
{"id": 42952089, "time": "2025-01-13 11:23:41", "headline": "Morgan Stanley Maintains Equal-Weight on Booking Holdings, Raises Price Target to $5000", "summary": "", "symbols": ["BKNG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952089/morgan-stanley-maintains-equal-weight-on-booking-holdings-raises-price-target-to-5000", "tags": ["analyst_other", "price_target_up"]}
{"id": 42952205, "time": "2025-01-13 11:24:36", "headline": "Morgan Stanley Maintains Equal-Weight on Bumble, Raises Price Target to $8", "summary": "", "symbols": ["BMBL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952205/morgan-stanley-maintains-equal-weight-on-bumble-raises-price-target-to-8", "tags": ["analyst_other", "price_target_up"]}
{"id": 42952247, "time": "2025-01-13 11:25:27", "headline": "Kairos Pharma To Present At The Lytham Partners Investor Healthcare Summit On Monday, January 13, 2025 At 2:00 p.m ET", "summary": "", "symbols": ["KAPA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42952247/kairos-pharma-to-present-at-the-lytham-partners-investor-healthcare-summit-on-monday-january-13-2", "tags": []}
{"id": 42952256, "time": "2025-01-13 11:26:05", "headline": "Morgan Stanley Maintains Equal-Weight on Celanese, Lowers Price Target to $80", "summary": "", "symbols": ["CE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952256/morgan-stanley-maintains-equal-weight-on-celanese-lowers-price-target-to-80", "tags": ["analyst_other", "price_target_down"]}
{"id": 42952279, "time": "2025-01-13 11:26:56", "headline": "Morgan Stanley Maintains Equal-Weight on Chemours, Lowers Price Target to $22", "summary": "", "symbols": ["CC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952279/morgan-stanley-maintains-equal-weight-on-chemours-lowers-price-target-to-22", "tags": ["analyst_other", "price_target_down"]}
{"id": 42952295, "time": "2025-01-13 11:28:02", "headline": "Morgan Stanley Maintains Overweight on Chewy, Raises Price Target to $40", "summary": "", "symbols": ["CHWY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952295/morgan-stanley-maintains-overweight-on-chewy-raises-price-target-to-40", "tags": ["analyst_other", "price_target_up"]}
{"id": 42952342, "time": "2025-01-13 11:30:00", "headline": "Morgan Stanley Maintains Overweight on DoorDash, Raises Price Target to $200", "summary": "", "symbols": ["DASH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952342/morgan-stanley-maintains-overweight-on-doordash-raises-price-target-to-200", "tags": ["analyst_other", "price_target_up"]}
{"id": 42952356, "time": "2025-01-13 11:30:11", "headline": "$1000 Invested In LPL Finl Hldgs 5 Years Ago Would Be Worth This Much Today", "summary": " ", "symbols": ["LPLA"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42952356/1000-invested-in-lpl-finl-hldgs-5-years-ago-would-be-worth-this-much-today", "tags": []}
{"id": 42952357, "time": "2025-01-13 11:30:14", "headline": "(GRRR) - Analyzing Gorilla Tech Gr's Short Interest", "summary": " ", "symbols": ["GRRR"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42952357/grrr-analyzing-gorilla-tech-grs-short-interest", "tags": []}
{"id": 42952361, "time": "2025-01-13 11:30:19", "headline": "Looking Into Peloton Interactive's Recent Short Interest", "summary": " ", "symbols": ["PTON"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42952361/looking-into-peloton-interactives-recent-short-interest", "tags": []}
{"id": 42952367, "time": "2025-01-13 11:30:20", "headline": "HC Wainwright & Co. Reiterates Buy on Ocugen, Maintains $7 Price Target", "summary": "", "symbols": ["OCGN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952367/hc-wainwright-co-reiterates-buy-on-ocugen-maintains-7-price-target", "tags": ["analyst_other"]}
{"id": 42952372, "time": "2025-01-13 11:30:24", "headline": "How Is The Market Feeling About SES AI?", "summary": " ", "symbols": ["SES"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42952372/how-is-the-market-feeling-about-ses-ai", "tags": []}
{"id": 42952460, "time": "2025-01-13 11:32:22", "headline": "White House Says Biden Approves Student Loan Relief For More Than 150,000 Borrowers", "summary": "", "symbols": ["SLM", "SOFI", "SPY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/economics/macro-economic-events/25/01/42952460/white-house-says-biden-approves-student-loan-relief-for-more-than-150-000-borrowe", "tags": []}
{"id": 42952475, "time": "2025-01-13 11:33:17", "headline": "Morgan Stanley Maintains Equal-Weight on DoubleVerify Hldgs, Lowers Price Target to $19", "summary": "", "symbols": ["DV"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952475/morgan-stanley-maintains-equal-weight-on-doubleverify-hldgs-lowers-price-target-to-19", "tags": ["analyst_other", "price_target_down"]}
{"id": 42952491, "time": "2025-01-13 11:33:29", "headline": "HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target", "summary": "", "symbols": ["ALNY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952491/hc-wainwright-co-reiterates-buy-on-alnylam-pharmaceuticals-maintains-400-price-target", "tags": ["analyst_other"]}
{"id": 42952500, "time": "2025-01-13 11:34:08", "headline": "22nd Century Group Shares Halted On Circuit Breaker To The Upside, Stock Now Up 66.5%", "summary": "", "symbols": ["XXII"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/trading-ideas/25/01/42952500/22nd-century-group-shares-halted-on-circuit-breaker-to-the-upside-stock-now-up-66-5", "tags": ["halt"]}
{"id": 42952507, "time": "2025-01-13 11:34:26", "headline": "Morgan Stanley Maintains Equal-Weight on Dow, Lowers Price Target to $46", "summary": "", "symbols": ["DOW"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952507/morgan-stanley-maintains-equal-weight-on-dow-lowers-price-target-to-46", "tags": ["analyst_other", "price_target_down"]}
{"id": 42952587, "time": "2025-01-13 11:36:08", "headline": "Morgan Stanley Maintains Equal-Weight on E2open Parent Holdings, Lowers Price Target to $3", "summary": "", "symbols": ["ETWO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952587/morgan-stanley-maintains-equal-weight-on-e2open-parent-holdings-lowers-price-target-to-3", "tags": ["analyst_other", "price_target_down"]}
{"id": 42952590, "time": "2025-01-13 11:36:13", "headline": "Needham Maintains Buy on iRhythm Technologies, Raises Price Target to $112", "summary": "", "symbols": ["IRTC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952590/needham-maintains-buy-on-irhythm-technologies-raises-price-target-to-112", "tags": ["analyst_other", "price_target_up"]}
{"id": 42952591, "time": "2025-01-13 11:36:28", "headline": "THC-Infused Drinks, Gummies, Candy Coming Soon To Your Front Porch Via DoorDash", "summary": "Good move as the number of Americans who consume weed on a daily basis has surpassed the number of people who drink alcohol that often.", "symbols": ["DASH"], "source": "benzinga", "author": "Maureen Meehan", "url": "https://www.benzinga.com/news/retail-sales/25/01/42952591/thc-infused-drinks-gummies-candy-via-doordash", "tags": []}
{"id": 42952618, "time": "2025-01-13 11:37:27", "headline": "Morgan Stanley Maintains Overweight on eBay, Raises Price Target to $72", "summary": "", "symbols": ["EBAY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952618/morgan-stanley-maintains-overweight-on-ebay-raises-price-target-to-72", "tags": ["analyst_other", "price_target_up"]}
{"id": 42952631, "time": "2025-01-13 11:38:49", "headline": "22nd Century Group Shares Resume Trade", "summary": "", "symbols": ["XXII"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/trading-ideas/25/01/42952631/22nd-century-group-shares-resume-trade", "tags": []}
{"id": 42952643, "time": "2025-01-13 11:39:29", "headline": "Morgan Stanley Maintains Underweight on Etsy, Lowers Price Target to $45", "summary": "", "symbols": ["ETSY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952643/morgan-stanley-maintains-underweight-on-etsy-lowers-price-target-to-45", "tags": ["analyst_other", "price_target_down"]}
{"id": 42952672, "time": "2025-01-13 11:40:29", "headline": "Morgan Stanley Maintains Equal-Weight on Expedia Group, Raises Price Target to $185", "summary": "", "symbols": ["EXPE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952672/morgan-stanley-maintains-equal-weight-on-expedia-group-raises-price-target-to-185", "tags": ["analyst_other", "price_target_up"]}
{"id": 42952677, "time": "2025-01-13 11:40:38", "headline": "Redburn Atlantic Initiates Coverage On Cadence Design Sys with Buy Rating, Announces Price Target of $350", "summary": "", "symbols": ["CDNS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952677/redburn-atlantic-initiates-coverage-on-cadence-design-sys-with-buy-rating-announces-price-target-of", "tags": ["analyst_init"]}
{"id": 42952708, "time": "2025-01-13 11:41:26", "headline": "Morgan Stanley Maintains Equal-Weight on Freshworks, Raises Price Target to $19", "summary": "", "symbols": ["FRSH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952708/morgan-stanley-maintains-equal-weight-on-freshworks-raises-price-target-to-19", "tags": ["analyst_other", "price_target_up"]}
{"id": 42952735, "time": "2025-01-13 11:42:42", "headline": "Morgan Stanley Maintains Equal-Weight on GoDaddy, Raises Price Target to $227", "summary": "", "symbols": ["GDDY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952735/morgan-stanley-maintains-equal-weight-on-godaddy-raises-price-target-to-227", "tags": ["analyst_other", "price_target_up"]}
{"id": 42952753, "time": "2025-01-13 11:43:17", "headline": "Redburn Atlantic Initiates Coverage On Synopsys with Buy Rating, Announces Price Target of $600", "summary": "", "symbols": ["SNPS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952753/redburn-atlantic-initiates-coverage-on-synopsys-with-buy-rating-announces-price-target-of-600", "tags": ["analyst_init"]}
{"id": 42952766, "time": "2025-01-13 11:44:01", "headline": "Morgan Stanley Maintains Equal-Weight on Hologic, Lowers Price Target to $82", "summary": "", "symbols": ["HOLX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952766/morgan-stanley-maintains-equal-weight-on-hologic-lowers-price-target-to-82", "tags": ["analyst_other", "price_target_down"]}
{"id": 42952821, "time": "2025-01-13 11:45:11", "headline": "Here's How Much You Would Have Made Owning Fair Isaac Stock In The Last 10 Years", "summary": " ", "symbols": ["FICO"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42952821/heres-how-much-you-would-have-made-owning-fair-isaac-stock-in-the-last-10-years", "tags": []}
{"id": 42952823, "time": "2025-01-13 11:45:14", "headline": "Looking Into Starbucks's Recent Short Interest", "summary": " ", "symbols": ["SBUX"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42952823/looking-into-starbuckss-recent-short-interest", "tags": []}
{"id": 42952828, "time": "2025-01-13 11:45:20", "headline": "How Is The Market Feeling About Cleveland-Cliffs?", "summary": " ", "symbols": ["CLF"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42952828/how-is-the-market-feeling-about-cleveland-cliffs", "tags": []}
{"id": 42952836, "time": "2025-01-13 11:45:23", "headline": "Morgan Stanley Maintains Overweight on HubSpot, Raises Price Target to $835", "summary": "", "symbols": ["HUBS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42952836/morgan-stanley-maintains-overweight-on-hubspot-raises-price-target-to-835", "tags": ["analyst_other", "price_target_up"]}
{"id": 42952837, "time": "2025-01-13 11:45:25", "headline": "(LHX) - Analyzing L3Harris Technologies's Short Interest", "summary": " ", "symbols": ["LHX"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42952837/lhx-analyzing-l3harris-technologiess-short-interest", "tags": []}
{"id": 42952934, "time": "2025-01-13 11:48:28", "headline": "22nd Century Group Shares Halted On Circuit Breaker To The Upside, Stock Now Up 113.7%", "summary": "", "symbols": ["XXII"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/trading-ideas/25/01/42952934/22nd-century-group-shares-halted-on-circuit-breaker-to-the-upside-stock-now-up-113-7", "tags": ["halt"]}
{"id": 42953041, "time": "2025-01-13 11:52:58", "headline": "22nd Century Group Shares Resume Trading", "summary": "", "symbols": ["XXII"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/trading-ideas/25/01/42953041/22nd-century-group-shares-resume-trading", "tags": []}
{"id": 42953168, "time": "2025-01-13 11:54:19", "headline": "22nd Century Group Shares Halted On Circuit Breaker To The Upside, Stock Now Up 155.2%", "summary": "", "symbols": ["XXII"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/trading-ideas/25/01/42953168/22nd-century-group-shares-halted-on-circuit-breaker-to-the-upside-stock-now-up-155-2", "tags": ["halt"]}
{"id": 42953248, "time": "2025-01-13 11:55:30", "headline": "JMP Securities Downgrades PJT Partners to Market Perform", "summary": "", "symbols": ["PJT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42953248/jmp-securities-downgrades-pjt-partners-to-market-perform", "tags": ["analyst_down"]}
{"id": 42953261, "time": "2025-01-13 11:55:59", "headline": "Nvidia, Broadcom, Marvell Positioned For Growth As AI Demand Drives Semiconductor Momentum", "summary": "Analyst N. Quinn Bolton notes 2024&#39;s divergence in fortunes for semiconductor companies exposed to different end markets. AI stocks outperformed.", "symbols": ["ALAB", "ALGM", "AVGO", "CRDO", "LSCC", "MRVL", "MTSI", "NVDA", "ON", "SLAB", "SMTC"], "source": "benzinga", "author": "Anusuya Lahiri", "url": "https://www.benzinga.com/25/01/42953261/nvidia-broadcom-and-marvell-positioned-for-growth-as-ai-demand-drives-semiconductor-momentum", "tags": []}
{"id": 42953333, "time": "2025-01-13 11:58:06", "headline": "Texas Sues Allstate, Accusing It Of Unlawfully Collecting And Selling Data About The Location And Movement Of Texans' Cellphones", "summary": "", "symbols": ["ALL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42953333/texas-sues-allstate-accusing-it-of-unlawfully-collecting-and-selling-data-about-the-location-and-mov", "tags": []}
{"id": 42953361, "time": "2025-01-13 11:59:34", "headline": "HSBC Maintains Buy on Amazon.com, Raises Price Target to $270", "summary": "", "symbols": ["AMZN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42953361/hsbc-maintains-buy-on-amazon-com-raises-price-target-to-270", "tags": ["analyst_other", "price_target_up"]}
{"id": 42953410, "time": "2025-01-13 12:00:14", "headline": "Price Over Earnings Overview: First Citizens BancShares", "summary": " ", "symbols": ["FCNCA"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42953410/price-over-earnings-overview-first-citizens-bancshares", "tags": ["earnings"]}
{"id": 42953471, "time": "2025-01-13 12:01:14", "headline": "HSBC Upgrades Itau Unibanco Holding to Buy, Announces $6.8 Price Target", "summary": "", "symbols": ["ITUB"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42953471/hsbc-upgrades-itau-unibanco-holding-to-buy-announces-6-8-price-target", "tags": ["analyst_up"]}
{"id": 42953532, "time": "2025-01-13 12:02:57", "headline": "BioMarin Pharmaceutical Announces The Company Has Initiated A Legal Action Against Ascendis Pharma A/S For Infringement Of European Patent EP 3 175 863 B1 At The Unified Patent Court In Munich, Germany", "summary": "", "symbols": ["BMRN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42953532/biomarin-pharmaceutical-announces-the-company-has-initiated-a-legal-action-against-ascendis-pharma-a", "tags": ["legal"]}
{"id": 42953537, "time": "2025-01-13 12:03:21", "headline": "HSBC Upgrades Bank Bradesco to Buy, Announces $2.8 Price Target", "summary": "", "symbols": ["BBD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42953537/hsbc-upgrades-bank-bradesco-to-buy-announces-2-8-price-target", "tags": ["analyst_up"]}
{"id": 42953581, "time": "2025-01-13 12:04:20", "headline": "UBS Maintains Neutral on EchoStar, Raises Price Target to $28", "summary": "", "symbols": ["SATS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42953581/ubs-maintains-neutral-on-echostar-raises-price-target-to-28", "tags": ["analyst_other", "price_target_up"]}
{"id": 42953612, "time": "2025-01-13 12:04:52", "headline": "Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge", "summary": " ", "symbols": ["ANF", "BIIB", "CMTL", "ITCI", "MRNA", "PHIO", "SAGE", "SLRX"], "source": "benzinga", "author": "Avi Kapoor", "url": "https://www.benzinga.com/25/01/42953612/crude-oil-surges-3-abercrombie-fitch-shares-plunge", "tags": []}
{"id": 42953675, "time": "2025-01-13 12:05:35", "headline": "12 Information Technology Stocks Moving In Monday's Pre-Market Session", "summary": " ", "symbols": ["CMTL", "CTM", "CVV", "DATS", "GRRR", "INTZ", "LAES", "PROP", "QBTS", "RGTI", "VRME", "XTKG"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/movers/25/01/42953675/12-information-technology-stocks-moving-in-mondays-pre-market-session", "tags": ["why_moving"]}
{"id": 42953714, "time": "2025-01-13 12:06:26", "headline": "UBS Upgrades Capital One Finl to Buy, Raises Price Target to $235", "summary": "", "symbols": ["COF"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42953714/ubs-upgrades-capital-one-finl-to-buy-raises-price-target-to-235", "tags": ["analyst_up", "price_target_up"]}
{"id": 42953754, "time": "2025-01-13 12:07:21", "headline": "Keefe, Bruyette & Woods Maintains Underperform on Brookfield Asset Mgmt, Lowers Price Target to $56", "summary": "", "symbols": ["BAM"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42953754/keefe-bruyette-woods-maintains-underperform-on-brookfield-asset-mgmt-lowers-price-target-to-56", "tags": ["analyst_other", "price_target_down"]}
{"id": 42953757, "time": "2025-01-13 12:07:25", "headline": "What's Going On With Trump Media & Technology Group Stock?", "summary": "Trump Media &amp; Technology Group Corp (NASDAQ:DJT) shares are trading higher Monday, a week ahead of President-elect Donald Trump&#39;s inauguration. Here&#39;s what you need to know.", "symbols": ["DJT"], "source": "benzinga", "author": "Adam Eckert", "url": "https://www.benzinga.com/trading-ideas/movers/25/01/42953757/whats-going-on-with-trump-media-technology-group-stock-4", "tags": ["why_moving"]}
{"id": 42953761, "time": "2025-01-13 12:07:50", "headline": "Santa Ana Winds Return As LA Wildfire Damage Estimates Rise To At Least $250 Billion, Fire Officials Investigate Downed Power Lines", "summary": "The National Weather Service again issued its most severe fire warning for Los Angeles county on Monday as fires continue to burn in the area.", "symbols": ["EIX"], "source": "benzinga", "author": "Erica Kollmann", "url": "https://www.benzinga.com/news/legal/25/01/42953761/santa-ana-winds-return-as-la-wildfire-damage-estimates-rise-to-at-least-250-billion-fire-officials-investigate-downed-power-lines", "tags": []}
{"id": 42953792, "time": "2025-01-13 12:08:20", "headline": "HSBC Maintains Buy on NVIDIA, Lowers Price Target to $185", "summary": "", "symbols": ["NVDA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42953792/hsbc-maintains-buy-on-nvidia-lowers-price-target-to-185", "tags": ["analyst_other", "price_target_down"]}
{"id": 42953817, "time": "2025-01-13 12:08:51", "headline": "UBS Upgrades Discover Finl to Buy, Raises Price Target to $239", "summary": "", "symbols": ["DFS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42953817/ubs-upgrades-discover-finl-to-buy-raises-price-target-to-239", "tags": ["analyst_up", "price_target_up"]}
{"id": 42953818, "time": "2025-01-13 12:08:56", "headline": "Keefe, Bruyette & Woods Maintains Outperform on BlackRock, Lowers Price Target to $1160", "summary": "", "symbols": ["BLK"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42953818/keefe-bruyette-woods-maintains-outperform-on-blackrock-lowers-price-target-to-1160", "tags": ["analyst_other", "price_target_down"]}
{"id": 42953837, "time": "2025-01-13 12:10:02", "headline": "Keefe, Bruyette & Woods Maintains Market Perform on Blackstone, Lowers Price Target to $174", "summary": "", "symbols": ["BX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42953837/keefe-bruyette-woods-maintains-market-perform-on-blackstone-lowers-price-target-to-174", "tags": ["analyst_other", "price_target_down"]}
{"id": 42953855, "time": "2025-01-13 12:10:27", "headline": "Guggenheim Maintains Buy on Netflix, Raises Price Target to $950", "summary": "", "symbols": ["NFLX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42953855/guggenheim-maintains-buy-on-netflix-raises-price-target-to-950", "tags": ["analyst_other", "price_target_up"]}
{"id": 42953859, "time": "2025-01-13 12:10:49", "headline": "UBS Maintains Neutral on Synchrony Finl, Raises Price Target to $66", "summary": "", "symbols": ["SYF"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42953859/ubs-maintains-neutral-on-synchrony-finl-raises-price-target-to-66", "tags": ["analyst_other", "price_target_up"]}
{"id": 42953875, "time": "2025-01-13 12:11:50", "headline": "UBS Maintains Neutral on American Express, Raises Price Target to $320", "summary": "", "symbols": ["AXP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42953875/ubs-maintains-neutral-on-american-express-raises-price-target-to-320", "tags": ["analyst_other", "price_target_up"]}
{"id": 42953890, "time": "2025-01-13 12:12:19", "headline": "Keefe, Bruyette & Woods Maintains Market Perform on Cboe Global Markets, Lowers Price Target to $215", "summary": "", "symbols": ["CBOE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42953890/keefe-bruyette-woods-maintains-market-perform-on-cboe-global-markets-lowers-price-target-to-215", "tags": ["analyst_other", "price_target_down"]}
{"id": 42953916, "time": "2025-01-13 12:12:41", "headline": "Hut 8 Is This Analyst's Top Pick For 2025 - Here's Why", "summary": "Needham analyst John Todaro maintains a Buy rating on Hut 8 Corp (NASDAQ: HUT) with a price target of $38.00. The analyst highlights HUT&#39;s diversified mining approach, significant HPC plans, and strong pipeline as key drivers for 2025 growth. ", "symbols": ["HUT"], "source": "benzinga", "author": "Shivani Kumaresan", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42953916/hut-8-is-this-analysts-top-pick-for-2025-heres-why", "tags": ["analyst_other"]}
{"id": 42953940, "time": "2025-01-13 12:13:20", "headline": "Tuesday's Producer Inflation Report Could Stoke Market Volatility As Fed Path Remains Unclear", "summary": "Market volatility is primed to intensify this week as traders await December&#39;s Producer Price Index data on Tuesday.", "symbols": ["QQQ", "SPY", "TLT"], "source": "benzinga", "author": "Piero Cingari", "url": "https://www.benzinga.com/economics/macro-economic-events/25/01/42953940/tuesdays-producer-inflation-report-could-stoke-market-volatility-as-fed-path-remains-unclear", "tags": []}
{"id": 42954075, "time": "2025-01-13 12:15:19", "headline": "This Is What Whales Are Betting On Charles Schwab", "summary": " ", "symbols": ["SCHW"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42954075/this-is-what-whales-are-betting-on-charles-schwab", "tags": []}
{"id": 42954080, "time": "2025-01-13 12:15:30", "headline": "Looking At Archer Aviation's Recent Unusual Options Activity", "summary": " ", "symbols": ["ACHR"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42954080/looking-at-archer-aviations-recent-unusual-options-activity", "tags": []}
{"id": 42954089, "time": "2025-01-13 12:15:43", "headline": "TD Cowen Initiates Coverage On Skyward Specialty with Hold Rating", "summary": "", "symbols": ["SKWD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954089/td-cowen-initiates-coverage-on-skyward-specialty-with-hold-rating", "tags": ["analyst_init"]}
{"id": 42954129, "time": "2025-01-13 12:16:44", "headline": "Citigroup Maintains Neutral on A.O. Smith, Lowers Price Target to $73", "summary": "", "symbols": ["AOS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954129/citigroup-maintains-neutral-on-a-o-smith-lowers-price-target-to-73", "tags": ["analyst_other", "price_target_down"]}
{"id": 42954151, "time": "2025-01-13 12:17:43", "headline": "Citigroup Maintains Buy on APi Gr, Lowers Price Target to $43", "summary": "", "symbols": ["APG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954151/citigroup-maintains-buy-on-api-gr-lowers-price-target-to-43", "tags": ["analyst_other", "price_target_down"]}
{"id": 42954168, "time": "2025-01-13 12:18:30", "headline": "Investors Bet Big On Alphabet, Uber, GenAI In 2025: What JPMorgan Survey Reveals", "summary": "2025 brings a bullish outlook for the internet sector, with investors anticipating tech-driven innovation and growth despite challenges.", "symbols": ["GOOG", "GOOGL", "META", "UBER"], "source": "benzinga", "author": "Surbhi Jain", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42954168/investors-bet-big-on-alphabet-uber-genai-in-2025-what-jpmorgan-survey-reveals", "tags": ["guidance"]}
{"id": 42954171, "time": "2025-01-13 12:18:37", "headline": "Keefe, Bruyette & Woods Maintains Market Perform on CNB Financial, Lowers Price Target to $28", "summary": "", "symbols": ["CCNE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954171/keefe-bruyette-woods-maintains-market-perform-on-cnb-financial-lowers-price-target-to-28", "tags": ["analyst_other", "price_target_down"]}
{"id": 42954175, "time": "2025-01-13 12:18:46", "headline": "TD Cowen Upgrades Linde to Buy, Raises Price Target to $515", "summary": "", "symbols": ["LIN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954175/td-cowen-upgrades-linde-to-buy-raises-price-target-to-515", "tags": ["analyst_up", "price_target_up"]}
{"id": 42954206, "time": "2025-01-13 12:19:18", "headline": "FuzzyPanda Posts On X \"Ozempic has sucked all the EBITDA out of $AIRS. Mgmt just guided to $AIRS just tripped their debt covenants.  Needed to guide to EBITDA >$26.5m by our est's. Remediation for tripping debt covenants = all Airsculpt's debt is due immediately. Next stop bankruptcy?\"", "summary": "", "symbols": ["AIRS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954206/fuzzypanda-posts-on-x-ozempic-has-sucked-all-the-ebitda-out-of-airs-mgmt-just-guided-to-airs-just-tr", "tags": []}
{"id": 42954209, "time": "2025-01-13 12:19:25", "headline": "Citigroup Maintains Buy on Carrier Global, Lowers Price Target to $90", "summary": "", "symbols": ["CARR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954209/citigroup-maintains-buy-on-carrier-global-lowers-price-target-to-90", "tags": ["analyst_other", "price_target_down"]}
{"id": 42954216, "time": "2025-01-13 12:19:37", "headline": "Keefe, Bruyette & Woods Maintains Market Perform on CME Gr, Lowers Price Target to $256", "summary": "", "symbols": ["CME"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954216/keefe-bruyette-woods-maintains-market-perform-on-cme-gr-lowers-price-target-to-256", "tags": ["analyst_other", "price_target_down"]}
{"id": 42954246, "time": "2025-01-13 12:20:36", "headline": "Citigroup Maintains Neutral on Cognex, Lowers Price Target to $42", "summary": "", "symbols": ["CGNX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954246/citigroup-maintains-neutral-on-cognex-lowers-price-target-to-42", "tags": ["analyst_other", "price_target_down"]}
{"id": 42954251, "time": "2025-01-13 12:20:48", "headline": "Keefe, Bruyette & Woods Maintains Market Perform on Coinbase Glb, Lowers Price Target to $255", "summary": "", "symbols": ["COIN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954251/keefe-bruyette-woods-maintains-market-perform-on-coinbase-glb-lowers-price-target-to-255", "tags": ["analyst_other", "price_target_down"]}
{"id": 42954253, "time": "2025-01-13 12:20:54", "headline": "BTIG Maintains Buy on Boot Barn Holdings, Raises Price Target to $190", "summary": "", "symbols": ["BOOT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954253/btig-maintains-buy-on-boot-barn-holdings-raises-price-target-to-190", "tags": ["analyst_other", "price_target_up"]}
{"id": 42954300, "time": "2025-01-13 12:22:53", "headline": "Keefe, Bruyette & Woods Maintains Outperform on Evercore, Lowers Price Target to $319", "summary": "", "symbols": ["EVR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954300/keefe-bruyette-woods-maintains-outperform-on-evercore-lowers-price-target-to-319", "tags": ["analyst_other", "price_target_down"]}
{"id": 42954425, "time": "2025-01-13 12:24:14", "headline": "Keefe, Bruyette & Woods Maintains Market Perform on Houlihan Lokey, Lowers Price Target to $170", "summary": "", "symbols": ["HLI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954425/keefe-bruyette-woods-maintains-market-perform-on-houlihan-lokey-lowers-price-target-to-170", "tags": ["analyst_other", "price_target_down"]}
{"id": 42954529, "time": "2025-01-13 12:25:49", "headline": "Short Seller Accuses TransMedics Of 'Mafia Style' Scheme, Organ Transplant Company Says Short Seller Manipulating Market", "summary": "TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as baseless market manipulation.", "symbols": ["GKOS", "ISRG", "TMDX"], "source": "benzinga", "author": "Vandana Singh", "url": "https://www.benzinga.com/general/health-care/25/01/42954529/short-seller-accuses-transmedics-works-of-mafia-style-scheme-organ-transplant-company-says-short-seller-manipulating-market", "tags": []}
{"id": 42954545, "time": "2025-01-13 12:26:01", "headline": "Needham Reiterates Buy on Lululemon Athletica, Maintains $475 Price Target", "summary": "", "symbols": ["LULU"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954545/needham-reiterates-buy-on-lululemon-athletica-maintains-475-price-target", "tags": ["analyst_other"]}
{"id": 42954546, "time": "2025-01-13 12:26:04", "headline": "Keefe, Bruyette & Woods Maintains Market Perform on Hamilton Lane, Lowers Price Target to $158", "summary": "", "symbols": ["HLNE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954546/keefe-bruyette-woods-maintains-market-perform-on-hamilton-lane-lowers-price-target-to-158", "tags": ["analyst_other", "price_target_down"]}
{"id": 42954566, "time": "2025-01-13 12:26:41", "headline": "Citigroup Maintains Neutral on CSW Industrials, Lowers Price Target to $404", "summary": "", "symbols": ["CSWI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954566/citigroup-maintains-neutral-on-csw-industrials-lowers-price-target-to-404", "tags": ["analyst_other", "price_target_down"]}
{"id": 42954583, "time": "2025-01-13 12:26:52", "headline": "Sarepta Announces Q4 2024 Revenue Of $638.2M, Exceeding Guidance; ELEVIDYS Revenue At $384.2M; RNA PMO Revenue At $254M; FY24 Revenue Totals $1.79B; $1.5B In Cash And Investments At Year-End 2024; Reiterates 2025 Revenue Guidance Of $2.9B-$3.1B", "summary": "", "symbols": ["SRPT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42954583/sarepta-announces-q4-2024-revenue-of-638-2m-exceeding-guidance-elevidys-revenue-at-384-2m-rna-pmo-r", "tags": ["analyst_other", "earnings", "guidance"]}
{"id": 42954595, "time": "2025-01-13 12:27:23", "headline": "'Cursed Coin' Ethereum Down 8%: What Is Going On?", "summary": "Ethereum (CRYPTO: ETH) is down 8% on the day to $3,020, leading analysts to discuss whether there is any bullish hope left for the second-largest cryptocurrency.", "symbols": ["ETHUSD"], "source": "benzinga", "author": "Khyathi Dalal", "url": "https://www.benzinga.com/markets/cryptocurrency/25/01/42954595/cursed-coin-ethereum-down-8-what-is-going-on", "tags": []}
{"id": 42954596, "time": "2025-01-13 12:27:30", "headline": "Keefe, Bruyette & Woods Maintains Market Perform on Interactive Brokers Gr, Raises Price Target to $195", "summary": "", "symbols": ["IBKR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954596/keefe-bruyette-woods-maintains-market-perform-on-interactive-brokers-gr-raises-price-target-to-195", "tags": ["analyst_other", "price_target_up"]}
{"id": 42954618, "time": "2025-01-13 12:28:20", "headline": "Citigroup Maintains Buy on Dover, Lowers Price Target to $222", "summary": "", "symbols": ["DOV"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954618/citigroup-maintains-buy-on-dover-lowers-price-target-to-222", "tags": ["analyst_other", "price_target_down"]}
{"id": 42954648, "time": "2025-01-13 12:29:11", "headline": "HC Wainwright & Co. Maintains Buy on Calumet, Raises Price Target to $33", "summary": "", "symbols": ["CLMT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954648/hc-wainwright-co-maintains-buy-on-calumet-raises-price-target-to-33", "tags": ["analyst_other", "price_target_up"]}
{"id": 42954652, "time": "2025-01-13 12:29:16", "headline": "Keefe, Bruyette & Woods Maintains Outperform on Intercontinental Exchange, Lowers Price Target to $178", "summary": "", "symbols": ["ICE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954652/keefe-bruyette-woods-maintains-outperform-on-intercontinental-exchange-lowers-price-target-to-178", "tags": ["analyst_other", "price_target_down"]}
{"id": 42954738, "time": "2025-01-13 12:30:11", "headline": "P/E Ratio Insights for Crown Castle", "summary": " ", "symbols": ["CCI"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42954738/pe-ratio-insights-for-crown-castle", "tags": []}
{"id": 42954834, "time": "2025-01-13 12:30:52", "headline": "Citigroup Maintains Buy on Eaton Corp, Lowers Price Target to $410", "summary": "", "symbols": ["ETN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954834/citigroup-maintains-buy-on-eaton-corp-lowers-price-target-to-410", "tags": ["analyst_other", "price_target_down"]}
{"id": 42954856, "time": "2025-01-13 12:31:03", "headline": "Keefe, Bruyette & Woods Maintains Outperform on KKR, Lowers Price Target to $168", "summary": "", "symbols": ["KKR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954856/keefe-bruyette-woods-maintains-outperform-on-kkr-lowers-price-target-to-168", "tags": ["analyst_other", "price_target_down"]}
{"id": 42954865, "time": "2025-01-13 12:31:31", "headline": "Argus Research Downgrades Ethan Allen Interiors to Hold", "summary": "", "symbols": ["ETD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954865/argus-research-downgrades-ethan-allen-interiors-to-hold", "tags": ["analyst_down"]}
{"id": 42954900, "time": "2025-01-13 12:31:59", "headline": "Keefe, Bruyette & Woods Maintains Market Perform on Lazard, Lowers Price Target to $52", "summary": "", "symbols": ["LAZ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954900/keefe-bruyette-woods-maintains-market-perform-on-lazard-lowers-price-target-to-52", "tags": ["analyst_other", "price_target_down"]}
{"id": 42954905, "time": "2025-01-13 12:32:30", "headline": "Live On CNBC, Rob Sechan Announces Sold Regeneron", "summary": "", "symbols": ["REGN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954905/live-on-cnbc-rob-sechan-announces-sold-regeneron", "tags": []}
{"id": 42954925, "time": "2025-01-13 12:33:10", "headline": "Keefe, Bruyette & Woods Maintains Market Perform on MarketAxess Holdings, Lowers Price Target to $251", "summary": "", "symbols": ["MKTX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954925/keefe-bruyette-woods-maintains-market-perform-on-marketaxess-holdings-lowers-price-target-to-251", "tags": ["analyst_other", "price_target_down"]}
{"id": 42954932, "time": "2025-01-13 12:33:29", "headline": "Live On CNBC, Rob Sechan Announces Bought NRG Energy; Bought Amazon", "summary": "", "symbols": ["AMZN", "NRG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954932/live-on-cnbc-rob-sechan-announces-bought-nrg-energy-bought-amazon", "tags": []}
{"id": 42954938, "time": "2025-01-13 12:33:48", "headline": "PUBG Developer Krafton Invests $136 Million in Game Studios, Expands AI Team for Future Gaming Innovations", "summary": "Tencent&#39;s partner Krafton invests over $136M in 12 game studios, focusing on AI development. Elon Musk&#39;s xAI also plans AI-driven game studio.", "symbols": ["APP", "EA", "MSFT", "NVDA", "RBLX", "TCEHY"], "source": "benzinga", "author": "Anusuya Lahiri", "url": "https://www.benzinga.com/25/01/42954938/pubg-developer-krafton-invests-136-million-in-game-studios-expands-ai-team-for-future-gaming-innovations", "tags": []}
{"id": 42954956, "time": "2025-01-13 12:34:21", "headline": "Live On CNBC, Rob Sechan Announces Sold Cadence Design Systems", "summary": "", "symbols": ["CDNS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954956/live-on-cnbc-rob-sechan-announces-sold-cadence-design-systems", "tags": []}
{"id": 42954957, "time": "2025-01-13 12:34:31", "headline": "Alliance Global Partners Initiates Coverage On Intensity Therapeutics with Buy Rating, Announces Price Target of $8.5", "summary": "", "symbols": ["INTS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954957/alliance-global-partners-initiates-coverage-on-intensity-therapeutics-with-buy-rating-announces-pric", "tags": ["analyst_init"]}
{"id": 42954974, "time": "2025-01-13 12:34:49", "headline": "On CNBC, Josh Brown Announced Got Stopped Out Of Block", "summary": "", "symbols": ["SQ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954974/on-cnbc-josh-brown-announced-got-stopped-out-of-block", "tags": []}
{"id": 42954983, "time": "2025-01-13 12:35:11", "headline": "10 Information Technology Stocks With Whale Alerts In Today's Session", "summary": " ", "symbols": ["CLSK", "CRWD", "DDOG", "MSTR", "NVDA", "PLTR", "RGTI", "S", "SMCI", "WULF"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42954983/10-information-technology-stocks-with-whale-alerts-in-todays-session", "tags": []}
{"id": 42954984, "time": "2025-01-13 12:35:13", "headline": "Citigroup Maintains Buy on Flowserve, Lowers Price Target to $72", "summary": "", "symbols": ["FLS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42954984/citigroup-maintains-buy-on-flowserve-lowers-price-target-to-72", "tags": ["analyst_other", "price_target_down"]}
{"id": 42955002, "time": "2025-01-13 12:35:17", "headline": "10 Consumer Discretionary Stocks With Whale Alerts In Today's Session", "summary": " ", "symbols": ["AMZN", "CVNA", "DKNG", "FL", "GENI", "GME", "JD", "RIVN", "TPR", "TSLA"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42955002/10-consumer-discretionary-stocks-with-whale-alerts-in-todays-session", "tags": []}
{"id": 42955004, "time": "2025-01-13 12:35:22", "headline": "10 Industrials Stocks Whale Activity In Today's Session", "summary": " ", "symbols": ["BA", "BE", "CHRW", "DAL", "FTAI", "GWW", "KULR", "PAYX", "SMR", "UAL"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42955004/10-industrials-stocks-whale-activity-in-todays-session", "tags": []}
{"id": 42955018, "time": "2025-01-13 12:35:49", "headline": "Keefe, Bruyette & Woods Maintains Market Perform on PJT Partners, Lowers Price Target to $152", "summary": "", "symbols": ["PJT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955018/keefe-bruyette-woods-maintains-market-perform-on-pjt-partners-lowers-price-target-to-152", "tags": ["analyst_other", "price_target_down"]}
{"id": 42955068, "time": "2025-01-13 12:37:06", "headline": "Citigroup Maintains Buy on Gates Industrial Corp, Lowers Price Target to $24", "summary": "", "symbols": ["GTES"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955068/citigroup-maintains-buy-on-gates-industrial-corp-lowers-price-target-to-24", "tags": ["analyst_other", "price_target_down"]}
{"id": 42955080, "time": "2025-01-13 12:37:44", "headline": "Keefe, Bruyette & Woods Maintains Market Perform on T. Rowe Price Gr, Lowers Price Target to $111", "summary": "", "symbols": ["TROW"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955080/keefe-bruyette-woods-maintains-market-perform-on-t-rowe-price-gr-lowers-price-target-to-111", "tags": ["analyst_other", "price_target_down"]}
{"id": 42955114, "time": "2025-01-13 12:38:36", "headline": "Citigroup Maintains Buy on Honeywell Intl, Lowers Price Target to $266", "summary": "", "symbols": ["HON"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955114/citigroup-maintains-buy-on-honeywell-intl-lowers-price-target-to-266", "tags": ["analyst_other", "price_target_down"]}
{"id": 42955116, "time": "2025-01-13 12:39:02", "headline": "Tesla Embodied AI, Robotaxi Dreams Propel Bullish Sentiment: Stock Chart Flashes Mixed Signals", "summary": "Tesla stock drops 12% in past month; why is Morgan Stanley raising the stock&#39;s price target?", "symbols": ["TSLA"], "source": "benzinga", "author": "Surbhi Jain", "url": "https://www.benzinga.com/analyst-ratings/price-target/25/01/42955116/tesla-embodied-ai-robotaxi-dreams-propel-bullish-sentiment-stock-chart-flashes-mixed-signals", "tags": ["why_moving"]}
{"id": 42955168, "time": "2025-01-13 12:40:22", "headline": "Morgan Stanley Maintains Equal-Weight on Webtoon Entertainment, Lowers Price Target to $16", "summary": "", "symbols": ["WBTN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955168/morgan-stanley-maintains-equal-weight-on-webtoon-entertainment-lowers-price-target-to-16", "tags": ["analyst_other", "price_target_down"]}
{"id": 42955174, "time": "2025-01-13 12:40:36", "headline": "Citigroup Maintains Buy on IDEX, Lowers Price Target to $267", "summary": "", "symbols": ["IEX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955174/citigroup-maintains-buy-on-idex-lowers-price-target-to-267", "tags": ["analyst_other", "price_target_down"]}
{"id": 42955199, "time": "2025-01-13 12:41:24", "headline": "Morgan Stanley Maintains Equal-Weight on Westlake, Lowers Price Target to $130", "summary": "", "symbols": ["WLK"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955199/morgan-stanley-maintains-equal-weight-on-westlake-lowers-price-target-to-130", "tags": ["analyst_other", "price_target_down"]}
{"id": 42955200, "time": "2025-01-13 12:41:31", "headline": "M&T Bank Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call", "summary": " ", "symbols": ["MTB"], "source": "benzinga", "author": "Avi Kapoor", "url": "https://www.benzinga.com/analyst-ratings/price-target/25/01/42955200/m-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call", "tags": ["earnings"]}
{"id": 42955216, "time": "2025-01-13 12:42:04", "headline": "Citigroup Maintains Neutral on Illinois Tool Works, Lowers Price Target to $265", "summary": "", "symbols": ["ITW"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955216/citigroup-maintains-neutral-on-illinois-tool-works-lowers-price-target-to-265", "tags": ["analyst_other", "price_target_down"]}
{"id": 42955225, "time": "2025-01-13 12:42:36", "headline": "Morgan Stanley Maintains Underweight on Yelp, Raises Price Target to $35", "summary": "", "symbols": ["YELP"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955225/morgan-stanley-maintains-underweight-on-yelp-raises-price-target-to-35", "tags": ["analyst_other", "price_target_up"]}
{"id": 42955235, "time": "2025-01-13 12:42:44", "headline": "'EU Considers Expanding Probe Into Musk's X, Digital Chief Says' - Bloomberg News", "summary": "", "symbols": ["META", "VGK"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/economics/macro-economic-events/25/01/42955235/eu-considers-expanding-probe-into-musks-x-digital-chief-says-bloomberg-news", "tags": []}
{"id": 42955263, "time": "2025-01-13 12:44:30", "headline": "Citigroup Maintains Buy on Ingersoll Rand, Lowers Price Target to $115", "summary": "", "symbols": ["IR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955263/citigroup-maintains-buy-on-ingersoll-rand-lowers-price-target-to-115", "tags": ["analyst_other", "price_target_down"]}
{"id": 42955275, "time": "2025-01-13 12:45:14", "headline": "Peering Into Amgen's Recent Short Interest", "summary": " ", "symbols": ["AMGN"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42955275/peering-into-amgens-recent-short-interest", "tags": []}
{"id": 42955297, "time": "2025-01-13 12:45:19", "headline": "How Is The Market Feeling About Simon Property Group?", "summary": " ", "symbols": ["SPG"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42955297/how-is-the-market-feeling-about-simon-property-group", "tags": []}
{"id": 42955303, "time": "2025-01-13 12:45:24", "headline": "Peering Into Lithia Motors's Recent Short Interest", "summary": " ", "symbols": ["LAD"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42955303/peering-into-lithia-motorss-recent-short-interest", "tags": []}
{"id": 42955324, "time": "2025-01-13 12:45:44", "headline": "Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why", "summary": "Phio Pharmaceuticals reports promising Phase 1b trial results for PH-762, showing complete tumor clearance in two patients with no significant adverse effects.", "symbols": ["PHIO"], "source": "benzinga", "author": "Vandana Singh", "url": "https://www.benzinga.com/general/biotech/25/01/42955324/cancer-focused-phio-pharmaceuticals-stock-gains-300-on-monday-heres-why", "tags": ["fda"]}
{"id": 42955372, "time": "2025-01-13 12:47:07", "headline": "Bitdeer Growth Fueled By Strong Machine Sales, Efficient ASICs, Diversified Revenue, And High-Performance Computing Potential: Analyst", "summary": "Needham analyst John Todaro maintained Bitdeer Technologies (NASDAQ:BTDR) with a Buy and raised the price target from\u00a0$14\u00a0to\u00a0$22.", "symbols": ["BTCUSD", "BTDR", "CAN"], "source": "benzinga", "author": "Anusuya Lahiri", "url": "https://www.benzinga.com/25/01/42955372/bitdeer-growth-fueled-by-strong-machine-sales-efficient-asics-diversified-revenue-and-high-performance-computing-potential-analyst", "tags": ["earnings"]}
{"id": 42955439, "time": "2025-01-13 12:49:34", "headline": "Citigroup Maintains Buy on ITT, Lowers Price Target to $181", "summary": "", "symbols": ["ITT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955439/citigroup-maintains-buy-on-itt-lowers-price-target-to-181", "tags": ["analyst_other", "price_target_down"]}
{"id": 42955475, "time": "2025-01-13 12:50:31", "headline": "Citigroup Maintains Neutral on Johnson Controls Intl, Lowers Price Target to $84", "summary": "", "symbols": ["JCI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955475/citigroup-maintains-neutral-on-johnson-controls-intl-lowers-price-target-to-84", "tags": ["analyst_other", "price_target_down"]}
{"id": 42955662, "time": "2025-01-13 12:54:28", "headline": "Citigroup Maintains Buy on nVent Electric, Lowers Price Target to $90", "summary": "", "symbols": ["NVT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955662/citigroup-maintains-buy-on-nvent-electric-lowers-price-target-to-90", "tags": ["analyst_other", "price_target_down"]}
{"id": 42955663, "time": "2025-01-13 12:54:34", "headline": "Morgan Stanley Maintains Equal-Weight on Zeta Global Holdings, Lowers Price Target to $23", "summary": "", "symbols": ["ZETA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955663/morgan-stanley-maintains-equal-weight-on-zeta-global-holdings-lowers-price-target-to-23", "tags": ["analyst_other", "price_target_down"]}
{"id": 42955726, "time": "2025-01-13 12:56:53", "headline": "Citigroup Maintains Buy on Pentair, Lowers Price Target to $119", "summary": "", "symbols": ["PNR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955726/citigroup-maintains-buy-on-pentair-lowers-price-target-to-119", "tags": ["analyst_other", "price_target_down"]}
{"id": 42955769, "time": "2025-01-13 12:59:47", "headline": "Morgan Stanley Maintains Equal-Weight on Huntsman, Lowers Price Target to $20", "summary": "", "symbols": ["HUN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955769/morgan-stanley-maintains-equal-weight-on-huntsman-lowers-price-target-to-20", "tags": ["analyst_other", "price_target_down"]}
{"id": 42955798, "time": "2025-01-13 13:00:15", "headline": "Beyond The Numbers: 9 Analysts Discuss Marex Group Stock", "summary": " ", "symbols": ["MRX"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42955798/beyond-the-numbers-9-analysts-discuss-marex-group-stock", "tags": []}
{"id": 42955811, "time": "2025-01-13 13:00:22", "headline": "This Is What Whales Are Betting On Ford Motor", "summary": " ", "symbols": ["F"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42955811/this-is-what-whales-are-betting-on-ford-motor", "tags": []}
{"id": 42955812, "time": "2025-01-13 13:00:22", "headline": "Deep Dive Into Advanced Micro Devices Stock: Analyst Perspectives (18 Ratings)", "summary": " ", "symbols": ["AMD"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42955812/deep-dive-into-advanced-micro-devices-stock-analyst-perspectives-18-ratings", "tags": []}
{"id": 42955826, "time": "2025-01-13 13:00:23", "headline": "Citigroup Maintains Buy on Trane Technologies, Lowers Price Target to $476", "summary": "", "symbols": ["TT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955826/citigroup-maintains-buy-on-trane-technologies-lowers-price-target-to-476", "tags": ["analyst_other", "price_target_down"]}
{"id": 42955842, "time": "2025-01-13 13:00:27", "headline": "A Closer Look at Elevance Health's Options Market Dynamics", "summary": " ", "symbols": ["ELV"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42955842/a-closer-look-at-elevance-healths-options-market-dynamics", "tags": []}
{"id": 42955847, "time": "2025-01-13 13:00:30", "headline": "Where Trade Desk Stands With Analysts", "summary": " ", "symbols": ["TTD"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42955847/where-trade-desk-stands-with-analysts", "tags": []}
{"id": 42955849, "time": "2025-01-13 13:00:37", "headline": "Assessing Skyward Specialty: Insights From 4 Financial Analysts", "summary": " ", "symbols": ["SKWD"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42955849/assessing-skyward-specialty-insights-from-4-financial-analysts", "tags": []}
{"id": 42955854, "time": "2025-01-13 13:00:40", "headline": "Morgan Stanley Maintains Equal-Weight on Illumina, Lowers Price Target to $150", "summary": "", "symbols": ["ILMN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955854/morgan-stanley-maintains-equal-weight-on-illumina-lowers-price-target-to-150", "tags": ["analyst_other", "price_target_down"]}
{"id": 42955855, "time": "2025-01-13 13:00:45", "headline": "13 Analysts Have This To Say About Intellia Therapeutics", "summary": " ", "symbols": ["NTLA"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42955855/13-analysts-have-this-to-say-about-intellia-therapeutics", "tags": []}
{"id": 42955856, "time": "2025-01-13 13:00:51", "headline": "Analyst Expectations For Huntsman's Future", "summary": " ", "symbols": ["HUN"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42955856/analyst-expectations-for-huntsmans-future", "tags": []}
{"id": 42955879, "time": "2025-01-13 13:01:38", "headline": "CNBC Halftime Report Final Trades: Leidos Holdings, JP Morgan Chase & Co., Amazon, VanEck BDC Income ETF", "summary": "", "symbols": ["AMZN", "BIZD", "JPM", "LDOS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955879/cnbc-halftime-report-final-trades-leidos-holdings-jp-morgan-chase-co-amazon-vaneck-bdc-income-etf", "tags": []}
{"id": 42955887, "time": "2025-01-13 13:01:42", "headline": "Morgan Stanley Maintains Equal-Weight on Maplebear, Raises Price Target to $44", "summary": "", "symbols": ["CART"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955887/morgan-stanley-maintains-equal-weight-on-maplebear-raises-price-target-to-44", "tags": ["analyst_other", "price_target_up"]}
{"id": 42955913, "time": "2025-01-13 13:02:52", "headline": "Morgan Stanley Maintains Equal-Weight on Klaviyo, Raises Price Target to $47", "summary": "", "symbols": ["KVYO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955913/morgan-stanley-maintains-equal-weight-on-klaviyo-raises-price-target-to-47", "tags": ["analyst_other", "price_target_up"]}
{"id": 42955924, "time": "2025-01-13 13:03:18", "headline": "Citigroup Maintains Neutral on Veralto, Lowers Price Target to $116", "summary": "", "symbols": ["VLTO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955924/citigroup-maintains-neutral-on-veralto-lowers-price-target-to-116", "tags": ["analyst_other", "price_target_down"]}
{"id": 42955944, "time": "2025-01-13 13:04:09", "headline": "Morgan Stanley Maintains Underweight on LegalZoom.com, Raises Price Target to $8", "summary": "", "symbols": ["LZ"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955944/morgan-stanley-maintains-underweight-on-legalzoom-com-raises-price-target-to-8", "tags": ["analyst_other", "price_target_up"]}
{"id": 42955955, "time": "2025-01-13 13:04:38", "headline": "Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market", "summary": "Exact Sciences&#39; 2024 sales grew 10% to $2.76 billion, exceeding estimates. New cancer tests, including Cologuard Plus, are set for 2025 launch.", "symbols": ["EXAS"], "source": "benzinga", "author": "Vandana Singh", "url": "https://www.benzinga.com/general/health-care/25/01/42955955/exact-sciences-sparks-analyst-optimism-amid-competitive-multi-cancer-test-market", "tags": []}
{"id": 42955985, "time": "2025-01-13 13:04:54", "headline": "Citigroup Maintains Buy on Vontier, Lowers Price Target to $44", "summary": "", "symbols": ["VNT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42955985/citigroup-maintains-buy-on-vontier-lowers-price-target-to-44", "tags": ["analyst_other", "price_target_down"]}
{"id": 42956034, "time": "2025-01-13 13:05:42", "headline": "Netflix Stock Has 'Long Term Runway For Dominance In Streaming': Analyst Highlights 4 Key Catalysts", "summary": "A Netflix analyst says the company could beat subscriber growth estimates and highlights its growing advertising monetization in the fourth quarter.", "symbols": ["NFLX"], "source": "benzinga", "author": "Chris Katje", "url": "https://www.benzinga.com/general/entertainment/25/01/42956034/netflix-stock-has-long-term-runway-for-dominance-in-streaming-analyst-highlights-4-key-catalysts", "tags": []}
{"id": 42956044, "time": "2025-01-13 13:05:56", "headline": "Morgan Stanley Maintains Overweight on LyondellBasell Industries, Lowers Price Target to $90", "summary": "", "symbols": ["LYB"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42956044/morgan-stanley-maintains-overweight-on-lyondellbasell-industries-lowers-price-target-to-90", "tags": ["analyst_other", "price_target_down"]}
{"id": 42956067, "time": "2025-01-13 13:06:37", "headline": "Citigroup Maintains Buy on Xylem, Lowers Price Target to $147", "summary": "", "symbols": ["XYL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42956067/citigroup-maintains-buy-on-xylem-lowers-price-target-to-147", "tags": ["analyst_other", "price_target_down"]}
{"id": 42956075, "time": "2025-01-13 13:06:54", "headline": "Morgan Stanley Maintains Equal-Weight on Match Group, Raises Price Target to $32", "summary": "", "symbols": ["MTCH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42956075/morgan-stanley-maintains-equal-weight-on-match-group-raises-price-target-to-32", "tags": ["analyst_other", "price_target_up"]}
{"id": 42956098, "time": "2025-01-13 13:08:01", "headline": "Morgan Stanley Maintains Overweight on Meta Platforms, Raises Price Target to $660", "summary": "", "symbols": ["META"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42956098/morgan-stanley-maintains-overweight-on-meta-platforms-raises-price-target-to-660", "tags": ["analyst_other", "price_target_up"]}
{"id": 42956112, "time": "2025-01-13 13:08:56", "headline": "Morgan Stanley Maintains Equal-Weight on Mosaic, Lowers Price Target to $30", "summary": "", "symbols": ["MOS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42956112/morgan-stanley-maintains-equal-weight-on-mosaic-lowers-price-target-to-30", "tags": ["analyst_other", "price_target_down"]}
{"id": 42956125, "time": "2025-01-13 13:10:04", "headline": "Morgan Stanley Maintains Underweight on Olin, Lowers Price Target to $31", "summary": "", "symbols": ["OLN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42956125/morgan-stanley-maintains-underweight-on-olin-lowers-price-target-to-31", "tags": ["analyst_other", "price_target_down"]}
{"id": 42956159, "time": "2025-01-13 13:11:37", "headline": "Morgan Stanley Maintains Equal-Weight on Pinterest, Raises Price Target to $36", "summary": "", "symbols": ["PINS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42956159/morgan-stanley-maintains-equal-weight-on-pinterest-raises-price-target-to-36", "tags": ["analyst_other", "price_target_up"]}
{"id": 42956183, "time": "2025-01-13 13:13:22", "headline": "Morgan Stanley Maintains Overweight on Roblox, Raises Price Target to $75", "summary": "", "symbols": ["RBLX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42956183/morgan-stanley-maintains-overweight-on-roblox-raises-price-target-to-75", "tags": ["analyst_other", "price_target_up"]}
{"id": 42956202, "time": "2025-01-13 13:14:16", "headline": "Morgan Stanley Maintains Equal-Weight on Sealed Air, Lowers Price Target to $38", "summary": "", "symbols": ["SEE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42956202/morgan-stanley-maintains-equal-weight-on-sealed-air-lowers-price-target-to-38", "tags": ["analyst_other", "price_target_down"]}
{"id": 42956214, "time": "2025-01-13 13:15:15", "headline": "(SUM) - Analyzing Summit Materials's Short Interest", "summary": " ", "symbols": ["SUM"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42956214/sum-analyzing-summit-materialss-short-interest", "tags": []}
{"id": 42956215, "time": "2025-01-13 13:15:19", "headline": "Morgan Stanley Maintains Equal-Weight on Sprout Social, Raises Price Target to $37", "summary": "", "symbols": ["SPT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42956215/morgan-stanley-maintains-equal-weight-on-sprout-social-raises-price-target-to-37", "tags": ["analyst_other", "price_target_up"]}
{"id": 42956217, "time": "2025-01-13 13:15:20", "headline": "How Is The Market Feeling About GitLab?", "summary": " ", "symbols": ["GTLB"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42956217/how-is-the-market-feeling-about-gitlab", "tags": []}
{"id": 42956218, "time": "2025-01-13 13:15:26", "headline": "How Is The Market Feeling About Insmed?", "summary": " ", "symbols": ["INSM"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/short-sellers/25/01/42956218/how-is-the-market-feeling-about-insmed", "tags": []}
{"id": 42956262, "time": "2025-01-13 13:15:43", "headline": "'Lilly Asks Biden Administration to Pause Drug-Price Negotiations' - Bloomberg News", "summary": "", "symbols": ["LLY", "SPY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42956262/lilly-asks-biden-administration-to-pause-drug-price-negotiations-bloomberg-news", "tags": []}
{"id": 42956301, "time": "2025-01-13 13:17:02", "headline": "Morgan Stanley Maintains Overweight on Thermo Fisher Scientific, Lowers Price Target to $647", "summary": "", "symbols": ["TMO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42956301/morgan-stanley-maintains-overweight-on-thermo-fisher-scientific-lowers-price-target-to-647", "tags": ["analyst_other", "price_target_down"]}
{"id": 42956318, "time": "2025-01-13 13:18:06", "headline": "Morgan Stanley Maintains Overweight on Trade Desk, Raises Price Target to $145", "summary": "", "symbols": ["TTD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42956318/morgan-stanley-maintains-overweight-on-trade-desk-raises-price-target-to-145", "tags": ["analyst_other", "price_target_up"]}
{"id": 42956342, "time": "2025-01-13 13:19:55", "headline": "Morgan Stanley Maintains Equal-Weight on Tronox Holdings, Lowers Price Target to $12", "summary": "", "symbols": ["TROX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42956342/morgan-stanley-maintains-equal-weight-on-tronox-holdings-lowers-price-target-to-12", "tags": ["analyst_other", "price_target_down"]}
{"id": 42956389, "time": "2025-01-13 13:20:52", "headline": "Morgan Stanley Maintains Overweight on Unity Software, Raises Price Target to $26", "summary": "", "symbols": ["U"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42956389/morgan-stanley-maintains-overweight-on-unity-software-raises-price-target-to-26", "tags": ["analyst_other", "price_target_up"]}
{"id": 42956350, "time": "2025-01-13 13:20:30", "headline": "Pfizer CEO Albert Bourla Says \"Looking At Everything\" In The Obesity Market Beyond Injectable GLP-1 Drugs; Says \"All In\" On Obesity Drug Development", "summary": "", "symbols": ["PFE"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42956350/pfizer-ceo-albert-bourla-says-looking-at-everything-in-the-obesity-market-beyond-injectable-glp-1", "tags": ["management"]}
{"id": 42956414, "time": "2025-01-13 13:22:11", "headline": "Morgan Stanley Maintains Overweight on Warner Music Gr, Lowers Price Target to $37", "summary": "", "symbols": ["WMG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42956414/morgan-stanley-maintains-overweight-on-warner-music-gr-lowers-price-target-to-37", "tags": ["analyst_other", "price_target_down"]}
{"id": 42956569, "time": "2025-01-13 13:27:30", "headline": "Tether To Relocate Headquarters To El Salvador", "summary": "Tether (CRYPTO: USDT) on Monday announced it has acquired a Digital Asset Service Provider (DASP) license by El Salvador, allowing it to subsequently relocate its operations to ", "symbols": ["BTCUSD", "ETHUSD", "USDTUSD"], "source": "benzinga", "author": "Murtuza Merchant", "url": "https://www.benzinga.com/markets/cryptocurrency/25/01/42956569/tether-to-relocate-headquarters-to-el-salvador", "tags": ["merger"]}
{"id": 42956618, "time": "2025-01-13 13:30:27", "headline": "Looking At McDonald's's Recent Unusual Options Activity", "summary": " ", "symbols": ["MCD"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42956618/looking-at-mcdonaldss-recent-unusual-options-activity", "tags": []}
{"id": 42956810, "time": "2025-01-13 13:37:06", "headline": "What's Going On With 22nd Century Group Shares Monday?", "summary": "22nd Century stock is moving higher on Monday after the company announced its readiness to support the FDA&#39;s proposed standard to mandate reduced nicotine content in cigarettes.", "symbols": ["XXII"], "source": "benzinga", "author": "Dylan Berman", "url": "https://www.benzinga.com/25/01/42956810/whats-going-on-with-22nd-century-group-shares-monday", "tags": ["why_moving", "fda"]}
{"id": 42956879, "time": "2025-01-13 13:40:36", "headline": "American Electric Power Is Attractive Going Forward, Analyst Double-Upgrades Stock", "summary": "Bank of America Securities analyst Julien Dumoulin-Smith upgraded American Electric Power to a Buy rating and raised the price target to $104, up from $98. The upgrade follows AEP&#39;s sale of a 19.9% stake in transmission assets for $2.8 billion and the appointment of Trevor Mihalik as CFO. ", "symbols": ["AEP", "KKR"], "source": "benzinga", "author": "Shivani Kumaresan", "url": "https://www.benzinga.com/25/01/42956879/aep-stock-boosted-by-asset-sale-and-new-cfo-appointment-says-analyst", "tags": ["analyst_up", "management"]}
{"id": 42956918, "time": "2025-01-13 13:41:48", "headline": "BWS Financial Initiates Coverage On Nebius Group with Buy Rating, Announces Price Target of $51", "summary": "", "symbols": ["NBIS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42956918/bws-financial-initiates-coverage-on-nebius-group-with-buy-rating-announces-price-target-of-51", "tags": ["analyst_init"]}
{"id": 42956943, "time": "2025-01-13 13:43:13", "headline": "Trump Cabinet Confirmation Hearings Begin Tuesday: Pete Hegseth, Doug Collins Up First", "summary": "President-elect Donald Trump&#39;s cabinet picks are set to begin the confirmation process with several appearing before Senate committees this week. Former Fox News host Pete Segeth and former Georgia congressman Doug Collins are up first on Tuesday.", "symbols": ["GD", "ITA", "LMT", "RTX"], "source": "benzinga", "author": "Erica Kollmann", "url": "https://www.benzinga.com/etfs/sector-etfs/25/01/42956943/trump-cabinet-confirmation-hearings-begin-tuesday-pete-hegseth-doug-collins-up-first", "tags": []}
{"id": 42956993, "time": "2025-01-13 13:45:26", "headline": "Check Out What Whales Are Doing With AXON", "summary": " ", "symbols": ["AXON"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42956993/check-out-what-whales-are-doing-with-axon", "tags": []}
{"id": 42956995, "time": "2025-01-13 13:45:31", "headline": "Looking At Microsoft's Recent Unusual Options Activity", "summary": " ", "symbols": ["MSFT"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42956995/looking-at-microsofts-recent-unusual-options-activity", "tags": []}
{"id": 42957000, "time": "2025-01-13 13:45:38", "headline": "Compass Point Maintains Buy on Saratoga Investment, Lowers Price Target to $25.25", "summary": "", "symbols": ["SAR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42957000/compass-point-maintains-buy-on-saratoga-investment-lowers-price-target-to-25-25", "tags": ["analyst_other", "price_target_down"]}
{"id": 42957189, "time": "2025-01-13 13:52:09", "headline": "JP Morgan Upgrades IGM Biosciences to Neutral", "summary": "", "symbols": ["IGMS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42957189/jp-morgan-upgrades-igm-biosciences-to-neutral", "tags": ["analyst_up"]}
{"id": 42957201, "time": "2025-01-13 13:52:35", "headline": "Stock Of The Day: Will Mondelez Rally? There's A Chance The Selloff Will End", "summary": "There is also a good chance that the stock reverses and moves higher. This is why Mondelez is our Stock of the Day.", "symbols": ["MDLZ"], "source": "benzinga", "author": "Mark Putrino", "url": "https://www.benzinga.com/trading-ideas/technicals/25/01/42957201/stock-of-the-day-mondelez-rally-chance-selloff-will-end", "tags": []}
{"id": 42957289, "time": "2025-01-13 13:55:01", "headline": "JP Morgan Maintains Neutral on Morgan Stanley, Raises Price Target to $108", "summary": "", "symbols": ["MS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42957289/jp-morgan-maintains-neutral-on-morgan-stanley-raises-price-target-to-108", "tags": ["analyst_other", "price_target_up"]}
{"id": 42957309, "time": "2025-01-13 13:55:54", "headline": "Can A K-9 Drug Sniffer Land You In Jail For Cannabis? Florida Court Sets New Limits", "summary": "In possible landmark ruling, a Florida appeals court has determined that a drug-sniffing dog&#39;s alert alone does justify a police search.", "symbols": [], "source": "benzinga", "author": "Maureen Meehan", "url": "https://www.benzinga.com/news/legal/25/01/42957309/can-a-k-9-drug-sniffer-land-you-in-jail-for-cannabis-florida-court-sets-new-limits", "tags": ["legal"]}
{"id": 42957365, "time": "2025-01-13 13:58:26", "headline": "Nordstrom Balances Strong Holiday Sales And Competition, Analysts Highlight Margin Pressure", "summary": "Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating for Nordstrom, setting a $24 price target.  While showing strong momentum, Nordstrom faces potential gross margin pressure from competitive strategies.", "symbols": ["JWN"], "source": "benzinga", "author": "Shivani Kumaresan", "url": "https://www.benzinga.com/25/01/42957365/analysts-remain-optimistic-on-nordstrom-despite-competitive-retail-environment", "tags": []}
{"id": 42957368, "time": "2025-01-13 13:58:34", "headline": "JP Morgan Maintains Overweight on PACCAR, Raises Price Target to $125", "summary": "", "symbols": ["PCAR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42957368/jp-morgan-maintains-overweight-on-paccar-raises-price-target-to-125", "tags": ["analyst_other", "price_target_up"]}
{"id": 42957400, "time": "2025-01-13 14:00:00", "headline": "Bitcoin's Big Macro Data Week: Here's What To Watch", "summary": "Bitcoin (CRYPTO: BTC) faces several key macroeconomic data releases this week, causing heightened volatility in the markets.", "symbols": ["BTCUSD"], "source": "benzinga", "author": "Khyathi Dalal", "url": "https://www.benzinga.com/markets/cryptocurrency/25/01/42957400/bitcoins-big-macro-data-week-heres-what-to-watch", "tags": []}
{"id": 42957417, "time": "2025-01-13 14:00:15", "headline": "The Analyst Verdict: Blackstone In The Eyes Of 19 Experts", "summary": " ", "symbols": ["BX"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42957417/the-analyst-verdict-blackstone-in-the-eyes-of-19-experts", "tags": []}
{"id": 42957429, "time": "2025-01-13 14:00:25", "headline": "Pure Storage's Options: A Look at What the Big Money is Thinking", "summary": " ", "symbols": ["PSTG"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42957429/pure-storages-options-a-look-at-what-the-big-money-is-thinking", "tags": []}
{"id": 42957434, "time": "2025-01-13 14:00:30", "headline": "Demystifying ARM Holdings: Insights From 10 Analyst Reviews", "summary": " ", "symbols": ["ARM"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42957434/demystifying-arm-holdings-insights-from-10-analyst-reviews", "tags": []}
{"id": 42957439, "time": "2025-01-13 14:00:37", "headline": "Market Whales and Their Recent Bets on LRCX Options", "summary": " ", "symbols": ["LRCX"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42957439/market-whales-and-their-recent-bets-on-lrcx-options", "tags": []}
{"id": 42957441, "time": "2025-01-13 14:00:37", "headline": "Deep Dive Into Xylem Stock: Analyst Perspectives (6 Ratings)", "summary": " ", "symbols": ["XYL"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42957441/deep-dive-into-xylem-stock-analyst-perspectives-6-ratings", "tags": []}
{"id": 42957462, "time": "2025-01-13 14:00:45", "headline": "Demystifying Magnolia Oil & Gas: Insights From 5 Analyst Reviews", "summary": " ", "symbols": ["MGY"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42957462/demystifying-magnolia-oil-gas-insights-from-5-analyst-reviews", "tags": []}
{"id": 42957472, "time": "2025-01-13 14:00:54", "headline": "Analyst Expectations For Halozyme Therapeutics's Future", "summary": " ", "symbols": ["HALO"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42957472/analyst-expectations-for-halozyme-therapeuticss-future", "tags": []}
{"id": 42957476, "time": "2025-01-13 14:01:02", "headline": "Where BKV Stands With Analysts", "summary": " ", "symbols": ["BKV"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42957476/where-bkv-stands-with-analysts", "tags": []}
{"id": 42957518, "time": "2025-01-13 14:01:52", "headline": "Lake Street Maintains Buy on ModivCare, Lowers Price Target to $10", "summary": "", "symbols": ["MODV"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42957518/lake-street-maintains-buy-on-modivcare-lowers-price-target-to-10", "tags": ["analyst_other", "price_target_down"]}
{"id": 42957610, "time": "2025-01-13 14:04:54", "headline": "Macquarie Maintains Outperform on Netflix, Raises Price Target to $965", "summary": "", "symbols": ["NFLX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42957610/macquarie-maintains-outperform-on-netflix-raises-price-target-to-965", "tags": ["analyst_other", "price_target_up"]}
{"id": 42957657, "time": "2025-01-13 14:06:20", "headline": "Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts", "summary": "Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae&#39;s success in postpartum depression.", "symbols": ["BIIB", "SAGE"], "source": "benzinga", "author": "Vandana Singh", "url": "https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say", "tags": ["merger"]}
{"id": 42957709, "time": "2025-01-13 14:08:19", "headline": "JP Morgan Maintains Neutral on TD Synnex, Raises Price Target to $150", "summary": "", "symbols": ["SNX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42957709/jp-morgan-maintains-neutral-on-td-synnex-raises-price-target-to-150", "tags": ["analyst_other", "price_target_up"]}
{"id": 42957741, "time": "2025-01-13 14:10:06", "headline": "TikTok Ban Deadline Ahead: What Will Happen To App On Your Phone?", "summary": "A TikTok ban could be bad for content creators and good for social media rivals. A look at what&#39;s next, including what happens to the app on your phone.", "symbols": ["AAPL", "EBAY", "GOOG", "GOOGL", "META", "RDDT", "SNAP"], "source": "benzinga", "author": "Chris Katje", "url": "https://www.benzinga.com/general/social-media/25/01/42957741/tiktok-ban-deadline-ahead-what-will-happen-to-app-on-your-phone", "tags": []}
{"id": 42957769, "time": "2025-01-13 14:10:48", "headline": "Rounds Of Intensive Talks Planned In Cairo To Put Final Touches On Remaining Details For Gaza Ceasefire Deal", "summary": "", "symbols": ["BNO", "USO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/economics/macro-economic-events/25/01/42957769/rounds-of-intensive-talks-planned-in-cairo-to-put-final-touches-on-remaining-deta", "tags": ["contract"]}
{"id": 42957822, "time": "2025-01-13 14:12:59", "headline": "Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge", "summary": " ", "symbols": ["ANF", "CMTL", "ITCI", "MRNA", "PHIO", "SLRX"], "source": "benzinga", "author": "Avi Kapoor", "url": "https://www.benzinga.com/news/earnings/25/01/42957822/gold-down-over-1-salarius-pharmaceuticals-shares-surge", "tags": []}
{"id": 42957874, "time": "2025-01-13 14:15:33", "headline": "Spotlight on GameStop: Analyzing the Surge in Options Activity", "summary": " ", "symbols": ["GME"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42957874/spotlight-on-gamestop-analyzing-the-surge-in-options-activity", "tags": []}
{"id": 42957948, "time": "2025-01-13 14:17:48", "headline": "Instacart, Uber Deal 'Makes More Sense Now,' Analyst Says: Here's Why", "summary": "Maplebear, which owns Instacart, could be an enticing acquisition for Uber as it looks to diversify revenue streams away from mobility.", "symbols": ["CART", "DASH", "UBER"], "source": "benzinga", "author": "Adam Eckert", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42957948/instacart-uber-deal-makes-more-sense-now-analyst-says-heres-why", "tags": ["earnings", "contract"]}
{"id": 42957969, "time": "2025-01-13 14:18:37", "headline": "What's Going On With CVS, Humana and UnitedHealth Shares Monday?", "summary": "Shares of health insurance companies are trading higher after The Centers for Medicare and Medicaid Services proposed a rise to Medicare Advantage payments.", "symbols": ["CVS", "HUM", "UNH"], "source": "benzinga", "author": "Dylan Berman", "url": "https://www.benzinga.com/25/01/42957969/whats-going-on-with-cvs-humana-and-unitedhealth-shares-monday", "tags": ["why_moving"]}
{"id": 42958003, "time": "2025-01-13 14:20:04", "headline": "UBS Maintains Buy on Avadel Pharmaceuticals, Lowers Price Target to $14", "summary": "", "symbols": ["AVDL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42958003/ubs-maintains-buy-on-avadel-pharmaceuticals-lowers-price-target-to-14", "tags": ["analyst_other", "price_target_down"]}
{"id": 42958097, "time": "2025-01-13 14:22:09", "headline": "DatChat (DATS) Stock Jumps After Last Week's Plunge: What's Going On?", "summary": "DatChat shares climbed 14.5% on Monday. Monday&#39;s rally occurred despite no new company-specific updates.", "symbols": ["DATS"], "source": "benzinga", "author": "Henry Khederian", "url": "https://www.benzinga.com/news/25/01/42958097/datchat-dats-stock-jumps-after-last-weeks-plunge-whats-going-on", "tags": ["why_moving"]}
{"id": 42958107, "time": "2025-01-13 14:22:33", "headline": "Stocks Edge Down Ahead Of Key Inflation Reports, Crude Hits 5-Month High, Bitcoin Sinks: What's Driving Markets Monday?", "summary": "Traders adopted a cautious approach on Monday as they awaited two critical inflation reports due later this week, seeking clarity on Federal Reserve interest rate policy. ", "symbols": ["BKR", "BTCUSD", "COIN", "CVS", "DIA", "EIX", "HUM", "IWM", "MPC", "MRNA", "MSTR", "NVDA", "QQQ", "SPY", "UNH", "VLO", "XLC", "XLE", "XLK", "XLV"], "source": "benzinga", "author": "Piero Cingari", "url": "https://www.benzinga.com/economics/macro-economic-events/25/01/42958107/stocks-edge-down-ahead-of-key-inflation-reports-crude-hits-5-month-high-bitcoin-sinks-whats-driving-markets-monday", "tags": []}
{"id": 42958123, "time": "2025-01-13 14:23:21", "headline": "William Blair Downgrades Enfusion to Market Perform", "summary": "", "symbols": ["ENFN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42958123/william-blair-downgrades-enfusion-to-market-perform", "tags": ["analyst_down"]}
{"id": 42958209, "time": "2025-01-13 14:25:10", "headline": "What's Going On With Vera Therapeutics Stock?", "summary": "Vera Therapeutics shares are trading lower by 4.7% Monday afternoon. The company announced an exclusive license agreement with Stanford University for VT-109.", "symbols": ["VERA"], "source": "benzinga", "author": "Henry Khederian", "url": "https://www.benzinga.com/news/25/01/42958209/whats-going-on-with-vera-therapeutics-stock", "tags": ["why_moving", "contract"]}
{"id": 42958224, "time": "2025-01-13 14:25:39", "headline": "Wells Fargo Upgrades Xcel Energy to Overweight, Raises Price Target to $72", "summary": "", "symbols": ["XEL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42958224/wells-fargo-upgrades-xcel-energy-to-overweight-raises-price-target-to-72", "tags": ["analyst_up", "price_target_up"]}
{"id": 42958251, "time": "2025-01-13 14:26:59", "headline": "ON Semi Sees Utilization Cuts As EV Demand Softens, Analyst Warns", "summary": "Bolton maintains Buy rating for ON Semiconductor and lowers price target to $66. Weak demand, inventory digestion, and lowered utilization rates expected to impact revenue and margins in near term.", "symbols": ["ON"], "source": "benzinga", "author": "Anusuya Lahiri", "url": "https://www.benzinga.com/analyst-ratings/price-target/25/01/42958251/on-semi-sees-utilization-cuts-as-ev-demand-softens-analyst-warns", "tags": ["analyst_other", "price_target_down", "earnings"]}
{"id": 42958298, "time": "2025-01-13 14:29:22", "headline": "Wells Fargo Maintains Equal-Weight on RxSight, Lowers Price Target to $40", "summary": "", "symbols": ["RXST"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42958298/wells-fargo-maintains-equal-weight-on-rxsight-lowers-price-target-to-40", "tags": ["analyst_other", "price_target_down"]}
{"id": 42958327, "time": "2025-01-13 14:30:27", "headline": "Northrop Grumman's Options Frenzy: What You Need to Know", "summary": " ", "symbols": ["NOC"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42958327/northrop-grummans-options-frenzy-what-you-need-to-know", "tags": []}
{"id": 42958334, "time": "2025-01-13 14:30:32", "headline": "Decoding CrowdStrike Holdings's Options Activity: What's the Big Picture?", "summary": " ", "symbols": ["CRWD"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42958334/decoding-crowdstrike-holdingss-options-activity-whats-the-big-picture", "tags": []}
{"id": 42958531, "time": "2025-01-13 14:40:04", "headline": "Hamas Delegation In Doha Says Gaza Ceasefire Talks Progressing Well With Group Dealing With Developments In Positive Manner", "summary": "", "symbols": ["BNO", "USO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/economics/macro-economic-events/25/01/42958531/hamas-delegation-in-doha-says-gaza-ceasefire-talks-progressing-well-with-group-de", "tags": []}
{"id": 42958533, "time": "2025-01-13 14:40:17", "headline": "How Trump's 'Maganomics' Could Power Industrials-Focused ETFs", "summary": "Maganomics is Trump&#39;s economic plan to boost domestic manufacturing, attracting investors and causing divided opinions. ETFs heavy in manufacturing may benefit.", "symbols": ["GE", "HON", "IYJ", "LMT", "VIS", "XME"], "source": "benzinga", "author": "Chandrima Sanyal", "url": "https://www.benzinga.com/etfs/sector-etfs/25/01/42958533/how-trumps-maganomics-could-power-industrials-focused-etfs", "tags": []}
{"id": 42958685, "time": "2025-01-13 14:45:36", "headline": "Behind the Scenes of Qualcomm's Latest Options Trends", "summary": " ", "symbols": ["QCOM"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42958685/behind-the-scenes-of-qualcomms-latest-options-trends", "tags": []}
{"id": 42958689, "time": "2025-01-13 14:45:41", "headline": "Unpacking the Latest Options Trading Trends in Amgen", "summary": " ", "symbols": ["AMGN"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42958689/unpacking-the-latest-options-trading-trends-in-amgen", "tags": []}
{"id": 42958773, "time": "2025-01-13 14:47:21", "headline": "United Airlines Earnings Preview: Could Airline Impress Investors After Delta's Strong Guidance?", "summary": "A United Airlines analyst sees clear skies ahead for company after Delta&#39;s recent earnings per share and revenue beat.", "symbols": ["DAL", "UAL"], "source": "benzinga", "author": "Chris Katje", "url": "https://www.benzinga.com/general/travel/25/01/42958773/united-airlines-earnings-preview-could-airline-impress-investors-after-deltas-strong-guidance", "tags": ["earnings", "guidance"]}
{"id": 42958774, "time": "2025-01-13 14:47:22", "headline": "Gilead Exec Says Co Expects To Do \"Something Like A Cymabay Acquisition Every Couple Of Years", "summary": "", "symbols": ["GILD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/health-care/25/01/42958774/gilead-exec-says-co-expects-to-do-something-like-a-cymabay-acquisition-every-couple-of-years", "tags": []}
{"id": 42958916, "time": "2025-01-13 14:53:20", "headline": "Broadcom's $3 Billion Bet: Balancing Market Signals, AI-Driven Growth", "summary": "Broadcom Inc. (AVGO) navigates bullish trend but faces selling pressure.", "symbols": ["AVGO", "NVDA"], "source": "benzinga", "author": "Surbhi Jain", "url": "https://www.benzinga.com/trading-ideas/long-ideas/25/01/42958916/broadcoms-3-billion-bet-balancing-market-signals-ai-driven-growth", "tags": []}
{"id": 42959061, "time": "2025-01-13 14:58:11", "headline": "Intra-Cellular Therapies Stock Is Surging Monday: What's Going On?", "summary": "Shares of Intra-Cellular Therapies Inc. (NASDAQ: ITCI) are trading higher Monday after Johnson &amp; Johnson agreed to acquire the company.", "symbols": ["ITCI"], "source": "benzinga", "author": "Vaishali Prayag", "url": "https://www.benzinga.com/trading-ideas/movers/25/01/42959061/intra-cellular-therapies-stock-is-surging-monday-whats-going-on", "tags": ["why_moving", "merger"]}
{"id": 42959100, "time": "2025-01-13 15:00:12", "headline": "If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today", "summary": " ", "symbols": ["RJF"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42959100/if-you-invested-1000-in-this-stock-10-years-ago-you-would-have-this-much-today", "tags": []}
{"id": 42959103, "time": "2025-01-13 15:00:16", "headline": "Where Vontier Stands With Analysts", "summary": " ", "symbols": ["VNT"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42959103/where-vontier-stands-with-analysts", "tags": []}
{"id": 42959118, "time": "2025-01-13 15:00:24", "headline": "Beyond The Numbers: 8 Analysts Discuss KLA Stock", "summary": " ", "symbols": ["KLAC"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42959118/beyond-the-numbers-8-analysts-discuss-kla-stock", "tags": []}
{"id": 42959128, "time": "2025-01-13 15:00:34", "headline": "Expert Outlook: Lazard Through The Eyes Of 5 Analysts", "summary": " ", "symbols": ["LAZ"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42959128/expert-outlook-lazard-through-the-eyes-of-5-analysts", "tags": ["guidance"]}
{"id": 42959132, "time": "2025-01-13 15:00:41", "headline": "A Glimpse Into The Expert Outlook On Chemours Through 7 Analysts", "summary": " ", "symbols": ["CC"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42959132/a-glimpse-into-the-expert-outlook-on-chemours-through-7-analysts", "tags": ["guidance"]}
{"id": 42959135, "time": "2025-01-13 15:00:48", "headline": "Demystifying Doximity: Insights From 15 Analyst Reviews", "summary": " ", "symbols": ["DOCS"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42959135/demystifying-doximity-insights-from-15-analyst-reviews", "tags": []}
{"id": 42959148, "time": "2025-01-13 15:00:56", "headline": "Texas Instruments Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)", "summary": " ", "symbols": ["TXN"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42959148/texas-instruments-stock-a-deep-dive-into-analyst-perspectives-12-ratings", "tags": []}
{"id": 42959182, "time": "2025-01-13 15:01:16", "headline": "Starbucks to Roll Out New Code of Conduct, Require Cafe Users to Be Paying Customers", "summary": "", "symbols": ["SBUX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42959182/starbucks-to-roll-out-new-code-of-conduct-require-cafe-users-to-be-paying-customers", "tags": []}
{"id": 42959280, "time": "2025-01-13 15:04:22", "headline": "Salarius Pharmaceuticals Shares Are Skyrocketing Today: What's Going On?", "summary": "Salarius Pharmaceuticals (NASDAQ: SLRX) shares are trading higher Monday after the company announced a merger agreement with Decoy Therapeutics, a privately held biopharmaceutical company. ", "symbols": ["SLRX"], "source": "benzinga", "author": "Vaishali Prayag", "url": "https://www.benzinga.com/trading-ideas/movers/25/01/42959280/salarius-pharmaceuticals-shares-are-skyrocketing-today-whats-going-on", "tags": ["why_moving", "merger", "contract"]}
{"id": 42959264, "time": "2025-01-13 15:03:55", "headline": "Accuray's Radixact SynC System And CyberKnife S7 System Have Been Approved By The Chinese National Medical Products Administration", "summary": "", "symbols": ["ARAY"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42959264/accuray-incorporated-announced-the-companys-radixact-sync-system-and-cyberknife-s7-system-have-be", "tags": []}
{"id": 42959405, "time": "2025-01-13 15:10:21", "headline": "JD Vance Says Violent Jan. 6 Rioters 'Shouldn't Be Pardoned,' Veers From Trump's 'Major Pardons' Promise", "summary": "Jake Lang, who is awaiting trial on Jan. 6 charges, addressed JD Vance: &#39;J6 families have been CRUSHED by mixed messaging.&#39;", "symbols": [], "source": "benzinga", "author": "Maureen Meehan", "url": "https://www.benzinga.com/news/25/01/42959405/jd-vance-says-violent-jan-6-rioters-shouldnt-be-pardoned-veers-from-trumps-major-pardons-promise", "tags": ["fda"]}
{"id": 42959459, "time": "2025-01-13 15:11:55", "headline": "What's Going On With United States Steel Shares Monday?", "summary": "United States Steel Corp. (NYSE:X) stock is trading higher Monday following a report that Cleveland-Cliffs Inc. (NYSE:CLF) will partner with Nucor Corp. (NYSE:NUE) to make a potential bid to acquire the company.", "symbols": ["CLF", "NUE", "X"], "source": "benzinga", "author": "Dylan Berman", "url": "https://www.benzinga.com/trading-ideas/movers/25/01/42959459/whats-going-on-with-united-states-steel-shares-monday", "tags": ["why_moving", "merger"]}
{"id": 42959535, "time": "2025-01-13 15:15:11", "headline": "$100 Invested In Cheniere Energy 20 Years Ago Would Be Worth This Much Today", "summary": " ", "symbols": ["LNG"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42959535/100-invested-in-cheniere-energy-20-years-ago-would-be-worth-this-much-today", "tags": []}
{"id": 42959955, "time": "2025-01-13 15:26:54", "headline": "Options Corner: ON Semiconductor Is Discounted But There's One Big Catch", "summary": "While ON Semiconductor appears to offer a legitimate value play, investors need to be aware of an unusual risk factor.", "symbols": ["ON"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/trading-ideas/long-ideas/25/01/42959955/on-semiconductor-stock-offers-discount-with-twist", "tags": []}
{"id": 42960000, "time": "2025-01-13 15:28:45", "headline": "Goldman Sachs Restructures Business for Financing Growth", "summary": "Goldman Sachs Inc. (NYSE: GS)  is reorganizing its structure to focus on financing, reflecting its ambition to be a leader in the growing private credit market and private-equity dealmaking. The firm is combining three units in its global banking and markets division into a new group called the Capital Solutions Group.", "symbols": ["GS"], "source": "benzinga", "author": "Vaishali Prayag", "url": "https://www.benzinga.com/25/01/42960000/goldman-sachs-restructures-business-for-financing-growth", "tags": []}
{"id": 42960046, "time": "2025-01-13 15:30:22", "headline": "What the Options Market Tells Us About Coca-Cola", "summary": " ", "symbols": ["KO"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42960046/what-the-options-market-tells-us-about-coca-cola", "tags": []}
{"id": 42960057, "time": "2025-01-13 15:30:32", "headline": "This Is What Whales Are Betting On Constellation Energy", "summary": " ", "symbols": ["CEG"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42960057/this-is-what-whales-are-betting-on-constellation-energy", "tags": []}
{"id": 42960104, "time": "2025-01-13 15:31:17", "headline": "Congressman Who Wanted Airport Named After Trump Buys Bitcoin, Solana, XRP Token Ahead Of Inauguration", "summary": "A member of Congress disclosed buying three cryptocurrencies in December, as the sector gets ready to welcome in a pro-cryptocurrency White House administration.", "symbols": ["BTCUSD", "SOLUSD", "XRPUSD"], "source": "benzinga", "author": "Chris Katje", "url": "https://www.benzinga.com/25/01/42960104/congressman-who-wanted-airport-named-after-donald-trump-buys-bitcoin-solana-xrp-token-ahead-of-inauguration", "tags": []}
{"id": 42960291, "time": "2025-01-13 15:38:29", "headline": "Meta's Content Moderation Changes Alarm Advertisers as Zuckerberg Aligns with Trump and Musk", "summary": "Meta Platforms Inc (NASDAQ: META) has sparked concerns among advertisers with its restructuring of content moderation and ties to Trump and Musk.\n\nZuckerberg&#39;s move to appease Trump and Musk has raised concerns among advertisers due to fears of harmful content and misinformation on Facebook and Instagram.", "symbols": ["DJT", "META"], "source": "benzinga", "author": "Anusuya Lahiri", "url": "https://www.benzinga.com/25/01/42960291/metas-content-moderation-changes-alarm-advertisers-as-zuckerberg-aligns-with-trump-and-musk", "tags": []}
{"id": 42836363, "time": "2025-01-13 15:43:33", "headline": "Looking For Bitcoin Exposure With Downside Protection? There's Now An ETF For That (CORRECTED)", "summary": "Editor\u2019s note: This story has been updated to correct a reference to the stock ticker for an upcoming Calamos 100% downside-protected Bitcoin ETF. ", "symbols": ["BLK", "BTCUSD", "CPRY", "CPSY", "IBIT"], "source": "benzinga", "author": "Aniket Verma", "url": "https://www.benzinga.com/markets/cryptocurrency/25/01/42836363/looking-for-bitcoin-exposure-with-downside-protection-theres-now-an-etf-for-that", "tags": []}
{"id": 42960425, "time": "2025-01-13 15:45:13", "headline": "$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today", "summary": " ", "symbols": ["RSG"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42960425/100-invested-in-this-stock-20-years-ago-would-be-worth-this-much-today", "tags": []}
{"id": 42960429, "time": "2025-01-13 15:45:16", "headline": "'Google Cloud Forms New AI Sales Team, Cuts 60 Jobs' - The Information", "summary": "", "symbols": ["GOOG", "GOOGL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42960429/google-cloud-forms-new-ai-sales-team-cuts-60-jobs-the-information", "tags": []}
{"id": 42960444, "time": "2025-01-13 15:45:25", "headline": "MARA Holdings Unusual Options Activity", "summary": " ", "symbols": ["MARA"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42960444/mara-holdings-unusual-options-activity", "tags": []}
{"id": 42960446, "time": "2025-01-13 15:45:30", "headline": "IonQ's Options: A Look at What the Big Money is Thinking", "summary": " ", "symbols": ["IONQ"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42960446/ionqs-options-a-look-at-what-the-big-money-is-thinking", "tags": []}
{"id": 42960449, "time": "2025-01-13 15:45:35", "headline": "MercadoLibre Unusual Options Activity", "summary": " ", "symbols": ["MELI"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/options/25/01/42960449/mercadolibre-unusual-options-activity", "tags": []}
{"id": 42960562, "time": "2025-01-13 15:48:29", "headline": "'HCLTech and Microsoft expand partnership to revolutionise contact centers with Generative AI' - CNBC", "summary": "", "symbols": ["MSFT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42960562/hcltech-and-microsoft-expand-partnership-to-revolutionise-contact-centers-with-generative-ai-cnbc", "tags": ["contract"]}
{"id": 42941361, "time": "2025-01-13 07:21:17", "headline": "Edible Garden shares are trading higher after the company announced it signed a non-binding letter of intent to acquire Narayan Group.", "summary": "", "symbols": ["EDBL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/wiim/25/01/42941361/edible-garden-shares-are-trading-higher-after-the-company-announced-it-signed-a-non-binding-letter-o", "tags": ["why_moving", "merger"]}
{"id": 42942114, "time": "2025-01-13 07:42:05", "headline": "X4 Pharmaceuticals shares are trading higher after the company announced an exclusive licensing agreement with Norgine to commercialize Mavorixafor in Europe, Australia, and New Zealand.", "summary": "", "symbols": ["XFOR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/wiim/25/01/42942114/x4-pharmaceuticals-shares-are-trading-higher-after-the-company-announced-an-exclusive-licensing-agre", "tags": ["why_moving", "contract"]}
{"id": 42943173, "time": "2025-01-13 08:11:11", "headline": "American Eagle Outfitters shares are trading higher after the company raised its Q4 operating profit outlook.", "summary": "", "symbols": ["AEO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/wiim/25/01/42943173/american-eagle-outfitters-shares-are-trading-higher-after-the-company-raised-its-q4-operating-profit", "tags": ["guidance", "why_moving"]}
{"id": 42944581, "time": "2025-01-13 08:49:53", "headline": "Natera shares are trading higher after the company reported preliminary FY24 financial results.", "summary": "", "symbols": ["NTRA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/wiim/25/01/42944581/natera-shares-are-trading-higher-after-the-company-reported-preliminary-fy24-financial-results", "tags": ["why_moving"]}
{"id": 42944989, "time": "2025-01-13 08:59:04", "headline": "N2OFF shares are trading higher after the company announced Germany regulatory approval of its 111 MWp solar PV project.", "summary": "", "symbols": ["NITO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/wiim/25/01/42944989/n2off-shares-are-trading-higher-after-the-company-announced-germany-regulatory-approval-of-its-111-m", "tags": ["why_moving"]}
{"id": 42951170, "time": "2025-01-13 11:01:12", "headline": "Caterpillar shares are trading lower after Evercore ISI upgraded the stock from Underperform to In-Line.", "summary": "", "symbols": ["CAT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/wiim/25/01/42951170/caterpillar-shares-are-trading-lower-after-evercore-isi-upgraded-the-stock-from-underperform-to-in-l", "tags": ["analyst_up", "why_moving"]}
{"id": 42960843, "time": "2025-01-13 15:58:25", "headline": "Avinger Has Been Granted European Patent Number EP3322338 Titled \"MICRO-MOLDED ANAMORPHIC REFLECTOR LENS FOR IMAGE GUIDED THERAPEUTIC/DIAGNOSTIC CATHETERS\".", "summary": "", "symbols": ["AVGR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42960843/avinger-has-been-granted-european-patent-number-ep3322338-titled-micro-molded-anamorphic-reflecto", "tags": []}
{"id": 42960919, "time": "2025-01-13 16:00:13", "headline": "What Analysts Are Saying About Tronox Holdings Stock", "summary": " ", "symbols": ["TROX"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42960919/what-analysts-are-saying-about-tronox-holdings-stock", "tags": []}
{"id": 42960920, "time": "2025-01-13 16:00:14", "headline": "$1000 Invested In Workday 10 Years Ago Would Be Worth This Much Today", "summary": " ", "symbols": ["WDAY"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42960920/1000-invested-in-workday-10-years-ago-would-be-worth-this-much-today", "tags": []}
{"id": 42960923, "time": "2025-01-13 16:00:25", "headline": "Forecasting The Future: 10 Analyst Projections For Flowserve", "summary": " ", "symbols": ["FLS"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42960923/forecasting-the-future-10-analyst-projections-for-flowserve", "tags": []}
{"id": 42960924, "time": "2025-01-13 16:00:32", "headline": "What 5 Analyst Ratings Have To Say About Allegro Microsystems", "summary": " ", "symbols": ["ALGM"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42960924/what-5-analyst-ratings-have-to-say-about-allegro-microsystems", "tags": []}
{"id": 42960927, "time": "2025-01-13 16:00:39", "headline": "Expert Outlook: Essex Property Trust Through The Eyes Of 4 Analysts", "summary": " ", "symbols": ["ESS"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42960927/expert-outlook-essex-property-trust-through-the-eyes-of-4-analysts", "tags": ["guidance"]}
{"id": 42960932, "time": "2025-01-13 16:00:48", "headline": "Analyst Expectations For MaxLinear's Future", "summary": " ", "symbols": ["MXL"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42960932/analyst-expectations-for-maxlinears-future", "tags": []}
{"id": 42960949, "time": "2025-01-13 16:00:56", "headline": "Breaking Down ASML Holding: 5 Analysts Share Their Views", "summary": " ", "symbols": ["ASML"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42960949/breaking-down-asml-holding-5-analysts-share-their-views", "tags": []}
{"id": 42960974, "time": "2025-01-13 16:01:13", "headline": "OrthoPediatrics Reports Preliminary 2024 Revenue Hits $205M, Grows 38% YoY; 2025 Projected Revenue $235M-$242M With 15%-18% Growth; Adjusted EBITDA Forecast $15M-$17M", "summary": "", "symbols": ["KIDS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42960974/orthopediatrics-reports-preliminary-2024-revenue-hits-205m-grows-38-yoy-2025-projected-revenue-235m", "tags": ["earnings", "guidance"]}
{"id": 42960989, "time": "2025-01-13 16:01:39", "headline": "Israel-Hamas Ceasefire Deal Nears As Mediators Push For Breakthrough In Doha Talks", "summary": "After weeks of diplomacy, a draft ceasefire has been handed to Israel and Hamas with provisions for hostage release. Talks continue for finalization.", "symbols": ["ISRA"], "source": "benzinga", "author": "Piero Cingari", "url": "https://www.benzinga.com/25/01/42960989/israel-hamas-ceasefire-deal-nears", "tags": ["contract"]}
{"id": 42961014, "time": "2025-01-13 16:02:18", "headline": "Insulet Launches Omnipod 5 In Five More Countries In Italy, Denmark, Finland, Norway And Sweden", "summary": "", "symbols": ["PODD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961014/insulet-launches-omnipod-5-in-five-more-countries-in-italy-denmark-finland-norway-and-sweden", "tags": []}
{"id": 42961046, "time": "2025-01-13 16:03:11", "headline": "The Shyft Group Provides Supplemental Information Reinforcing Significant Value Creation Potential Of Proposed Merger With Aebi Schmidt; Projects $2.7B Revenue, $315M Adjusted EBITDA By 2028 In Transaction Plan; Aims For $3B+ Longer-Term Goal. Deal Offers 30% Premium Excluding Synergies, 58% With, To Dec 2024 Share Price. Board Secures 48% Ownership For Shyft; Engaged Six Potential Strategic Partners.", "summary": "", "symbols": ["SHYF"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42961046/the-shyft-group-provides-supplemental-information-reinforcing-significant-value-creation-potential-o", "tags": ["earnings", "merger", "contract"]}
{"id": 42961004, "time": "2025-01-13 16:02:02", "headline": "Leonardo DRS Awarded Contract To Provide The U.S. Army With Next-Generation Mortar Fire Control Systems; Contract Is Worth More Than $99M", "summary": "", "symbols": ["DRS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961004/leonardo-drs-announced-it-has-been-awarded-a-contract-to-provide-the-u-s-army-with-next-generation-m", "tags": ["contract"]}
{"id": 42961022, "time": "2025-01-13 16:02:25", "headline": "Inogen  Estimates Preliminary Q4 Total Revenue Of $79M - $80M, Reflecting YoY Growth Of 4% To 5%; Est $73.91M", "summary": "", "symbols": ["INGN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961022/inogen-estimates-preliminary-q4-total-revenue-of-79m-80m-reflecting-yoy-growth-of-4-to-5-est-73-91m", "tags": ["earnings"]}
{"id": 42961153, "time": "2025-01-13 16:05:34", "headline": "12 Industrials Stocks Moving In Monday's Pre-Market Session", "summary": " ", "symbols": ["EHGO", "FGL", "FRGT", "HOVR", "HTCO", "HYFM", "KULR", "LIQT", "LSH", "NNBR", "PSIG", "STEM"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/movers/25/01/42961153/12-industrials-stocks-moving-in-mondays-pre-market-session", "tags": ["why_moving"]}
{"id": 42961179, "time": "2025-01-13 16:05:39", "headline": "12 Health Care Stocks Moving In Monday's Pre-Market Session", "summary": " ", "symbols": ["AEON", "AIRS", "ATPC", "DYAI", "GTBP", "ITCI", "KAPA", "MRNA", "NAYA", "PHIO", "SAGE", "SLRX"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/movers/25/01/42961179/12-health-care-stocks-moving-in-mondays-pre-market-session", "tags": ["why_moving"]}
{"id": 42961184, "time": "2025-01-13 16:05:44", "headline": "12 Financials Stocks Moving In Monday's Pre-Market Session", "summary": " ", "symbols": ["EHTH", "FCFS", "GRNQ", "HLNE", "HNNA", "PMAX", "PRA", "RNR", "STBA", "SYBT", "VINP", "XHG"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/movers/25/01/42961184/12-financials-stocks-moving-in-mondays-pre-market-session", "tags": ["why_moving"]}
{"id": 42961223, "time": "2025-01-13 16:06:21", "headline": "Inogen Estimates Preliminary FY24 Total Revenue Of $334.5M - $335.5M (Est $329.615M), Exceeding Prior Guidance Range Of $329M - $331M", "summary": "", "symbols": ["INGN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961223/inogen-estimates-preliminary-fy24-total-revenue-of-334-5m-335-5m-est-329-615m-exceeding-prior-guidan", "tags": ["earnings", "guidance"]}
{"id": 42961233, "time": "2025-01-13 16:06:33", "headline": "ICF International Wins $40M Digital Engagement Task Order From Department Of Homeland Security Center For Countering Human Trafficking", "summary": "", "symbols": ["ICFI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961233/icf-international-wins-40m-digital-engagement-task-order-from-department-of-homeland-security-center", "tags": []}
{"id": 42961154, "time": "2025-01-13 16:05:33", "headline": "Educational Development Corporation Q3 2025 GAAP EPS $(0.10); Sales $11.1M", "summary": "", "symbols": ["EDUC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42961154/educational-development-corporation-q3-2025-gaap-eps-0-10-sales-11-1m", "tags": ["earnings"]}
{"id": 42961308, "time": "2025-01-13 16:08:51", "headline": "BlueLinx Appoints Kimberly DeBrock As Interim Principal Financial Officer; Andrew Wamser To Resign As CFO", "summary": "", "symbols": ["BXC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961308/bluelinx-appoints-kimberly-debrock-as-interim-principal-financial-officer-andrew-wamser-to-resign-as", "tags": ["management"]}
{"id": 42961309, "time": "2025-01-13 16:08:52", "headline": "Aehr Reiterates Its Previously Provided Guidance For FY24 Total Revenue Of At Least $70M And Non-GAAP Net Profit Before Taxes Of At Least 10% Of Revenue", "summary": "", "symbols": ["AEHR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961309/aehr-reiterates-its-previously-provided-guidance-for-fy24-total-revenue-of-at-least-70m-and-non-gaap", "tags": ["analyst_other", "earnings", "guidance"]}
{"id": 42961323, "time": "2025-01-13 16:09:14", "headline": "ServiceTitan Q3 Sales $199.28M Beat $198.52M Estimate", "summary": "", "symbols": ["TTAN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42961323/servicetitan-q3-sales-199-28m-beat-198-52m-estimate", "tags": []}
{"id": 42961296, "time": "2025-01-13 16:07:55", "headline": "Aehr Test Systems Q2 Adj EPS $0.02 Misses $0.04 Estimate, Sales $13.45M Miss $15.03M Estimate", "summary": "", "symbols": ["AEHR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42961296/aehr-test-systems-q2-adj-0-02-misses-0-04-estimate-sales-13-45m-miss-15-03m-estimate", "tags": ["earnings"]}
{"id": 42961330, "time": "2025-01-13 16:09:43", "headline": "Climb Global Solutions Announced Matthew Sullivan As CFO Effective January 10, 2025", "summary": "", "symbols": ["CLMB"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961330/climb-global-solutions-announced-matthew-sullivan-as-cfo-effective-january-10-2025", "tags": ["management"]}
{"id": 42961339, "time": "2025-01-13 16:10:06", "headline": "Earnings Summary: Aehr Test System Q2", "summary": " ", "symbols": ["AEHR"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/earnings/25/01/42961339/earnings-summary-aehr-test-system-q2", "tags": ["earnings"]}
{"id": 42961372, "time": "2025-01-13 16:10:40", "headline": "KB Home Q4 2024 GAAP EPS $2.52 Beats $2.39 Estimate, Sales $2.000B Beat $1.987B Estimate", "summary": "", "symbols": ["KBH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42961372/kb-home-q4-2024-gaap-eps-2-52-beats-2-39-estimate-sales-2-000b-beat-1-987b-estimate", "tags": ["earnings"]}
{"id": 42961381, "time": "2025-01-13 16:11:04", "headline": "Scott Mezvinsky Promoted To KFC Division CEO, Effective March 1, 2025; Mezvinsky Will Succeed Sabir Sami", "summary": "", "symbols": ["YUM"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961381/scott-mezvinsky-promoted-to-kfc-division-ceo-effective-march-1-2025-mezvinsky-will-succeed-sabir-sam", "tags": ["management"]}
{"id": 42961385, "time": "2025-01-13 16:11:21", "headline": "KB Home Sees FY25 Housing Revenues $7.00B-$7.50B, Sees FY25 average selling price $488K-$498K", "summary": "", "symbols": ["KBH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961385/kb-home-sees-fy25-housing-revenues-7-00b-7-50b-sees-fy25-average-selling-price-488k-498k", "tags": []}
{"id": 42961411, "time": "2025-01-13 16:12:30", "headline": "DBV Technologies Reports H2 Liquidity Contract Update: 267K Shares, \u20ac107K In Account; 1,682 Buy And 1,800 Sales Transactions Covering 404K Shares Purchased, \u20ac296K And 441K Shares Sold, \u20ac341K", "summary": "", "symbols": ["DBVT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961411/dbv-technologies-reports-h2-liquidity-contract-update-267k-shares-107k-in-account-1-682-buy-and-1-80", "tags": ["contract"]}
{"id": 42961431, "time": "2025-01-13 16:13:19", "headline": "Ameresco Awarded $183M Contract To Deliver Energy Resiliency And Net-Zero Solutions At U.S. General Services Administration's Denver Federal Center", "summary": "", "symbols": ["AMRC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961431/ameresco-awarded-183m-contract-to-deliver-energy-resiliency-and-net-zero-solutions-at-u-s-general-se", "tags": ["contract"]}
{"id": 42961406, "time": "2025-01-13 16:12:09", "headline": "AeroVironment Awarded Its Second Delivery Order Totaling $55.3M Of Switchblade Loitering Munition Systems As Part Of U.S. Army's Directed Requirement Lethal Unmanned Systems", "summary": "", "symbols": ["AVAV"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961406/aerovironment-announced-it-has-been-awarded-its-second-delivery-order-totaling-55-3-million-of-switc", "tags": ["contract"]}
{"id": 42961442, "time": "2025-01-13 16:14:32", "headline": "ServiceTitan Q3 2025 Adj EPS $(0.03), Inline", "summary": "", "symbols": ["TTAN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42961442/servicetitan-q3-2025-adj-eps-0-03-inline", "tags": ["earnings"]}
{"id": 42961483, "time": "2025-01-13 16:15:11", "headline": "$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today", "summary": " ", "symbols": ["ALNY"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42961483/1000-invested-in-alnylam-pharmaceuticals-15-years-ago-would-be-worth-this-much-today", "tags": []}
{"id": 42961451, "time": "2025-01-13 16:14:59", "headline": "ServiceTitan Expects Q4 Total Revenue Of $199M - $201M (Est $222.549M), FY25 Total Revenue Of $761.6M - $763.6M (Est $755.722M)", "summary": "", "symbols": ["TTAN"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961451/servicetitan-expects-q4-total-revenue-of-199m-201m-222-549m-fy25-total-revenue-of-761-6m-763-6m-est", "tags": ["earnings"]}
{"id": 42961527, "time": "2025-01-13 16:15:57", "headline": "Dover Acquires Dryer Manufacturer Technology For The Global Processing Industry; Terms Of The Transaction Were Not Disclosed", "summary": "", "symbols": ["DOV"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42961527/dover-acquires-dryer-manufacturer-technology-for-the-global-processing-industry-terms-of-the-transac", "tags": ["merger"]}
{"id": 42961642, "time": "2025-01-13 16:17:12", "headline": "DHI Group Announces Restructuring Of Its Operations To Separate The Dice And ClearanceJobs Businesses; 8% Workforce Reduction, Sees $2.2M In Cash Charges, Expects Annual Cost Savings $4M-$6M", "summary": "", "symbols": ["DHI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961642/dhi-group-announces-restructuring-of-its-operations-to-separate-the-dice-and-clearancejobs-businesse", "tags": []}
{"id": 42961645, "time": "2025-01-13 16:17:14", "headline": "S&W Seed Company Commences Process To Explore And Evaluate Various Strategic Alternatives", "summary": "", "symbols": ["SANW"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961645/s-w-seed-company-commences-process-to-explore-and-evaluate-various-strategic-alternatives", "tags": []}
{"id": 42961649, "time": "2025-01-13 16:17:33", "headline": "Danaher CEO Says \"For Q4 2024, Estimated Revenues Are Anticipated To Increase In The Low-Single Digit Percent Range YoY; Estimated Non-GAAP Core Revenue For Q4 2024 Is Expected To Be Essentially Flat YoY, Which Would Be Above The Company's Previously Announced Guidance Of A Low-Single Digit Percent Decline\"", "summary": "", "symbols": ["DHR"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961649/danaher-ceo-says-for-q4-2024-estimated-revenues-are-anticipated-to-increase-in-the-low-single-digit", "tags": ["earnings", "guidance", "management"]}
{"id": 42961650, "time": "2025-01-13 16:17:39", "headline": "Plains All American Pipeline Have Priced An Underwritten Public Offering Of $1 Billion Aggregate Principal Amount Of 5.950% Senior Unsecured Notes Due 2035 At A Price To The Public of 99.761% Of Their Face Value", "summary": "", "symbols": ["PAA"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961650/plains-all-american-pipeline-have-priced-an-underwritten-public-offering-of-1-billion-aggregate-prin", "tags": ["offering"]}
{"id": 42961654, "time": "2025-01-13 16:17:57", "headline": "What's Going On With Merus Stock Monday?", "summary": "Merus announced a research collaboration and license agreement with Biohaven.", "symbols": ["BHVN", "MRUS"], "source": "benzinga", "author": "Dylan Berman", "url": "https://www.benzinga.com/25/01/42961654/whats-going-on-with-merus-stock-monday", "tags": ["why_moving", "contract"]}
{"id": 42961680, "time": "2025-01-13 16:19:42", "headline": "Zenvia Launches Zenvia Customer Cloud, Aiming For 25%-30% Growth With New Strategic Cycle; 2024 Revenues Estimated Between R$180 Million-R$200 Million From 5.7K Companies; 20% International Clients; Gross Margin 68%-70%", "summary": "", "symbols": ["ZENV"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961680/zenvia-launches-zenvia-customer-cloud-aiming-for-25-30-growth-with-new-strategic-cycle-2024-revenues", "tags": []}
{"id": 42961715, "time": "2025-01-13 16:21:02", "headline": "Joey Levin To Leave IAC As CEO, Co. Does Not Indent To Appoint new CEO", "summary": "", "symbols": ["IAC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961715/joey-levin-to-leave-iac-as-ceo-co-does-not-indent-to-appoint-new-ceo", "tags": ["management"]}
{"id": 42961666, "time": "2025-01-13 16:18:19", "headline": "IAC To Spin Off Angi", "summary": "", "symbols": ["ANGI", "IAC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961666/iac-to-spin-off-angi", "tags": []}
{"id": 42961735, "time": "2025-01-13 16:21:47", "headline": "IAC Plans To Spin Off Angi; Joey Levin Will Guide Angi's Next Chapter As Executive Chairman; Transaction Is Expected To Close In The First Half Of 2025 But No Sooner Than March 31, 2025.", "summary": "", "symbols": ["ANGI", "IAC"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961735/iac-plans-to-spin-off-angi-joey-levin-will-guide-angis-next-chapter-as-executive-chairman-transactio", "tags": []}
{"id": 42961749, "time": "2025-01-13 16:22:16", "headline": "DHI Group Reveals Strategic Reorganization, Restructuring Its Operations Into Two Distinct Divisions; Expects To Reduce Total Workforce By Approximately 8%", "summary": "", "symbols": ["DHX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961749/dhi-group-reveals-strategic-reorganization-restructuring-its-operations-into-two-distinct-divisions", "tags": []}
{"id": 42961753, "time": "2025-01-13 16:23:06", "headline": "Analyst Sees 'Broadening Rally' In Semiconductors In 2025: 2 Top Stock Picks, 2 To Avoid", "summary": "A semiconductor analyst sees a continued focus on AI growth for the sector in 2025 and highlights some winners and stocks to avoid.", "symbols": ["AMD", "INTC", "MRVL", "NVDA"], "source": "benzinga", "author": "Chris Katje", "url": "https://www.benzinga.com/25/01/42961753/analyst-sees-broadening-rally-in-semis-coming-in-2025-2-top-stock-picks-and-2-to-avoid", "tags": []}
{"id": 42961863, "time": "2025-01-13 16:25:06", "headline": "Earnings Breakdown: KB Home Q4", "summary": " ", "symbols": ["KBH"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/earnings/25/01/42961863/earnings-breakdown-kb-home-q4", "tags": ["earnings"]}
{"id": 42961895, "time": "2025-01-13 16:26:39", "headline": "Honeywell Shares Are Up Today: What's Going On?", "summary": "Honeywell International Inc. (NASDAQ: HON) shares are trading higher Monday. The company is preparing to break up into two independent publicly traded companies, according to sources familiar with the matter. ", "symbols": ["HON"], "source": "benzinga", "author": "Vaishali Prayag", "url": "https://www.benzinga.com/25/01/42961895/honeywell-shares-are-up-today-whats-going-on", "tags": ["why_moving"]}
{"id": 42961979, "time": "2025-01-13 16:27:55", "headline": "Grove Collaborative Says CFO Sergio Cervantes Agreed To Depart  Company, Effective February 16, 2025; Tom Siragusa Named As Interim CFO - Filing", "summary": "", "symbols": ["GROV"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961979/grove-collaborative-says-cfo-sergio-cervantes-agreed-to-depart-company-effective-february-16-2025-to", "tags": ["management"]}
{"id": 42961989, "time": "2025-01-13 16:28:48", "headline": "Diamondback Energy Q4 Average Unhedged Realized Prices Were $69.48 Per Barrel Of Oil, $0.48 Per Mcf Of Natural Gas & $19.27 Per Barrel Of NGLs; Q4 Average Realized Hedged Prices Were $68.72 Per Barrel Of Oil, $0.82 Per Mcf Of Natural Gas And $19.27 Per Barrel Of NGLs; For Q4 Sees Net Loss On Cash Settlements For Derivative Instruments Of $15M", "summary": "", "symbols": ["FANG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/earnings/25/01/42961989/diamondback-energy-q4-average-unhedged-realized-prices-were-69-48-per-barrel-of-oil-0-48-per-mcf-of", "tags": []}
{"id": 42961990, "time": "2025-01-13 16:28:49", "headline": "Howard Hughes Confirms Receipt Of Unsolicited Acquisition Proposal From Pershing Square; Special Committee Will Evaluate Proposal", "summary": "", "symbols": ["HHH"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42961990/howard-hughes-confirms-receipt-of-unsolicited-acquisition-proposal-from-pershing-square-special-comm", "tags": []}
{"id": 42961994, "time": "2025-01-13 16:28:53", "headline": "Constellation Energy-On Termination Of Constellation-Calpine Deal Under Certain Specified Circumstances, To Pay Calpine Termination Fee Of $500M", "summary": "", "symbols": ["CEG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961994/constellation-energy-on-termination-of-constellation-calpine-deal-under-certain-specified-circumstan", "tags": ["contract"]}
{"id": 42962007, "time": "2025-01-13 16:29:31", "headline": "CCC Intelligent Solutions Files Prospectus For Resale, From Time To Time, By Selling Stockholders Of Up To 26.0M Shares Of Common Stock", "summary": "", "symbols": ["CCCS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42962007/ccc-intelligent-solutions-files-prospectus-for-resale-from-time-to-time-by-selling-stockholders-of-u", "tags": []}
{"id": 42962008, "time": "2025-01-13 16:29:33", "headline": "Broadcom Terminates All Outstanding Commitments Under 2021 Credit Agreement; Enters New $7.5B 5-Year Unsecured Revolving Credit Facility", "summary": "", "symbols": ["AVGO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42962008/broadcom-terminates-all-outstanding-commitments-under-2021-credit-agreement-enters-new-7-5b-5-year-u", "tags": ["contract"]}
{"id": 42962036, "time": "2025-01-13 16:30:12", "headline": "Here's How Much $100 Invested In Deckers Outdoor 20 Years Ago Would Be Worth Today", "summary": " ", "symbols": ["DECK"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42962036/heres-how-much-100-invested-in-deckers-outdoor-20-years-ago-would-be-worth-today", "tags": []}
{"id": 42961998, "time": "2025-01-13 16:29:07", "headline": "U.S. SEC Says Two Robinhood Broker-dealers To Pay $45 Million In Combined Penalties For Violating More Than 10 Separate Securities Law Provisions; SEC Says Robinhood Failed To Timely Investigate Suspicious Transactions, Implement Policies To Protect Customers From Risk Of Identity Theft; Robinhood Failed To Adequately Address Known Risks Posed By A Cybersecurity Vulnerability; Robinhood Had Longstanding Failures To Preserve Electronic Communications, Retain Brokerage Data", "summary": "", "symbols": ["HOOD"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42961998/u-s-sec-says-two-robinhood-broker-dealers-to-pay-45-million-in-combined-penalties-for-violating-more", "tags": []}
{"id": 42962074, "time": "2025-01-13 16:30:56", "headline": "Coherus Biosciences Sees FY24 Prelim. Net Revenues $255M-$260M", "summary": "", "symbols": ["CHRS"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42962074/coherus-biosciences-sees-fy24-prelim-net-revenues-255m-260m", "tags": []}
{"id": 42962079, "time": "2025-01-13 16:31:40", "headline": "Atlas Energy Solutions Announces First Commercial Delivery Off Dune Express Conveyor System", "summary": "", "symbols": ["AESI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/25/01/42962079/atlas-energy-solutions-announces-first-commercial-delivery-off-dune-express-conveyor-system", "tags": []}
{"id": 42962095, "time": "2025-01-13 16:31:56", "headline": "Angi Shares Surge As IAC Announces Spin-Off Plans", "summary": "Angi Inc (NASDAQ:ANGI) shares are trading higher in Monday&#39;s after-hours session after IAC (NASDAQ:IAC) announced plans to spin off its stake in Angi.", "symbols": ["ANGI", "IAC"], "source": "benzinga", "author": "Adam Eckert", "url": "https://www.benzinga.com/news/management/25/01/42962095/angi-shares-surge-as-iac-announces-spin-off-plans", "tags": ["why_moving"]}
{"id": 42962111, "time": "2025-01-13 16:32:30", "headline": "Glacier Bancorp Announces Acquisition Of Bank Of Idaho Holding Co.; BOID Shareholders Are To Receive 1.100 Shares Of Glacier Stock For Each BOID Share", "summary": "", "symbols": ["BOID", "GBCI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/m-a/25/01/42962111/glacier-bancorp-announces-acquisition-of-bank-of-idaho-holding-co-boid-shareholders-are-to-receive-1", "tags": []}
{"id": 42962123, "time": "2025-01-13 16:33:02", "headline": "Barrick Warns About Unsolicited Mini Tender Offer As It Faces Malian Crisis", "summary": "TRC Capital seeks to purchase up to 5 million of Barrick&#39;s common shares, representing about 0.29% of the outstanding shares of the second-largest gold miner.", "symbols": ["GOLD"], "source": "benzinga", "author": "Stjepan Kalinic", "url": "https://www.benzinga.com/25/01/42962123/barrick-warns-about-unsolicited-mini-tender-offer-as-it-faces-malian-crisis", "tags": []}
{"id": 42962169, "time": "2025-01-13 16:35:20", "headline": "Medtronic Receives CMS National Coverage Analysis For Symplicity Spyral Renal Denervation System; Expected Completion Date For National Coverage Analysis Is Oct 11", "summary": "", "symbols": ["MDT"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/general/biotech/25/01/42962169/medtronic-announces-cms-national-coverage-analysis-for-symplicity-spyral-renal-denervation-system", "tags": []}
{"id": 42962183, "time": "2025-01-13 16:36:24", "headline": "Aehr Test Systems Stock Falls After Q2 Results: Here's Why", "summary": "Aehr Test Systems reported its second-quarter financial results after Monday&#39;s closing bell. Here&#39;s a look at the details from the report:", "symbols": ["AEHR"], "source": "benzinga", "author": "Erica Kollmann", "url": "https://www.benzinga.com/news/earnings/25/01/42962183/aehr-test-systems-stock-falls-after-q2-results-heres-why", "tags": ["earnings"]}
{"id": 42962238, "time": "2025-01-13 16:37:02", "headline": "Oracle Says Chief Corporate Architect Edward Screven Provided Notice Of His Intention To Retire By End Of February 2025 - Filing", "summary": "", "symbols": ["ORCL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42962238/oracle-says-chief-corporate-architect-edward-screven-provided-notice-of-his-intention-to-retire-by-e", "tags": []}
{"id": 42962269, "time": "2025-01-13 16:38:40", "headline": "U.S. SEC Says Twelve Firms To Pay More Than $63M Combined To Settle SEC's Charges For Recordkeeping Failures", "summary": "", "symbols": ["APO", "SCHW", "TPG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42962269/u-s-sec-says-twelve-firms-to-pay-more-than-63m-combined-to-settle-secs-charges-for-recordkeeping-fai", "tags": []}
{"id": 42962279, "time": "2025-01-13 16:39:31", "headline": "Trump Could Sign Crypto-Related Executive Orders On Day 1: Report", "summary": "Marc Andreessen has been interviewing and recommending candidates for various roles, including those related to cryptocurrency policy.", "symbols": [], "source": "benzinga", "author": "Ivan Crnogati\u0107", "url": "https://www.benzinga.com/markets/cryptocurrency/25/01/42962279/trump-could-sign-crypto-related-executive-orders-on-day-1-report", "tags": []}
{"id": 42962334, "time": "2025-01-13 16:45:11", "headline": "Portillo's Expects 2025 Revenue Growth Of 11%-12%, Same Restaurant Sales To Be Flat To Up 2%", "summary": "", "symbols": ["PTLO"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42962334/portillos-expects-2025-revenue-growth-of-11-12-same-restaurant-sales-to-be-flat-to-up-2", "tags": ["earnings"]}
{"id": 42962335, "time": "2025-01-13 16:45:11", "headline": "Here's How Much $1000 Invested In Ares Management 5 Years Ago Would Be Worth Today", "summary": " ", "symbols": ["ARES"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42962335/heres-how-much-1000-invested-in-ares-management-5-years-ago-would-be-worth-today", "tags": []}
{"id": 42962366, "time": "2025-01-13 16:46:09", "headline": "KB Home Q4 Earnings: Revenue Beat, EPS Beat, Home Deliveries Up 17%, Net Orders Soar And More", "summary": "KB Home (NYSE:KBH) reported financial results for the fourth quarter after the market close on Monday. Here&#39;s a rundown of the report.", "symbols": ["KBH"], "source": "benzinga", "author": "Adam Eckert", "url": "https://www.benzinga.com/news/earnings/25/01/42962366/kb-home-q4-earnings-revenue-beat-eps-beat-home-deliveries-up-17-net-orders-soar-and-more", "tags": ["earnings"]}
{"id": 42962368, "time": "2025-01-13 16:46:16", "headline": "RPM Appoints Three Individuals, Craig Morford, Christopher Mapes And Julie Beck, To Its Board", "summary": "", "symbols": ["RPM"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42962368/rpm-appoints-three-individuals-craig-morford-christopher-mapes-and-julie-beck-to-its-board", "tags": ["management"]}
{"id": 42962446, "time": "2025-01-13 16:49:33", "headline": "Bitcoin, Ethereum, XRP, Dogecoin Reverse 'Red Monday' On Bullish Trump News", "summary": "Cryptocurrency markets reversed a weak start to the week on news that Donald Trump reportedly plans signing sseveral crypto-related executive orders on his first day in office.", "symbols": ["BSVUSD", "BTCUSD", "DEXEUSD", "DOGEUSD", "ENAUSD", "ETHUSD", "SHIBUSD", "SOLUSD", "XRPUSD"], "source": "benzinga", "author": "Khyathi Dalal", "url": "https://www.benzinga.com/markets/cryptocurrency/25/01/42962446/bitcoin-ethereum-xrp-dogecoin-reverse-red-monday-on-bullish-trump-news", "tags": []}
{"id": 42962518, "time": "2025-01-13 16:54:29", "headline": "Meghan Markle, Netflix Delay Launch Of Cooking Reality Show After California Fires: 'Focus on The Needs Of Those Impacted'", "summary": "A new reality series on Netflix features Meghan Markle cooking and gardening with friends and celebrities. The show is delayed due to the California fires.", "symbols": ["NFLX"], "source": "benzinga", "author": "Chris Katje", "url": "https://www.benzinga.com/general/entertainment/25/01/42962518/meghan-markle-netflix-delay-launch-of-cooking-reality-show-after-california-fires-focus-on-the-needs-of-those-impacted", "tags": []}
{"id": 42962739, "time": "2025-01-13 16:59:18", "headline": "Comstock Holding Signs Three New Retail Leases At Loudoun Station", "summary": "", "symbols": ["CHCI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42962739/comstock-holding-signs-three-new-retail-leases-at-loudoun-station", "tags": []}
{"id": 42962755, "time": "2025-01-13 17:00:11", "headline": "$1000 Invested In Parker Hannifin 10 Years Ago Would Be Worth This Much Today", "summary": " ", "symbols": ["PH"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42962755/1000-invested-in-parker-hannifin-10-years-ago-would-be-worth-this-much-today", "tags": []}
{"id": 42962761, "time": "2025-01-13 17:00:14", "headline": "What 7 Analyst Ratings Have To Say About A.O. Smith", "summary": " ", "symbols": ["AOS"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42962761/what-7-analyst-ratings-have-to-say-about-a-o-smith", "tags": []}
{"id": 42962770, "time": "2025-01-13 17:00:23", "headline": "Forecasting The Future: 11 Analyst Projections For Bicycle Therapeutics", "summary": " ", "symbols": ["BCYC"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42962770/forecasting-the-future-11-analyst-projections-for-bicycle-therapeutics", "tags": []}
{"id": 42962782, "time": "2025-01-13 17:00:31", "headline": "Deep Dive Into APi Gr Stock: Analyst Perspectives (5 Ratings)", "summary": " ", "symbols": ["APG"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42962782/deep-dive-into-api-gr-stock-analyst-perspectives-5-ratings", "tags": []}
{"id": 42962785, "time": "2025-01-13 17:00:42", "headline": "Forecasting The Future: 14 Analyst Projections For Coterra Energy", "summary": " ", "symbols": ["CTRA"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42962785/forecasting-the-future-14-analyst-projections-for-coterra-energy", "tags": []}
{"id": 42962788, "time": "2025-01-13 17:00:50", "headline": "Assessing ITT: Insights From 6 Financial Analysts", "summary": " ", "symbols": ["ITT"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42962788/assessing-itt-insights-from-6-financial-analysts", "tags": []}
{"id": 42962796, "time": "2025-01-13 17:01:00", "headline": "Forecasting The Future: 4 Analyst Projections For Houlihan Lokey", "summary": " ", "symbols": ["HLI"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/analyst-ratings/25/01/42962796/forecasting-the-future-4-analyst-projections-for-houlihan-lokey", "tags": []}
{"id": 42962852, "time": "2025-01-13 17:02:25", "headline": "Alamos Gold Says 3-Year Operating Guidance Outlines 24% Production Growth By 2027; Starts Construction On Lynn Lake", "summary": "", "symbols": ["AGI"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42962852/alamos-gold-says-3-year-operating-guidance-outlines-24-production-growth-by-2027-starts-construction", "tags": ["guidance"]}
{"id": 42962908, "time": "2025-01-13 17:05:51", "headline": "B2Gold Expects Total Gold Production To Be 970K - 1.075M Ounces; Reports Total Gold Production Of 186,001 Ounces In Q4", "summary": "", "symbols": ["BTG"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42962908/b2gold-expects-total-gold-production-to-be-970k-1-075m-ounces-reports-total-gold-production-of-186-0", "tags": []}
{"id": 42962940, "time": "2025-01-13 17:07:00", "headline": "'This Is How You Make Quality Joints' - How One Machine Produces 900 Pre-Rolls An Hour And Why They're Better Than Cones", "summary": "Discover how RollPros is transforming cannabis pre-rolls with its Blackbird machine, producing 80M+ joints and redefining industry standards.", "symbols": [], "source": "benzinga", "author": "Javier Hasse", "url": "https://www.benzinga.com/markets/cannabis/25/01/42962940/this-is-how-you-make-quality-joints-how-one-machine-produces-900-pre-rolls-an-hour-and-why-theyre-better-than-cones", "tags": []}
{"id": 42962689, "time": "2025-01-13 16:56:38", "headline": "Trump-Appointed Federal Judge Greenlights Jan 6. Report: Could Be Made Public As Early As Tuesday", "summary": "The DOJ&#39;s decision to release the Jan. 6 report comes after dropping federal cases against Trump, since he&#39;ll be a sitting president.", "symbols": [], "source": "benzinga", "author": "Maureen Meehan", "url": "https://www.benzinga.com/news/legal/25/01/42962689/trump-appointed-federal-judge-greenlights-jan-6-report-could-be-made-public-as-early-as-tuesday", "tags": []}
{"id": 42963046, "time": "2025-01-13 17:15:11", "headline": "Here's How Much You Would Have Made Owning Celsius Holdings Stock In The Last 10 Years", "summary": " ", "symbols": ["CELH"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42963046/heres-how-much-you-would-have-made-owning-celsius-holdings-stock-in-the-last-10-years", "tags": []}
{"id": 42963491, "time": "2025-01-13 17:45:42", "headline": "Here's How Much $100 Invested In AutoZone 5 Years Ago Would Be Worth Today", "summary": " ", "symbols": ["AZO"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42963491/heres-how-much-100-invested-in-autozone-5-years-ago-would-be-worth-today", "tags": []}
{"id": 42963511, "time": "2025-01-13 17:48:19", "headline": "RumbleOn Says Michael Kennedy Is No Longer CEO Or Member Of Board Of Directors; Names Chairman Michael Quartieri As CEO", "summary": "", "symbols": ["RMBL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42963511/rumbleon-says-michael-kennedy-is-no-longer-ceo-or-member-of-board-of-directors-names-chairman-michae", "tags": ["management"]}
{"id": 42963518, "time": "2025-01-13 17:49:26", "headline": "RumbleOn Promotes Cameron Tkach To Executive Vice President And COO; Becca Polak Named As Vice Chairman And Lead Independent Director", "summary": "", "symbols": ["RMBL"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42963518/rumbleon-promotes-cameron-tkach-to-executive-vice-president-and-coo-becca-polak-named-as-vice-chairm", "tags": []}
{"id": 42963718, "time": "2025-01-13 17:57:31", "headline": "Beyonc\u00e9 Pledges $2.5 Million To Help California Wildfire Relief Efforts; NFL Donates $5 Million, Moves Monday's Playoff Game To Arizona", "summary": "A look at how the entertainment and sports worlds are stepping up donation efforts for the California wildfires and facing schedule changes.", "symbols": ["DIS", "DKNG"], "source": "benzinga", "author": "Chris Katje", "url": "https://www.benzinga.com/general/sports/25/01/42963718/beyonce-pledges-25-million-to-help-california-wildfire-relief-efforts-nfl-donates-5-million-moves-mondays-playoff-game-to-arizona", "tags": []}
{"id": 42963738, "time": "2025-01-13 18:00:11", "headline": "If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today", "summary": " ", "symbols": ["MPWR"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42963738/if-you-invested-100-in-this-stock-5-years-ago-you-would-have-this-much-today", "tags": []}
{"id": 42963973, "time": "2025-01-13 18:26:16", "headline": "Housing Demand Falls As Average 30-Year Mortgage Rate Above 7%", "summary": "Experts see rates remaining elevated through the first six months of 2025.", "symbols": [], "source": "benzinga", "author": "Erica Kollmann", "url": "https://www.benzinga.com/markets/bonds/25/01/42963973/housing-demand-falls-as-average-30-year-mortgage-rate-above-7", "tags": []}
{"id": 42964011, "time": "2025-01-13 18:30:11", "headline": "$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today", "summary": " ", "symbols": ["FTAI"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42964011/100-invested-in-this-stock-5-years-ago-would-be-worth-this-much-today", "tags": []}
{"id": 42964087, "time": "2025-01-13 18:45:10", "headline": "Here's How Much $1000 Invested In Axon Enterprise 5 Years Ago Would Be Worth Today", "summary": " ", "symbols": ["AXON"], "source": "benzinga", "author": "Benzinga Insights", "url": "https://www.benzinga.com/insights/news/25/01/42964087/heres-how-much-1000-invested-in-axon-enterprise-5-years-ago-would-be-worth-today", "tags": []}
{"id": 42964097, "time": "2025-01-13 18:45:39", "headline": "NFL Star Helps Self-Help Book Hit #1 On Amazon: 'My Teammates Call It The Recipe'", "summary": "The top-selling book on Amazon Monday Jan. 13 has an NFL player and the NFL Playoffs to thank.", "symbols": ["AMZN", "CMCSA", "DKNG", "FOX", "FOXA"], "source": "benzinga", "author": "Chris Katje", "url": "https://www.benzinga.com/general/psychology/25/01/42964097/nfl-star-helps-self-help-book-hit-1-on-amazon-my-teammates-call-it-the-recipe", "tags": []}
{"id": 42964291, "time": "2025-01-13 19:01:06", "headline": "Walmart Refreshes Image With New Brand Identity", "summary": "Walmart announces on Monday an updated brand identity which includes subtle changes to its wordmark and spark logo, as well as its color palette.\u00a0", "symbols": ["WMT"], "source": "benzinga", "author": "Erica Kollmann", "url": "https://www.benzinga.com/news/large-cap/25/01/42964291/walmart-refreshes-image-with-new-brand-identity", "tags": []}
{"id": 42964774, "time": "2025-01-13 19:50:04", "headline": "Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending", "summary": "", "symbols": ["EVAX"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/25/01/42964774/trading-halt-halted-at-7-50-00-p-m-et-trading-halt-halt-news-pending", "tags": ["halt"]}
{"id": 42938578, "time": "2025-01-13 03:57:50", "headline": "Jamie Dimon Calls Elon Musk 'An Extraordinary Talent' \u2014 JP Morgan CEO Shares Why Trump's Election Victory Didn't Surprise Him", "summary": "Jamie Dimon offered a praise for Tesla CEO Elon Musk while sharing insights on American political dynamics in an interview.", "symbols": ["JPM", "TSLA"], "source": "benzinga", "author": "Kaustubh Bagalkote", "url": "https://www.benzinga.com/markets/equities/25/01/42938578/jamie-dimon-calls-elon-musk-an-extraordinary-talent-jp-morgan-ceo-shares-why-trumps-election-victory-didnt-surprise-him", "tags": ["management"]}
{"id": 42964888, "time": "2025-01-13 20:09:29", "headline": "'Honeywell Plans Breakup Under Pressure From Elliott' -Earlier Bloomberg Report", "summary": "", "symbols": ["HON"], "source": "benzinga", "author": "Benzinga Newsdesk", "url": "https://www.benzinga.com/news/25/01/42964888/honeywell-plans-breakup-under-pressure-from-elliott-earlier-bloomberg-report", "tags": []}
{"id": 42965139, "time": "2025-01-13 20:48:07", "headline": "Tesla Shares Rise Over 2% After Hours On Morgan Stanley's Price Target Hike, FSD Breakthroughs: Gary Black Highlights Key Drivers", "summary": "Tesla stock rose 2% after-hours on Morgan Stanley&#39;s price target increase and positive developments in Full Self-Driving technology.", "symbols": ["JPM", "TSLA"], "source": "benzinga", "author": "Kaustubh Bagalkote", "url": "https://www.benzinga.com/markets/equities/25/01/42965139/tesla-soars-over-2-after-hours-on-morgan-stanleys-430-target-upgrade-and-breakthrough-fsd-advancements-says-gary-black", "tags": []}
{"id": 42965533, "time": "2025-01-13 21:46:11", "headline": "Elon Musk Emerges As Potential TikTok US Buyer As Ban Deadline Looms, Company Terms It 'Pure Fiction'", "summary": "Chinese officials are considering Tesla Inc. CEO Elon Musk as a potential buyer for TikTok&#39;s U.S. operations.", "symbols": ["GOOG", "GOOGL", "META", "MSFT", "ORCL", "TSLA"], "source": "benzinga", "author": "Kaustubh Bagalkote", "url": "https://www.benzinga.com/general/social-media/25/01/42965533/elon-musk-emerges-as-potential-tiktok-us-buyer-as-ban-deadline-looms-company-terms-it-pure-fiction", "tags": ["management"]}
{"id": 42965710, "time": "2025-01-13 22:48:34", "headline": "Jeff Bezos' Blue Origin Now Eyeing Thursday For New Glenn's First Launch To Orbit", "summary": "Jeff Bezos\u2018\u00a0Blue Origin said on Monday evening that it is now looking to launch its New Glenn launch vehicle to orbit for the first time no earlier than Thursday, Jan. 16, after scrapping liftoff on Monday morning. ", "symbols": [], "source": "benzinga", "author": "Anan Ashraf", "url": "https://www.benzinga.com/general/space/25/01/42965710/jeff-bezos-blue-origin-now-eyeing-thursday-for-new-glenns-first-launch-to-orbit", "tags": []}
{"id": 42965795, "time": "2025-01-13 23:17:46", "headline": "Tom Lee Forecasts Bitcoin Could Dip To $50K, But Maintains Long-Term Target Of $250K Amid Market Volatility", "summary": "Wall Street strategist Tom Lee suggests Bitcoin (CRYPTO: BTC) could retreat significantly from recent highs, potentially testing support levels at $70,000 or even the $50,000 range, while maintaining a long-term bullish stance targeting $250,000.", "symbols": ["BTCUSD", "ETHUSD"], "source": "benzinga", "author": "Kaustubh Bagalkote", "url": "https://www.benzinga.com/markets/cryptocurrency/25/01/42965795/tom-lee-forecasts-bitcoin-could-dip-to-50k-but-maintains-long-term-target-of-250k-amid-market-volatility", "tags": ["analyst_other"]}
{"id": 42965859, "time": "2025-01-13 23:43:59", "headline": "Ray Dalio Warns US Could 'Go Broke' As Debt Soars, Urges Action To Avert Crisis", "summary": "Ray Dalio, founder of Bridgewater Associates, warned that the United States could &#34;go broke&#34; due to mounting government debt problems.", "symbols": [], "source": "benzinga", "author": "Kaustubh Bagalkote", "url": "https://www.benzinga.com/news/25/01/42965859/ray-dalio-warns-us-could-go-broke-as-debt-soars-urges-action-to-avert-crisis", "tags": []}
